Javascript doit fonctionner ! Activez-le et rechargez cette page.
Le Rézo de JeuxDeMots
• Types de relations
• Types de noeuds
• Consolider
le terme
  Options  
             

  Filtrage type relations : +   - (ex: 4, 12, 18, 36, 444, 555, 777)
  Filtrage valeur :          min   max
  Filtrage type noeuds :   +   - (ex: 4, 6, 8, 9, 10, 12, 18, 36, 444, 555, 777)

  Présentation de sortie :   (ex: -rien-, cloud, nicecloud)
 

'en:hyperintense'
(id=7775756 ; fe=en:hyperintense ; type=1 ; niveau=200 ; luminosité=25 ; somme entrante=1122 creation date=2017-07-07 touchdate=2025-04-23 23:24:19.000)
≈ 2857 relations sortantes

  1. en:hyperintense -- r_associated #0: 50 / 1 -> hyperintense
    n1=en:hyperintense | n2=hyperintense | rel=r_associated | relid=0 | w=50
  2. en:hyperintense -- r_associated #0: 43 / 0.86 -> en:hypointense
    n1=en:hyperintense | n2=en:hypointense | rel=r_associated | relid=0 | w=43
  3. en:hyperintense -- r_associated #0: 34 / 0.68 -> en:isointense
    n1=en:hyperintense | n2=en:isointense | rel=r_associated | relid=0 | w=34
  4. en:hyperintense -- r_associated #0: 34 / 0.68 -> hypo-intense
    n1=en:hyperintense | n2=hypo-intense | rel=r_associated | relid=0 | w=34
  5. en:hyperintense -- r_associated #0: 33 / 0.66 -> en:intermediate signal intensity
    n1=en:hyperintense | n2=en:intermediate signal intensity | rel=r_associated | relid=0 | w=33
  6. en:hyperintense -- r_associated #0: 32 / 0.64 -> hypersignal (en IRM)
    n1=en:hyperintense | n2=hypersignal (en IRM) | rel=r_associated | relid=0 | w=32
  7. en:hyperintense -- r_associated #0: 31 / 0.62 -> en:high signal intensity
    n1=en:hyperintense | n2=en:high signal intensity | rel=r_associated | relid=0 | w=31
  8. en:hyperintense -- r_associated #0: 28 / 0.56 -> hyperintense (signal IRM)
    n1=en:hyperintense | n2=hyperintense (signal IRM) | rel=r_associated | relid=0 | w=28
  9. en:hyperintense -- r_associated #0: 27 / 0.54 -> en:low signal intensity
    n1=en:hyperintense | n2=en:low signal intensity | rel=r_associated | relid=0 | w=27
  10. en:hyperintense -- r_associated #0: 27 / 0.54 -> signal
    n1=en:hyperintense | n2=signal | rel=r_associated | relid=0 | w=27
  11. en:hyperintense -- r_associated #0: 25 / 0.5 -> hyperkaliémie
    n1=en:hyperintense | n2=hyperkaliémie | rel=r_associated | relid=0 | w=25
  12. en:hyperintense -- r_associated #0: 25 / 0.5 -> hyperkaliémie chronique
    n1=en:hyperintense | n2=hyperkaliémie chronique | rel=r_associated | relid=0 | w=25
  13. en:hyperintense -- r_associated #0: 25 / 0.5 -> hyperkératose
    n1=en:hyperintense | n2=hyperkératose | rel=r_associated | relid=0 | w=25
  14. en:hyperintense -- r_associated #0: 24 / 0.48 -> IRM
    n1=en:hyperintense | n2=IRM | rel=r_associated | relid=0 | w=24
  15. en:hyperintense -- r_associated #0: 24 / 0.48 -> processus pathologique
    n1=en:hyperintense | n2=processus pathologique | rel=r_associated | relid=0 | w=24
  16. en:hyperintense -- r_associated #0: 20 / 0.4 -> en:hyperintense lesions in the basal ganglia and brainstem
    n1=en:hyperintense | n2=en:hyperintense lesions in the basal ganglia and brainstem | rel=r_associated | relid=0 | w=20
  17. en:hyperintense -- r_associated #0: 20 / 0.4 -> en:hyperintense lesions in the thalamus and basal ganglia
    n1=en:hyperintense | n2=en:hyperintense lesions in the thalamus and basal ganglia | rel=r_associated | relid=0 | w=20
  18. en:hyperintense -- r_associated #0: 20 / 0.4 -> hypo-intense (signal IRM)
    n1=en:hyperintense | n2=hypo-intense (signal IRM) | rel=r_associated | relid=0 | w=20
  19. en:hyperintense -- r_associated #0: 15 / 0.3 -> hyperkératose épidermolytique
    n1=en:hyperintense | n2=hyperkératose épidermolytique | rel=r_associated | relid=0 | w=15
  20. en:hyperintense -- r_associated #0: 15 / 0.3 -> hyperkératose ichtiosiforme
    n1=en:hyperintense | n2=hyperkératose ichtiosiforme | rel=r_associated | relid=0 | w=15
  21. en:hyperintense -- r_associated #0: 10 / 0.2 -> 726 hyperkératoses
    n1=en:hyperintense | n2=726 hyperkératoses | rel=r_associated | relid=0 | w=10
  22. en:hyperintense -- r_associated #0: 10 / 0.2 -> acanthokérotolyse
    n1=en:hyperintense | n2=acanthokérotolyse | rel=r_associated | relid=0 | w=10
  23. en:hyperintense -- r_associated #0: 10 / 0.2 -> acanthome épidermolytique
    n1=en:hyperintense | n2=acanthome épidermolytique | rel=r_associated | relid=0 | w=10
  24. en:hyperintense -- r_associated #0: 10 / 0.2 -> acanthosis nigricans
    n1=en:hyperintense | n2=acanthosis nigricans | rel=r_associated | relid=0 | w=10
  25. en:hyperintense -- r_associated #0: 10 / 0.2 -> antialdostérone
    n1=en:hyperintense | n2=antialdostérone | rel=r_associated | relid=0 | w=10
  26. en:hyperintense -- r_associated #0: 10 / 0.2 -> bulleuse
    n1=en:hyperintense | n2=bulleuse | rel=r_associated | relid=0 | w=10
  27. en:hyperintense -- r_associated #0: 10 / 0.2 -> callosité
    n1=en:hyperintense | n2=callosité | rel=r_associated | relid=0 | w=10
  28. en:hyperintense -- r_associated #0: 10 / 0.2 -> callosité cutanée
    n1=en:hyperintense | n2=callosité cutanée | rel=r_associated | relid=0 | w=10
  29. en:hyperintense -- r_associated #0: 10 / 0.2 -> callosités
    n1=en:hyperintense | n2=callosités | rel=r_associated | relid=0 | w=10
  30. en:hyperintense -- r_associated #0: 10 / 0.2 -> chronique
    n1=en:hyperintense | n2=chronique | rel=r_associated | relid=0 | w=10
  31. en:hyperintense -- r_associated #0: 10 / 0.2 -> congénitale
    n1=en:hyperintense | n2=congénitale | rel=r_associated | relid=0 | w=10
  32. en:hyperintense -- r_associated #0: 10 / 0.2 -> cornée
    n1=en:hyperintense | n2=cornée | rel=r_associated | relid=0 | w=10
  33. en:hyperintense -- r_associated #0: 10 / 0.2 -> cors et callosités
    n1=en:hyperintense | n2=cors et callosités | rel=r_associated | relid=0 | w=10
  34. en:hyperintense -- r_associated #0: 10 / 0.2 -> durillon
    n1=en:hyperintense | n2=durillon | rel=r_associated | relid=0 | w=10
  35. en:hyperintense -- r_associated #0: 10 / 0.2 -> dyskaliémie
    n1=en:hyperintense | n2=dyskaliémie | rel=r_associated | relid=0 | w=10
  36. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:'cloudy' or 'pink' blood (lipemia)
    n1=en:hyperintense | n2=en:'cloudy' or 'pink' blood (lipemia) | rel=r_associated | relid=0 | w=10
  37. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:'compensated hypothyroidism' with increased tsh and normal t4
    n1=en:hyperintense | n2=en:'compensated hypothyroidism' with increased tsh and normal t4 | rel=r_associated | relid=0 | w=10
  38. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:'rectilinear profiles' ultrastructurally in cells
    n1=en:hyperintense | n2=en:'rectilinear profiles' ultrastructurally in cells | rel=r_associated | relid=0 | w=10
  39. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:1,25-dihydroxyvitamin d was elevated in childhood but deficient in adulthood
    n1=en:hyperintense | n2=en:1,25-dihydroxyvitamin d was elevated in childhood but deficient in adulthood | rel=r_associated | relid=0 | w=10
  40. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:1.61- and 1.76-mb microduplication of 3q29
    n1=en:hyperintense | n2=en:1.61- and 1.76-mb microduplication of 3q29 | rel=r_associated | relid=0 | w=10
  41. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:12 hr acetazolamide 500 mg extended release oral capsule
    n1=en:hyperintense | n2=en:12 hr acetazolamide 500 mg extended release oral capsule | rel=r_associated | relid=0 | w=10
  42. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:2-aminoadipic aciduria
    n1=en:hyperintense | n2=en:2-aminoadipic aciduria | rel=r_associated | relid=0 | w=10
  43. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:2-oxoadipic aciduria
    n1=en:hyperintense | n2=en:2-oxoadipic aciduria | rel=r_associated | relid=0 | w=10
  44. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:2,8-dihydroxyadenine (dha) urinary stones
    n1=en:hyperintense | n2=en:2,8-dihydroxyadenine (dha) urinary stones | rel=r_associated | relid=0 | w=10
  45. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:3-methylglutaconic aciduria
    n1=en:hyperintense | n2=en:3-methylglutaconic aciduria | rel=r_associated | relid=0 | w=10
  46. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:3-methylglutaconic aciduria (3-mgc)
    n1=en:hyperintense | n2=en:3-methylglutaconic aciduria (3-mgc) | rel=r_associated | relid=0 | w=10
  47. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:3-methylglutaric aciduria
    n1=en:hyperintense | n2=en:3-methylglutaric aciduria | rel=r_associated | relid=0 | w=10
  48. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:3-methylglutaric aciduria (3-mga)
    n1=en:hyperintense | n2=en:3-methylglutaric aciduria (3-mga) | rel=r_associated | relid=0 | w=10
  49. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:4-hydroxycyclohexylacetic aciduria (adults)
    n1=en:hyperintense | n2=en:4-hydroxycyclohexylacetic aciduria (adults) | rel=r_associated | relid=0 | w=10
  50. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:4-hydroxyphenylacetic aciduria
    n1=en:hyperintense | n2=en:4-hydroxyphenylacetic aciduria | rel=r_associated | relid=0 | w=10
  51. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:4-hydroxyphenylactic aciduria
    n1=en:hyperintense | n2=en:4-hydroxyphenylactic aciduria | rel=r_associated | relid=0 | w=10
  52. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:4-hydroxyphenyllactic aciduria
    n1=en:hyperintense | n2=en:4-hydroxyphenyllactic aciduria | rel=r_associated | relid=0 | w=10
  53. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:4-hydroxyphenylpyruvic acid dioxygenase deficiency (hpd)
    n1=en:hyperintense | n2=en:4-hydroxyphenylpyruvic acid dioxygenase deficiency (hpd) | rel=r_associated | relid=0 | w=10
  54. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:4-hydroxyphenylpyruvic aciduria
    n1=en:hyperintense | n2=en:4-hydroxyphenylpyruvic aciduria | rel=r_associated | relid=0 | w=10
  55. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:5-alpha-reductase-2 enzyme deficiency
    n1=en:hyperintense | n2=en:5-alpha-reductase-2 enzyme deficiency | rel=r_associated | relid=0 | w=10
  56. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:5-hiaa csf may be normal or decreased
    n1=en:hyperintense | n2=en:5-hiaa csf may be normal or decreased | rel=r_associated | relid=0 | w=10
  57. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:5-oxoprolinase deficiency
    n1=en:hyperintense | n2=en:5-oxoprolinase deficiency | rel=r_associated | relid=0 | w=10
  58. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:85-90% dgs patients have deletion of 22q11.2
    n1=en:hyperintense | n2=en:85-90% dgs patients have deletion of 22q11.2 | rel=r_associated | relid=0 | w=10
  59. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:a small minority of patients have translocations and inversions involving 16p13.3
    n1=en:hyperintense | n2=en:a small minority of patients have translocations and inversions involving 16p13.3 | rel=r_associated | relid=0 | w=10
  60. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:a subset of group b patients have absence of pc protein and mrna
    n1=en:hyperintense | n2=en:a subset of group b patients have absence of pc protein and mrna | rel=r_associated | relid=0 | w=10
  61. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abacterial leukocyturia
    n1=en:hyperintense | n2=en:abacterial leukocyturia | rel=r_associated | relid=0 | w=10
  62. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aberrant gamma-interferon-mediated inflammation
    n1=en:hyperintense | n2=en:aberrant gamma-interferon-mediated inflammation | rel=r_associated | relid=0 | w=10
  63. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abetalipoproteinemia (lab finding)
    n1=en:hyperintense | n2=en:abetalipoproteinemia (lab finding) | rel=r_associated | relid=0 | w=10
  64. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal acylcarnitine profiles
    n1=en:hyperintense | n2=en:abnormal acylcarnitine profiles | rel=r_associated | relid=0 | w=10
  65. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal blood antidiuretic hormone
    n1=en:hyperintense | n2=en:abnormal blood antidiuretic hormone | rel=r_associated | relid=0 | w=10
  66. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal blood gas measurement
    n1=en:hyperintense | n2=en:abnormal blood gas measurement | rel=r_associated | relid=0 | w=10
  67. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal blood gonadotrophin
    n1=en:hyperintense | n2=en:abnormal blood gonadotrophin | rel=r_associated | relid=0 | w=10
  68. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal blood prolactin
    n1=en:hyperintense | n2=en:abnormal blood prolactin | rel=r_associated | relid=0 | w=10
  69. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal bone marrow karyotype, t(8,21)
    n1=en:hyperintense | n2=en:abnormal bone marrow karyotype, t(8,21) | rel=r_associated | relid=0 | w=10
  70. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal cardiolipin subspecies composition
    n1=en:hyperintense | n2=en:abnormal cardiolipin subspecies composition | rel=r_associated | relid=0 | w=10
  71. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal cartilage collagen on em
    n1=en:hyperintense | n2=en:abnormal cartilage collagen on em | rel=r_associated | relid=0 | w=10
  72. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal cholesterol homeostasis
    n1=en:hyperintense | n2=en:abnormal cholesterol homeostasis | rel=r_associated | relid=0 | w=10
  73. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal columnization of chondrocytes
    n1=en:hyperintense | n2=en:abnormal columnization of chondrocytes | rel=r_associated | relid=0 | w=10
  74. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal dystrophin on muscle biopsy
    n1=en:hyperintense | n2=en:abnormal dystrophin on muscle biopsy | rel=r_associated | relid=0 | w=10
  75. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal eeg in 25% hospitalized patients
    n1=en:hyperintense | n2=en:abnormal eeg in 25% hospitalized patients | rel=r_associated | relid=0 | w=10
  76. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal electrophoretic mobility of type ii collagen
    n1=en:hyperintense | n2=en:abnormal electrophoretic mobility of type ii collagen | rel=r_associated | relid=0 | w=10
  77. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal extrarenal response to ddavp (no increase in von willebrand factor or factor viii)
    n1=en:hyperintense | n2=en:abnormal extrarenal response to ddavp (no increase in von willebrand factor or factor viii) | rel=r_associated | relid=0 | w=10
  78. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal fecal fat
    n1=en:hyperintense | n2=en:abnormal fecal fat | rel=r_associated | relid=0 | w=10
  79. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal glycosylation of serum transferrin, type 1 pattern
    n1=en:hyperintense | n2=en:abnormal glycosylation of serum transferrin, type 1 pattern | rel=r_associated | relid=0 | w=10
  80. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal growth hormone
    n1=en:hyperintense | n2=en:abnormal growth hormone | rel=r_associated | relid=0 | w=10
  81. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal hematology test result
    n1=en:hyperintense | n2=en:abnormal hematology test result | rel=r_associated | relid=0 | w=10
  82. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal igfr1 function
    n1=en:hyperintense | n2=en:abnormal igfr1 function | rel=r_associated | relid=0 | w=10
  83. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal isoelectric focusing of serum transferrin
    n1=en:hyperintense | n2=en:abnormal isoelectric focusing of serum transferrin | rel=r_associated | relid=0 | w=10
  84. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal isoelectric focusing of serum transferrin (type 1 pattern without increase of asialotransferrin)
    n1=en:hyperintense | n2=en:abnormal isoelectric focusing of serum transferrin (type 1 pattern without increase of asialotransferrin) | rel=r_associated | relid=0 | w=10
  85. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal isoelectric focusing of serum transferrin (type 1 pattern)
    n1=en:hyperintense | n2=en:abnormal isoelectric focusing of serum transferrin (type 1 pattern) | rel=r_associated | relid=0 | w=10
  86. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal isoelectric focusing of serum transferrin (type 1 pattern) (in 1 patient)
    n1=en:hyperintense | n2=en:abnormal isoelectric focusing of serum transferrin (type 1 pattern) (in 1 patient) | rel=r_associated | relid=0 | w=10
  87. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal isoelectric focusing of serum transferrin (type 1 pattern) loss of complete n-glycans
    n1=en:hyperintense | n2=en:abnormal isoelectric focusing of serum transferrin (type 1 pattern) loss of complete n-glycans | rel=r_associated | relid=0 | w=10
  88. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal isoelectric focusing of serum transferrin (type 2 pattern)
    n1=en:hyperintense | n2=en:abnormal isoelectric focusing of serum transferrin (type 2 pattern) | rel=r_associated | relid=0 | w=10
  89. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal karyotype in 3 patients involving distal 6p
    n1=en:hyperintense | n2=en:abnormal karyotype in 3 patients involving distal 6p | rel=r_associated | relid=0 | w=10
  90. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal karyotype in single reported female patient 46, xx,r(18)(p14q23)
    n1=en:hyperintense | n2=en:abnormal karyotype in single reported female patient 46, xx,r(18)(p14q23) | rel=r_associated | relid=0 | w=10
  91. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal lipid profile
    n1=en:hyperintense | n2=en:abnormal lipid profile | rel=r_associated | relid=0 | w=10
  92. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal liver enzymes (1 patient)
    n1=en:hyperintense | n2=en:abnormal liver enzymes (1 patient) | rel=r_associated | relid=0 | w=10
  93. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal liver enzymes (in some patients)
    n1=en:hyperintense | n2=en:abnormal liver enzymes (in some patients) | rel=r_associated | relid=0 | w=10
  94. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal liver enzymes (rare)
    n1=en:hyperintense | n2=en:abnormal liver enzymes (rare) | rel=r_associated | relid=0 | w=10
  95. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal liver enzymes during illness
    n1=en:hyperintense | n2=en:abnormal liver enzymes during illness | rel=r_associated | relid=0 | w=10
  96. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal liver enzymes in those with hepatic cysts or fibrosis
    n1=en:hyperintense | n2=en:abnormal liver enzymes in those with hepatic cysts or fibrosis | rel=r_associated | relid=0 | w=10
  97. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal liver enzymes, episodic
    n1=en:hyperintense | n2=en:abnormal liver enzymes, episodic | rel=r_associated | relid=0 | w=10
  98. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal liver enzymes, intermittent
    n1=en:hyperintense | n2=en:abnormal liver enzymes, intermittent | rel=r_associated | relid=0 | w=10
  99. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal liver enzymes, intermittent (1 patient)
    n1=en:hyperintense | n2=en:abnormal liver enzymes, intermittent (1 patient) | rel=r_associated | relid=0 | w=10
  100. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal liver function test
    n1=en:hyperintense | n2=en:abnormal liver function test | rel=r_associated | relid=0 | w=10
  101. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal liver function tests (in some patients)
    n1=en:hyperintense | n2=en:abnormal liver function tests (in some patients) | rel=r_associated | relid=0 | w=10
  102. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal liver function tests (less common)
    n1=en:hyperintense | n2=en:abnormal liver function tests (less common) | rel=r_associated | relid=0 | w=10
  103. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal liver function tests (sgot, sgpt)
    n1=en:hyperintense | n2=en:abnormal liver function tests (sgot, sgpt) | rel=r_associated | relid=0 | w=10
  104. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal liver function tests during pregnancy, resolves postpartum
    n1=en:hyperintense | n2=en:abnormal liver function tests during pregnancy, resolves postpartum | rel=r_associated | relid=0 | w=10
  105. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal myelination in sural nerve biopsies
    n1=en:hyperintense | n2=en:abnormal myelination in sural nerve biopsies | rel=r_associated | relid=0 | w=10
  106. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal n-glycosylation of transferrin
    n1=en:hyperintense | n2=en:abnormal n-glycosylation of transferrin | rel=r_associated | relid=0 | w=10
  107. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal nasal potential difference
    n1=en:hyperintense | n2=en:abnormal nasal potential difference | rel=r_associated | relid=0 | w=10
  108. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal nuclear morphology
    n1=en:hyperintense | n2=en:abnormal nuclear morphology | rel=r_associated | relid=0 | w=10
  109. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal oral glucose tolerance
    n1=en:hyperintense | n2=en:abnormal oral glucose tolerance | rel=r_associated | relid=0 | w=10
  110. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal phenolsulfonphthalein test result
    n1=en:hyperintense | n2=en:abnormal phenolsulfonphthalein test result | rel=r_associated | relid=0 | w=10
  111. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal phosphatidylglycerol profile (increased 34-to-1 and decreased 36-to-1 ratio)
    n1=en:hyperintense | n2=en:abnormal phosphatidylglycerol profile (increased 34-to-1 and decreased 36-to-1 ratio) | rel=r_associated | relid=0 | w=10
  112. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal phospholipid profile
    n1=en:hyperintense | n2=en:abnormal phospholipid profile | rel=r_associated | relid=0 | w=10
  113. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal response of 25-hydroxyvitamin d-1-alpha-hydroxylase activity (609506) to hypophosphatemia
    n1=en:hyperintense | n2=en:abnormal response of 25-hydroxyvitamin d-1-alpha-hydroxylase activity (609506) to hypophosphatemia | rel=r_associated | relid=0 | w=10
  114. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal response to human chorionic gonadotropin indicates decreased testosterone
    n1=en:hyperintense | n2=en:abnormal response to human chorionic gonadotropin indicates decreased testosterone | rel=r_associated | relid=0 | w=10
  115. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal schilling test (not normalized by addition of intrinsic factor)
    n1=en:hyperintense | n2=en:abnormal schilling test (not normalized by addition of intrinsic factor) | rel=r_associated | relid=0 | w=10
  116. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal secretin test
    n1=en:hyperintense | n2=en:abnormal secretin test | rel=r_associated | relid=0 | w=10
  117. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal serum glycoproteins
    n1=en:hyperintense | n2=en:abnormal serum glycoproteins | rel=r_associated | relid=0 | w=10
  118. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal serum lipoprotein levels (in 3 of 10 patients)
    n1=en:hyperintense | n2=en:abnormal serum lipoprotein levels (in 3 of 10 patients) | rel=r_associated | relid=0 | w=10
  119. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal serum liver enzyme levels
    n1=en:hyperintense | n2=en:abnormal serum liver enzyme levels | rel=r_associated | relid=0 | w=10
  120. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal serum protein electrophoresis (elevated alpha-2 band)
    n1=en:hyperintense | n2=en:abnormal serum protein electrophoresis (elevated alpha-2 band) | rel=r_associated | relid=0 | w=10
  121. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal serum transferrin pattern (in some patients)
    n1=en:hyperintense | n2=en:abnormal serum transferrin pattern (in some patients) | rel=r_associated | relid=0 | w=10
  122. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal serum transferrin pattern by isoelectric focusing (hyposialylation)
    n1=en:hyperintense | n2=en:abnormal serum transferrin pattern by isoelectric focusing (hyposialylation) | rel=r_associated | relid=0 | w=10
  123. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal spinocerebellar tracts, dorsal columns, pyramidal tracts, cerebellum and brainstem
    n1=en:hyperintense | n2=en:abnormal spinocerebellar tracts, dorsal columns, pyramidal tracts, cerebellum and brainstem | rel=r_associated | relid=0 | w=10
  124. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal transaminases (1 patient)
    n1=en:hyperintense | n2=en:abnormal transaminases (1 patient) | rel=r_associated | relid=0 | w=10
  125. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal transferrin isoelectric focusing (ief)
    n1=en:hyperintense | n2=en:abnormal transferrin isoelectric focusing (ief) | rel=r_associated | relid=0 | w=10
  126. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal urinary collagen-derived pyridinium crosslinks (absent glc-gal-pyd)
    n1=en:hyperintense | n2=en:abnormal urinary collagen-derived pyridinium crosslinks (absent glc-gal-pyd) | rel=r_associated | relid=0 | w=10
  127. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal urinary compounds
    n1=en:hyperintense | n2=en:abnormal urinary compounds | rel=r_associated | relid=0 | w=10
  128. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal urinary mucopolysaccharides (elevated unsaturated nonsulfated disaccharides and decreased unsaturated 6-sulfated disaccharides)
    n1=en:hyperintense | n2=en:abnormal urinary mucopolysaccharides (elevated unsaturated nonsulfated disaccharides and decreased unsaturated 6-sulfated disaccharides) | rel=r_associated | relid=0 | w=10
  129. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal urinary oligosaccharides
    n1=en:hyperintense | n2=en:abnormal urinary oligosaccharides | rel=r_associated | relid=0 | w=10
  130. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormal urinary organic acids
    n1=en:hyperintense | n2=en:abnormal urinary organic acids | rel=r_associated | relid=0 | w=10
  131. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormally low cerebrospinal fluid cystatin c
    n1=en:hyperintense | n2=en:abnormally low cerebrospinal fluid cystatin c | rel=r_associated | relid=0 | w=10
  132. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:abnormally triglyceride-rich low and high density lipoproteins and beta-migrating very low density lipoproteins
    n1=en:hyperintense | n2=en:abnormally triglyceride-rich low and high density lipoproteins and beta-migrating very low density lipoproteins | rel=r_associated | relid=0 | w=10
  133. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:above reference range
    n1=en:hyperintense | n2=en:above reference range | rel=r_associated | relid=0 | w=10
  134. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absence of beta-ureidopropionase activity and protein in liver biopsy
    n1=en:hyperintense | n2=en:absence of beta-ureidopropionase activity and protein in liver biopsy | rel=r_associated | relid=0 | w=10
  135. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absence of cd59 expression on red cells
    n1=en:hyperintense | n2=en:absence of cd59 expression on red cells | rel=r_associated | relid=0 | w=10
  136. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absence of chylomicrons in lymph and plasma
    n1=en:hyperintense | n2=en:absence of chylomicrons in lymph and plasma | rel=r_associated | relid=0 | w=10
  137. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absence of cpt ii protein
    n1=en:hyperintense | n2=en:absence of cpt ii protein | rel=r_associated | relid=0 | w=10
  138. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absence of emerin by immunohistochemistry on muscle biopsy
    n1=en:hyperintense | n2=en:absence of emerin by immunohistochemistry on muscle biopsy | rel=r_associated | relid=0 | w=10
  139. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absence of hepatic udp-glucuronyl-transferase
    n1=en:hyperintense | n2=en:absence of hepatic udp-glucuronyl-transferase | rel=r_associated | relid=0 | w=10
  140. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absence of outer dynein arms
    n1=en:hyperintense | n2=en:absence of outer dynein arms | rel=r_associated | relid=0 | w=10
  141. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absence of peroxidase staining in neutrophils and monocytes
    n1=en:hyperintense | n2=en:absence of peroxidase staining in neutrophils and monocytes | rel=r_associated | relid=0 | w=10
  142. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent 7-dehydrocholesterol
    n1=en:hyperintense | n2=en:absent 7-dehydrocholesterol | rel=r_associated | relid=0 | w=10
  143. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent alkyl-dhap synthase activity
    n1=en:hyperintense | n2=en:absent alkyl-dhap synthase activity | rel=r_associated | relid=0 | w=10
  144. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent anti-insulin receptor antibodies
    n1=en:hyperintense | n2=en:absent anti-insulin receptor antibodies | rel=r_associated | relid=0 | w=10
  145. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent axonal flare response after intradermal histamine injection
    n1=en:hyperintense | n2=en:absent axonal flare response after intradermal histamine injection | rel=r_associated | relid=0 | w=10
  146. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent axonal flare response to intradermal histamine injection
    n1=en:hyperintense | n2=en:absent axonal flare response to intradermal histamine injection | rel=r_associated | relid=0 | w=10
  147. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent ch50 activity in complete c4 deficiency
    n1=en:hyperintense | n2=en:absent ch50 activity in complete c4 deficiency | rel=r_associated | relid=0 | w=10
  148. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent dystrophin on muscle biopsy
    n1=en:hyperintense | n2=en:absent dystrophin on muscle biopsy | rel=r_associated | relid=0 | w=10
  149. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent enteric ganglia beginning at rectum and extending proximally by varying degrees
    n1=en:hyperintense | n2=en:absent enteric ganglia beginning at rectum and extending proximally by varying degrees | rel=r_associated | relid=0 | w=10
  150. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent igg2 subclass
    n1=en:hyperintense | n2=en:absent igg2 subclass | rel=r_associated | relid=0 | w=10
  151. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent or abnormal thyroglobulin
    n1=en:hyperintense | n2=en:absent or abnormal thyroglobulin | rel=r_associated | relid=0 | w=10
  152. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent or severely reduced levels of serum immunoglobulins
    n1=en:hyperintense | n2=en:absent or severely reduced levels of serum immunoglobulins | rel=r_associated | relid=0 | w=10
  153. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent platelet agglutination in presence of ristocetin
    n1=en:hyperintense | n2=en:absent platelet agglutination in presence of ristocetin | rel=r_associated | relid=0 | w=10
  154. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent pro alpha 2(i) chain synthesis (fibroblasts)
    n1=en:hyperintense | n2=en:absent pro alpha 2(i) chain synthesis (fibroblasts) | rel=r_associated | relid=0 | w=10
  155. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent tyrosinase activity
    n1=en:hyperintense | n2=en:absent tyrosinase activity | rel=r_associated | relid=0 | w=10
  156. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent-decreased prolyl 3-hydroxylation at collagen i alpha-1 pro986
    n1=en:hyperintense | n2=en:absent-decreased prolyl 3-hydroxylation at collagen i alpha-1 pro986 | rel=r_associated | relid=0 | w=10
  157. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent/reduced free proteins and absent total protein s
    n1=en:hyperintense | n2=en:absent/reduced free proteins and absent total protein s | rel=r_associated | relid=0 | w=10
  158. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:absent/reduced protein s and normal total proteins in heterozygote
    n1=en:hyperintense | n2=en:absent/reduced protein s and normal total proteins in heterozygote | rel=r_associated | relid=0 | w=10
  159. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acanthokeratodermia
    n1=en:hyperintense | n2=en:acanthokeratodermia | rel=r_associated | relid=0 | w=10
  160. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acanthosis nigricans
    n1=en:hyperintense | n2=en:acanthosis nigricans | rel=r_associated | relid=0 | w=10
  161. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acanthotic epidermis
    n1=en:hyperintense | n2=en:acanthotic epidermis | rel=r_associated | relid=0 | w=10
  162. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:accumulation of cholesterol esters in various tissues
    n1=en:hyperintense | n2=en:accumulation of cholesterol esters in various tissues | rel=r_associated | relid=0 | w=10
  163. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:accumulation of guanidinoacetate in brain
    n1=en:hyperintense | n2=en:accumulation of guanidinoacetate in brain | rel=r_associated | relid=0 | w=10
  164. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:accumulation of neutral lipids (triglycerides) in leukocytes, muscle cells, fibroblasts, and cardiomyocytes
    n1=en:hyperintense | n2=en:accumulation of neutral lipids (triglycerides) in leukocytes, muscle cells, fibroblasts, and cardiomyocytes | rel=r_associated | relid=0 | w=10
  165. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:accumulation of shortened dolichol-linked oligosaccharides in patient fibroblasts
    n1=en:hyperintense | n2=en:accumulation of shortened dolichol-linked oligosaccharides in patient fibroblasts | rel=r_associated | relid=0 | w=10
  166. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:accumulation of sulfatides, glycosaminoglycans, sphingolipids, and steroid sulfates in tissues and body fluids
    n1=en:hyperintense | n2=en:accumulation of sulfatides, glycosaminoglycans, sphingolipids, and steroid sulfates in tissues and body fluids | rel=r_associated | relid=0 | w=10
  167. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:accumulation of unprocessed mt-trna intermediates in skeletal muscle cells and fibroblasts
    n1=en:hyperintense | n2=en:accumulation of unprocessed mt-trna intermediates in skeletal muscle cells and fibroblasts | rel=r_associated | relid=0 | w=10
  168. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acetazolamide
    n1=en:hyperintense | n2=en:acetazolamide | rel=r_associated | relid=0 | w=10
  169. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acetazolamide 125mg tablet
    n1=en:hyperintense | n2=en:acetazolamide 125mg tablet | rel=r_associated | relid=0 | w=10
  170. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acetazolamide 250mg tablet
    n1=en:hyperintense | n2=en:acetazolamide 250mg tablet | rel=r_associated | relid=0 | w=10
  171. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acetazolamide 500mg powder and solvent for injection solution vial
    n1=en:hyperintense | n2=en:acetazolamide 500mg powder and solvent for injection solution vial | rel=r_associated | relid=0 | w=10
  172. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acetazolamide sodium
    n1=en:hyperintense | n2=en:acetazolamide sodium | rel=r_associated | relid=0 | w=10
  173. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acetyl coa:alpha-glucosaminidase n-acetyltransferase deficiency in fibroblasts
    n1=en:hyperintense | n2=en:acetyl coa:alpha-glucosaminidase n-acetyltransferase deficiency in fibroblasts | rel=r_associated | relid=0 | w=10
  174. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acetylcholinesterase staining reveals nerve trunk hypertrophy
    n1=en:hyperintense | n2=en:acetylcholinesterase staining reveals nerve trunk hypertrophy | rel=r_associated | relid=0 | w=10
  175. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acid-base imbalance
    n1=en:hyperintense | n2=en:acid-base imbalance | rel=r_associated | relid=0 | w=10
  176. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acid-labile subunit deficiency
    n1=en:hyperintense | n2=en:acid-labile subunit deficiency | rel=r_associated | relid=0 | w=10
  177. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acne keloid
    n1=en:hyperintense | n2=en:acne keloid | rel=r_associated | relid=0 | w=10
  178. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acquired acrodermatitis enteropathica
    n1=en:hyperintense | n2=en:acquired acrodermatitis enteropathica | rel=r_associated | relid=0 | w=10
  179. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acquired keratoderma
    n1=en:hyperintense | n2=en:acquired keratoderma | rel=r_associated | relid=0 | w=10
  180. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acrodermatitis enteropathica
    n1=en:hyperintense | n2=en:acrodermatitis enteropathica | rel=r_associated | relid=0 | w=10
  181. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acrokeratosis verruciformis
    n1=en:hyperintense | n2=en:acrokeratosis verruciformis | rel=r_associated | relid=0 | w=10
  182. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acth normal
    n1=en:hyperintense | n2=en:acth normal | rel=r_associated | relid=0 | w=10
  183. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:actinic (solar) keratosis
    n1=en:hyperintense | n2=en:actinic (solar) keratosis | rel=r_associated | relid=0 | w=10
  184. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acute hyperammonemia
    n1=en:hyperintense | n2=en:acute hyperammonemia | rel=r_associated | relid=0 | w=10
  185. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acute-phase reactants during fever
    n1=en:hyperintense | n2=en:acute-phase reactants during fever | rel=r_associated | relid=0 | w=10
  186. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acyl-coa:dihydroxyacetonephosphate acyltransferase deficiency
    n1=en:hyperintense | n2=en:acyl-coa:dihydroxyacetonephosphate acyltransferase deficiency | rel=r_associated | relid=0 | w=10
  187. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:acylglycinuria
    n1=en:hyperintense | n2=en:acylglycinuria | rel=r_associated | relid=0 | w=10
  188. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:adenylosuccinase deficiency (finding)
    n1=en:hyperintense | n2=en:adenylosuccinase deficiency (finding) | rel=r_associated | relid=0 | w=10
  189. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:adrenocorticotropic hormone, increased
    n1=en:hyperintense | n2=en:adrenocorticotropic hormone, increased | rel=r_associated | relid=0 | w=10
  190. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:affected mother has normal plasma zinc levels and is not zinc-deficient
    n1=en:hyperintense | n2=en:affected mother has normal plasma zinc levels and is not zinc-deficient | rel=r_associated | relid=0 | w=10
  191. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:affected mother has reduced zinc levels in breast milk (may be up to 40% less than normal breast milk)
    n1=en:hyperintense | n2=en:affected mother has reduced zinc levels in breast milk (may be up to 40% less than normal breast milk) | rel=r_associated | relid=0 | w=10
  192. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:agammaglobulinemia
    n1=en:hyperintense | n2=en:agammaglobulinemia | rel=r_associated | relid=0 | w=10
  193. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:alanine aminotransferase increased
    n1=en:hyperintense | n2=en:alanine aminotransferase increased | rel=r_associated | relid=0 | w=10
  194. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:albuminuria
    n1=en:hyperintense | n2=en:albuminuria | rel=r_associated | relid=0 | w=10
  195. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aldolase a deficiency
    n1=en:hyperintense | n2=en:aldolase a deficiency | rel=r_associated | relid=0 | w=10
  196. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aldosterone concentration below normal
    n1=en:hyperintense | n2=en:aldosterone concentration below normal | rel=r_associated | relid=0 | w=10
  197. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aldosterone level increased above normal
    n1=en:hyperintense | n2=en:aldosterone level increased above normal | rel=r_associated | relid=0 | w=10
  198. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aldosterone synthase deficiency
    n1=en:hyperintense | n2=en:aldosterone synthase deficiency | rel=r_associated | relid=0 | w=10
  199. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:alkaline phosphatase decreased
    n1=en:hyperintense | n2=en:alkaline phosphatase decreased | rel=r_associated | relid=0 | w=10
  200. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:alkaline phosphatase normal
    n1=en:hyperintense | n2=en:alkaline phosphatase normal | rel=r_associated | relid=0 | w=10
  201. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:alkaline phosphatase serum increased
    n1=en:hyperintense | n2=en:alkaline phosphatase serum increased | rel=r_associated | relid=0 | w=10
  202. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:alkalosis
    n1=en:hyperintense | n2=en:alkalosis | rel=r_associated | relid=0 | w=10
  203. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:allelic loss on 16p13.3 in angiomyolipoma, cardiac rhabdomyoma, cortical tuber, and giant cell astrocytoma
    n1=en:hyperintense | n2=en:allelic loss on 16p13.3 in angiomyolipoma, cardiac rhabdomyoma, cortical tuber, and giant cell astrocytoma | rel=r_associated | relid=0 | w=10
  204. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:alpha 1 foetoprotein amniotic fluid increased
    n1=en:hyperintense | n2=en:alpha 1 foetoprotein amniotic fluid increased | rel=r_associated | relid=0 | w=10
  205. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:alpha fetoprotein increased
    n1=en:hyperintense | n2=en:alpha fetoprotein increased | rel=r_associated | relid=0 | w=10
  206. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:alpha ketoadipic aciduria
    n1=en:hyperintense | n2=en:alpha ketoadipic aciduria | rel=r_associated | relid=0 | w=10
  207. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:alpha-fetoprotein normal
    n1=en:hyperintense | n2=en:alpha-fetoprotein normal | rel=r_associated | relid=0 | w=10
  208. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:alpha-galactosidase a deficiency in plasma, leukocytes, or fibroblasts
    n1=en:hyperintense | n2=en:alpha-galactosidase a deficiency in plasma, leukocytes, or fibroblasts | rel=r_associated | relid=0 | w=10
  209. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:alpha-hydroxyadipic aciduria alpha-aminoadipic aciduria
    n1=en:hyperintense | n2=en:alpha-hydroxyadipic aciduria alpha-aminoadipic aciduria | rel=r_associated | relid=0 | w=10
  210. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:amiloride
    n1=en:hyperintense | n2=en:amiloride | rel=r_associated | relid=0 | w=10
  211. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:amiloride hydrochloride
    n1=en:hyperintense | n2=en:amiloride hydrochloride | rel=r_associated | relid=0 | w=10
  212. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:amiloride hydrochloride 5mg tablet
    n1=en:hyperintense | n2=en:amiloride hydrochloride 5mg tablet | rel=r_associated | relid=0 | w=10
  213. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aminoaciduria
    n1=en:hyperintense | n2=en:aminoaciduria | rel=r_associated | relid=0 | w=10
  214. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aminoaciduria (1 patient)
    n1=en:hyperintense | n2=en:aminoaciduria (1 patient) | rel=r_associated | relid=0 | w=10
  215. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aminoaciduria (in some patients)
    n1=en:hyperintense | n2=en:aminoaciduria (in some patients) | rel=r_associated | relid=0 | w=10
  216. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aminoaciduria (less common)
    n1=en:hyperintense | n2=en:aminoaciduria (less common) | rel=r_associated | relid=0 | w=10
  217. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aminoaciduria (rare)
    n1=en:hyperintense | n2=en:aminoaciduria (rare) | rel=r_associated | relid=0 | w=10
  218. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aminoaciduria, intermittent
    n1=en:hyperintense | n2=en:aminoaciduria, intermittent | rel=r_associated | relid=0 | w=10
  219. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aminoaciduria, mild (in some patients)
    n1=en:hyperintense | n2=en:aminoaciduria, mild (in some patients) | rel=r_associated | relid=0 | w=10
  220. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aminoadipic semialdehyde synthase (aass) deficiency
    n1=en:hyperintense | n2=en:aminoadipic semialdehyde synthase (aass) deficiency | rel=r_associated | relid=0 | w=10
  221. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:amorphous hyaline substance (skin biopsy and visceral organs)
    n1=en:hyperintense | n2=en:amorphous hyaline substance (skin biopsy and visceral organs) | rel=r_associated | relid=0 | w=10
  222. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:amylo-1,6-glucosidase deficiency
    n1=en:hyperintense | n2=en:amylo-1,6-glucosidase deficiency | rel=r_associated | relid=0 | w=10
  223. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:amylo(1,4 - 1,6) transglucosidase deficiency (brancher enzyme)
    n1=en:hyperintense | n2=en:amylo(1,4 - 1,6) transglucosidase deficiency (brancher enzyme) | rel=r_associated | relid=0 | w=10
  224. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:amyloidosis, (iowa type 107680.0010, nonneuropathic 107680.0016)
    n1=en:hyperintense | n2=en:amyloidosis, (iowa type 107680.0010, nonneuropathic 107680.0016) | rel=r_associated | relid=0 | w=10
  225. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:anaphase loss or nondisjunction with trisomies, tetrasomies, monosomies
    n1=en:hyperintense | n2=en:anaphase loss or nondisjunction with trisomies, tetrasomies, monosomies | rel=r_associated | relid=0 | w=10
  226. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:androgens increased
    n1=en:hyperintense | n2=en:androgens increased | rel=r_associated | relid=0 | w=10
  227. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aneuploidy of the x chromosome
    n1=en:hyperintense | n2=en:aneuploidy of the x chromosome | rel=r_associated | relid=0 | w=10
  228. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:anhydrous citric acid
    n1=en:hyperintense | n2=en:anhydrous citric acid | rel=r_associated | relid=0 | w=10
  229. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:anomalies of cholesterol levels
    n1=en:hyperintense | n2=en:anomalies of cholesterol levels | rel=r_associated | relid=0 | w=10
  230. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:anti-ds dna antibody
    n1=en:hyperintense | n2=en:anti-ds dna antibody | rel=r_associated | relid=0 | w=10
  231. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:anti-factor viii positive
    n1=en:hyperintense | n2=en:anti-factor viii positive | rel=r_associated | relid=0 | w=10
  232. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:anti-iga antibodies commonly present
    n1=en:hyperintense | n2=en:anti-iga antibodies commonly present | rel=r_associated | relid=0 | w=10
  233. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:anti-ssb positive
    n1=en:hyperintense | n2=en:anti-ssb positive | rel=r_associated | relid=0 | w=10
  234. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:anti-tissue transglutaminase antibodies (anti-ttg)
    n1=en:hyperintense | n2=en:anti-tissue transglutaminase antibodies (anti-ttg) | rel=r_associated | relid=0 | w=10
  235. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:antineutrophil antibody positivity
    n1=en:hyperintense | n2=en:antineutrophil antibody positivity | rel=r_associated | relid=0 | w=10
  236. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:antineutrophil cytoplasmic antibody
    n1=en:hyperintense | n2=en:antineutrophil cytoplasmic antibody | rel=r_associated | relid=0 | w=10
  237. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:antiphospholipid antibody
    n1=en:hyperintense | n2=en:antiphospholipid antibody | rel=r_associated | relid=0 | w=10
  238. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:antiribonuclear protein positive
    n1=en:hyperintense | n2=en:antiribonuclear protein positive | rel=r_associated | relid=0 | w=10
  239. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:antithrombin iii decreased
    n1=en:hyperintense | n2=en:antithrombin iii decreased | rel=r_associated | relid=0 | w=10
  240. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:antithrombin iii deficiency
    n1=en:hyperintense | n2=en:antithrombin iii deficiency | rel=r_associated | relid=0 | w=10
  241. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:appropriately increased serum 1,25-dihydroxyvitamin d3
    n1=en:hyperintense | n2=en:appropriately increased serum 1,25-dihydroxyvitamin d3 | rel=r_associated | relid=0 | w=10
  242. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aprt deficiency measured in erythrocyte lysate
    n1=en:hyperintense | n2=en:aprt deficiency measured in erythrocyte lysate | rel=r_associated | relid=0 | w=10
  243. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aquagenic wrinkling of palms
    n1=en:hyperintense | n2=en:aquagenic wrinkling of palms | rel=r_associated | relid=0 | w=10
  244. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:argininosuccinic aciduria
    n1=en:hyperintense | n2=en:argininosuccinic aciduria | rel=r_associated | relid=0 | w=10
  245. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:arsenical keratosis
    n1=en:hyperintense | n2=en:arsenical keratosis | rel=r_associated | relid=0 | w=10
  246. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:arylsulfatase b deficiency in fibroblasts and white blood cells
    n1=en:hyperintense | n2=en:arylsulfatase b deficiency in fibroblasts and white blood cells | rel=r_associated | relid=0 | w=10
  247. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aspartate aminotransferase increased
    n1=en:hyperintense | n2=en:aspartate aminotransferase increased | rel=r_associated | relid=0 | w=10
  248. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aspartylglycosaminuria
    n1=en:hyperintense | n2=en:aspartylglycosaminuria | rel=r_associated | relid=0 | w=10
  249. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aspects of mortality statistics
    n1=en:hyperintense | n2=en:aspects of mortality statistics | rel=r_associated | relid=0 | w=10
  250. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:aspects of radionuclide imaging
    n1=en:hyperintense | n2=en:aspects of radionuclide imaging | rel=r_associated | relid=0 | w=10
  251. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:associated with serum anti-phospholipid antibodies in about 50% of patients
    n1=en:hyperintense | n2=en:associated with serum anti-phospholipid antibodies in about 50% of patients | rel=r_associated | relid=0 | w=10
  252. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:at least 2 complementation groups
    n1=en:hyperintense | n2=en:at least 2 complementation groups | rel=r_associated | relid=0 | w=10
  253. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:atrial abnormalities on electrocardiogram
    n1=en:hyperintense | n2=en:atrial abnormalities on electrocardiogram | rel=r_associated | relid=0 | w=10
  254. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:autosomal dominant ichthyosis
    n1=en:hyperintense | n2=en:autosomal dominant ichthyosis | rel=r_associated | relid=0 | w=10
  255. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:autosomal dominant inheritance
    n1=en:hyperintense | n2=en:autosomal dominant inheritance | rel=r_associated | relid=0 | w=10
  256. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:autosomal recessive ichthyosis
    n1=en:hyperintense | n2=en:autosomal recessive ichthyosis | rel=r_associated | relid=0 | w=10
  257. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:axonemes show normal structure
    n1=en:hyperintense | n2=en:axonemes show normal structure | rel=r_associated | relid=0 | w=10
  258. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:azoospermia/oligospermia (present at diagnosis)
    n1=en:hyperintense | n2=en:azoospermia/oligospermia (present at diagnosis) | rel=r_associated | relid=0 | w=10
  259. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:azotemia
    n1=en:hyperintense | n2=en:azotemia | rel=r_associated | relid=0 | w=10
  260. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:b lymphocytopenia
    n1=en:hyperintense | n2=en:b lymphocytopenia | rel=r_associated | relid=0 | w=10
  261. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:bacteremia
    n1=en:hyperintense | n2=en:bacteremia | rel=r_associated | relid=0 | w=10
  262. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:balance, electrolyte
    n1=en:hyperintense | n2=en:balance, electrolyte | rel=r_associated | relid=0 | w=10
  263. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:balanced translocation carrier 46,xy,+(11:18)(p13:q21)mat
    n1=en:hyperintense | n2=en:balanced translocation carrier 46,xy,+(11:18)(p13:q21)mat | rel=r_associated | relid=0 | w=10
  264. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:balanced/unbalanced chromosomal translocation t(2,13)(q36,q11)
    n1=en:hyperintense | n2=en:balanced/unbalanced chromosomal translocation t(2,13)(q36,q11) | rel=r_associated | relid=0 | w=10
  265. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ballooned neurons
    n1=en:hyperintense | n2=en:ballooned neurons | rel=r_associated | relid=0 | w=10
  266. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:benign squamous keratosis
    n1=en:hyperintense | n2=en:benign squamous keratosis | rel=r_associated | relid=0 | w=10
  267. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:beta-2 microglobulin greater than 5.5 g/ml
    n1=en:hyperintense | n2=en:beta-2 microglobulin greater than 5.5 g/ml | rel=r_associated | relid=0 | w=10
  268. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:beta-galactosidase deficiency in fibroblasts and white blood cells
    n1=en:hyperintense | n2=en:beta-galactosidase deficiency in fibroblasts and white blood cells | rel=r_associated | relid=0 | w=10
  269. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:beta-glucuronidase deficiency in fibroblasts and leukocytes
    n1=en:hyperintense | n2=en:beta-glucuronidase deficiency in fibroblasts and leukocytes | rel=r_associated | relid=0 | w=10
  270. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:bicarbonaturia
    n1=en:hyperintense | n2=en:bicarbonaturia | rel=r_associated | relid=0 | w=10
  271. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:biclonal gammopathy
    n1=en:hyperintense | n2=en:biclonal gammopathy | rel=r_associated | relid=0 | w=10
  272. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:bile contains cholesterol crystals
    n1=en:hyperintense | n2=en:bile contains cholesterol crystals | rel=r_associated | relid=0 | w=10
  273. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:bile shows increased cholesterol/phospholipid ratio
    n1=en:hyperintense | n2=en:bile shows increased cholesterol/phospholipid ratio | rel=r_associated | relid=0 | w=10
  274. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:bilirubin conjugated increased
    n1=en:hyperintense | n2=en:bilirubin conjugated increased | rel=r_associated | relid=0 | w=10
  275. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:bilirubin may or may not be increased
    n1=en:hyperintense | n2=en:bilirubin may or may not be increased | rel=r_associated | relid=0 | w=10
  276. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:biotinidase deficiency
    n1=en:hyperintense | n2=en:biotinidase deficiency | rel=r_associated | relid=0 | w=10
  277. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:blastic phase
    n1=en:hyperintense | n2=en:blastic phase | rel=r_associated | relid=0 | w=10
  278. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:bleeding time normal
    n1=en:hyperintense | n2=en:bleeding time normal | rel=r_associated | relid=0 | w=10
  279. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:blennorrhagicas, keratosis
    n1=en:hyperintense | n2=en:blennorrhagicas, keratosis | rel=r_associated | relid=0 | w=10
  280. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:blood alkaline phosphatase increased
    n1=en:hyperintense | n2=en:blood alkaline phosphatase increased | rel=r_associated | relid=0 | w=10
  281. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:blood cardiac troponin increased
    n1=en:hyperintense | n2=en:blood cardiac troponin increased | rel=r_associated | relid=0 | w=10
  282. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:blood corticotrophin decreased
    n1=en:hyperintense | n2=en:blood corticotrophin decreased | rel=r_associated | relid=0 | w=10
  283. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:blood glucose normal
    n1=en:hyperintense | n2=en:blood glucose normal | rel=r_associated | relid=0 | w=10
  284. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:blood pyruvic acid increased
    n1=en:hyperintense | n2=en:blood pyruvic acid increased | rel=r_associated | relid=0 | w=10
  285. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:blood urea nitrogen increased
    n1=en:hyperintense | n2=en:blood urea nitrogen increased | rel=r_associated | relid=0 | w=10
  286. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:blunted cortisol response to adrenocorticotropic hormone (acth)
    n1=en:hyperintense | n2=en:blunted cortisol response to adrenocorticotropic hormone (acth) | rel=r_associated | relid=0 | w=10
  287. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:bone marrow hypoplasia (in some patients)
    n1=en:hyperintense | n2=en:bone marrow hypoplasia (in some patients) | rel=r_associated | relid=0 | w=10
  288. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:borderline elevated low-density lipoprotein
    n1=en:hyperintense | n2=en:borderline elevated low-density lipoprotein | rel=r_associated | relid=0 | w=10
  289. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:branched chain ketoaciduria (alpha-keto isocaproate, alpha-keto-beta methylisovalerate, alpha-keto isovalerate)
    n1=en:hyperintense | n2=en:branched chain ketoaciduria (alpha-keto isocaproate, alpha-keto-beta methylisovalerate, alpha-keto isovalerate) | rel=r_associated | relid=0 | w=10
  290. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:breastfed offspring have transient decrease of plasma zinc levels
    n1=en:hyperintense | n2=en:breastfed offspring have transient decrease of plasma zinc levels | rel=r_associated | relid=0 | w=10
  291. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:broad tissue deposition of amylopectin-like material
    n1=en:hyperintense | n2=en:broad tissue deposition of amylopectin-like material | rel=r_associated | relid=0 | w=10
  292. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:Brocq's bullous erythroderma ichthyosiformis congenita
    n1=en:hyperintense | n2=en:Brocq's bullous erythroderma ichthyosiformis congenita | rel=r_associated | relid=0 | w=10
  293. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:bromosulfophthalein test - secondary rise at 90 minutes
    n1=en:hyperintense | n2=en:bromosulfophthalein test - secondary rise at 90 minutes | rel=r_associated | relid=0 | w=10
  294. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:bullous congenital ichthyosiform erythroderma
    n1=en:hyperintense | n2=en:bullous congenital ichthyosiform erythroderma | rel=r_associated | relid=0 | w=10
  295. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:bullous ichthyosiform hyperkeratosis
    n1=en:hyperintense | n2=en:bullous ichthyosiform hyperkeratosis | rel=r_associated | relid=0 | w=10
  296. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:bullous ichthyosis
    n1=en:hyperintense | n2=en:bullous ichthyosis | rel=r_associated | relid=0 | w=10
  297. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:c-band karyotype shows 'railroad track' appearance
    n1=en:hyperintense | n2=en:c-band karyotype shows 'railroad track' appearance | rel=r_associated | relid=0 | w=10
  298. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:calcium metabolism
    n1=en:hyperintense | n2=en:calcium metabolism | rel=r_associated | relid=0 | w=10
  299. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:calcium normal
    n1=en:hyperintense | n2=en:calcium normal | rel=r_associated | relid=0 | w=10
  300. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:calciuria
    n1=en:hyperintense | n2=en:calciuria | rel=r_associated | relid=0 | w=10
  301. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cardiac enzyme elevation
    n1=en:hyperintense | n2=en:cardiac enzyme elevation | rel=r_associated | relid=0 | w=10
  302. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:carnitine deficiency
    n1=en:hyperintense | n2=en:carnitine deficiency | rel=r_associated | relid=0 | w=10
  303. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:carnitine palmitoyltransferase i deficiency (fibroblast, liver, leukocytes)
    n1=en:hyperintense | n2=en:carnitine palmitoyltransferase i deficiency (fibroblast, liver, leukocytes) | rel=r_associated | relid=0 | w=10
  304. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:carnitine palmitoyltransferase ii deficiency (25% of controls)
    n1=en:hyperintense | n2=en:carnitine palmitoyltransferase ii deficiency (25% of controls) | rel=r_associated | relid=0 | w=10
  305. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:carotenemia
    n1=en:hyperintense | n2=en:carotenemia | rel=r_associated | relid=0 | w=10
  306. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:carriers have balanced constitutional translocation - 46,xx(or xy), +(11:22)(q23:q11)
    n1=en:hyperintense | n2=en:carriers have balanced constitutional translocation - 46,xx(or xy), +(11:22)(q23:q11) | rel=r_associated | relid=0 | w=10
  307. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:caused by mutation in the keratin 1 gene (krt1, 139350.0001)
    n1=en:hyperintense | n2=en:caused by mutation in the keratin 1 gene (krt1, 139350.0001) | rel=r_associated | relid=0 | w=10
  308. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:caused by mutation in the keratin 10 gene (krt10, 148080.0001)
    n1=en:hyperintense | n2=en:caused by mutation in the keratin 10 gene (krt10, 148080.0001) | rel=r_associated | relid=0 | w=10
  309. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cd4/cd8 ratio decreased
    n1=en:hyperintense | n2=en:cd4/cd8 ratio decreased | rel=r_associated | relid=0 | w=10
  310. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cd4+/cd8+ ratio is reversed
    n1=en:hyperintense | n2=en:cd4+/cd8+ ratio is reversed | rel=r_associated | relid=0 | w=10
  311. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cd4+/cd8+ ratio often reversed
    n1=en:hyperintense | n2=en:cd4+/cd8+ ratio often reversed | rel=r_associated | relid=0 | w=10
  312. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cell studies show increased dna breakage
    n1=en:hyperintense | n2=en:cell studies show increased dna breakage | rel=r_associated | relid=0 | w=10
  313. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cells show defective transcription-coupled nucleotide excision repair (tc-ner) after uv irradiation
    n1=en:hyperintense | n2=en:cells show defective transcription-coupled nucleotide excision repair (tc-ner) after uv irradiation | rel=r_associated | relid=0 | w=10
  314. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cells show increased sensitivity to ionizing radiation
    n1=en:hyperintense | n2=en:cells show increased sensitivity to ionizing radiation | rel=r_associated | relid=0 | w=10
  315. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cellular arrest at g2 of the cell cycle
    n1=en:hyperintense | n2=en:cellular arrest at g2 of the cell cycle | rel=r_associated | relid=0 | w=10
  316. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cerebrospinal fluid lymphocytosis
    n1=en:hyperintense | n2=en:cerebrospinal fluid lymphocytosis | rel=r_associated | relid=0 | w=10
  317. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cerebrospinal fluid oligoclonal bands
    n1=en:hyperintense | n2=en:cerebrospinal fluid oligoclonal bands | rel=r_associated | relid=0 | w=10
  318. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ceruloplasmin decreased
    n1=en:hyperintense | n2=en:ceruloplasmin decreased | rel=r_associated | relid=0 | w=10
  319. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:characteristic spheroids can be found in peripheral tissue, such as skin and conjunctiva
    n1=en:hyperintense | n2=en:characteristic spheroids can be found in peripheral tissue, such as skin and conjunctiva | rel=r_associated | relid=0 | w=10
  320. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:characteristic urinary coproporphyrin pattern (mostly isomer i (80%) instead of isomer iii)
    n1=en:hyperintense | n2=en:characteristic urinary coproporphyrin pattern (mostly isomer i (80%) instead of isomer iii) | rel=r_associated | relid=0 | w=10
  321. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chemically induced
    n1=en:hyperintense | n2=en:chemically induced | rel=r_associated | relid=0 | w=10
  322. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cholesteatoma
    n1=en:hyperintense | n2=en:cholesteatoma | rel=r_associated | relid=0 | w=10
  323. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cholesterol low
    n1=en:hyperintense | n2=en:cholesterol low | rel=r_associated | relid=0 | w=10
  324. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cholesterol normal
    n1=en:hyperintense | n2=en:cholesterol normal | rel=r_associated | relid=0 | w=10
  325. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chondroitin 4-, 6-sulfate excretion in urine
    n1=en:hyperintense | n2=en:chondroitin 4-, 6-sulfate excretion in urine | rel=r_associated | relid=0 | w=10
  326. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chondroitin 6-sulfate excretion in urine
    n1=en:hyperintense | n2=en:chondroitin 6-sulfate excretion in urine | rel=r_associated | relid=0 | w=10
  327. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chromosomal breakage and abnormalities of the juxtacentromeric regions of chromosomes 1, 9, and 16
    n1=en:hyperintense | n2=en:chromosomal breakage and abnormalities of the juxtacentromeric regions of chromosomes 1, 9, and 16 | rel=r_associated | relid=0 | w=10
  328. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chromosomal instability
    n1=en:hyperintense | n2=en:chromosomal instability | rel=r_associated | relid=0 | w=10
  329. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chromosomal mosaicism in cultured cells
    n1=en:hyperintense | n2=en:chromosomal mosaicism in cultured cells | rel=r_associated | relid=0 | w=10
  330. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chromosomal mosaicism in fibroblast and/or peripheral lymphocytes no consistent karyotypic finding
    n1=en:hyperintense | n2=en:chromosomal mosaicism in fibroblast and/or peripheral lymphocytes no consistent karyotypic finding | rel=r_associated | relid=0 | w=10
  331. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chromosomal rearrangement
    n1=en:hyperintense | n2=en:chromosomal rearrangement | rel=r_associated | relid=0 | w=10
  332. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chromosomal translocations involving c-myc (190080, 8q24) and the immunoglobin heavy chain (147100, 14q32) locus
    n1=en:hyperintense | n2=en:chromosomal translocations involving c-myc (190080, 8q24) and the immunoglobin heavy chain (147100, 14q32) locus | rel=r_associated | relid=0 | w=10
  333. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chromosomal translocations involving c-myc (190080, 8q24) and the immunoglobin kappa light chain (147200, 2p12) locus
    n1=en:hyperintense | n2=en:chromosomal translocations involving c-myc (190080, 8q24) and the immunoglobin kappa light chain (147200, 2p12) locus | rel=r_associated | relid=0 | w=10
  334. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chromosomal translocations involving c-myc (190080, 8q24) and the immunoglobin lambda light chain (147220, 22q11.2) locus
    n1=en:hyperintense | n2=en:chromosomal translocations involving c-myc (190080, 8q24) and the immunoglobin lambda light chain (147220, 22q11.2) locus | rel=r_associated | relid=0 | w=10
  335. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chromosome 11q23.3 deletion
    n1=en:hyperintense | n2=en:chromosome 11q23.3 deletion | rel=r_associated | relid=0 | w=10
  336. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chromosome deletion extending from 8q24.11 to 8q24.13
    n1=en:hyperintense | n2=en:chromosome deletion extending from 8q24.11 to 8q24.13 | rel=r_associated | relid=0 | w=10
  337. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chromosome instability (hypo-/hyperdiploidy, chromosomal breaks, premature centromere division)
    n1=en:hyperintense | n2=en:chromosome instability (hypo-/hyperdiploidy, chromosomal breaks, premature centromere division) | rel=r_associated | relid=0 | w=10
  338. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chromosome inversion - inv2(p12q14) in 2 patients
    n1=en:hyperintense | n2=en:chromosome inversion - inv2(p12q14) in 2 patients | rel=r_associated | relid=0 | w=10
  339. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chronic hypercapnia
    n1=en:hyperintense | n2=en:chronic hypercapnia | rel=r_associated | relid=0 | w=10
  340. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chronic hyperkalemia
    n1=en:hyperintense | n2=en:chronic hyperkalemia | rel=r_associated | relid=0 | w=10
  341. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chronic hyperkaliemia
    n1=en:hyperintense | n2=en:chronic hyperkaliemia | rel=r_associated | relid=0 | w=10
  342. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chronic hypoxemia
    n1=en:hyperintense | n2=en:chronic hypoxemia | rel=r_associated | relid=0 | w=10
  343. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:chylomicronemia, refractory fasting
    n1=en:hyperintense | n2=en:chylomicronemia, refractory fasting | rel=r_associated | relid=0 | w=10
  344. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cilia may also be static, with slow activity
    n1=en:hyperintense | n2=en:cilia may also be static, with slow activity | rel=r_associated | relid=0 | w=10
  345. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cilia show inner and outer dynein arm defects
    n1=en:hyperintense | n2=en:cilia show inner and outer dynein arm defects | rel=r_associated | relid=0 | w=10
  346. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cilia show nonflexible and hyperkinetic beating of axonemes
    n1=en:hyperintense | n2=en:cilia show nonflexible and hyperkinetic beating of axonemes | rel=r_associated | relid=0 | w=10
  347. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:circumungual hyperkeratosis
    n1=en:hyperintense | n2=en:circumungual hyperkeratosis | rel=r_associated | relid=0 | w=10
  348. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:citric acid
    n1=en:hyperintense | n2=en:citric acid | rel=r_associated | relid=0 | w=10
  349. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:citric acid granules
    n1=en:hyperintense | n2=en:citric acid granules | rel=r_associated | relid=0 | w=10
  350. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:citric acid monohydrate
    n1=en:hyperintense | n2=en:citric acid monohydrate | rel=r_associated | relid=0 | w=10
  351. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:citric acid,hydrous
    n1=en:hyperintense | n2=en:citric acid,hydrous | rel=r_associated | relid=0 | w=10
  352. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:citrullinemia
    n1=en:hyperintense | n2=en:citrullinemia | rel=r_associated | relid=0 | w=10
  353. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:citrus naringinine
    n1=en:hyperintense | n2=en:citrus naringinine | rel=r_associated | relid=0 | w=10
  354. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:coagulopathy (inr = 2.2 - 3.5)
    n1=en:hyperintense | n2=en:coagulopathy (inr = 2.2 - 3.5) | rel=r_associated | relid=0 | w=10
  355. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:coarse metachromatic granules in white blood cells
    n1=en:hyperintense | n2=en:coarse metachromatic granules in white blood cells | rel=r_associated | relid=0 | w=10
  356. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:complex organic aciduria
    n1=en:hyperintense | n2=en:complex organic aciduria | rel=r_associated | relid=0 | w=10
  357. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:complication aspects
    n1=en:hyperintense | n2=en:complication aspects | rel=r_associated | relid=0 | w=10
  358. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:confluent and reticulate papillomatosis
    n1=en:hyperintense | n2=en:confluent and reticulate papillomatosis | rel=r_associated | relid=0 | w=10
  359. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:congenital
    n1=en:hyperintense | n2=en:congenital | rel=r_associated | relid=0 | w=10
  360. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:congenital abnormality
    n1=en:hyperintense | n2=en:congenital abnormality | rel=r_associated | relid=0 | w=10
  361. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:congenital ichthyosiform erythroderma, dry type
    n1=en:hyperintense | n2=en:congenital ichthyosiform erythroderma, dry type | rel=r_associated | relid=0 | w=10
  362. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:congenital ichthyosiform erythroderma, wet type
    n1=en:hyperintense | n2=en:congenital ichthyosiform erythroderma, wet type | rel=r_associated | relid=0 | w=10
  363. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:congenital ichthyosis
    n1=en:hyperintense | n2=en:congenital ichthyosis | rel=r_associated | relid=0 | w=10
  364. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:congenital mesh qualifier
    n1=en:hyperintense | n2=en:congenital mesh qualifier | rel=r_associated | relid=0 | w=10
  365. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:congenital reticular ichthyosiform erythroderma
    n1=en:hyperintense | n2=en:congenital reticular ichthyosiform erythroderma | rel=r_associated | relid=0 | w=10
  366. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:contiguous gene deletion syndrome
    n1=en:hyperintense | n2=en:contiguous gene deletion syndrome | rel=r_associated | relid=0 | w=10
  367. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:continuous urinary iodine loss
    n1=en:hyperintense | n2=en:continuous urinary iodine loss | rel=r_associated | relid=0 | w=10
  368. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:coombs positive hemolytic anemia
    n1=en:hyperintense | n2=en:coombs positive hemolytic anemia | rel=r_associated | relid=0 | w=10
  369. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:corn
    n1=en:hyperintense | n2=en:corn | rel=r_associated | relid=0 | w=10
  370. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:corns and callus
    n1=en:hyperintense | n2=en:corns and callus | rel=r_associated | relid=0 | w=10
  371. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:corticosterone methyl oxidase type ii deficiency
    n1=en:hyperintense | n2=en:corticosterone methyl oxidase type ii deficiency | rel=r_associated | relid=0 | w=10
  372. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cortisol does not decrease on dexamethasone suppression test
    n1=en:hyperintense | n2=en:cortisol does not decrease on dexamethasone suppression test | rel=r_associated | relid=0 | w=10
  373. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:creatine decreased
    n1=en:hyperintense | n2=en:creatine decreased | rel=r_associated | relid=0 | w=10
  374. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:creatine kinase levels may normalize with disease progression
    n1=en:hyperintense | n2=en:creatine kinase levels may normalize with disease progression | rel=r_associated | relid=0 | w=10
  375. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:creatine kinase normal between episodes
    n1=en:hyperintense | n2=en:creatine kinase normal between episodes | rel=r_associated | relid=0 | w=10
  376. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:creatine phosphokinase increased
    n1=en:hyperintense | n2=en:creatine phosphokinase increased | rel=r_associated | relid=0 | w=10
  377. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:creatine phosphokinase serum increased
    n1=en:hyperintense | n2=en:creatine phosphokinase serum increased | rel=r_associated | relid=0 | w=10
  378. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cryohydrocytosis, stomatin-deficient, with mental retardation, seizures, cataracts, and massive hepatosplenomegaly
    n1=en:hyperintense | n2=en:cryohydrocytosis, stomatin-deficient, with mental retardation, seizures, cataracts, and massive hepatosplenomegaly | rel=r_associated | relid=0 | w=10
  379. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:csf pleocytosis, particularly of lymphocytes
    n1=en:hyperintense | n2=en:csf pleocytosis, particularly of lymphocytes | rel=r_associated | relid=0 | w=10
  380. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:curvilinear intracellular accumulation of autofluorescent lipopigment storage material
    n1=en:hyperintense | n2=en:curvilinear intracellular accumulation of autofluorescent lipopigment storage material | rel=r_associated | relid=0 | w=10
  381. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cutaneous anergy
    n1=en:hyperintense | n2=en:cutaneous anergy | rel=r_associated | relid=0 | w=10
  382. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cutaneous horn
    n1=en:hyperintense | n2=en:cutaneous horn | rel=r_associated | relid=0 | w=10
  383. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cutaneous horn of eyelid
    n1=en:hyperintense | n2=en:cutaneous horn of eyelid | rel=r_associated | relid=0 | w=10
  384. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cutaneous syndrome with ichthyosis
    n1=en:hyperintense | n2=en:cutaneous syndrome with ichthyosis | rel=r_associated | relid=0 | w=10
  385. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cystathionine beta-synthase deficiency disease
    n1=en:hyperintense | n2=en:cystathionine beta-synthase deficiency disease | rel=r_associated | relid=0 | w=10
  386. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cystathioninemia
    n1=en:hyperintense | n2=en:cystathioninemia | rel=r_associated | relid=0 | w=10
  387. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cystathioninuria (lab finding)
    n1=en:hyperintense | n2=en:cystathioninuria (lab finding) | rel=r_associated | relid=0 | w=10
  388. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cytochrome c oxidase deficiency in skeletal muscle and brain
    n1=en:hyperintense | n2=en:cytochrome c oxidase deficiency in skeletal muscle and brain | rel=r_associated | relid=0 | w=10
  389. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cytogenetic breakpoints range from 10q23.3-q26.2
    n1=en:hyperintense | n2=en:cytogenetic breakpoints range from 10q23.3-q26.2 | rel=r_associated | relid=0 | w=10
  390. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cytogenetic deletion of chromosome 17p13.3
    n1=en:hyperintense | n2=en:cytogenetic deletion of chromosome 17p13.3 | rel=r_associated | relid=0 | w=10
  391. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cytogenetic deletion of chromosome 19q13
    n1=en:hyperintense | n2=en:cytogenetic deletion of chromosome 19q13 | rel=r_associated | relid=0 | w=10
  392. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cytogenetic deletion of the terminal region of chromosome 10 (del(10)(q23.3-qter))
    n1=en:hyperintense | n2=en:cytogenetic deletion of the terminal region of chromosome 10 (del(10)(q23.3-qter)) | rel=r_associated | relid=0 | w=10
  393. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cytogenetics - recombinant chromosome 8 characterized by duplication of 8q22.1-qter and deletion of 8pter-p23.1
    n1=en:hyperintense | n2=en:cytogenetics - recombinant chromosome 8 characterized by duplication of 8q22.1-qter and deletion of 8pter-p23.1 | rel=r_associated | relid=0 | w=10
  394. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cytoplasmic lamellar concentric inclusions
    n1=en:hyperintense | n2=en:cytoplasmic lamellar concentric inclusions | rel=r_associated | relid=0 | w=10
  395. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cytoplasmic lamellar inclusions consistent with neuronal ceroid lipofuscinosis (in some patients)
    n1=en:hyperintense | n2=en:cytoplasmic lamellar inclusions consistent with neuronal ceroid lipofuscinosis (in some patients) | rel=r_associated | relid=0 | w=10
  396. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:cytosolic phosphoenolpyruvate carboxykinase deficiency
    n1=en:hyperintense | n2=en:cytosolic phosphoenolpyruvate carboxykinase deficiency | rel=r_associated | relid=0 | w=10
  397. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:d-2-hydroxyglutaric aciduria
    n1=en:hyperintense | n2=en:d-2-hydroxyglutaric aciduria | rel=r_associated | relid=0 | w=10
  398. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:darier disease
    n1=en:hyperintense | n2=en:darier disease | rel=r_associated | relid=0 | w=10
  399. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decrease or absence of cathepsin d (ctsd) protein immunostaining
    n1=en:hyperintense | n2=en:decrease or absence of cathepsin d (ctsd) protein immunostaining | rel=r_associated | relid=0 | w=10
  400. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decrease plasma serine (fasting)
    n1=en:hyperintense | n2=en:decrease plasma serine (fasting) | rel=r_associated | relid=0 | w=10
  401. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased 3-beta-hydroxysteroid-delta-5-desaturase (sc5d)
    n1=en:hyperintense | n2=en:decreased 3-beta-hydroxysteroid-delta-5-desaturase (sc5d) | rel=r_associated | relid=0 | w=10
  402. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased 5-hydroxyindoleacetic acid (5-hiaa) in csf
    n1=en:hyperintense | n2=en:decreased 5-hydroxyindoleacetic acid (5-hiaa) in csf | rel=r_associated | relid=0 | w=10
  403. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased acetyl-coa carboxylase activity
    n1=en:hyperintense | n2=en:decreased acetyl-coa carboxylase activity | rel=r_associated | relid=0 | w=10
  404. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased acid beta galactosidase protein and activity
    n1=en:hyperintense | n2=en:decreased acid beta galactosidase protein and activity | rel=r_associated | relid=0 | w=10
  405. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased acid sphingomyelinase activity
    n1=en:hyperintense | n2=en:decreased acid sphingomyelinase activity | rel=r_associated | relid=0 | w=10
  406. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased acid sphingomyelinase activity (less than 5%)
    n1=en:hyperintense | n2=en:decreased acid sphingomyelinase activity (less than 5%) | rel=r_associated | relid=0 | w=10
  407. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activities of multiple sulfatases
    n1=en:hyperintense | n2=en:decreased activities of multiple sulfatases | rel=r_associated | relid=0 | w=10
  408. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activities of the pyruvate dehydrogenase complex, the alpha-ketoglutarate dehydrogenase complex, and the branched-chain alpha-keto acid dehydrogenase complex
    n1=en:hyperintense | n2=en:decreased activities of the pyruvate dehydrogenase complex, the alpha-ketoglutarate dehydrogenase complex, and the branched-chain alpha-keto acid dehydrogenase complex | rel=r_associated | relid=0 | w=10
  409. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of 2-methyl-3-hydroxybutyryl co-a dehydrogenase
    n1=en:hyperintense | n2=en:decreased activity of 2-methyl-3-hydroxybutyryl co-a dehydrogenase | rel=r_associated | relid=0 | w=10
  410. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of 2-oxoacid dehydrogenases
    n1=en:hyperintense | n2=en:decreased activity of 2-oxoacid dehydrogenases | rel=r_associated | relid=0 | w=10
  411. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of 3-hydroxyacyl-coa dehydrogenase in various tissues (liver, muscle, fibroblasts)
    n1=en:hyperintense | n2=en:decreased activity of 3-hydroxyacyl-coa dehydrogenase in various tissues (liver, muscle, fibroblasts) | rel=r_associated | relid=0 | w=10
  412. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of 3-methylcrotonyl-coa carboxylase (less than 2%)
    n1=en:hyperintense | n2=en:decreased activity of 3-methylcrotonyl-coa carboxylase (less than 2%) | rel=r_associated | relid=0 | w=10
  413. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of 3-methylglutaconyl-coa hydratase
    n1=en:hyperintense | n2=en:decreased activity of 3-methylglutaconyl-coa hydratase | rel=r_associated | relid=0 | w=10
  414. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of ampd1 in skeletal muscle increased serum creatine kinase
    n1=en:hyperintense | n2=en:decreased activity of ampd1 in skeletal muscle increased serum creatine kinase | rel=r_associated | relid=0 | w=10
  415. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of aromatic l-amino acid decarboxylase (aadc)
    n1=en:hyperintense | n2=en:decreased activity of aromatic l-amino acid decarboxylase (aadc) | rel=r_associated | relid=0 | w=10
  416. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of coenzyme q10-dependent respiratory chain complexes
    n1=en:hyperintense | n2=en:decreased activity of coenzyme q10-dependent respiratory chain complexes | rel=r_associated | relid=0 | w=10
  417. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of complement factor d
    n1=en:hyperintense | n2=en:decreased activity of complement factor d | rel=r_associated | relid=0 | w=10
  418. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of cytochrome c oxidase in muscle and fibroblasts
    n1=en:hyperintense | n2=en:decreased activity of cytochrome c oxidase in muscle and fibroblasts | rel=r_associated | relid=0 | w=10
  419. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of cytosolic acetoacetyl-coa thiolase (acat2, 100678)
    n1=en:hyperintense | n2=en:decreased activity of cytosolic acetoacetyl-coa thiolase (acat2, 100678) | rel=r_associated | relid=0 | w=10
  420. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of dihydrofolate reductase
    n1=en:hyperintense | n2=en:decreased activity of dihydrofolate reductase | rel=r_associated | relid=0 | w=10
  421. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of galactocerebrosidase
    n1=en:hyperintense | n2=en:decreased activity of galactocerebrosidase | rel=r_associated | relid=0 | w=10
  422. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of glycosylceramidase, galactosylceramidase, ceramidase, and other lysosomal enzymes
    n1=en:hyperintense | n2=en:decreased activity of glycosylceramidase, galactosylceramidase, ceramidase, and other lysosomal enzymes | rel=r_associated | relid=0 | w=10
  423. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of long-chain 3-hydroxyacyl-coa dehydrogenase, long-chain 3-oxoacyl-coa thiolase, and long-chain 2-enoyl-coa hydratase
    n1=en:hyperintense | n2=en:decreased activity of long-chain 3-hydroxyacyl-coa dehydrogenase, long-chain 3-oxoacyl-coa thiolase, and long-chain 2-enoyl-coa hydratase | rel=r_associated | relid=0 | w=10
  424. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of mitochondrial complex i
    n1=en:hyperintense | n2=en:decreased activity of mitochondrial complex i | rel=r_associated | relid=0 | w=10
  425. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of mitochondrial complex ii (succinate dehydrogenase)
    n1=en:hyperintense | n2=en:decreased activity of mitochondrial complex ii (succinate dehydrogenase) | rel=r_associated | relid=0 | w=10
  426. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of mitochondrial respiratory chain complex i
    n1=en:hyperintense | n2=en:decreased activity of mitochondrial respiratory chain complex i | rel=r_associated | relid=0 | w=10
  427. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of mitochondrial respiratory complexes
    n1=en:hyperintense | n2=en:decreased activity of mitochondrial respiratory complexes | rel=r_associated | relid=0 | w=10
  428. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of mitochondrial respiratory complexes i, ii+iii, iv, and v
    n1=en:hyperintense | n2=en:decreased activity of mitochondrial respiratory complexes i, ii+iii, iv, and v | rel=r_associated | relid=0 | w=10
  429. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of mitochondrial respiratory complexes i, iii, and iv
    n1=en:hyperintense | n2=en:decreased activity of mitochondrial respiratory complexes i, iii, and iv | rel=r_associated | relid=0 | w=10
  430. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of nadph oxidase
    n1=en:hyperintense | n2=en:decreased activity of nadph oxidase | rel=r_associated | relid=0 | w=10
  431. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of phosphoglycerate kinase 1
    n1=en:hyperintense | n2=en:decreased activity of phosphoglycerate kinase 1 | rel=r_associated | relid=0 | w=10
  432. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of ppt1
    n1=en:hyperintense | n2=en:decreased activity of ppt1 | rel=r_associated | relid=0 | w=10
  433. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of pyruvate decarboxylase (e1 component)
    n1=en:hyperintense | n2=en:decreased activity of pyruvate decarboxylase (e1 component) | rel=r_associated | relid=0 | w=10
  434. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of pyruvate dehydrogenase complex
    n1=en:hyperintense | n2=en:decreased activity of pyruvate dehydrogenase complex | rel=r_associated | relid=0 | w=10
  435. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of succinic semialdehyde dehydrogenase (ssadh, aldh5a1), less than 5% of control values
    n1=en:hyperintense | n2=en:decreased activity of succinic semialdehyde dehydrogenase (ssadh, aldh5a1), less than 5% of control values | rel=r_associated | relid=0 | w=10
  436. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of the e2 subunit (lipoyl transacetylase, 608770) of the pdh
    n1=en:hyperintense | n2=en:decreased activity of the e2 subunit (lipoyl transacetylase, 608770) of the pdh | rel=r_associated | relid=0 | w=10
  437. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of the pdh phosphatase
    n1=en:hyperintense | n2=en:decreased activity of the pdh phosphatase | rel=r_associated | relid=0 | w=10
  438. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of the pyruvate dehydrogenase (pdh) complex
    n1=en:hyperintense | n2=en:decreased activity of the pyruvate dehydrogenase (pdh) complex | rel=r_associated | relid=0 | w=10
  439. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of the pyruvate dehydrogenase complex (highly variable, 1-70% of controls)
    n1=en:hyperintense | n2=en:decreased activity of the pyruvate dehydrogenase complex (highly variable, 1-70% of controls) | rel=r_associated | relid=0 | w=10
  440. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of thiopurine s-methyltransferase
    n1=en:hyperintense | n2=en:decreased activity of thiopurine s-methyltransferase | rel=r_associated | relid=0 | w=10
  441. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of thymidine phosphorylase
    n1=en:hyperintense | n2=en:decreased activity of thymidine phosphorylase | rel=r_associated | relid=0 | w=10
  442. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of triosephosphate isomerase
    n1=en:hyperintense | n2=en:decreased activity of triosephosphate isomerase | rel=r_associated | relid=0 | w=10
  443. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased activity of tyrosine hydroxylase
    n1=en:hyperintense | n2=en:decreased activity of tyrosine hydroxylase | rel=r_associated | relid=0 | w=10
  444. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased adenosylcobalamin
    n1=en:hyperintense | n2=en:decreased adenosylcobalamin | rel=r_associated | relid=0 | w=10
  445. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased adiponectin
    n1=en:hyperintense | n2=en:decreased adiponectin | rel=r_associated | relid=0 | w=10
  446. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased agt activity
    n1=en:hyperintense | n2=en:decreased agt activity | rel=r_associated | relid=0 | w=10
  447. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased alpha-n-acetylgalactosaminidase activity (less than 2% of control)
    n1=en:hyperintense | n2=en:decreased alpha-n-acetylgalactosaminidase activity (less than 2% of control) | rel=r_associated | relid=0 | w=10
  448. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased alpha-n-acetylgalactosaminidase protein
    n1=en:hyperintense | n2=en:decreased alpha-n-acetylgalactosaminidase protein | rel=r_associated | relid=0 | w=10
  449. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased aminoacylase-1 activity
    n1=en:hyperintense | n2=en:decreased aminoacylase-1 activity | rel=r_associated | relid=0 | w=10
  450. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased amount and activity of mitochondrial complexes i and iv
    n1=en:hyperintense | n2=en:decreased amount and activity of mitochondrial complexes i and iv | rel=r_associated | relid=0 | w=10
  451. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased antithrombin iii (rare)
    n1=en:hyperintense | n2=en:decreased antithrombin iii (rare) | rel=r_associated | relid=0 | w=10
  452. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased apoa-i and apoa-ii
    n1=en:hyperintense | n2=en:decreased apoa-i and apoa-ii | rel=r_associated | relid=0 | w=10
  453. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased arylsulfatase a (arsa) activity in urine, leukocytes, fibroblasts
    n1=en:hyperintense | n2=en:decreased arylsulfatase a (arsa) activity in urine, leukocytes, fibroblasts | rel=r_associated | relid=0 | w=10
  454. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased asparagine levels (in some patients)
    n1=en:hyperintense | n2=en:decreased asparagine levels (in some patients) | rel=r_associated | relid=0 | w=10
  455. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased atp synthase in muscle, heart, liver, and brain
    n1=en:hyperintense | n2=en:decreased atp synthase in muscle, heart, liver, and brain | rel=r_associated | relid=0 | w=10
  456. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased axonal flare response after intradermal histamine injection
    n1=en:hyperintense | n2=en:decreased axonal flare response after intradermal histamine injection | rel=r_associated | relid=0 | w=10
  457. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased b cells
    n1=en:hyperintense | n2=en:decreased b cells | rel=r_associated | relid=0 | w=10
  458. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased beta-galactosidase activity
    n1=en:hyperintense | n2=en:decreased beta-galactosidase activity | rel=r_associated | relid=0 | w=10
  459. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased beta-glucocerebrosidase protein and activity
    n1=en:hyperintense | n2=en:decreased beta-glucocerebrosidase protein and activity | rel=r_associated | relid=0 | w=10
  460. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased beta-glucosidase protein and activity
    n1=en:hyperintense | n2=en:decreased beta-glucosidase protein and activity | rel=r_associated | relid=0 | w=10
  461. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased beta-mannosidase activity in plasma, fibroblasts, and leukocytes
    n1=en:hyperintense | n2=en:decreased beta-mannosidase activity in plasma, fibroblasts, and leukocytes | rel=r_associated | relid=0 | w=10
  462. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased beta-oxidation of pristanic acid
    n1=en:hyperintense | n2=en:decreased beta-oxidation of pristanic acid | rel=r_associated | relid=0 | w=10
  463. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased beta-thromboglobulin
    n1=en:hyperintense | n2=en:decreased beta-thromboglobulin | rel=r_associated | relid=0 | w=10
  464. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased blood levels of cationic amino acids
    n1=en:hyperintense | n2=en:decreased blood levels of cationic amino acids | rel=r_associated | relid=0 | w=10
  465. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased c3 activity
    n1=en:hyperintense | n2=en:decreased c3 activity | rel=r_associated | relid=0 | w=10
  466. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased c3 antigen
    n1=en:hyperintense | n2=en:decreased c3 antigen | rel=r_associated | relid=0 | w=10
  467. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased carnitine in serum, muscle, heart, and liver
    n1=en:hyperintense | n2=en:decreased carnitine in serum, muscle, heart, and liver | rel=r_associated | relid=0 | w=10
  468. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased carnitine palmitoyltransferase ii (cpt2) activity
    n1=en:hyperintense | n2=en:decreased carnitine palmitoyltransferase ii (cpt2) activity | rel=r_associated | relid=0 | w=10
  469. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased cerebrospinal fluid folic acid
    n1=en:hyperintense | n2=en:decreased cerebrospinal fluid folic acid | rel=r_associated | relid=0 | w=10
  470. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased cholesterol (less common)
    n1=en:hyperintense | n2=en:decreased cholesterol (less common) | rel=r_associated | relid=0 | w=10
  471. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased ciliary motility
    n1=en:hyperintense | n2=en:decreased ciliary motility | rel=r_associated | relid=0 | w=10
  472. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased circulating aldosterone level
    n1=en:hyperintense | n2=en:decreased circulating aldosterone level | rel=r_associated | relid=0 | w=10
  473. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased circulating cortisol level
    n1=en:hyperintense | n2=en:decreased circulating cortisol level | rel=r_associated | relid=0 | w=10
  474. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased circulating renin level
    n1=en:hyperintense | n2=en:decreased circulating renin level | rel=r_associated | relid=0 | w=10
  475. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased clot retraction
    n1=en:hyperintense | n2=en:decreased clot retraction | rel=r_associated | relid=0 | w=10
  476. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased cobalamin in liver, kidney, and cultured fibroblasts
    n1=en:hyperintense | n2=en:decreased cobalamin in liver, kidney, and cultured fibroblasts | rel=r_associated | relid=0 | w=10
  477. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased complement factor d
    n1=en:hyperintense | n2=en:decreased complement factor d | rel=r_associated | relid=0 | w=10
  478. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased conversion of beta-carotene to vitamin a (retinol)
    n1=en:hyperintense | n2=en:decreased conversion of beta-carotene to vitamin a (retinol) | rel=r_associated | relid=0 | w=10
  479. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased copper, iron, zinc
    n1=en:hyperintense | n2=en:decreased copper, iron, zinc | rel=r_associated | relid=0 | w=10
  480. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased coproporphyrinogen oxidase activity (hcp, lymphocytes, 50% of normal)
    n1=en:hyperintense | n2=en:decreased coproporphyrinogen oxidase activity (hcp, lymphocytes, 50% of normal) | rel=r_associated | relid=0 | w=10
  481. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased coq10 levels in lymphoblasts or fibroblasts
    n1=en:hyperintense | n2=en:decreased coq10 levels in lymphoblasts or fibroblasts | rel=r_associated | relid=0 | w=10
  482. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased cortisol-binding globulin
    n1=en:hyperintense | n2=en:decreased cortisol-binding globulin | rel=r_associated | relid=0 | w=10
  483. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased cpt1 activity
    n1=en:hyperintense | n2=en:decreased cpt1 activity | rel=r_associated | relid=0 | w=10
  484. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased csf 3-methoxy-4-hydroxyphenylethyleneglycol (mhpg)
    n1=en:hyperintense | n2=en:decreased csf 3-methoxy-4-hydroxyphenylethyleneglycol (mhpg) | rel=r_associated | relid=0 | w=10
  485. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased csf 5-hydroxyindoleacetic acid (5-hiaa)
    n1=en:hyperintense | n2=en:decreased csf 5-hydroxyindoleacetic acid (5-hiaa) | rel=r_associated | relid=0 | w=10
  486. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased csf 5-hydroxyindoleacetic acid (5hiaa)
    n1=en:hyperintense | n2=en:decreased csf 5-hydroxyindoleacetic acid (5hiaa) | rel=r_associated | relid=0 | w=10
  487. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased csf arginine
    n1=en:hyperintense | n2=en:decreased csf arginine | rel=r_associated | relid=0 | w=10
  488. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased csf ferritin despite normal serum ferritin levels
    n1=en:hyperintense | n2=en:decreased csf ferritin despite normal serum ferritin levels | rel=r_associated | relid=0 | w=10
  489. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased csf folate
    n1=en:hyperintense | n2=en:decreased csf folate | rel=r_associated | relid=0 | w=10
  490. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased csf glycine
    n1=en:hyperintense | n2=en:decreased csf glycine | rel=r_associated | relid=0 | w=10
  491. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased csf homovanillic acid (hva)
    n1=en:hyperintense | n2=en:decreased csf homovanillic acid (hva) | rel=r_associated | relid=0 | w=10
  492. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased csf hypocretin
    n1=en:hyperintense | n2=en:decreased csf hypocretin | rel=r_associated | relid=0 | w=10
  493. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased csf methyltetrahydrofolate (mthf)
    n1=en:hyperintense | n2=en:decreased csf methyltetrahydrofolate (mthf) | rel=r_associated | relid=0 | w=10
  494. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased csf pyridoxal
    n1=en:hyperintense | n2=en:decreased csf pyridoxal | rel=r_associated | relid=0 | w=10
  495. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased csf pyridoxal 5-prime-phosphate (plp)
    n1=en:hyperintense | n2=en:decreased csf pyridoxal 5-prime-phosphate (plp) | rel=r_associated | relid=0 | w=10
  496. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased csf serine
    n1=en:hyperintense | n2=en:decreased csf serine | rel=r_associated | relid=0 | w=10
  497. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased csf tetrahydrofolate and 5-methyltetrahydrofolate
    n1=en:hyperintense | n2=en:decreased csf tetrahydrofolate and 5-methyltetrahydrofolate | rel=r_associated | relid=0 | w=10
  498. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased cytochrome c oxidase activity in skin fibroblasts, liver, and skeletal muscle
    n1=en:hyperintense | n2=en:decreased cytochrome c oxidase activity in skin fibroblasts, liver, and skeletal muscle | rel=r_associated | relid=0 | w=10
  499. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased decr enzyme activity
    n1=en:hyperintense | n2=en:decreased decr enzyme activity | rel=r_associated | relid=0 | w=10
  500. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased dermal hydroxylysine content
    n1=en:hyperintense | n2=en:decreased dermal hydroxylysine content | rel=r_associated | relid=0 | w=10
  501. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased dihydroxyacetone phosphate acyltransferase (dhap-at) activity
    n1=en:hyperintense | n2=en:decreased dihydroxyacetone phosphate acyltransferase (dhap-at) activity | rel=r_associated | relid=0 | w=10
  502. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased dihydroxyacetonephosphate acyltransferase (dhap-at) activity
    n1=en:hyperintense | n2=en:decreased dihydroxyacetonephosphate acyltransferase (dhap-at) activity | rel=r_associated | relid=0 | w=10
  503. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased dna excision repair
    n1=en:hyperintense | n2=en:decreased dna excision repair | rel=r_associated | relid=0 | w=10
  504. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased dna polymerase-gamma (polg, 174763) activity
    n1=en:hyperintense | n2=en:decreased dna polymerase-gamma (polg, 174763) activity | rel=r_associated | relid=0 | w=10
  505. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased eno3 activity
    n1=en:hyperintense | n2=en:decreased eno3 activity | rel=r_associated | relid=0 | w=10
  506. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased erythrocyte 2,3-diphosphoglycerate (2,3-dpg)
    n1=en:hyperintense | n2=en:decreased erythrocyte 2,3-diphosphoglycerate (2,3-dpg) | rel=r_associated | relid=0 | w=10
  507. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased erythrocyte lactate clearance (transport), 40 to 50% of normal values
    n1=en:hyperintense | n2=en:decreased erythrocyte lactate clearance (transport), 40 to 50% of normal values | rel=r_associated | relid=0 | w=10
  508. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased erythrocyte plasmalogen
    n1=en:hyperintense | n2=en:decreased erythrocyte plasmalogen | rel=r_associated | relid=0 | w=10
  509. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased expression of glycosylphosphatidylinositol-anchored membrane proteins
    n1=en:hyperintense | n2=en:decreased expression of glycosylphosphatidylinositol-anchored membrane proteins | rel=r_associated | relid=0 | w=10
  510. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased expression of glycosylphosphatidylinositol-linked proteins (e.g., cd59 107271 and cd24 600274) on hematopoietic cells
    n1=en:hyperintense | n2=en:decreased expression of glycosylphosphatidylinositol-linked proteins (e.g., cd59 107271 and cd24 600274) on hematopoietic cells | rel=r_associated | relid=0 | w=10
  511. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased expression of gpi-anchored proteins on blood cells
    n1=en:hyperintense | n2=en:decreased expression of gpi-anchored proteins on blood cells | rel=r_associated | relid=0 | w=10
  512. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased factor xi
    n1=en:hyperintense | n2=en:decreased factor xi | rel=r_associated | relid=0 | w=10
  513. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased fbp1 enzyme activity
    n1=en:hyperintense | n2=en:decreased fbp1 enzyme activity | rel=r_associated | relid=0 | w=10
  514. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased fibrillin-1 immunostaining in the dermis
    n1=en:hyperintense | n2=en:decreased fibrillin-1 immunostaining in the dermis | rel=r_associated | relid=0 | w=10
  515. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased fibrinogen (in some patients)
    n1=en:hyperintense | n2=en:decreased fibrinogen (in some patients) | rel=r_associated | relid=0 | w=10
  516. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased fibroblast alpha-mannosidase
    n1=en:hyperintense | n2=en:decreased fibroblast alpha-mannosidase | rel=r_associated | relid=0 | w=10
  517. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased fibroblast arylsulfatase a
    n1=en:hyperintense | n2=en:decreased fibroblast arylsulfatase a | rel=r_associated | relid=0 | w=10
  518. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased fibroblast beta-hexosaminidase
    n1=en:hyperintense | n2=en:decreased fibroblast beta-hexosaminidase | rel=r_associated | relid=0 | w=10
  519. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased fibroblast iduronate sulfatase
    n1=en:hyperintense | n2=en:decreased fibroblast iduronate sulfatase | rel=r_associated | relid=0 | w=10
  520. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased formation of complex (tri-, tetra-antennary) n-glycans
    n1=en:hyperintense | n2=en:decreased formation of complex (tri-, tetra-antennary) n-glycans | rel=r_associated | relid=0 | w=10
  521. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased free t(3)/free t(4)
    n1=en:hyperintense | n2=en:decreased free t(3)/free t(4) | rel=r_associated | relid=0 | w=10
  522. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased fumarate hydratase activity
    n1=en:hyperintense | n2=en:decreased fumarate hydratase activity | rel=r_associated | relid=0 | w=10
  523. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased galactokinase activity
    n1=en:hyperintense | n2=en:decreased galactokinase activity | rel=r_associated | relid=0 | w=10
  524. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased glomerular filtration rate (gfr)
    n1=en:hyperintense | n2=en:decreased glomerular filtration rate (gfr) | rel=r_associated | relid=0 | w=10
  525. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased glutamine in bodily fluids
    n1=en:hyperintense | n2=en:decreased glutamine in bodily fluids | rel=r_associated | relid=0 | w=10
  526. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased glycerol kinase activity
    n1=en:hyperintense | n2=en:decreased glycerol kinase activity | rel=r_associated | relid=0 | w=10
  527. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased grhpr activity
    n1=en:hyperintense | n2=en:decreased grhpr activity | rel=r_associated | relid=0 | w=10
  528. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased gtp cyclohydrolase i activity (about 20% of normal)
    n1=en:hyperintense | n2=en:decreased gtp cyclohydrolase i activity (about 20% of normal) | rel=r_associated | relid=0 | w=10
  529. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased hdl cholesterol
    n1=en:hyperintense | n2=en:decreased hdl cholesterol | rel=r_associated | relid=0 | w=10
  530. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased heme-heme interaction (e.g. hb kanagawa 141800.0169)
    n1=en:hyperintense | n2=en:decreased heme-heme interaction (e.g. hb kanagawa 141800.0169) | rel=r_associated | relid=0 | w=10
  531. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased hepatic gaba transaminase activity
    n1=en:hyperintense | n2=en:decreased hepatic gaba transaminase activity | rel=r_associated | relid=0 | w=10
  532. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased hepatic udp-glucuronyl-transferase activity
    n1=en:hyperintense | n2=en:decreased hepatic udp-glucuronyl-transferase activity | rel=r_associated | relid=0 | w=10
  533. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased hexokinase activity in red blood cells
    n1=en:hyperintense | n2=en:decreased hexokinase activity in red blood cells | rel=r_associated | relid=0 | w=10
  534. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased high molecular weight plasma factor viii/ vwf multimers
    n1=en:hyperintense | n2=en:decreased high molecular weight plasma factor viii/ vwf multimers | rel=r_associated | relid=0 | w=10
  535. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased homovanillic acid (hva) and 5-hydroxyindoleacetic acid (5hiaa) in csf
    n1=en:hyperintense | n2=en:decreased homovanillic acid (hva) and 5-hydroxyindoleacetic acid (5hiaa) in csf | rel=r_associated | relid=0 | w=10
  536. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased iga, igg, igm
    n1=en:hyperintense | n2=en:decreased iga, igg, igm | rel=r_associated | relid=0 | w=10
  537. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased insulin receptor binding
    n1=en:hyperintense | n2=en:decreased insulin receptor binding | rel=r_associated | relid=0 | w=10
  538. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased intracellular fmr protein
    n1=en:hyperintense | n2=en:decreased intracellular fmr protein | rel=r_associated | relid=0 | w=10
  539. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased ldl cholesterol
    n1=en:hyperintense | n2=en:decreased ldl cholesterol | rel=r_associated | relid=0 | w=10
  540. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased lecithin:cholesterol acyltransferase mass and activity
    n1=en:hyperintense | n2=en:decreased lecithin:cholesterol acyltransferase mass and activity | rel=r_associated | relid=0 | w=10
  541. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased leptin
    n1=en:hyperintense | n2=en:decreased leptin | rel=r_associated | relid=0 | w=10
  542. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased levels of cellular and mitochondrial fes-containing proteins
    n1=en:hyperintense | n2=en:decreased levels of cellular and mitochondrial fes-containing proteins | rel=r_associated | relid=0 | w=10
  543. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased levels of certain coagulation factors
    n1=en:hyperintense | n2=en:decreased levels of certain coagulation factors | rel=r_associated | relid=0 | w=10
  544. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased levels of coenzyme q10 in skeletal muscle (5-35%)
    n1=en:hyperintense | n2=en:decreased levels of coenzyme q10 in skeletal muscle (5-35%) | rel=r_associated | relid=0 | w=10
  545. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased levels of component x protein of the pdh complex
    n1=en:hyperintense | n2=en:decreased levels of component x protein of the pdh complex | rel=r_associated | relid=0 | w=10
  546. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased levels of cpt2 protein
    n1=en:hyperintense | n2=en:decreased levels of cpt2 protein | rel=r_associated | relid=0 | w=10
  547. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased levels of csf hypocretin (hcrt, 602358)
    n1=en:hyperintense | n2=en:decreased levels of csf hypocretin (hcrt, 602358) | rel=r_associated | relid=0 | w=10
  548. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased levels of plasma factor viii
    n1=en:hyperintense | n2=en:decreased levels of plasma factor viii | rel=r_associated | relid=0 | w=10
  549. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased levels of plasma factor viii in patients with type 2n
    n1=en:hyperintense | n2=en:decreased levels of plasma factor viii in patients with type 2n | rel=r_associated | relid=0 | w=10
  550. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased levels of plasma vwf antigen
    n1=en:hyperintense | n2=en:decreased levels of plasma vwf antigen | rel=r_associated | relid=0 | w=10
  551. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased levels of serum vitamin b12
    n1=en:hyperintense | n2=en:decreased levels of serum vitamin b12 | rel=r_associated | relid=0 | w=10
  552. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased levels of the e2 subunit protein
    n1=en:hyperintense | n2=en:decreased levels of the e2 subunit protein | rel=r_associated | relid=0 | w=10
  553. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased lipid-linked oligosaccharides (llo)
    n1=en:hyperintense | n2=en:decreased lipid-linked oligosaccharides (llo) | rel=r_associated | relid=0 | w=10
  554. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased liver homogentisate 1,2-dioxygenase activity
    n1=en:hyperintense | n2=en:decreased liver homogentisate 1,2-dioxygenase activity | rel=r_associated | relid=0 | w=10
  555. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased long-chain fatty acid oxidation
    n1=en:hyperintense | n2=en:decreased long-chain fatty acid oxidation | rel=r_associated | relid=0 | w=10
  556. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased lysosomal alpha-mannosidase activity in plasma and leukocytes
    n1=en:hyperintense | n2=en:decreased lysosomal alpha-mannosidase activity in plasma and leukocytes | rel=r_associated | relid=0 | w=10
  557. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased metabolism of thiopurine drugs
    n1=en:hyperintense | n2=en:decreased metabolism of thiopurine drugs | rel=r_associated | relid=0 | w=10
  558. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased methionine synthase activity
    n1=en:hyperintense | n2=en:decreased methionine synthase activity | rel=r_associated | relid=0 | w=10
  559. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased methylcobalamin (mecbl)
    n1=en:hyperintense | n2=en:decreased methylcobalamin (mecbl) | rel=r_associated | relid=0 | w=10
  560. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased methylmalonyl-coa mutase activity
    n1=en:hyperintense | n2=en:decreased methylmalonyl-coa mutase activity | rel=r_associated | relid=0 | w=10
  561. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased mitochondrial complex iii activity (in fibroblasts of 1 patient)
    n1=en:hyperintense | n2=en:decreased mitochondrial complex iii activity (in fibroblasts of 1 patient) | rel=r_associated | relid=0 | w=10
  562. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased mitochondrial complex iii activity (in liver, muscle, and fibroblasts)
    n1=en:hyperintense | n2=en:decreased mitochondrial complex iii activity (in liver, muscle, and fibroblasts) | rel=r_associated | relid=0 | w=10
  563. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased mitochondrial complex iii activity (skeletal muscle, fibroblasts)
    n1=en:hyperintense | n2=en:decreased mitochondrial complex iii activity (skeletal muscle, fibroblasts) | rel=r_associated | relid=0 | w=10
  564. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased mitochondrial complex iii activity in liver and fibroblasts
    n1=en:hyperintense | n2=en:decreased mitochondrial complex iii activity in liver and fibroblasts | rel=r_associated | relid=0 | w=10
  565. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased mitochondrial complex iii activity in muscle
    n1=en:hyperintense | n2=en:decreased mitochondrial complex iii activity in muscle | rel=r_associated | relid=0 | w=10
  566. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased mitochondrial complex iii activity seen in muscle
    n1=en:hyperintense | n2=en:decreased mitochondrial complex iii activity seen in muscle | rel=r_associated | relid=0 | w=10
  567. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased mitochondrial complex v assembly
    n1=en:hyperintense | n2=en:decreased mitochondrial complex v assembly | rel=r_associated | relid=0 | w=10
  568. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased mitochondrial nadp(h)
    n1=en:hyperintense | n2=en:decreased mitochondrial nadp(h) | rel=r_associated | relid=0 | w=10
  569. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased mitochondrial respiratory chain complex (2p21del)
    n1=en:hyperintense | n2=en:decreased mitochondrial respiratory chain complex (2p21del) | rel=r_associated | relid=0 | w=10
  570. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased mitochondrial respiratory complexes i, iii, and iv in brain, heart, and skeletal muscle
    n1=en:hyperintense | n2=en:decreased mitochondrial respiratory complexes i, iii, and iv in brain, heart, and skeletal muscle | rel=r_associated | relid=0 | w=10
  571. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased monoamine oxidase a activity
    n1=en:hyperintense | n2=en:decreased monoamine oxidase a activity | rel=r_associated | relid=0 | w=10
  572. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased mucosal alkaline phosphatase
    n1=en:hyperintense | n2=en:decreased mucosal alkaline phosphatase | rel=r_associated | relid=0 | w=10
  573. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased n-acetylglucosamine-1-phosphotransferase (glcnac - phosphotransferase) using lysosomal enzymes
    n1=en:hyperintense | n2=en:decreased n-acetylglucosamine-1-phosphotransferase (glcnac - phosphotransferase) using lysosomal enzymes | rel=r_associated | relid=0 | w=10
  574. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased nasal nitric oxide
    n1=en:hyperintense | n2=en:decreased nasal nitric oxide | rel=r_associated | relid=0 | w=10
  575. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased nasal nitric oxide (in some patients)
    n1=en:hyperintense | n2=en:decreased nasal nitric oxide (in some patients) | rel=r_associated | relid=0 | w=10
  576. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased natural killer cells
    n1=en:hyperintense | n2=en:decreased natural killer cells | rel=r_associated | relid=0 | w=10
  577. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased neopterin and biopterin in csf
    n1=en:hyperintense | n2=en:decreased neopterin and biopterin in csf | rel=r_associated | relid=0 | w=10
  578. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased neopterin and biopterin in urine
    n1=en:hyperintense | n2=en:decreased neopterin and biopterin in urine | rel=r_associated | relid=0 | w=10
  579. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased nk cells (in some patients)
    n1=en:hyperintense | n2=en:decreased nk cells (in some patients) | rel=r_associated | relid=0 | w=10
  580. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased number of igf1 receptors (igf1r, 147370) on cell surface
    n1=en:hyperintense | n2=en:decreased number of igf1 receptors (igf1r, 147370) on cell surface | rel=r_associated | relid=0 | w=10
  581. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased numbers of t regulatory cells
    n1=en:hyperintense | n2=en:decreased numbers of t regulatory cells | rel=r_associated | relid=0 | w=10
  582. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent alpha-n-acetylgalactosaminidase activity
    n1=en:hyperintense | n2=en:decreased or absent alpha-n-acetylgalactosaminidase activity | rel=r_associated | relid=0 | w=10
  583. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent alpha-n-acetylgalactosaminidase protein
    n1=en:hyperintense | n2=en:decreased or absent alpha-n-acetylgalactosaminidase protein | rel=r_associated | relid=0 | w=10
  584. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent apolipoprotein a-i
    n1=en:hyperintense | n2=en:decreased or absent apolipoprotein a-i | rel=r_associated | relid=0 | w=10
  585. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent ciliary motility
    n1=en:hyperintense | n2=en:decreased or absent ciliary motility | rel=r_associated | relid=0 | w=10
  586. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent d-bifunctional protein activity and protein
    n1=en:hyperintense | n2=en:decreased or absent d-bifunctional protein activity and protein | rel=r_associated | relid=0 | w=10
  587. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent dihydropteridine reductase activity
    n1=en:hyperintense | n2=en:decreased or absent dihydropteridine reductase activity | rel=r_associated | relid=0 | w=10
  588. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent dihydropyrimidine dehydrogenase activity
    n1=en:hyperintense | n2=en:decreased or absent dihydropyrimidine dehydrogenase activity | rel=r_associated | relid=0 | w=10
  589. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent gch1 activity
    n1=en:hyperintense | n2=en:decreased or absent gch1 activity | rel=r_associated | relid=0 | w=10
  590. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent glycogen branching enzyme activity
    n1=en:hyperintense | n2=en:decreased or absent glycogen branching enzyme activity | rel=r_associated | relid=0 | w=10
  591. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent histidase activity
    n1=en:hyperintense | n2=en:decreased or absent histidase activity | rel=r_associated | relid=0 | w=10
  592. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent peroxisome acyl-coa oxidase activity and protein
    n1=en:hyperintense | n2=en:decreased or absent peroxisome acyl-coa oxidase activity and protein | rel=r_associated | relid=0 | w=10
  593. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent pts activity
    n1=en:hyperintense | n2=en:decreased or absent pts activity | rel=r_associated | relid=0 | w=10
  594. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent serum and urinary chenodeoxycholic acid and cholic acid
    n1=en:hyperintense | n2=en:decreased or absent serum and urinary chenodeoxycholic acid and cholic acid | rel=r_associated | relid=0 | w=10
  595. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent serum ceruloplasmin
    n1=en:hyperintense | n2=en:decreased or absent serum ceruloplasmin | rel=r_associated | relid=0 | w=10
  596. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent serum citrulline
    n1=en:hyperintense | n2=en:decreased or absent serum citrulline | rel=r_associated | relid=0 | w=10
  597. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent steroid sulfatase activity
    n1=en:hyperintense | n2=en:decreased or absent steroid sulfatase activity | rel=r_associated | relid=0 | w=10
  598. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or absent udp-glucuronyl-transferase activity
    n1=en:hyperintense | n2=en:decreased or absent udp-glucuronyl-transferase activity | rel=r_associated | relid=0 | w=10
  599. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or increased serum testosterone
    n1=en:hyperintense | n2=en:decreased or increased serum testosterone | rel=r_associated | relid=0 | w=10
  600. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or low-normal serum parathyroid hormone (pth)
    n1=en:hyperintense | n2=en:decreased or low-normal serum parathyroid hormone (pth) | rel=r_associated | relid=0 | w=10
  601. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or normal plasma insulin
    n1=en:hyperintense | n2=en:decreased or normal plasma insulin | rel=r_associated | relid=0 | w=10
  602. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or normal serum c3
    n1=en:hyperintense | n2=en:decreased or normal serum c3 | rel=r_associated | relid=0 | w=10
  603. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or normal serum factor b
    n1=en:hyperintense | n2=en:decreased or normal serum factor b | rel=r_associated | relid=0 | w=10
  604. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased or normal serum factor i
    n1=en:hyperintense | n2=en:decreased or normal serum factor i | rel=r_associated | relid=0 | w=10
  605. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased palmitate oxidation
    n1=en:hyperintense | n2=en:decreased palmitate oxidation | rel=r_associated | relid=0 | w=10
  606. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased peroxisomal fatty acid beta-oxidation
    n1=en:hyperintense | n2=en:decreased peroxisomal fatty acid beta-oxidation | rel=r_associated | relid=0 | w=10
  607. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased phgdh activity (fibroblasts)
    n1=en:hyperintense | n2=en:decreased phgdh activity (fibroblasts) | rel=r_associated | relid=0 | w=10
  608. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased phk activity in liver
    n1=en:hyperintense | n2=en:decreased phk activity in liver | rel=r_associated | relid=0 | w=10
  609. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased phosphoglucomutase 1 (pgm1) activity (less than 10% of normal values)
    n1=en:hyperintense | n2=en:decreased phosphoglucomutase 1 (pgm1) activity (less than 10% of normal values) | rel=r_associated | relid=0 | w=10
  610. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased phosphoglycerate mutase 1 (pgam2) activity (2 to 6% of normal values)
    n1=en:hyperintense | n2=en:decreased phosphoglycerate mutase 1 (pgam2) activity (2 to 6% of normal values) | rel=r_associated | relid=0 | w=10
  611. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased phytanic acid oxidase activity
    n1=en:hyperintense | n2=en:decreased phytanic acid oxidase activity | rel=r_associated | relid=0 | w=10
  612. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma and urinary guanidinoacetate (gaa)
    n1=en:hyperintense | n2=en:decreased plasma and urinary guanidinoacetate (gaa) | rel=r_associated | relid=0 | w=10
  613. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma and urinary ornithine
    n1=en:hyperintense | n2=en:decreased plasma and urinary ornithine | rel=r_associated | relid=0 | w=10
  614. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma apolipoprotein b (apob, 107730)
    n1=en:hyperintense | n2=en:decreased plasma apolipoprotein b (apob, 107730) | rel=r_associated | relid=0 | w=10
  615. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma apolipoprotein c-ii
    n1=en:hyperintense | n2=en:decreased plasma apolipoprotein c-ii | rel=r_associated | relid=0 | w=10
  616. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma arginine
    n1=en:hyperintense | n2=en:decreased plasma arginine | rel=r_associated | relid=0 | w=10
  617. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma esterified cholesterol
    n1=en:hyperintense | n2=en:decreased plasma esterified cholesterol | rel=r_associated | relid=0 | w=10
  618. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma free carnitine
    n1=en:hyperintense | n2=en:decreased plasma free carnitine | rel=r_associated | relid=0 | w=10
  619. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma glycine
    n1=en:hyperintense | n2=en:decreased plasma glycine | rel=r_associated | relid=0 | w=10
  620. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma gonadotrophin
    n1=en:hyperintense | n2=en:decreased plasma gonadotrophin | rel=r_associated | relid=0 | w=10
  621. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma hdl (<1/10 of normal levels)
    n1=en:hyperintense | n2=en:decreased plasma hdl (<1/10 of normal levels) | rel=r_associated | relid=0 | w=10
  622. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma lpl levels (in some patients)
    n1=en:hyperintense | n2=en:decreased plasma lpl levels (in some patients) | rel=r_associated | relid=0 | w=10
  623. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma lysine, glutamic acid, and glutamine
    n1=en:hyperintense | n2=en:decreased plasma lysine, glutamic acid, and glutamine | rel=r_associated | relid=0 | w=10
  624. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma serine
    n1=en:hyperintense | n2=en:decreased plasma serine | rel=r_associated | relid=0 | w=10
  625. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma total and free carnitine
    n1=en:hyperintense | n2=en:decreased plasma total and free carnitine | rel=r_associated | relid=0 | w=10
  626. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma total cholesterol
    n1=en:hyperintense | n2=en:decreased plasma total cholesterol | rel=r_associated | relid=0 | w=10
  627. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma triglycerides
    n1=en:hyperintense | n2=en:decreased plasma triglycerides | rel=r_associated | relid=0 | w=10
  628. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasma zinc levels
    n1=en:hyperintense | n2=en:decreased plasma zinc levels | rel=r_associated | relid=0 | w=10
  629. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasmalogens
    n1=en:hyperintense | n2=en:decreased plasmalogens | rel=r_associated | relid=0 | w=10
  630. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasminogen activity
    n1=en:hyperintense | n2=en:decreased plasminogen activity | rel=r_associated | relid=0 | w=10
  631. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased plasminogen antigen
    n1=en:hyperintense | n2=en:decreased plasminogen antigen | rel=r_associated | relid=0 | w=10
  632. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased platelet derived growth factor
    n1=en:hyperintense | n2=en:decreased platelet derived growth factor | rel=r_associated | relid=0 | w=10
  633. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased prpp synthetase activity in erythrocytes and fibroblasts
    n1=en:hyperintense | n2=en:decreased prpp synthetase activity in erythrocytes and fibroblasts | rel=r_associated | relid=0 | w=10
  634. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased pyruvate carboxylase (pc) activity (less than 5%)
    n1=en:hyperintense | n2=en:decreased pyruvate carboxylase (pc) activity (less than 5%) | rel=r_associated | relid=0 | w=10
  635. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased red cell pyruvate kinase activity
    n1=en:hyperintense | n2=en:decreased red cell pyruvate kinase activity | rel=r_associated | relid=0 | w=10
  636. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased renal calcium excretion
    n1=en:hyperintense | n2=en:decreased renal calcium excretion | rel=r_associated | relid=0 | w=10
  637. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased respiratory chain complex iii activity in multiple tissues
    n1=en:hyperintense | n2=en:decreased respiratory chain complex iii activity in multiple tissues | rel=r_associated | relid=0 | w=10
  638. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased reversible oxygen-binding capacity (e.g. hb l (bombay) 141800.9999)
    n1=en:hyperintense | n2=en:decreased reversible oxygen-binding capacity (e.g. hb l (bombay) 141800.9999) | rel=r_associated | relid=0 | w=10
  639. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased s-ado:saicar ratio
    n1=en:hyperintense | n2=en:decreased s-ado:saicar ratio | rel=r_associated | relid=0 | w=10
  640. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased scad activity
    n1=en:hyperintense | n2=en:decreased scad activity | rel=r_associated | relid=0 | w=10
  641. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased secretion of igf1 in response to gh administration
    n1=en:hyperintense | n2=en:decreased secretion of igf1 in response to gh administration | rel=r_associated | relid=0 | w=10
  642. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum 18-ohb
    n1=en:hyperintense | n2=en:decreased serum 18-ohb | rel=r_associated | relid=0 | w=10
  643. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum 25-hydroxyvitamin d
    n1=en:hyperintense | n2=en:decreased serum 25-hydroxyvitamin d | rel=r_associated | relid=0 | w=10
  644. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum acth
    n1=en:hyperintense | n2=en:decreased serum acth | rel=r_associated | relid=0 | w=10
  645. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum alpha-2 macroglobulin levels
    n1=en:hyperintense | n2=en:decreased serum alpha-2 macroglobulin levels | rel=r_associated | relid=0 | w=10
  646. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum and muscle coenzyme q
    n1=en:hyperintense | n2=en:decreased serum and muscle coenzyme q | rel=r_associated | relid=0 | w=10
  647. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum and salivary lactoferrin has been described in 1 family
    n1=en:hyperintense | n2=en:decreased serum and salivary lactoferrin has been described in 1 family | rel=r_associated | relid=0 | w=10
  648. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum androgens
    n1=en:hyperintense | n2=en:decreased serum androgens | rel=r_associated | relid=0 | w=10
  649. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum b12 levels
    n1=en:hyperintense | n2=en:decreased serum b12 levels | rel=r_associated | relid=0 | w=10
  650. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum bun
    n1=en:hyperintense | n2=en:decreased serum bun | rel=r_associated | relid=0 | w=10
  651. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum c3 (atypical hus)
    n1=en:hyperintense | n2=en:decreased serum c3 (atypical hus) | rel=r_associated | relid=0 | w=10
  652. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum carnitine in acute stage
    n1=en:hyperintense | n2=en:decreased serum carnitine in acute stage | rel=r_associated | relid=0 | w=10
  653. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum ceruloplasmin
    n1=en:hyperintense | n2=en:decreased serum ceruloplasmin | rel=r_associated | relid=0 | w=10
  654. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum cholesterol (in some)
    n1=en:hyperintense | n2=en:decreased serum cholesterol (in some) | rel=r_associated | relid=0 | w=10
  655. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum cobalamin
    n1=en:hyperintense | n2=en:decreased serum cobalamin | rel=r_associated | relid=0 | w=10
  656. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum complement factor h
    n1=en:hyperintense | n2=en:decreased serum complement factor h | rel=r_associated | relid=0 | w=10
  657. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum factor b (atypical hus)
    n1=en:hyperintense | n2=en:decreased serum factor b (atypical hus) | rel=r_associated | relid=0 | w=10
  658. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum factor h (atypical hus)
    n1=en:hyperintense | n2=en:decreased serum factor h (atypical hus) | rel=r_associated | relid=0 | w=10
  659. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum factor i (atypical hus)
    n1=en:hyperintense | n2=en:decreased serum factor i (atypical hus) | rel=r_associated | relid=0 | w=10
  660. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum ferritin
    n1=en:hyperintense | n2=en:decreased serum ferritin | rel=r_associated | relid=0 | w=10
  661. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum follicle-stimulating hormone (fsh)
    n1=en:hyperintense | n2=en:decreased serum follicle-stimulating hormone (fsh) | rel=r_associated | relid=0 | w=10
  662. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum free thyroxine
    n1=en:hyperintense | n2=en:decreased serum free thyroxine | rel=r_associated | relid=0 | w=10
  663. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum glucosyltransferase (ggt) activity
    n1=en:hyperintense | n2=en:decreased serum glucosyltransferase (ggt) activity | rel=r_associated | relid=0 | w=10
  664. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum haptoglobin
    n1=en:hyperintense | n2=en:decreased serum haptoglobin | rel=r_associated | relid=0 | w=10
  665. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum haptoglobin (in some patients)
    n1=en:hyperintense | n2=en:decreased serum haptoglobin (in some patients) | rel=r_associated | relid=0 | w=10
  666. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum iga
    n1=en:hyperintense | n2=en:decreased serum iga | rel=r_associated | relid=0 | w=10
  667. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum igm
    n1=en:hyperintense | n2=en:decreased serum igm | rel=r_associated | relid=0 | w=10
  668. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum insulin-like growth factor-1 (igf1, 147440)
    n1=en:hyperintense | n2=en:decreased serum insulin-like growth factor-1 (igf1, 147440) | rel=r_associated | relid=0 | w=10
  669. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum insulin-like growth factor-1 (igf1)
    n1=en:hyperintense | n2=en:decreased serum insulin-like growth factor-1 (igf1) | rel=r_associated | relid=0 | w=10
  670. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum iron (in some patients)
    n1=en:hyperintense | n2=en:decreased serum iron (in some patients) | rel=r_associated | relid=0 | w=10
  671. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum l-transferrin (heterozygous patient)
    n1=en:hyperintense | n2=en:decreased serum l-transferrin (heterozygous patient) | rel=r_associated | relid=0 | w=10
  672. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum leptin
    n1=en:hyperintense | n2=en:decreased serum leptin | rel=r_associated | relid=0 | w=10
  673. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum levels of maoa products
    n1=en:hyperintense | n2=en:decreased serum levels of maoa products | rel=r_associated | relid=0 | w=10
  674. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum luteinizing hormone (lh)
    n1=en:hyperintense | n2=en:decreased serum luteinizing hormone (lh) | rel=r_associated | relid=0 | w=10
  675. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum rt3
    n1=en:hyperintense | n2=en:decreased serum rt3 | rel=r_associated | relid=0 | w=10
  676. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum thiamine pyrophosphate
    n1=en:hyperintense | n2=en:decreased serum thiamine pyrophosphate | rel=r_associated | relid=0 | w=10
  677. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum thyroid-stimulating hormone (tsh)
    n1=en:hyperintense | n2=en:decreased serum thyroid-stimulating hormone (tsh) | rel=r_associated | relid=0 | w=10
  678. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum thyroxine (t4)
    n1=en:hyperintense | n2=en:decreased serum thyroxine (t4) | rel=r_associated | relid=0 | w=10
  679. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum trypsinogen
    n1=en:hyperintense | n2=en:decreased serum trypsinogen | rel=r_associated | relid=0 | w=10
  680. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased serum vitamin a
    n1=en:hyperintense | n2=en:decreased serum vitamin a | rel=r_associated | relid=0 | w=10
  681. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased short/branched-chain acyl-coa dehydrogenase protein levels and enzyme activity
    n1=en:hyperintense | n2=en:decreased short/branched-chain acyl-coa dehydrogenase protein levels and enzyme activity | rel=r_associated | relid=0 | w=10
  682. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased sulfite oxidase activity
    n1=en:hyperintense | n2=en:decreased sulfite oxidase activity | rel=r_associated | relid=0 | w=10
  683. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased sulfite oxidase activity in fibroblasts
    n1=en:hyperintense | n2=en:decreased sulfite oxidase activity in fibroblasts | rel=r_associated | relid=0 | w=10
  684. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased switched memory b cells
    n1=en:hyperintense | n2=en:decreased switched memory b cells | rel=r_associated | relid=0 | w=10
  685. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased switched memory b cells (in some patients)
    n1=en:hyperintense | n2=en:decreased switched memory b cells (in some patients) | rel=r_associated | relid=0 | w=10
  686. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased t cells
    n1=en:hyperintense | n2=en:decreased t cells | rel=r_associated | relid=0 | w=10
  687. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased telomerase activity
    n1=en:hyperintense | n2=en:decreased telomerase activity | rel=r_associated | relid=0 | w=10
  688. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased telomere length in lymphocytes
    n1=en:hyperintense | n2=en:decreased telomere length in lymphocytes | rel=r_associated | relid=0 | w=10
  689. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased testosterone level
    n1=en:hyperintense | n2=en:decreased testosterone level | rel=r_associated | relid=0 | w=10
  690. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased tetrahydrobiopterin (bh4) in csf
    n1=en:hyperintense | n2=en:decreased tetrahydrobiopterin (bh4) in csf | rel=r_associated | relid=0 | w=10
  691. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased tetrasialo-transferrin
    n1=en:hyperintense | n2=en:decreased tetrasialo-transferrin | rel=r_associated | relid=0 | w=10
  692. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased tetrasialotransferrin levels
    n1=en:hyperintense | n2=en:decreased tetrasialotransferrin levels | rel=r_associated | relid=0 | w=10
  693. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased thrombospondin
    n1=en:hyperintense | n2=en:decreased thrombospondin | rel=r_associated | relid=0 | w=10
  694. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased thyroxine level
    n1=en:hyperintense | n2=en:decreased thyroxine level | rel=r_associated | relid=0 | w=10
  695. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased tissue and serum alkaline phosphatase
    n1=en:hyperintense | n2=en:decreased tissue and serum alkaline phosphatase | rel=r_associated | relid=0 | w=10
  696. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased tissue total and free carnitine
    n1=en:hyperintense | n2=en:decreased tissue total and free carnitine | rel=r_associated | relid=0 | w=10
  697. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased transcobalamin i in saliva, serum, gastric juice, and cerebrospinal fluid
    n1=en:hyperintense | n2=en:decreased transcobalamin i in saliva, serum, gastric juice, and cerebrospinal fluid | rel=r_associated | relid=0 | w=10
  698. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased transferrin increased serum iron
    n1=en:hyperintense | n2=en:decreased transferrin increased serum iron | rel=r_associated | relid=0 | w=10
  699. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased triiodothyronine level
    n1=en:hyperintense | n2=en:decreased triiodothyronine level | rel=r_associated | relid=0 | w=10
  700. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased ubiquinone-10
    n1=en:hyperintense | n2=en:decreased ubiquinone-10 | rel=r_associated | relid=0 | w=10
  701. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased udp-glcnac
    n1=en:hyperintense | n2=en:decreased udp-glcnac | rel=r_associated | relid=0 | w=10
  702. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased urinary calcium and phosphate excretion
    n1=en:hyperintense | n2=en:decreased urinary calcium and phosphate excretion | rel=r_associated | relid=0 | w=10
  703. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased urinary excretion of uromodulin
    n1=en:hyperintense | n2=en:decreased urinary excretion of uromodulin | rel=r_associated | relid=0 | w=10
  704. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased urinary hva, 5-hiaa, and vanillyl mandelic acid (vma)
    n1=en:hyperintense | n2=en:decreased urinary hva, 5-hiaa, and vanillyl mandelic acid (vma) | rel=r_associated | relid=0 | w=10
  705. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased urinary sulfate
    n1=en:hyperintense | n2=en:decreased urinary sulfate | rel=r_associated | relid=0 | w=10
  706. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased urocanic acid in blood, urine, and skin cells
    n1=en:hyperintense | n2=en:decreased urocanic acid in blood, urine, and skin cells | rel=r_associated | relid=0 | w=10
  707. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased uros activity (1 patient)
    n1=en:hyperintense | n2=en:decreased uros activity (1 patient) | rel=r_associated | relid=0 | w=10
  708. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased very long-chain acyl-coa dehydrogenase protein and activity
    n1=en:hyperintense | n2=en:decreased very long-chain acyl-coa dehydrogenase protein and activity | rel=r_associated | relid=0 | w=10
  709. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased von willebrand factor
    n1=en:hyperintense | n2=en:decreased von willebrand factor | rel=r_associated | relid=0 | w=10
  710. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased whole blood serotonin
    n1=en:hyperintense | n2=en:decreased whole blood serotonin | rel=r_associated | relid=0 | w=10
  711. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased xanthine dehydrogenase activity
    n1=en:hyperintense | n2=en:decreased xanthine dehydrogenase activity | rel=r_associated | relid=0 | w=10
  712. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:decreased-absent intestinal mucosa lactase activity
    n1=en:hyperintense | n2=en:decreased-absent intestinal mucosa lactase activity | rel=r_associated | relid=0 | w=10
  713. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defect in chylomicron secretion
    n1=en:hyperintense | n2=en:defect in chylomicron secretion | rel=r_associated | relid=0 | w=10
  714. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defect in dna repair
    n1=en:hyperintense | n2=en:defect in dna repair | rel=r_associated | relid=0 | w=10
  715. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defect in double-stranded dna repair
    n1=en:hyperintense | n2=en:defect in double-stranded dna repair | rel=r_associated | relid=0 | w=10
  716. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defect in mitochondrial and peroxisomal fission
    n1=en:hyperintense | n2=en:defect in mitochondrial and peroxisomal fission | rel=r_associated | relid=0 | w=10
  717. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defect in n- and o-glycosylation
    n1=en:hyperintense | n2=en:defect in n- and o-glycosylation | rel=r_associated | relid=0 | w=10
  718. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defect in oxidative phosphorylation
    n1=en:hyperintense | n2=en:defect in oxidative phosphorylation | rel=r_associated | relid=0 | w=10
  719. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defect in retrograde intraflagellar transport in cilia
    n1=en:hyperintense | n2=en:defect in retrograde intraflagellar transport in cilia | rel=r_associated | relid=0 | w=10
  720. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defective (ca2+) mobilization in t cells
    n1=en:hyperintense | n2=en:defective (ca2+) mobilization in t cells | rel=r_associated | relid=0 | w=10
  721. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defective bile acid metabolism
    n1=en:hyperintense | n2=en:defective bile acid metabolism | rel=r_associated | relid=0 | w=10
  722. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defective dna repair
    n1=en:hyperintense | n2=en:defective dna repair | rel=r_associated | relid=0 | w=10
  723. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defective dna repair after ultraviolet radiation damage
    n1=en:hyperintense | n2=en:defective dna repair after ultraviolet radiation damage | rel=r_associated | relid=0 | w=10
  724. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defective glcnac-pi synthesis
    n1=en:hyperintense | n2=en:defective glcnac-pi synthesis | rel=r_associated | relid=0 | w=10
  725. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defective heavy chain present
    n1=en:hyperintense | n2=en:defective heavy chain present | rel=r_associated | relid=0 | w=10
  726. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defective mitochondrial respiratory enzyme activity
    n1=en:hyperintense | n2=en:defective mitochondrial respiratory enzyme activity | rel=r_associated | relid=0 | w=10
  727. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defective t-cell proliferative responses (in some patients)
    n1=en:hyperintense | n2=en:defective t-cell proliferative responses (in some patients) | rel=r_associated | relid=0 | w=10
  728. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:defects in mitochondrial oxidative phosphorylation
    n1=en:hyperintense | n2=en:defects in mitochondrial oxidative phosphorylation | rel=r_associated | relid=0 | w=10
  729. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency of alpha-1,4-glucosidase (acid maltase)
    n1=en:hyperintense | n2=en:deficiency of alpha-1,4-glucosidase (acid maltase) | rel=r_associated | relid=0 | w=10
  730. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency of creatine phosphate in brain
    n1=en:hyperintense | n2=en:deficiency of creatine phosphate in brain | rel=r_associated | relid=0 | w=10
  731. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency of fat-soluble vitamins
    n1=en:hyperintense | n2=en:deficiency of fat-soluble vitamins | rel=r_associated | relid=0 | w=10
  732. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency of fructokinase
    n1=en:hyperintense | n2=en:deficiency of fructokinase | rel=r_associated | relid=0 | w=10
  733. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency of glycoprotein (gp)iib-iiia complex
    n1=en:hyperintense | n2=en:deficiency of glycoprotein (gp)iib-iiia complex | rel=r_associated | relid=0 | w=10
  734. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency of laminin alpha-2 chain of merosin (lama2, 156225) in muscle
    n1=en:hyperintense | n2=en:deficiency of laminin alpha-2 chain of merosin (lama2, 156225) in muscle | rel=r_associated | relid=0 | w=10
  735. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency of laminin in basement membranes
    n1=en:hyperintense | n2=en:deficiency of laminin in basement membranes | rel=r_associated | relid=0 | w=10
  736. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency of mitochondrial isovaleryl-coa dehydrogenase in fibroblasts
    n1=en:hyperintense | n2=en:deficiency of mitochondrial isovaleryl-coa dehydrogenase in fibroblasts | rel=r_associated | relid=0 | w=10
  737. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency of phosphatidylinositol (4,5) bisphosphate 5-phosphatase (ptdins(4,5)p(2) 5-phosphatase) in cultured fibroblasts
    n1=en:hyperintense | n2=en:deficiency of phosphatidylinositol (4,5) bisphosphate 5-phosphatase (ptdins(4,5)p(2) 5-phosphatase) in cultured fibroblasts | rel=r_associated | relid=0 | w=10
  738. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency of prolidase activity in erythrocytes, leukocytes, or fibroblasts
    n1=en:hyperintense | n2=en:deficiency of prolidase activity in erythrocytes, leukocytes, or fibroblasts | rel=r_associated | relid=0 | w=10
  739. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency of saposins a, b, c, and d
    n1=en:hyperintense | n2=en:deficiency of saposins a, b, c, and d | rel=r_associated | relid=0 | w=10
  740. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency of serum properdin p factor
    n1=en:hyperintense | n2=en:deficiency of serum properdin p factor | rel=r_associated | relid=0 | w=10
  741. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency or absence of cytochrome b(-245)
    n1=en:hyperintense | n2=en:deficiency or absence of cytochrome b(-245) | rel=r_associated | relid=0 | w=10
  742. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency or absence of p22-phox (608508) protein
    n1=en:hyperintense | n2=en:deficiency or absence of p22-phox (608508) protein | rel=r_associated | relid=0 | w=10
  743. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency or absence of p22-phox protein
    n1=en:hyperintense | n2=en:deficiency or absence of p22-phox protein | rel=r_associated | relid=0 | w=10
  744. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency or absence of p47-phox protein (type i)
    n1=en:hyperintense | n2=en:deficiency or absence of p47-phox protein (type i) | rel=r_associated | relid=0 | w=10
  745. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency or absence of p67-phox protein (type ii)
    n1=en:hyperintense | n2=en:deficiency or absence of p67-phox protein (type ii) | rel=r_associated | relid=0 | w=10
  746. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency or absence of p91-phox (300481) protein
    n1=en:hyperintense | n2=en:deficiency or absence of p91-phox (300481) protein | rel=r_associated | relid=0 | w=10
  747. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficiency or absence of p91-phox protein
    n1=en:hyperintense | n2=en:deficiency or absence of p91-phox protein | rel=r_associated | relid=0 | w=10
  748. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficient efflux of intracellular cholesterol
    n1=en:hyperintense | n2=en:deficient efflux of intracellular cholesterol | rel=r_associated | relid=0 | w=10
  749. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficient fibroblast aicar-tf activity
    n1=en:hyperintense | n2=en:deficient fibroblast aicar-tf activity | rel=r_associated | relid=0 | w=10
  750. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficient hepatic 4-hydroxyphenylpyruvate dioxygenase
    n1=en:hyperintense | n2=en:deficient hepatic 4-hydroxyphenylpyruvate dioxygenase | rel=r_associated | relid=0 | w=10
  751. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficient plasma alpha-lecithin:cholesterol acyltransferase (high-density) activity
    n1=en:hyperintense | n2=en:deficient plasma alpha-lecithin:cholesterol acyltransferase (high-density) activity | rel=r_associated | relid=0 | w=10
  752. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deficient ribose-s-phosphate isomerase (rpi) in fibroblasts
    n1=en:hyperintense | n2=en:deficient ribose-s-phosphate isomerase (rpi) in fibroblasts | rel=r_associated | relid=0 | w=10
  753. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dehydrated hereditary stomatocytosis, pseudohyperkalemia, and perinatal edema
    n1=en:hyperintense | n2=en:dehydrated hereditary stomatocytosis, pseudohyperkalemia, and perinatal edema | rel=r_associated | relid=0 | w=10
  754. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dehydration
    n1=en:hyperintense | n2=en:dehydration | rel=r_associated | relid=0 | w=10
  755. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dehydroepiandrosterone (dhea) at upper level of normal range
    n1=en:hyperintense | n2=en:dehydroepiandrosterone (dhea) at upper level of normal range | rel=r_associated | relid=0 | w=10
  756. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:delayed plasma clearance of unconjugated bromsulphthalein, an anionic diagnostic dye
    n1=en:hyperintense | n2=en:delayed plasma clearance of unconjugated bromsulphthalein, an anionic diagnostic dye | rel=r_associated | relid=0 | w=10
  757. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deletion (78kb to 1mb) of chromosome 8q24.3 including the scrib (607733) and puf60 (604819) genes
    n1=en:hyperintense | n2=en:deletion (78kb to 1mb) of chromosome 8q24.3 including the scrib (607733) and puf60 (604819) genes | rel=r_associated | relid=0 | w=10
  758. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:deletion of chromosome 18p11.2
    n1=en:hyperintense | n2=en:deletion of chromosome 18p11.2 | rel=r_associated | relid=0 | w=10
  759. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:delta-1-pyrroline-3-hydroxy-5-carboxylate levels increased in urine
    n1=en:hyperintense | n2=en:delta-1-pyrroline-3-hydroxy-5-carboxylate levels increased in urine | rel=r_associated | relid=0 | w=10
  760. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:delta-1-pyrroline-5-carboxylate (p5c) levels increased in plasma
    n1=en:hyperintense | n2=en:delta-1-pyrroline-5-carboxylate (p5c) levels increased in plasma | rel=r_associated | relid=0 | w=10
  761. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:delta-1-pyrroline-5-carboxylate dehydrogenase activity decreased in fibroblasts or leukocytes
    n1=en:hyperintense | n2=en:delta-1-pyrroline-5-carboxylate dehydrogenase activity decreased in fibroblasts or leukocytes | rel=r_associated | relid=0 | w=10
  762. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:depletion of mtdna (skeletal muscle, fibroblasts)
    n1=en:hyperintense | n2=en:depletion of mtdna (skeletal muscle, fibroblasts) | rel=r_associated | relid=0 | w=10
  763. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dermatan and heparan sulfate excretion in urine
    n1=en:hyperintense | n2=en:dermatan and heparan sulfate excretion in urine | rel=r_associated | relid=0 | w=10
  764. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dermatan sulfate excretion in urine
    n1=en:hyperintense | n2=en:dermatan sulfate excretion in urine | rel=r_associated | relid=0 | w=10
  765. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dermatosis papulosa nigra
    n1=en:hyperintense | n2=en:dermatosis papulosa nigra | rel=r_associated | relid=0 | w=10
  766. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:detection by rt-pcr and southern blot analysis for primary diagnosis and follow up for residual disease
    n1=en:hyperintense | n2=en:detection by rt-pcr and southern blot analysis for primary diagnosis and follow up for residual disease | rel=r_associated | relid=0 | w=10
  767. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:detection by rt-pcr, southern blot analysis, and fish for primary diagnosis and follow up for residual disease
    n1=en:hyperintense | n2=en:detection by rt-pcr, southern blot analysis, and fish for primary diagnosis and follow up for residual disease | rel=r_associated | relid=0 | w=10
  768. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dhea sulfotransferase below limit of detection
    n1=en:hyperintense | n2=en:dhea sulfotransferase below limit of detection | rel=r_associated | relid=0 | w=10
  769. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:di- and trihydroxycholestanoic acid accumulation
    n1=en:hyperintense | n2=en:di- and trihydroxycholestanoic acid accumulation | rel=r_associated | relid=0 | w=10
  770. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:diagnosis aspect
    n1=en:hyperintense | n2=en:diagnosis aspect | rel=r_associated | relid=0 | w=10
  771. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:diagnosis by exposing muscle biopsy to caffeine and/or halothane
    n1=en:hyperintense | n2=en:diagnosis by exposing muscle biopsy to caffeine and/or halothane | rel=r_associated | relid=0 | w=10
  772. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:diaminoaciduria (arginuria, lysinuria, cystinuria, ornithinuria)
    n1=en:hyperintense | n2=en:diaminoaciduria (arginuria, lysinuria, cystinuria, ornithinuria) | rel=r_associated | relid=0 | w=10
  773. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dibasic potassium phosphate 1.66 meq/ml / monobasic potassium phosphate 1.65 meq/ml injectable solution
    n1=en:hyperintense | n2=en:dibasic potassium phosphate 1.66 meq/ml / monobasic potassium phosphate 1.65 meq/ml injectable solution | rel=r_associated | relid=0 | w=10
  774. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dicarboxylic aciduria
    n1=en:hyperintense | n2=en:dicarboxylic aciduria | rel=r_associated | relid=0 | w=10
  775. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dietary potassium
    n1=en:hyperintense | n2=en:dietary potassium | rel=r_associated | relid=0 | w=10
  776. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:diffuse deposition of calcium oxalate in various tissues
    n1=en:hyperintense | n2=en:diffuse deposition of calcium oxalate in various tissues | rel=r_associated | relid=0 | w=10
  777. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dilated pore of winer
    n1=en:hyperintense | n2=en:dilated pore of winer | rel=r_associated | relid=0 | w=10
  778. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dilated rough endoplasmic reticulum (rer)
    n1=en:hyperintense | n2=en:dilated rough endoplasmic reticulum (rer) | rel=r_associated | relid=0 | w=10
  779. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dimethylglycine dehydrogenase (dmgdh) deficiency
    n1=en:hyperintense | n2=en:dimethylglycine dehydrogenase (dmgdh) deficiency | rel=r_associated | relid=0 | w=10
  780. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:diminished lymphocyte response to phytohemaglutinin
    n1=en:hyperintense | n2=en:diminished lymphocyte response to phytohemaglutinin | rel=r_associated | relid=0 | w=10
  781. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:direct coombs test negative
    n1=en:hyperintense | n2=en:direct coombs test negative | rel=r_associated | relid=0 | w=10
  782. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:direct hyperbilirubinemia
    n1=en:hyperintense | n2=en:direct hyperbilirubinemia | rel=r_associated | relid=0 | w=10
  783. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:disorder of fluid and/or electrolyte
    n1=en:hyperintense | n2=en:disorder of fluid and/or electrolyte | rel=r_associated | relid=0 | w=10
  784. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:disorganized growth plate cartilage
    n1=en:hyperintense | n2=en:disorganized growth plate cartilage | rel=r_associated | relid=0 | w=10
  785. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:disproportionate work-related increase in blood lactate and pyruvate
    n1=en:hyperintense | n2=en:disproportionate work-related increase in blood lactate and pyruvate | rel=r_associated | relid=0 | w=10
  786. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:disseminated intravascular coagulation
    n1=en:hyperintense | n2=en:disseminated intravascular coagulation | rel=r_associated | relid=0 | w=10
  787. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:distal xp22.3 segmental monosomy
    n1=en:hyperintense | n2=en:distal xp22.3 segmental monosomy | rel=r_associated | relid=0 | w=10
  788. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:disturbances of potassium balance of newborn
    n1=en:hyperintense | n2=en:disturbances of potassium balance of newborn | rel=r_associated | relid=0 | w=10
  789. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:disturbed visual and brainstem auditory evoked responses indicative of cns demyelination
    n1=en:hyperintense | n2=en:disturbed visual and brainstem auditory evoked responses indicative of cns demyelination | rel=r_associated | relid=0 | w=10
  790. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:diverse tissue cell types (vascular endothelial cells, adipocytes, schwann cells, leukocytes) have membrane-lined cytoplasmic vacuoles with amorphous and filamentous material
    n1=en:hyperintense | n2=en:diverse tissue cell types (vascular endothelial cells, adipocytes, schwann cells, leukocytes) have membrane-lined cytoplasmic vacuoles with amorphous and filamentous material | rel=r_associated | relid=0 | w=10
  791. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dolichyl-p-glc:man(9)glcnac(2)-pp-dolichyl glucosyltransferase deficiency
    n1=en:hyperintense | n2=en:dolichyl-p-glc:man(9)glcnac(2)-pp-dolichyl glucosyltransferase deficiency | rel=r_associated | relid=0 | w=10
  792. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dolichyl-p-man:man(5)glcnac(2)-pp-dolichyl mannosyltransferase deficiency
    n1=en:hyperintense | n2=en:dolichyl-p-man:man(5)glcnac(2)-pp-dolichyl mannosyltransferase deficiency | rel=r_associated | relid=0 | w=10
  793. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:duplication or deletion at 11p15.5
    n1=en:hyperintense | n2=en:duplication or deletion at 11p15.5 | rel=r_associated | relid=0 | w=10
  794. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dyskinetic ciliary motility
    n1=en:hyperintense | n2=en:dyskinetic ciliary motility | rel=r_associated | relid=0 | w=10
  795. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:dyslipidemia
    n1=en:hyperintense | n2=en:dyslipidemia | rel=r_associated | relid=0 | w=10
  796. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:echocardiogram abnormal
    n1=en:hyperintense | n2=en:echocardiogram abnormal | rel=r_associated | relid=0 | w=10
  797. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:effects of thirst
    n1=en:hyperintense | n2=en:effects of thirst | rel=r_associated | relid=0 | w=10
  798. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electrocardiogram abnormal
    n1=en:hyperintense | n2=en:electrocardiogram abnormal | rel=r_associated | relid=0 | w=10
  799. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electrolyte and fluid disorders nec in icd9cm_2014
    n1=en:hyperintense | n2=en:electrolyte and fluid disorders nec in icd9cm_2014 | rel=r_associated | relid=0 | w=10
  800. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electrolyte disorder
    n1=en:hyperintense | n2=en:electrolyte disorder | rel=r_associated | relid=0 | w=10
  801. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electrolyte disturbances from intractable diarrhea
    n1=en:hyperintense | n2=en:electrolyte disturbances from intractable diarrhea | rel=r_associated | relid=0 | w=10
  802. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electrolyte imbalance
    n1=en:hyperintense | n2=en:electrolyte imbalance | rel=r_associated | relid=0 | w=10
  803. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electrolyte management: hyperkalemia
    n1=en:hyperintense | n2=en:electrolyte management: hyperkalemia | rel=r_associated | relid=0 | w=10
  804. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electrolyturia (1 patient)
    n1=en:hyperintense | n2=en:electrolyturia (1 patient) | rel=r_associated | relid=0 | w=10
  805. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electron microscopy of foam cells shows lamellar inclusions
    n1=en:hyperintense | n2=en:electron microscopy of foam cells shows lamellar inclusions | rel=r_associated | relid=0 | w=10
  806. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electron microscopy of patient respiratory cells shows absent inner and outer dynein arms
    n1=en:hyperintense | n2=en:electron microscopy of patient respiratory cells shows absent inner and outer dynein arms | rel=r_associated | relid=0 | w=10
  807. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electron microscopy of patient respiratory cells shows absent outer dynein arms
    n1=en:hyperintense | n2=en:electron microscopy of patient respiratory cells shows absent outer dynein arms | rel=r_associated | relid=0 | w=10
  808. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electron microscopy of patient respiratory cells shows absent outer dynein arms in the axoneme
    n1=en:hyperintense | n2=en:electron microscopy of patient respiratory cells shows absent outer dynein arms in the axoneme | rel=r_associated | relid=0 | w=10
  809. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electron microscopy of patient respiratory cells shows defects in inner and outer dynein arms
    n1=en:hyperintense | n2=en:electron microscopy of patient respiratory cells shows defects in inner and outer dynein arms | rel=r_associated | relid=0 | w=10
  810. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electron microscopy of patient respiratory cells shows defects of outer dynein arms
    n1=en:hyperintense | n2=en:electron microscopy of patient respiratory cells shows defects of outer dynein arms | rel=r_associated | relid=0 | w=10
  811. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electron microscopy of patient respiratory cells shows loss of ciliary outer dynein arms
    n1=en:hyperintense | n2=en:electron microscopy of patient respiratory cells shows loss of ciliary outer dynein arms | rel=r_associated | relid=0 | w=10
  812. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electron microscopy of patient respiratory cells shows reduced inner dynein arms and nexin links
    n1=en:hyperintense | n2=en:electron microscopy of patient respiratory cells shows reduced inner dynein arms and nexin links | rel=r_associated | relid=0 | w=10
  813. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:electroretinogram is abnormal--rod responses are mildly abnormal and cone responses are markedly diminished
    n1=en:hyperintense | n2=en:electroretinogram is abnormal--rod responses are mildly abnormal and cone responses are markedly diminished | rel=r_associated | relid=0 | w=10
  814. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated 1,25(oh)2 d3
    n1=en:hyperintense | n2=en:elevated 1,25(oh)2 d3 | rel=r_associated | relid=0 | w=10
  815. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated 17-hydroxyprogesterone
    n1=en:hyperintense | n2=en:elevated 17-hydroxyprogesterone | rel=r_associated | relid=0 | w=10
  816. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated 2-ketoglutarate (urine)
    n1=en:hyperintense | n2=en:elevated 2-ketoglutarate (urine) | rel=r_associated | relid=0 | w=10
  817. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated 3-hydroxypropionic acid
    n1=en:hyperintense | n2=en:elevated 3-hydroxypropionic acid | rel=r_associated | relid=0 | w=10
  818. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated 3-methylcitric acid
    n1=en:hyperintense | n2=en:elevated 3-methylcitric acid | rel=r_associated | relid=0 | w=10
  819. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated 7-dehydrocholesterol
    n1=en:hyperintense | n2=en:elevated 7-dehydrocholesterol | rel=r_associated | relid=0 | w=10
  820. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated 8-dehydrocholesterol
    n1=en:hyperintense | n2=en:elevated 8-dehydrocholesterol | rel=r_associated | relid=0 | w=10
  821. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated 8(9)-cholestenol
    n1=en:hyperintense | n2=en:elevated 8(9)-cholestenol | rel=r_associated | relid=0 | w=10
  822. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated acth
    n1=en:hyperintense | n2=en:elevated acth | rel=r_associated | relid=0 | w=10
  823. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated afp (endodermal sinus tumor)
    n1=en:hyperintense | n2=en:elevated afp (endodermal sinus tumor) | rel=r_associated | relid=0 | w=10
  824. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated alkaline phosphatase
    n1=en:hyperintense | n2=en:elevated alkaline phosphatase | rel=r_associated | relid=0 | w=10
  825. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated alkaline phosphatase (if more than one affected site)
    n1=en:hyperintense | n2=en:elevated alkaline phosphatase (if more than one affected site) | rel=r_associated | relid=0 | w=10
  826. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated alkaline phosphatase (in one patient)
    n1=en:hyperintense | n2=en:elevated alkaline phosphatase (in one patient) | rel=r_associated | relid=0 | w=10
  827. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated alkaline phosphatase (varies from 1.3-20 times age-adjusted upper limit of normal)
    n1=en:hyperintense | n2=en:elevated alkaline phosphatase (varies from 1.3-20 times age-adjusted upper limit of normal) | rel=r_associated | relid=0 | w=10
  828. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated alkaline phosphatase of bone origin
    n1=en:hyperintense | n2=en:elevated alkaline phosphatase of bone origin | rel=r_associated | relid=0 | w=10
  829. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated alpha-ketoglutarate (in most patients)
    n1=en:hyperintense | n2=en:elevated alpha-ketoglutarate (in most patients) | rel=r_associated | relid=0 | w=10
  830. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated ammonia
    n1=en:hyperintense | n2=en:elevated ammonia | rel=r_associated | relid=0 | w=10
  831. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated androstenedione
    n1=en:hyperintense | n2=en:elevated androstenedione | rel=r_associated | relid=0 | w=10
  832. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated androstenedione and testosterone
    n1=en:hyperintense | n2=en:elevated androstenedione and testosterone | rel=r_associated | relid=0 | w=10
  833. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated antinuclear antibody (ana) (speckled pattern)
    n1=en:hyperintense | n2=en:elevated antinuclear antibody (ana) (speckled pattern) | rel=r_associated | relid=0 | w=10
  834. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated apoa-i (1.8x normal) in homozygotes
    n1=en:hyperintense | n2=en:elevated apoa-i (1.8x normal) in homozygotes | rel=r_associated | relid=0 | w=10
  835. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated ast (aspartate aminotransferase) and cpk (creatine phosphokinase)
    n1=en:hyperintense | n2=en:elevated ast (aspartate aminotransferase) and cpk (creatine phosphokinase) | rel=r_associated | relid=0 | w=10
  836. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated ast and ldh, especially infantile-onset
    n1=en:hyperintense | n2=en:elevated ast and ldh, especially infantile-onset | rel=r_associated | relid=0 | w=10
  837. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated bilirubin (bilirubinemia)
    n1=en:hyperintense | n2=en:elevated bilirubin (bilirubinemia) | rel=r_associated | relid=0 | w=10
  838. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated biopterin in csf
    n1=en:hyperintense | n2=en:elevated biopterin in csf | rel=r_associated | relid=0 | w=10
  839. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated blood spot hydroxybutyryl carnitine
    n1=en:hyperintense | n2=en:elevated blood spot hydroxybutyryl carnitine | rel=r_associated | relid=0 | w=10
  840. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated branched-chain amino acids (in most patients)
    n1=en:hyperintense | n2=en:elevated branched-chain amino acids (in most patients) | rel=r_associated | relid=0 | w=10
  841. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated calcitonin
    n1=en:hyperintense | n2=en:elevated calcitonin | rel=r_associated | relid=0 | w=10
  842. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated catecholamines (in patients with pheochromocytoma)
    n1=en:hyperintense | n2=en:elevated catecholamines (in patients with pheochromocytoma) | rel=r_associated | relid=0 | w=10
  843. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated cerebrospinal fluid (csf) protein
    n1=en:hyperintense | n2=en:elevated cerebrospinal fluid (csf) protein | rel=r_associated | relid=0 | w=10
  844. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated cholesta-8,14-dien-3-beta-ol in cultured fibroblasts
    n1=en:hyperintense | n2=en:elevated cholesta-8,14-dien-3-beta-ol in cultured fibroblasts | rel=r_associated | relid=0 | w=10
  845. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated circulating parathyroid hormone (pth) level
    n1=en:hyperintense | n2=en:elevated circulating parathyroid hormone (pth) level | rel=r_associated | relid=0 | w=10
  846. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated creatine kinase (in some patients)
    n1=en:hyperintense | n2=en:elevated creatine kinase (in some patients) | rel=r_associated | relid=0 | w=10
  847. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated crp
    n1=en:hyperintense | n2=en:elevated crp | rel=r_associated | relid=0 | w=10
  848. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated csf amino acids (arginine, ornithine, aspartate, threonine, glycine, and methionine)
    n1=en:hyperintense | n2=en:elevated csf amino acids (arginine, ornithine, aspartate, threonine, glycine, and methionine) | rel=r_associated | relid=0 | w=10
  849. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated csf glycine
    n1=en:hyperintense | n2=en:elevated csf glycine | rel=r_associated | relid=0 | w=10
  850. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated csf/plasma glycine ratio
    n1=en:hyperintense | n2=en:elevated csf/plasma glycine ratio | rel=r_associated | relid=0 | w=10
  851. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated d-2-hydroxyglutaric acid (urine, plasma, csf)
    n1=en:hyperintense | n2=en:elevated d-2-hydroxyglutaric acid (urine, plasma, csf) | rel=r_associated | relid=0 | w=10
  852. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated dihydrobiopterin in csf
    n1=en:hyperintense | n2=en:elevated dihydrobiopterin in csf | rel=r_associated | relid=0 | w=10
  853. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated erythrocyte adenosine deaminase
    n1=en:hyperintense | n2=en:elevated erythrocyte adenosine deaminase | rel=r_associated | relid=0 | w=10
  854. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated erythrocyte adenosine deaminase (eada)
    n1=en:hyperintense | n2=en:elevated erythrocyte adenosine deaminase (eada) | rel=r_associated | relid=0 | w=10
  855. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated erythrocyte adenosine deaminase activity
    n1=en:hyperintense | n2=en:elevated erythrocyte adenosine deaminase activity | rel=r_associated | relid=0 | w=10
  856. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated erythrocyte aicar (zmp)
    n1=en:hyperintense | n2=en:elevated erythrocyte aicar (zmp) | rel=r_associated | relid=0 | w=10
  857. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated erythrocyte sedimentation rate (esr)
    n1=en:hyperintense | n2=en:elevated erythrocyte sedimentation rate (esr) | rel=r_associated | relid=0 | w=10
  858. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated erythrocyte sedimentation rate (mean 90mm/h)
    n1=en:hyperintense | n2=en:elevated erythrocyte sedimentation rate (mean 90mm/h) | rel=r_associated | relid=0 | w=10
  859. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated fasting glucose
    n1=en:hyperintense | n2=en:elevated fasting glucose | rel=r_associated | relid=0 | w=10
  860. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated fasting triglycerides
    n1=en:hyperintense | n2=en:elevated fasting triglycerides | rel=r_associated | relid=0 | w=10
  861. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated fasting triglycerides (seen in heterozygotes as well)
    n1=en:hyperintense | n2=en:elevated fasting triglycerides (seen in heterozygotes as well) | rel=r_associated | relid=0 | w=10
  862. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated fecal levels of protoporphyrin and coproporphyrin at all times
    n1=en:hyperintense | n2=en:elevated fecal levels of protoporphyrin and coproporphyrin at all times | rel=r_associated | relid=0 | w=10
  863. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated ferritin l subunit
    n1=en:hyperintense | n2=en:elevated ferritin l subunit | rel=r_associated | relid=0 | w=10
  864. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated fibroblast free sialic acid
    n1=en:hyperintense | n2=en:elevated fibroblast free sialic acid | rel=r_associated | relid=0 | w=10
  865. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated free carnitine
    n1=en:hyperintense | n2=en:elevated free carnitine | rel=r_associated | relid=0 | w=10
  866. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated gamma-glutamyltransferase
    n1=en:hyperintense | n2=en:elevated gamma-glutamyltransferase | rel=r_associated | relid=0 | w=10
  867. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated gamma-glutamyltransferase (ggt)
    n1=en:hyperintense | n2=en:elevated gamma-glutamyltransferase (ggt) | rel=r_associated | relid=0 | w=10
  868. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated gastrin concentration
    n1=en:hyperintense | n2=en:elevated gastrin concentration | rel=r_associated | relid=0 | w=10
  869. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated hcg (choriocarcinoma)
    n1=en:hyperintense | n2=en:elevated hcg (choriocarcinoma) | rel=r_associated | relid=0 | w=10
  870. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated hcg or afp or both (embryonal carcinoma)
    n1=en:hyperintense | n2=en:elevated hcg or afp or both (embryonal carcinoma) | rel=r_associated | relid=0 | w=10
  871. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated hdl (2-6x normal) in homozygotes
    n1=en:hyperintense | n2=en:elevated hdl (2-6x normal) in homozygotes | rel=r_associated | relid=0 | w=10
  872. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated hepatic transaminases
    n1=en:hyperintense | n2=en:elevated hepatic transaminases | rel=r_associated | relid=0 | w=10
  873. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated il1-beta
    n1=en:hyperintense | n2=en:elevated il1-beta | rel=r_associated | relid=0 | w=10
  874. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated il6
    n1=en:hyperintense | n2=en:elevated il6 | rel=r_associated | relid=0 | w=10
  875. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated inflammatory markers
    n1=en:hyperintense | n2=en:elevated inflammatory markers | rel=r_associated | relid=0 | w=10
  876. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated l-2-hydroxyglutaric acid (urine)
    n1=en:hyperintense | n2=en:elevated l-2-hydroxyglutaric acid (urine) | rel=r_associated | relid=0 | w=10
  877. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated lathosterol
    n1=en:hyperintense | n2=en:elevated lathosterol | rel=r_associated | relid=0 | w=10
  878. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated leukotriene e(4)
    n1=en:hyperintense | n2=en:elevated leukotriene e(4) | rel=r_associated | relid=0 | w=10
  879. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated levels of vitamin b12
    n1=en:hyperintense | n2=en:elevated levels of vitamin b12 | rel=r_associated | relid=0 | w=10
  880. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated liver enzymes
    n1=en:hyperintense | n2=en:elevated liver enzymes | rel=r_associated | relid=0 | w=10
  881. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated liver function tests
    n1=en:hyperintense | n2=en:elevated liver function tests | rel=r_associated | relid=0 | w=10
  882. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated liver transaminases
    n1=en:hyperintense | n2=en:elevated liver transaminases | rel=r_associated | relid=0 | w=10
  883. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated long chain fatty acids
    n1=en:hyperintense | n2=en:elevated long chain fatty acids | rel=r_associated | relid=0 | w=10
  884. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated long-chain acylcarnitine species (in some patients)
    n1=en:hyperintense | n2=en:elevated long-chain acylcarnitine species (in some patients) | rel=r_associated | relid=0 | w=10
  885. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated mchc
    n1=en:hyperintense | n2=en:elevated mchc | rel=r_associated | relid=0 | w=10
  886. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma acth
    n1=en:hyperintense | n2=en:elevated plasma acth | rel=r_associated | relid=0 | w=10
  887. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma adrenocorticotropic hormone (acth)
    n1=en:hyperintense | n2=en:elevated plasma adrenocorticotropic hormone (acth) | rel=r_associated | relid=0 | w=10
  888. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma alloisoleucine
    n1=en:hyperintense | n2=en:elevated plasma alloisoleucine | rel=r_associated | relid=0 | w=10
  889. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma ammonia
    n1=en:hyperintense | n2=en:elevated plasma ammonia | rel=r_associated | relid=0 | w=10
  890. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma and urine inorganic pyrophosphate (ppi)
    n1=en:hyperintense | n2=en:elevated plasma and urine inorganic pyrophosphate (ppi) | rel=r_associated | relid=0 | w=10
  891. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma and urine succinylacetone
    n1=en:hyperintense | n2=en:elevated plasma and urine succinylacetone | rel=r_associated | relid=0 | w=10
  892. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma beta-sitosterol (sitosterolemia or phytosterolemia)
    n1=en:hyperintense | n2=en:elevated plasma beta-sitosterol (sitosterolemia or phytosterolemia) | rel=r_associated | relid=0 | w=10
  893. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma branched chain amino acids (leucine, isoleucine, valine)
    n1=en:hyperintense | n2=en:elevated plasma branched chain amino acids (leucine, isoleucine, valine) | rel=r_associated | relid=0 | w=10
  894. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma campesterol
    n1=en:hyperintense | n2=en:elevated plasma campesterol | rel=r_associated | relid=0 | w=10
  895. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma cholestanol
    n1=en:hyperintense | n2=en:elevated plasma cholestanol | rel=r_associated | relid=0 | w=10
  896. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma citrulline (citrullinemia)
    n1=en:hyperintense | n2=en:elevated plasma citrulline (citrullinemia) | rel=r_associated | relid=0 | w=10
  897. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma desmosterol
    n1=en:hyperintense | n2=en:elevated plasma desmosterol | rel=r_associated | relid=0 | w=10
  898. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma estrogen
    n1=en:hyperintense | n2=en:elevated plasma estrogen | rel=r_associated | relid=0 | w=10
  899. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma follicle stimulating hormone (fsh)
    n1=en:hyperintense | n2=en:elevated plasma follicle stimulating hormone (fsh) | rel=r_associated | relid=0 | w=10
  900. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma galactose (galactosemia)
    n1=en:hyperintense | n2=en:elevated plasma galactose (galactosemia) | rel=r_associated | relid=0 | w=10
  901. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma insulin
    n1=en:hyperintense | n2=en:elevated plasma insulin | rel=r_associated | relid=0 | w=10
  902. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma levels of lp(a)
    n1=en:hyperintense | n2=en:elevated plasma levels of lp(a) | rel=r_associated | relid=0 | w=10
  903. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma luteinizing hormone (lh)
    n1=en:hyperintense | n2=en:elevated plasma luteinizing hormone (lh) | rel=r_associated | relid=0 | w=10
  904. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma methionine (methioninemia)
    n1=en:hyperintense | n2=en:elevated plasma methionine (methioninemia) | rel=r_associated | relid=0 | w=10
  905. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma ornithine (~10-fold)
    n1=en:hyperintense | n2=en:elevated plasma ornithine (~10-fold) | rel=r_associated | relid=0 | w=10
  906. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma phytanic acid
    n1=en:hyperintense | n2=en:elevated plasma phytanic acid | rel=r_associated | relid=0 | w=10
  907. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma propionylcarnitine
    n1=en:hyperintense | n2=en:elevated plasma propionylcarnitine | rel=r_associated | relid=0 | w=10
  908. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated plasma stigmasterol
    n1=en:hyperintense | n2=en:elevated plasma stigmasterol | rel=r_associated | relid=0 | w=10
  909. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated pregnenolone
    n1=en:hyperintense | n2=en:elevated pregnenolone | rel=r_associated | relid=0 | w=10
  910. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated progesterone
    n1=en:hyperintense | n2=en:elevated progesterone | rel=r_associated | relid=0 | w=10
  911. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated propionate
    n1=en:hyperintense | n2=en:elevated propionate | rel=r_associated | relid=0 | w=10
  912. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated prothrombin time
    n1=en:hyperintense | n2=en:elevated prothrombin time | rel=r_associated | relid=0 | w=10
  913. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated pth (parathyroid hormone)
    n1=en:hyperintense | n2=en:elevated pth (parathyroid hormone) | rel=r_associated | relid=0 | w=10
  914. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated pyruvate (in most patients)
    n1=en:hyperintense | n2=en:elevated pyruvate (in most patients) | rel=r_associated | relid=0 | w=10
  915. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated resting serum lactate, increased with exercise
    n1=en:hyperintense | n2=en:elevated resting serum lactate, increased with exercise | rel=r_associated | relid=0 | w=10
  916. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated sed rate
    n1=en:hyperintense | n2=en:elevated sed rate | rel=r_associated | relid=0 | w=10
  917. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated sepiapterin in csf
    n1=en:hyperintense | n2=en:elevated sepiapterin in csf | rel=r_associated | relid=0 | w=10
  918. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum acid phosphatase
    n1=en:hyperintense | n2=en:elevated serum acid phosphatase | rel=r_associated | relid=0 | w=10
  919. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum alkaline phosphatase during hyperplastic callus formation
    n1=en:hyperintense | n2=en:elevated serum alkaline phosphatase during hyperplastic callus formation | rel=r_associated | relid=0 | w=10
  920. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum alpha-fetoprotein
    n1=en:hyperintense | n2=en:elevated serum alpha-fetoprotein | rel=r_associated | relid=0 | w=10
  921. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum alpha-fetoprotein (dominant)
    n1=en:hyperintense | n2=en:elevated serum alpha-fetoprotein (dominant) | rel=r_associated | relid=0 | w=10
  922. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum angiotensin-converting enzyme (ace)
    n1=en:hyperintense | n2=en:elevated serum angiotensin-converting enzyme (ace) | rel=r_associated | relid=0 | w=10
  923. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum bile acids
    n1=en:hyperintense | n2=en:elevated serum bile acids | rel=r_associated | relid=0 | w=10
  924. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum glutamic oxaloacetic transaminase (sgot)
    n1=en:hyperintense | n2=en:elevated serum glutamic oxaloacetic transaminase (sgot) | rel=r_associated | relid=0 | w=10
  925. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum glutamic pyruvic transaminase (sgpt)
    n1=en:hyperintense | n2=en:elevated serum glutamic pyruvic transaminase (sgpt) | rel=r_associated | relid=0 | w=10
  926. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum insulin-to-c-peptide ratio
    n1=en:hyperintense | n2=en:elevated serum insulin-to-c-peptide ratio | rel=r_associated | relid=0 | w=10
  927. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum iron
    n1=en:hyperintense | n2=en:elevated serum iron | rel=r_associated | relid=0 | w=10
  928. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum iron and iron binding capacity
    n1=en:hyperintense | n2=en:elevated serum iron and iron binding capacity | rel=r_associated | relid=0 | w=10
  929. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum lactate
    n1=en:hyperintense | n2=en:elevated serum lactate | rel=r_associated | relid=0 | w=10
  930. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum levels of 2-prime deoxyadenosine
    n1=en:hyperintense | n2=en:elevated serum levels of 2-prime deoxyadenosine | rel=r_associated | relid=0 | w=10
  931. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum levels of adenosine
    n1=en:hyperintense | n2=en:elevated serum levels of adenosine | rel=r_associated | relid=0 | w=10
  932. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum levels of follicle stimulating hormone (fsh)
    n1=en:hyperintense | n2=en:elevated serum levels of follicle stimulating hormone (fsh) | rel=r_associated | relid=0 | w=10
  933. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum levels of luteinizing hormone (lh)
    n1=en:hyperintense | n2=en:elevated serum levels of luteinizing hormone (lh) | rel=r_associated | relid=0 | w=10
  934. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum long-chain fatty acids
    n1=en:hyperintense | n2=en:elevated serum long-chain fatty acids | rel=r_associated | relid=0 | w=10
  935. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum lysozyme
    n1=en:hyperintense | n2=en:elevated serum lysozyme | rel=r_associated | relid=0 | w=10
  936. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum n,n-dimethylglycine (dmg)
    n1=en:hyperintense | n2=en:elevated serum n,n-dimethylglycine (dmg) | rel=r_associated | relid=0 | w=10
  937. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum parathyroid hormone (pth)
    n1=en:hyperintense | n2=en:elevated serum parathyroid hormone (pth) | rel=r_associated | relid=0 | w=10
  938. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum parathyroid hormone (pth) level
    n1=en:hyperintense | n2=en:elevated serum parathyroid hormone (pth) level | rel=r_associated | relid=0 | w=10
  939. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum phosphate in heterozygotes
    n1=en:hyperintense | n2=en:elevated serum phosphate in heterozygotes | rel=r_associated | relid=0 | w=10
  940. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum phosphorus
    n1=en:hyperintense | n2=en:elevated serum phosphorus | rel=r_associated | relid=0 | w=10
  941. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum protein
    n1=en:hyperintense | n2=en:elevated serum protein | rel=r_associated | relid=0 | w=10
  942. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum transaminase levels
    n1=en:hyperintense | n2=en:elevated serum transaminase levels | rel=r_associated | relid=0 | w=10
  943. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum transaminases during infections
    n1=en:hyperintense | n2=en:elevated serum transaminases during infections | rel=r_associated | relid=0 | w=10
  944. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum transferrin saturation
    n1=en:hyperintense | n2=en:elevated serum transferrin saturation | rel=r_associated | relid=0 | w=10
  945. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated serum uric acid concentrations
    n1=en:hyperintense | n2=en:elevated serum uric acid concentrations | rel=r_associated | relid=0 | w=10
  946. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated sweat chloride
    n1=en:hyperintense | n2=en:elevated sweat chloride | rel=r_associated | relid=0 | w=10
  947. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated sweat chloride (some)
    n1=en:hyperintense | n2=en:elevated sweat chloride (some) | rel=r_associated | relid=0 | w=10
  948. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated testosterone
    n1=en:hyperintense | n2=en:elevated testosterone | rel=r_associated | relid=0 | w=10
  949. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated total bilirubin
    n1=en:hyperintense | n2=en:elevated total bilirubin | rel=r_associated | relid=0 | w=10
  950. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated total cholesterol (seen in heterozygotes as well)
    n1=en:hyperintense | n2=en:elevated total cholesterol (seen in heterozygotes as well) | rel=r_associated | relid=0 | w=10
  951. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated total iron-binding capacity
    n1=en:hyperintense | n2=en:elevated total iron-binding capacity | rel=r_associated | relid=0 | w=10
  952. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated uric acid on urinalysis (in some patients)
    n1=en:hyperintense | n2=en:elevated uric acid on urinalysis (in some patients) | rel=r_associated | relid=0 | w=10
  953. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary 2-ethylhydracrylate
    n1=en:hyperintense | n2=en:elevated urinary 2-ethylhydracrylate | rel=r_associated | relid=0 | w=10
  954. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary 3-methylglutaconate
    n1=en:hyperintense | n2=en:elevated urinary 3-methylglutaconate | rel=r_associated | relid=0 | w=10
  955. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary 3-methylglutarate
    n1=en:hyperintense | n2=en:elevated urinary 3-methylglutarate | rel=r_associated | relid=0 | w=10
  956. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary 7 alpha-hydroxylated bile alcohols
    n1=en:hyperintense | n2=en:elevated urinary 7 alpha-hydroxylated bile alcohols | rel=r_associated | relid=0 | w=10
  957. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary and csf 5-amino-4-imidazolecarboxyamide (aica-riboside)
    n1=en:hyperintense | n2=en:elevated urinary and csf 5-amino-4-imidazolecarboxyamide (aica-riboside) | rel=r_associated | relid=0 | w=10
  958. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary and csf ribitol and d-arabitol
    n1=en:hyperintense | n2=en:elevated urinary and csf ribitol and d-arabitol | rel=r_associated | relid=0 | w=10
  959. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary delta-aminolevulinic acid
    n1=en:hyperintense | n2=en:elevated urinary delta-aminolevulinic acid | rel=r_associated | relid=0 | w=10
  960. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary delta-aminolevulinic acid and porphyrins
    n1=en:hyperintense | n2=en:elevated urinary delta-aminolevulinic acid and porphyrins | rel=r_associated | relid=0 | w=10
  961. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary epinephrine
    n1=en:hyperintense | n2=en:elevated urinary epinephrine | rel=r_associated | relid=0 | w=10
  962. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary free sialic acid (n-acetylneuraminic acid)
    n1=en:hyperintense | n2=en:elevated urinary free sialic acid (n-acetylneuraminic acid) | rel=r_associated | relid=0 | w=10
  963. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary hyaluronic acid levels
    n1=en:hyperintense | n2=en:elevated urinary hyaluronic acid levels | rel=r_associated | relid=0 | w=10
  964. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary mevalonic acid
    n1=en:hyperintense | n2=en:elevated urinary mevalonic acid | rel=r_associated | relid=0 | w=10
  965. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary n,n-dimethylglycine (dmg)
    n1=en:hyperintense | n2=en:elevated urinary n,n-dimethylglycine (dmg) | rel=r_associated | relid=0 | w=10
  966. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary ornithine, lysine, arginine
    n1=en:hyperintense | n2=en:elevated urinary ornithine, lysine, arginine | rel=r_associated | relid=0 | w=10
  967. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary pge(2) levels
    n1=en:hyperintense | n2=en:elevated urinary pge(2) levels | rel=r_associated | relid=0 | w=10
  968. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary phosphoethanolamine
    n1=en:hyperintense | n2=en:elevated urinary phosphoethanolamine | rel=r_associated | relid=0 | w=10
  969. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urinary pyridinoline and deoxypyridinoline
    n1=en:hyperintense | n2=en:elevated urinary pyridinoline and deoxypyridinoline | rel=r_associated | relid=0 | w=10
  970. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urine ceramide levels
    n1=en:hyperintense | n2=en:elevated urine ceramide levels | rel=r_associated | relid=0 | w=10
  971. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated urine unsulfated chondroitin sulfate
    n1=en:hyperintense | n2=en:elevated urine unsulfated chondroitin sulfate | rel=r_associated | relid=0 | w=10
  972. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:elevated white blood cell cystine
    n1=en:hyperintense | n2=en:elevated white blood cell cystine | rel=r_associated | relid=0 | w=10
  973. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:embryologic
    n1=en:hyperintense | n2=en:embryologic | rel=r_associated | relid=0 | w=10
  974. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:enlarged cytoplasmic vacuoles in bone, muscle, and brain tissue
    n1=en:hyperintense | n2=en:enlarged cytoplasmic vacuoles in bone, muscle, and brain tissue | rel=r_associated | relid=0 | w=10
  975. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:enzyme deficiency
    n1=en:hyperintense | n2=en:enzyme deficiency | rel=r_associated | relid=0 | w=10
  976. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:enzyme replacement therapy has not been effective
    n1=en:hyperintense | n2=en:enzyme replacement therapy has not been effective | rel=r_associated | relid=0 | w=10
  977. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:enzymology
    n1=en:hyperintense | n2=en:enzymology | rel=r_associated | relid=0 | w=10
  978. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:eosinophilia
    n1=en:hyperintense | n2=en:eosinophilia | rel=r_associated | relid=0 | w=10
  979. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:eosinophilia, mild
    n1=en:hyperintense | n2=en:eosinophilia, mild | rel=r_associated | relid=0 | w=10
  980. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:epidemiologic
    n1=en:hyperintense | n2=en:epidemiologic | rel=r_associated | relid=0 | w=10
  981. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:epidermal hyperkeratosis
    n1=en:hyperintense | n2=en:epidermal hyperkeratosis | rel=r_associated | relid=0 | w=10
  982. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:epidermolytic acanthoma
    n1=en:hyperintense | n2=en:epidermolytic acanthoma | rel=r_associated | relid=0 | w=10
  983. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:epidermolytic hyperkeratosis
    n1=en:hyperintense | n2=en:epidermolytic hyperkeratosis | rel=r_associated | relid=0 | w=10
  984. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:epidermolytic hyperkeratosis, late-onset
    n1=en:hyperintense | n2=en:epidermolytic hyperkeratosis, late-onset | rel=r_associated | relid=0 | w=10
  985. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:epidermolytic palmoplantar keratoderma
    n1=en:hyperintense | n2=en:epidermolytic palmoplantar keratoderma | rel=r_associated | relid=0 | w=10
  986. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:epidermolytic palmoplantar keratoderma of vorner
    n1=en:hyperintense | n2=en:epidermolytic palmoplantar keratoderma of vorner | rel=r_associated | relid=0 | w=10
  987. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:eplerenone
    n1=en:hyperintense | n2=en:eplerenone | rel=r_associated | relid=0 | w=10
  988. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:eplerenone 100mg tablet
    n1=en:hyperintense | n2=en:eplerenone 100mg tablet | rel=r_associated | relid=0 | w=10
  989. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:eplerenone 25mg tablet
    n1=en:hyperintense | n2=en:eplerenone 25mg tablet | rel=r_associated | relid=0 | w=10
  990. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:eplerenone 50mg tablet
    n1=en:hyperintense | n2=en:eplerenone 50mg tablet | rel=r_associated | relid=0 | w=10
  991. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:epstein-barr viraemia
    n1=en:hyperintense | n2=en:epstein-barr viraemia | rel=r_associated | relid=0 | w=10
  992. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:erythrocyte delta-aminolevulinate dehydratase (alad) deficiency
    n1=en:hyperintense | n2=en:erythrocyte delta-aminolevulinate dehydratase (alad) deficiency | rel=r_associated | relid=0 | w=10
  993. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:erythrocyte porphobilinogen (pbg) deaminase deficiency (exception: type ii aip)
    n1=en:hyperintense | n2=en:erythrocyte porphobilinogen (pbg) deaminase deficiency (exception: type ii aip) | rel=r_associated | relid=0 | w=10
  994. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:erythroderma
    n1=en:hyperintense | n2=en:erythroderma | rel=r_associated | relid=0 | w=10
  995. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:erythroid colony-forming units show spontaneous growth in the absence of epo
    n1=en:hyperintense | n2=en:erythroid colony-forming units show spontaneous growth in the absence of epo | rel=r_associated | relid=0 | w=10
  996. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:erythrokeratoderma
    n1=en:hyperintense | n2=en:erythrokeratoderma | rel=r_associated | relid=0 | w=10
  997. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:erythrokeratodermia variabilis
    n1=en:hyperintense | n2=en:erythrokeratodermia variabilis | rel=r_associated | relid=0 | w=10
  998. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ethnologic
    n1=en:hyperintense | n2=en:ethnologic | rel=r_associated | relid=0 | w=10
  999. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ethylmalonic aciduria
    n1=en:hyperintense | n2=en:ethylmalonic aciduria | rel=r_associated | relid=0 | w=10
  1000. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:etiology aspects
    n1=en:hyperintense | n2=en:etiology aspects | rel=r_associated | relid=0 | w=10
  1001. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:euvolemia
    n1=en:hyperintense | n2=en:euvolemia | rel=r_associated | relid=0 | w=10
  1002. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:excess protoporphyrin in bile and feces but not in urine
    n1=en:hyperintense | n2=en:excess protoporphyrin in bile and feces but not in urine | rel=r_associated | relid=0 | w=10
  1003. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:excessive blood level of drug result
    n1=en:hyperintense | n2=en:excessive blood level of drug result | rel=r_associated | relid=0 | w=10
  1004. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:excessive iodide trapping
    n1=en:hyperintense | n2=en:excessive iodide trapping | rel=r_associated | relid=0 | w=10
  1005. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:excessive urinary 5-oxo-l-proline
    n1=en:hyperintense | n2=en:excessive urinary 5-oxo-l-proline | rel=r_associated | relid=0 | w=10
  1006. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:excretion of dermatan sulfate and heparan sulfate in urine
    n1=en:hyperintense | n2=en:excretion of dermatan sulfate and heparan sulfate in urine | rel=r_associated | relid=0 | w=10
  1007. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:exercise-induced myoglobinuria
    n1=en:hyperintense | n2=en:exercise-induced myoglobinuria | rel=r_associated | relid=0 | w=10
  1008. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:exercise-induced myoglobinuria in adults
    n1=en:hyperintense | n2=en:exercise-induced myoglobinuria in adults | rel=r_associated | relid=0 | w=10
  1009. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:exposure as collected domain
    n1=en:hyperintense | n2=en:exposure as collected domain | rel=r_associated | relid=0 | w=10
  1010. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:extremely low creatine excretion
    n1=en:hyperintense | n2=en:extremely low creatine excretion | rel=r_associated | relid=0 | w=10
  1011. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:factor vii deficiency
    n1=en:hyperintense | n2=en:factor vii deficiency | rel=r_associated | relid=0 | w=10
  1012. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:factor viii deficiency
    n1=en:hyperintense | n2=en:factor viii deficiency | rel=r_associated | relid=0 | w=10
  1013. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:farber lipogranulomatosis
    n1=en:hyperintense | n2=en:farber lipogranulomatosis | rel=r_associated | relid=0 | w=10
  1014. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fasting chylomicronemia
    n1=en:hyperintense | n2=en:fasting chylomicronemia | rel=r_associated | relid=0 | w=10
  1015. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fasting hyperinsulinemia
    n1=en:hyperintense | n2=en:fasting hyperinsulinemia | rel=r_associated | relid=0 | w=10
  1016. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fasting hypoglycemia (early in disease course)
    n1=en:hyperintense | n2=en:fasting hypoglycemia (early in disease course) | rel=r_associated | relid=0 | w=10
  1017. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fasting ketosis
    n1=en:hyperintense | n2=en:fasting ketosis | rel=r_associated | relid=0 | w=10
  1018. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fatty acid pattern of serum lecithin shows increased arachidonic acid and decreased linoleic acid
    n1=en:hyperintense | n2=en:fatty acid pattern of serum lecithin shows increased arachidonic acid and decreased linoleic acid | rel=r_associated | relid=0 | w=10
  1019. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fatty alcohol:nad+ oxidoreductase deficiency in leukocytes and fibroblasts
    n1=en:hyperintense | n2=en:fatty alcohol:nad+ oxidoreductase deficiency in leukocytes and fibroblasts | rel=r_associated | relid=0 | w=10
  1020. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:female carriers show markedly skewed x inactivation
    n1=en:hyperintense | n2=en:female carriers show markedly skewed x inactivation | rel=r_associated | relid=0 | w=10
  1021. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ferritin decreased
    n1=en:hyperintense | n2=en:ferritin decreased | rel=r_associated | relid=0 | w=10
  1022. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibrinogen decreased
    n1=en:hyperintense | n2=en:fibrinogen decreased | rel=r_associated | relid=0 | w=10
  1023. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibroblasts accumulate dol-pp-glcnac2man5
    n1=en:hyperintense | n2=en:fibroblasts accumulate dol-pp-glcnac2man5 | rel=r_associated | relid=0 | w=10
  1024. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibroblasts are small and rounded with prominent nucleoli
    n1=en:hyperintense | n2=en:fibroblasts are small and rounded with prominent nucleoli | rel=r_associated | relid=0 | w=10
  1025. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibroblasts attach poorly
    n1=en:hyperintense | n2=en:fibroblasts attach poorly | rel=r_associated | relid=0 | w=10
  1026. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibroblasts demonstrate rapid growth with increased dna synthesis
    n1=en:hyperintense | n2=en:fibroblasts demonstrate rapid growth with increased dna synthesis | rel=r_associated | relid=0 | w=10
  1027. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibroblasts have decreased levels of ceramide, sphingomyelin, lactosylceramide, ceramide trihexoside, and globoside
    n1=en:hyperintense | n2=en:fibroblasts have decreased levels of ceramide, sphingomyelin, lactosylceramide, ceramide trihexoside, and globoside | rel=r_associated | relid=0 | w=10
  1028. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibroblasts have increased activity of serine palmitoyltransferase (spt, 605712)
    n1=en:hyperintense | n2=en:fibroblasts have increased activity of serine palmitoyltransferase (spt, 605712) | rel=r_associated | relid=0 | w=10
  1029. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibroblasts show decreased activity of mitochondrial respiratory complex i, complex iii, complex iv, and complex v
    n1=en:hyperintense | n2=en:fibroblasts show decreased activity of mitochondrial respiratory complex i, complex iii, complex iv, and complex v | rel=r_associated | relid=0 | w=10
  1030. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibroblasts show decreased mitochondrial complex v activity
    n1=en:hyperintense | n2=en:fibroblasts show decreased mitochondrial complex v activity | rel=r_associated | relid=0 | w=10
  1031. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibroblasts show decreased peroxisomes arranged in rows
    n1=en:hyperintense | n2=en:fibroblasts show decreased peroxisomes arranged in rows | rel=r_associated | relid=0 | w=10
  1032. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibroblasts show elongated, tangled, tubular mitochondria
    n1=en:hyperintense | n2=en:fibroblasts show elongated, tangled, tubular mitochondria | rel=r_associated | relid=0 | w=10
  1033. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibroblasts show global defects in multiple mitochondrial respiratory chain activities
    n1=en:hyperintense | n2=en:fibroblasts show global defects in multiple mitochondrial respiratory chain activities | rel=r_associated | relid=0 | w=10
  1034. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibroblasts show hypersensitivity to uv irradiation due to defect in transcription-coupled nucleotide excision repair (tc-ner)
    n1=en:hyperintense | n2=en:fibroblasts show hypersensitivity to uv irradiation due to defect in transcription-coupled nucleotide excision repair (tc-ner) | rel=r_associated | relid=0 | w=10
  1035. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibroblasts show increased sensitivity to apoptosis
    n1=en:hyperintense | n2=en:fibroblasts show increased sensitivity to apoptosis | rel=r_associated | relid=0 | w=10
  1036. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibroblasts show lamellar lysosomal inclusions on electron microscopy
    n1=en:hyperintense | n2=en:fibroblasts show lamellar lysosomal inclusions on electron microscopy | rel=r_associated | relid=0 | w=10
  1037. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibroblasts shows defects in oxidative phosphorylation
    n1=en:hyperintense | n2=en:fibroblasts shows defects in oxidative phosphorylation | rel=r_associated | relid=0 | w=10
  1038. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fibronectin decreased
    n1=en:hyperintense | n2=en:fibronectin decreased | rel=r_associated | relid=0 | w=10
  1039. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fingerprint intracellular accumulation of autofluorescent lipopigment storage material
    n1=en:hyperintense | n2=en:fingerprint intracellular accumulation of autofluorescent lipopigment storage material | rel=r_associated | relid=0 | w=10
  1040. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fluid imbalance
    n1=en:hyperintense | n2=en:fluid imbalance | rel=r_associated | relid=0 | w=10
  1041. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fluorescence in situ hybridization specific probe for mds critical region
    n1=en:hyperintense | n2=en:fluorescence in situ hybridization specific probe for mds critical region | rel=r_associated | relid=0 | w=10
  1042. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fluorescence of red blood cells by uv microscopy
    n1=en:hyperintense | n2=en:fluorescence of red blood cells by uv microscopy | rel=r_associated | relid=0 | w=10
  1043. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:foam cells contain polymorphic cytoplasmic inclusions consisting of lamellar osmiophilic membranes on electron microscopy
    n1=en:hyperintense | n2=en:foam cells contain polymorphic cytoplasmic inclusions consisting of lamellar osmiophilic membranes on electron microscopy | rel=r_associated | relid=0 | w=10
  1044. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:foam cells in bone marrow and renal glomeruli
    n1=en:hyperintense | n2=en:foam cells in bone marrow and renal glomeruli | rel=r_associated | relid=0 | w=10
  1045. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:foam cells in visceral organs and cns
    n1=en:hyperintense | n2=en:foam cells in visceral organs and cns | rel=r_associated | relid=0 | w=10
  1046. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:focal hyperkeratosis
    n1=en:hyperintense | n2=en:focal hyperkeratosis | rel=r_associated | relid=0 | w=10
  1047. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:folate-dependent fragile site at xq28
    n1=en:hyperintense | n2=en:folate-dependent fragile site at xq28 | rel=r_associated | relid=0 | w=10
  1048. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:folic acid deficiency
    n1=en:hyperintense | n2=en:folic acid deficiency | rel=r_associated | relid=0 | w=10
  1049. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:follicular hyperkeratosis
    n1=en:hyperintense | n2=en:follicular hyperkeratosis | rel=r_associated | relid=0 | w=10
  1050. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:follicular ichthyosis
    n1=en:hyperintense | n2=en:follicular ichthyosis | rel=r_associated | relid=0 | w=10
  1051. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:foot callus
    n1=en:hyperintense | n2=en:foot callus | rel=r_associated | relid=0 | w=10
  1052. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fragmentation of the mitochondrial network
    n1=en:hyperintense | n2=en:fragmentation of the mitochondrial network | rel=r_associated | relid=0 | w=10
  1053. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:frequent deletions of chromosome 9 in melanoma
    n1=en:hyperintense | n2=en:frequent deletions of chromosome 9 in melanoma | rel=r_associated | relid=0 | w=10
  1054. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:frequent inv(10)(q11.2q21) producing chimeric transforming sequence ret/ptc
    n1=en:hyperintense | n2=en:frequent inv(10)(q11.2q21) producing chimeric transforming sequence ret/ptc | rel=r_associated | relid=0 | w=10
  1055. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fucosidosis
    n1=en:hyperintense | n2=en:fucosidosis | rel=r_associated | relid=0 | w=10
  1056. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fumarase activity (mitochondrial and cytosolic) is decreased
    n1=en:hyperintense | n2=en:fumarase activity (mitochondrial and cytosolic) is decreased | rel=r_associated | relid=0 | w=10
  1057. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fumarase deficiency
    n1=en:hyperintense | n2=en:fumarase deficiency | rel=r_associated | relid=0 | w=10
  1058. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fumarylacetoacetate hydrolase (fah) deficiency
    n1=en:hyperintense | n2=en:fumarylacetoacetate hydrolase (fah) deficiency | rel=r_associated | relid=0 | w=10
  1059. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:fungemia
    n1=en:hyperintense | n2=en:fungemia | rel=r_associated | relid=0 | w=10
  1060. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:galactocerebroside beta-galactosidase deficiency in serum, leukocytes, and fibroblasts
    n1=en:hyperintense | n2=en:galactocerebroside beta-galactosidase deficiency in serum, leukocytes, and fibroblasts | rel=r_associated | relid=0 | w=10
  1061. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:galactosemia
    n1=en:hyperintense | n2=en:galactosemia | rel=r_associated | relid=0 | w=10
  1062. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:galactosuria
    n1=en:hyperintense | n2=en:galactosuria | rel=r_associated | relid=0 | w=10
  1063. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:galactosuria without galactosemia
    n1=en:hyperintense | n2=en:galactosuria without galactosemia | rel=r_associated | relid=0 | w=10
  1064. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:galactosylation defects
    n1=en:hyperintense | n2=en:galactosylation defects | rel=r_associated | relid=0 | w=10
  1065. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:galactosyltransferase i deficiency in fibroblasts
    n1=en:hyperintense | n2=en:galactosyltransferase i deficiency in fibroblasts | rel=r_associated | relid=0 | w=10
  1066. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:gamma-glutamylcysteine deficiency
    n1=en:hyperintense | n2=en:gamma-glutamylcysteine deficiency | rel=r_associated | relid=0 | w=10
  1067. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:gamma-glutamylcysteine synthetase (glutamate-cysteine ligase) deficiency
    n1=en:hyperintense | n2=en:gamma-glutamylcysteine synthetase (glutamate-cysteine ligase) deficiency | rel=r_associated | relid=0 | w=10
  1068. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:gamma-glutamyltransferase increased
    n1=en:hyperintense | n2=en:gamma-glutamyltransferase increased | rel=r_associated | relid=0 | w=10
  1069. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:gaucher cells, diffuse, in spleen, liver, lymph nodes, bone marrow, central nervous system
    n1=en:hyperintense | n2=en:gaucher cells, diffuse, in spleen, liver, lymph nodes, bone marrow, central nervous system | rel=r_associated | relid=0 | w=10
  1070. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:gaucher disease, type 1
    n1=en:hyperintense | n2=en:gaucher disease, type 1 | rel=r_associated | relid=0 | w=10
  1071. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:generalized aminoaciduria
    n1=en:hyperintense | n2=en:generalized aminoaciduria | rel=r_associated | relid=0 | w=10
  1072. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:generalized amyloid deposition
    n1=en:hyperintense | n2=en:generalized amyloid deposition | rel=r_associated | relid=0 | w=10
  1073. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:generalized hyperkeratosis
    n1=en:hyperintense | n2=en:generalized hyperkeratosis | rel=r_associated | relid=0 | w=10
  1074. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:generalized ichthyosis
    n1=en:hyperintense | n2=en:generalized ichthyosis | rel=r_associated | relid=0 | w=10
  1075. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:genetic aspects
    n1=en:hyperintense | n2=en:genetic aspects | rel=r_associated | relid=0 | w=10
  1076. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:giant cells (degenerating chondrocytes) in resting zone of epiphyseal cartilage
    n1=en:hyperintense | n2=en:giant cells (degenerating chondrocytes) in resting zone of epiphyseal cartilage | rel=r_associated | relid=0 | w=10
  1077. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:gingival hyperkeratosis
    n1=en:hyperintense | n2=en:gingival hyperkeratosis | rel=r_associated | relid=0 | w=10
  1078. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glcnac-transferase ii deficiency in fibroblast and mononuclear cells
    n1=en:hyperintense | n2=en:glcnac-transferase ii deficiency in fibroblast and mononuclear cells | rel=r_associated | relid=0 | w=10
  1079. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:globulin gamma serum plasma increased result
    n1=en:hyperintense | n2=en:globulin gamma serum plasma increased result | rel=r_associated | relid=0 | w=10
  1080. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glomerular filtration rate decreased
    n1=en:hyperintense | n2=en:glomerular filtration rate decreased | rel=r_associated | relid=0 | w=10
  1081. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glucose breath hydrogen test shows malabsorption of glucose and galactose
    n1=en:hyperintense | n2=en:glucose breath hydrogen test shows malabsorption of glucose and galactose | rel=r_associated | relid=0 | w=10
  1082. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glucose-6-phosphate deficiency
    n1=en:hyperintense | n2=en:glucose-6-phosphate deficiency | rel=r_associated | relid=0 | w=10
  1083. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glucosidase i deficiency in liver and fibroblasts
    n1=en:hyperintense | n2=en:glucosidase i deficiency in liver and fibroblasts | rel=r_associated | relid=0 | w=10
  1084. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glucosuria, mild, intermittent
    n1=en:hyperintense | n2=en:glucosuria, mild, intermittent | rel=r_associated | relid=0 | w=10
  1085. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glutaric acidemia type 1
    n1=en:hyperintense | n2=en:glutaric acidemia type 1 | rel=r_associated | relid=0 | w=10
  1086. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glutaric aciduria
    n1=en:hyperintense | n2=en:glutaric aciduria | rel=r_associated | relid=0 | w=10
  1087. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glutathione deficiency
    n1=en:hyperintense | n2=en:glutathione deficiency | rel=r_associated | relid=0 | w=10
  1088. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glycinuria
    n1=en:hyperintense | n2=en:glycinuria | rel=r_associated | relid=0 | w=10
  1089. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glycoamino aciduria
    n1=en:hyperintense | n2=en:glycoamino aciduria | rel=r_associated | relid=0 | w=10
  1090. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glycogen accumulation in both liver and muscle
    n1=en:hyperintense | n2=en:glycogen accumulation in both liver and muscle | rel=r_associated | relid=0 | w=10
  1091. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glycogen storage disease type v
    n1=en:hyperintense | n2=en:glycogen storage disease type v | rel=r_associated | relid=0 | w=10
  1092. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glycogen storage disease type vi
    n1=en:hyperintense | n2=en:glycogen storage disease type vi | rel=r_associated | relid=0 | w=10
  1093. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glycogen storage disease type vii
    n1=en:hyperintense | n2=en:glycogen storage disease type vii | rel=r_associated | relid=0 | w=10
  1094. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glycosuria
    n1=en:hyperintense | n2=en:glycosuria | rel=r_associated | relid=0 | w=10
  1095. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glycosuria (less common)
    n1=en:hyperintense | n2=en:glycosuria (less common) | rel=r_associated | relid=0 | w=10
  1096. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:glyoxalase deficiency
    n1=en:hyperintense | n2=en:glyoxalase deficiency | rel=r_associated | relid=0 | w=10
  1097. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:gm2-ganglioside accumulation
    n1=en:hyperintense | n2=en:gm2-ganglioside accumulation | rel=r_associated | relid=0 | w=10
  1098. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:gonadotrophin increased
    n1=en:hyperintense | n2=en:gonadotrophin increased | rel=r_associated | relid=0 | w=10
  1099. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:granular osmiophilic cytoplasmic deposits (grod) ultrastructurally in cells
    n1=en:hyperintense | n2=en:granular osmiophilic cytoplasmic deposits (grod) ultrastructurally in cells | rel=r_associated | relid=0 | w=10
  1100. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:granular osmiophilic cytoplasmic deposits ultrastructurally in cells
    n1=en:hyperintense | n2=en:granular osmiophilic cytoplasmic deposits ultrastructurally in cells | rel=r_associated | relid=0 | w=10
  1101. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:granular osmiophilic deposits (grod) in cells
    n1=en:hyperintense | n2=en:granular osmiophilic deposits (grod) in cells | rel=r_associated | relid=0 | w=10
  1102. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:granular osmiophilic deposits (grod) in cells resulting in 'curvilinear' profiles ultrastructurally
    n1=en:hyperintense | n2=en:granular osmiophilic deposits (grod) in cells resulting in 'curvilinear' profiles ultrastructurally | rel=r_associated | relid=0 | w=10
  1103. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:granular osmiophilic deposits (grod) in cells resulting in 'fingerprint' profiles ultrastructurally
    n1=en:hyperintense | n2=en:granular osmiophilic deposits (grod) in cells resulting in 'fingerprint' profiles ultrastructurally | rel=r_associated | relid=0 | w=10
  1104. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:granular osmiophilic deposits (grod) in cells resulting in 'rectilinear' profiles ultrastructurally
    n1=en:hyperintense | n2=en:granular osmiophilic deposits (grod) in cells resulting in 'rectilinear' profiles ultrastructurally | rel=r_associated | relid=0 | w=10
  1105. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:greatly increased dopamine in plasma, urine, csf (approximately 10-fold increase)
    n1=en:hyperintense | n2=en:greatly increased dopamine in plasma, urine, csf (approximately 10-fold increase) | rel=r_associated | relid=0 | w=10
  1106. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:green serum
    n1=en:hyperintense | n2=en:green serum | rel=r_associated | relid=0 | w=10
  1107. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:green urine
    n1=en:hyperintense | n2=en:green urine | rel=r_associated | relid=0 | w=10
  1108. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:growth cartilage disorganized, with islands of cells and abnormal collagen arrangement
    n1=en:hyperintense | n2=en:growth cartilage disorganized, with islands of cells and abnormal collagen arrangement | rel=r_associated | relid=0 | w=10
  1109. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:guanidinoacetate methyltransferase (gamt) deficiency
    n1=en:hyperintense | n2=en:guanidinoacetate methyltransferase (gamt) deficiency | rel=r_associated | relid=0 | w=10
  1110. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hair bulb tyrosinase present
    n1=en:hyperintense | n2=en:hair bulb tyrosinase present | rel=r_associated | relid=0 | w=10
  1111. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hair bulbs will pigment when incubated with tyrosine
    n1=en:hyperintense | n2=en:hair bulbs will pigment when incubated with tyrosine | rel=r_associated | relid=0 | w=10
  1112. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:haptoglobin decreased
    n1=en:hyperintense | n2=en:haptoglobin decreased | rel=r_associated | relid=0 | w=10
  1113. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:harlequin ichthyosis
    n1=en:hyperintense | n2=en:harlequin ichthyosis | rel=r_associated | relid=0 | w=10
  1114. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hawkinsinuria
    n1=en:hyperintense | n2=en:hawkinsinuria | rel=r_associated | relid=0 | w=10
  1115. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:haxthausen's syndrome
    n1=en:hyperintense | n2=en:haxthausen's syndrome | rel=r_associated | relid=0 | w=10
  1116. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hb h erythrocyte inclusions
    n1=en:hyperintense | n2=en:hb h erythrocyte inclusions | rel=r_associated | relid=0 | w=10
  1117. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:heloma durum
    n1=en:hyperintense | n2=en:heloma durum | rel=r_associated | relid=0 | w=10
  1118. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hematuria
    n1=en:hyperintense | n2=en:hematuria | rel=r_associated | relid=0 | w=10
  1119. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hematuria (less common)
    n1=en:hyperintense | n2=en:hematuria (less common) | rel=r_associated | relid=0 | w=10
  1120. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hematuria, gross and microscopic
    n1=en:hyperintense | n2=en:hematuria, gross and microscopic | rel=r_associated | relid=0 | w=10
  1121. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hematuria, macroscopic and microscopic
    n1=en:hyperintense | n2=en:hematuria, macroscopic and microscopic | rel=r_associated | relid=0 | w=10
  1122. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hemizygous deletion at 4p16.3
    n1=en:hyperintense | n2=en:hemizygous deletion at 4p16.3 | rel=r_associated | relid=0 | w=10
  1123. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hemizygous deletion at 7q11.23
    n1=en:hyperintense | n2=en:hemizygous deletion at 7q11.23 | rel=r_associated | relid=0 | w=10
  1124. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hemoglobin decreased
    n1=en:hyperintense | n2=en:hemoglobin decreased | rel=r_associated | relid=0 | w=10
  1125. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hemoglobin f increased
    n1=en:hyperintense | n2=en:hemoglobin f increased | rel=r_associated | relid=0 | w=10
  1126. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hemoglobin increased
    n1=en:hyperintense | n2=en:hemoglobin increased | rel=r_associated | relid=0 | w=10
  1127. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hemophilia b
    n1=en:hyperintense | n2=en:hemophilia b | rel=r_associated | relid=0 | w=10
  1128. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:heparan n-sulfatase deficiency in fibroblasts and amniocytes
    n1=en:hyperintense | n2=en:heparan n-sulfatase deficiency in fibroblasts and amniocytes | rel=r_associated | relid=0 | w=10
  1129. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:heparan sulfate excretion in urine
    n1=en:hyperintense | n2=en:heparan sulfate excretion in urine | rel=r_associated | relid=0 | w=10
  1130. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:heparin cofactor ii deficiency (disorder)
    n1=en:hyperintense | n2=en:heparin cofactor ii deficiency (disorder) | rel=r_associated | relid=0 | w=10
  1131. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hepatic argininosuccinase deficiency
    n1=en:hyperintense | n2=en:hepatic argininosuccinase deficiency | rel=r_associated | relid=0 | w=10
  1132. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hepatic argininosuccinate synthetase deficiency
    n1=en:hyperintense | n2=en:hepatic argininosuccinate synthetase deficiency | rel=r_associated | relid=0 | w=10
  1133. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hepatic carbamoylphosphate synthetase i deficiency
    n1=en:hyperintense | n2=en:hepatic carbamoylphosphate synthetase i deficiency | rel=r_associated | relid=0 | w=10
  1134. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hepatic gamma-cystathionase deficiency
    n1=en:hyperintense | n2=en:hepatic gamma-cystathionase deficiency | rel=r_associated | relid=0 | w=10
  1135. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hepatic glycine cleavage defect
    n1=en:hyperintense | n2=en:hepatic glycine cleavage defect | rel=r_associated | relid=0 | w=10
  1136. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hepatic lipase deficiency (disorder)
    n1=en:hyperintense | n2=en:hepatic lipase deficiency (disorder) | rel=r_associated | relid=0 | w=10
  1137. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hepatic ornithine transcarbamylase deficiency
    n1=en:hyperintense | n2=en:hepatic ornithine transcarbamylase deficiency | rel=r_associated | relid=0 | w=10
  1138. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hereditary angioedema
    n1=en:hyperintense | n2=en:hereditary angioedema | rel=r_associated | relid=0 | w=10
  1139. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hereditary factor x deficiency
    n1=en:hyperintense | n2=en:hereditary factor x deficiency | rel=r_associated | relid=0 | w=10
  1140. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hereditary fructose intolerance
    n1=en:hyperintense | n2=en:hereditary fructose intolerance | rel=r_associated | relid=0 | w=10
  1141. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hereditary palmoplantar keratoderma
    n1=en:hyperintense | n2=en:hereditary palmoplantar keratoderma | rel=r_associated | relid=0 | w=10
  1142. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hereditary xanthinuria
    n1=en:hyperintense | n2=en:hereditary xanthinuria | rel=r_associated | relid=0 | w=10
  1143. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:heteroplasmic partial duplication of mtdna
    n1=en:hyperintense | n2=en:heteroplasmic partial duplication of mtdna | rel=r_associated | relid=0 | w=10
  1144. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high cobalt level in blood
    n1=en:hyperintense | n2=en:high cobalt level in blood | rel=r_associated | relid=0 | w=10
  1145. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high deoxypyridinoline/creatinine (in some patients)
    n1=en:hyperintense | n2=en:high deoxypyridinoline/creatinine (in some patients) | rel=r_associated | relid=0 | w=10
  1146. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high ebv viral load
    n1=en:hyperintense | n2=en:high ebv viral load | rel=r_associated | relid=0 | w=10
  1147. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high ft3/ft4 ratio
    n1=en:hyperintense | n2=en:high ft3/ft4 ratio | rel=r_associated | relid=0 | w=10
  1148. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high m-component
    n1=en:hyperintense | n2=en:high m-component | rel=r_associated | relid=0 | w=10
  1149. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high newborn serum levels of immunoreactive trypsinogen
    n1=en:hyperintense | n2=en:high newborn serum levels of immunoreactive trypsinogen | rel=r_associated | relid=0 | w=10
  1150. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high nonceruloplasmin-bound serum copper
    n1=en:hyperintense | n2=en:high nonceruloplasmin-bound serum copper | rel=r_associated | relid=0 | w=10
  1151. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high ornithine
    n1=en:hyperintense | n2=en:high ornithine | rel=r_associated | relid=0 | w=10
  1152. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high plasma asparagine
    n1=en:hyperintense | n2=en:high plasma asparagine | rel=r_associated | relid=0 | w=10
  1153. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high plasma citrulline (100-300 micromolar)
    n1=en:hyperintense | n2=en:high plasma citrulline (100-300 micromolar) | rel=r_associated | relid=0 | w=10
  1154. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high plasma citrulline (1000-5000 micromolar)
    n1=en:hyperintense | n2=en:high plasma citrulline (1000-5000 micromolar) | rel=r_associated | relid=0 | w=10
  1155. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high plasma renin activity
    n1=en:hyperintense | n2=en:high plasma renin activity | rel=r_associated | relid=0 | w=10
  1156. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high plasma triglyceride levels
    n1=en:hyperintense | n2=en:high plasma triglyceride levels | rel=r_associated | relid=0 | w=10
  1157. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high resolution g- and t- banding karyotype shows reciprocal translocation of distal 9p-6q
    n1=en:hyperintense | n2=en:high resolution g- and t- banding karyotype shows reciprocal translocation of distal 9p-6q | rel=r_associated | relid=0 | w=10
  1158. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high serum guanosine levels
    n1=en:hyperintense | n2=en:high serum guanosine levels | rel=r_associated | relid=0 | w=10
  1159. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high serum inosine levels
    n1=en:hyperintense | n2=en:high serum inosine levels | rel=r_associated | relid=0 | w=10
  1160. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high serum osmolality
    n1=en:hyperintense | n2=en:high serum osmolality | rel=r_associated | relid=0 | w=10
  1161. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high sister chromatid exchange (sce) rate
    n1=en:hyperintense | n2=en:high sister chromatid exchange (sce) rate | rel=r_associated | relid=0 | w=10
  1162. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high sweat electrolyte
    n1=en:hyperintense | n2=en:high sweat electrolyte | rel=r_associated | relid=0 | w=10
  1163. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high sweat sodium and chloride
    n1=en:hyperintense | n2=en:high sweat sodium and chloride | rel=r_associated | relid=0 | w=10
  1164. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high urinary copper
    n1=en:hyperintense | n2=en:high urinary copper | rel=r_associated | relid=0 | w=10
  1165. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high urinary excretion of inosine, 2'deoxyinosine, guanosine, and 2'deoxyguanosine
    n1=en:hyperintense | n2=en:high urinary excretion of inosine, 2'deoxyinosine, guanosine, and 2'deoxyguanosine | rel=r_associated | relid=0 | w=10
  1166. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high urinary orotic acid
    n1=en:hyperintense | n2=en:high urinary orotic acid | rel=r_associated | relid=0 | w=10
  1167. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high-normal plasma triglyceride concentration (in heterozygotes)
    n1=en:hyperintense | n2=en:high-normal plasma triglyceride concentration (in heterozygotes) | rel=r_associated | relid=0 | w=10
  1168. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:high-resolution electron microscopy tomography shows absence of projection c2b at the central pair (cp) apparatus of cilia
    n1=en:hyperintense | n2=en:high-resolution electron microscopy tomography shows absence of projection c2b at the central pair (cp) apparatus of cilia | rel=r_associated | relid=0 | w=10
  1169. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:histiocytic infiltration of liver, spleen, and lungs
    n1=en:hyperintense | n2=en:histiocytic infiltration of liver, spleen, and lungs | rel=r_associated | relid=0 | w=10
  1170. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:historical aspects qualifier
    n1=en:hyperintense | n2=en:historical aspects qualifier | rel=r_associated | relid=0 | w=10
  1171. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hiv positivity
    n1=en:hyperintense | n2=en:hiv positivity | rel=r_associated | relid=0 | w=10
  1172. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hla-b27 haplotype association (95% patients)
    n1=en:hyperintense | n2=en:hla-b27 haplotype association (95% patients) | rel=r_associated | relid=0 | w=10
  1173. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hla-dqw6 association (dqb1*0602)
    n1=en:hyperintense | n2=en:hla-dqw6 association (dqb1*0602) | rel=r_associated | relid=0 | w=10
  1174. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:holocarboxylase synthetase deficiency
    n1=en:hyperintense | n2=en:holocarboxylase synthetase deficiency | rel=r_associated | relid=0 | w=10
  1175. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:homocitrullinuria
    n1=en:hyperintense | n2=en:homocitrullinuria | rel=r_associated | relid=0 | w=10
  1176. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:homocysteinemia
    n1=en:hyperintense | n2=en:homocysteinemia | rel=r_associated | relid=0 | w=10
  1177. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:homocysteinemia (in some patients)
    n1=en:hyperintense | n2=en:homocysteinemia (in some patients) | rel=r_associated | relid=0 | w=10
  1178. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:homocystinemia
    n1=en:hyperintense | n2=en:homocystinemia | rel=r_associated | relid=0 | w=10
  1179. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:homocystinuria
    n1=en:hyperintense | n2=en:homocystinuria | rel=r_associated | relid=0 | w=10
  1180. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:homocystinuria (in some patients)
    n1=en:hyperintense | n2=en:homocystinuria (in some patients) | rel=r_associated | relid=0 | w=10
  1181. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:homozygous 122kb deletion 11p15-p14
    n1=en:hyperintense | n2=en:homozygous 122kb deletion 11p15-p14 | rel=r_associated | relid=0 | w=10
  1182. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:howell-jolly bodies seen in peripheral blood smear
    n1=en:hyperintense | n2=en:howell-jolly bodies seen in peripheral blood smear | rel=r_associated | relid=0 | w=10
  1183. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hydrocortisone decreased
    n1=en:hyperintense | n2=en:hydrocortisone decreased | rel=r_associated | relid=0 | w=10
  1184. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hydroxyprolinuria
    n1=en:hyperintense | n2=en:hydroxyprolinuria | rel=r_associated | relid=0 | w=10
  1185. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperalphalipoproteinemia
    n1=en:hyperintense | n2=en:hyperalphalipoproteinemia | rel=r_associated | relid=0 | w=10
  1186. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperammonemia
    n1=en:hyperintense | n2=en:hyperammonemia | rel=r_associated | relid=0 | w=10
  1187. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperammonemia after protein intake
    n1=en:hyperintense | n2=en:hyperammonemia after protein intake | rel=r_associated | relid=0 | w=10
  1188. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperammonemia, asymptomatic (2-5 times normal)
    n1=en:hyperintense | n2=en:hyperammonemia, asymptomatic (2-5 times normal) | rel=r_associated | relid=0 | w=10
  1189. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperammonemia, episodic
    n1=en:hyperintense | n2=en:hyperammonemia, episodic | rel=r_associated | relid=0 | w=10
  1190. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperamylasemia
    n1=en:hyperintense | n2=en:hyperamylasemia | rel=r_associated | relid=0 | w=10
  1191. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperarginemia
    n1=en:hyperintense | n2=en:hyperarginemia | rel=r_associated | relid=0 | w=10
  1192. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperbilirubinemia
    n1=en:hyperintense | n2=en:hyperbilirubinemia | rel=r_associated | relid=0 | w=10
  1193. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperbilirubinemia in those with liver failure
    n1=en:hyperintense | n2=en:hyperbilirubinemia in those with liver failure | rel=r_associated | relid=0 | w=10
  1194. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperbilirubinemia, non-hemolytic unconjugated (may rise with fasting or dehydration)
    n1=en:hyperintense | n2=en:hyperbilirubinemia, non-hemolytic unconjugated (may rise with fasting or dehydration) | rel=r_associated | relid=0 | w=10
  1195. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperbilirubinemia, unconjugated, <20mg/dl
    n1=en:hyperintense | n2=en:hyperbilirubinemia, unconjugated, <20mg/dl | rel=r_associated | relid=0 | w=10
  1196. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperbilirubinemia, unconjugated, 20-30mg/dl
    n1=en:hyperintense | n2=en:hyperbilirubinemia, unconjugated, 20-30mg/dl | rel=r_associated | relid=0 | w=10
  1197. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypercalcemia
    n1=en:hyperintense | n2=en:hypercalcemia | rel=r_associated | relid=0 | w=10
  1198. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypercalciuria
    n1=en:hyperintense | n2=en:hypercalciuria | rel=r_associated | relid=0 | w=10
  1199. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypercalciuria (in childhood)
    n1=en:hyperintense | n2=en:hypercalciuria (in childhood) | rel=r_associated | relid=0 | w=10
  1200. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypercalciuria (in some patients)
    n1=en:hyperintense | n2=en:hypercalciuria (in some patients) | rel=r_associated | relid=0 | w=10
  1201. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypercarbia
    n1=en:hyperintense | n2=en:hypercarbia | rel=r_associated | relid=0 | w=10
  1202. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperchloremia (mean >110 mm in both dominant and recessive)
    n1=en:hyperintense | n2=en:hyperchloremia (mean >110 mm in both dominant and recessive) | rel=r_associated | relid=0 | w=10
  1203. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperchloremia (mean 109 mm)
    n1=en:hyperintense | n2=en:hyperchloremia (mean 109 mm) | rel=r_associated | relid=0 | w=10
  1204. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperchloremia (mean 111 mm)
    n1=en:hyperintense | n2=en:hyperchloremia (mean 111 mm) | rel=r_associated | relid=0 | w=10
  1205. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperchloremia (mean 114 mm)
    n1=en:hyperintense | n2=en:hyperchloremia (mean 114 mm) | rel=r_associated | relid=0 | w=10
  1206. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperchloridura
    n1=en:hyperintense | n2=en:hyperchloridura | rel=r_associated | relid=0 | w=10
  1207. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypercholesterolemia
    n1=en:hyperintense | n2=en:hypercholesterolemia | rel=r_associated | relid=0 | w=10
  1208. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypercholesterolemia (10%)
    n1=en:hyperintense | n2=en:hypercholesterolemia (10%) | rel=r_associated | relid=0 | w=10
  1209. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypercholesterolemia (disorder)
    n1=en:hyperintense | n2=en:hypercholesterolemia (disorder) | rel=r_associated | relid=0 | w=10
  1210. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypercholesterolemia (in 75%)
    n1=en:hyperintense | n2=en:hypercholesterolemia (in 75%) | rel=r_associated | relid=0 | w=10
  1211. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypercholesterolemia (reported in 2 patients)
    n1=en:hyperintense | n2=en:hypercholesterolemia (reported in 2 patients) | rel=r_associated | relid=0 | w=10
  1212. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypercholesterolemia, 350-550 mg/l in heterozygotes, 650-1000 mg/l in homozygotes
    n1=en:hyperintense | n2=en:hypercholesterolemia, 350-550 mg/l in heterozygotes, 650-1000 mg/l in homozygotes | rel=r_associated | relid=0 | w=10
  1213. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypergammaglobulinemia
    n1=en:hyperintense | n2=en:hypergammaglobulinemia | rel=r_associated | relid=0 | w=10
  1214. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperglucagonemia
    n1=en:hyperintense | n2=en:hyperglucagonemia | rel=r_associated | relid=0 | w=10
  1215. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperglutaminemia
    n1=en:hyperintense | n2=en:hyperglutaminemia | rel=r_associated | relid=0 | w=10
  1216. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperglycemia
    n1=en:hyperintense | n2=en:hyperglycemia | rel=r_associated | relid=0 | w=10
  1217. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperglycemias, postprandial
    n1=en:hyperintense | n2=en:hyperglycemias, postprandial | rel=r_associated | relid=0 | w=10
  1218. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperglycinemia
    n1=en:hyperintense | n2=en:hyperglycinemia | rel=r_associated | relid=0 | w=10
  1219. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperglycinemia (1 patient)
    n1=en:hyperintense | n2=en:hyperglycinemia (1 patient) | rel=r_associated | relid=0 | w=10
  1220. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperglycinuria (disorder)
    n1=en:hyperintense | n2=en:hyperglycinuria (disorder) | rel=r_associated | relid=0 | w=10
  1221. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperglycolic aciduria
    n1=en:hyperintense | n2=en:hyperglycolic aciduria | rel=r_associated | relid=0 | w=10
  1222. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperhomocystinemia
    n1=en:hyperintense | n2=en:hyperhomocystinemia | rel=r_associated | relid=0 | w=10
  1223. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperinsulinemia
    n1=en:hyperintense | n2=en:hyperinsulinemia | rel=r_associated | relid=0 | w=10
  1224. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperinsulinemic hypoglycemia, familial, 7
    n1=en:hyperintense | n2=en:hyperinsulinemic hypoglycemia, familial, 7 | rel=r_associated | relid=0 | w=10
  1225. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkalemia
    n1=en:hyperintense | n2=en:hyperkalemia | rel=r_associated | relid=0 | w=10
  1226. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkalemia (>6.2 mm in both dominant and recessive)
    n1=en:hyperintense | n2=en:hyperkalemia (>6.2 mm in both dominant and recessive) | rel=r_associated | relid=0 | w=10
  1227. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkalemia (5.8 +/- 0.8 mm)
    n1=en:hyperintense | n2=en:hyperkalemia (5.8 +/- 0.8 mm) | rel=r_associated | relid=0 | w=10
  1228. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkalemia (6.4 +/- 0.7 mm)
    n1=en:hyperintense | n2=en:hyperkalemia (6.4 +/- 0.7 mm) | rel=r_associated | relid=0 | w=10
  1229. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkalemia (7.5 +/- 0.9 mm)
    n1=en:hyperintense | n2=en:hyperkalemia (7.5 +/- 0.9 mm) | rel=r_associated | relid=0 | w=10
  1230. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkalemia during attacks
    n1=en:hyperintense | n2=en:hyperkalemia during attacks | rel=r_associated | relid=0 | w=10
  1231. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkalemia, diminished renal excretion
    n1=en:hyperintense | n2=en:hyperkalemia, diminished renal excretion | rel=r_associated | relid=0 | w=10
  1232. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkalemic periodic paralysis
    n1=en:hyperintense | n2=en:hyperkalemic periodic paralysis | rel=r_associated | relid=0 | w=10
  1233. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkaliaemia
    n1=en:hyperintense | n2=en:hyperkaliaemia | rel=r_associated | relid=0 | w=10
  1234. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkaliuria
    n1=en:hyperintense | n2=en:hyperkaliuria | rel=r_associated | relid=0 | w=10
  1235. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkeratosis
    n1=en:hyperintense | n2=en:hyperkeratosis | rel=r_associated | relid=0 | w=10
  1236. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkeratosis lenticularis perstans
    n1=en:hyperintense | n2=en:hyperkeratosis lenticularis perstans | rel=r_associated | relid=0 | w=10
  1237. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkeratosis of stratum corneum
    n1=en:hyperintense | n2=en:hyperkeratosis of stratum corneum | rel=r_associated | relid=0 | w=10
  1238. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkeratosis over edematous areas
    n1=en:hyperintense | n2=en:hyperkeratosis over edematous areas | rel=r_associated | relid=0 | w=10
  1239. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkeratosis pilaris
    n1=en:hyperintense | n2=en:hyperkeratosis pilaris | rel=r_associated | relid=0 | w=10
  1240. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkeratosis with erythema
    n1=en:hyperintense | n2=en:hyperkeratosis with erythema | rel=r_associated | relid=0 | w=10
  1241. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkeratosis, epidermolytic
    n1=en:hyperintense | n2=en:hyperkeratosis, epidermolytic | rel=r_associated | relid=0 | w=10
  1242. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkeratotic
    n1=en:hyperintense | n2=en:hyperkeratotic | rel=r_associated | relid=0 | w=10
  1243. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperkeratotic papule
    n1=en:hyperintense | n2=en:hyperkeratotic papule | rel=r_associated | relid=0 | w=10
  1244. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperlactemia
    n1=en:hyperintense | n2=en:hyperlactemia | rel=r_associated | relid=0 | w=10
  1245. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperlipasemia
    n1=en:hyperintense | n2=en:hyperlipasemia | rel=r_associated | relid=0 | w=10
  1246. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperlipidemia
    n1=en:hyperintense | n2=en:hyperlipidemia | rel=r_associated | relid=0 | w=10
  1247. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperlipoproteinemia type i
    n1=en:hyperintense | n2=en:hyperlipoproteinemia type i | rel=r_associated | relid=0 | w=10
  1248. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperlipoproteinemia type iib
    n1=en:hyperintense | n2=en:hyperlipoproteinemia type iib | rel=r_associated | relid=0 | w=10
  1249. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperlysinemia
    n1=en:hyperintense | n2=en:hyperlysinemia | rel=r_associated | relid=0 | w=10
  1250. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypermagnesemia
    n1=en:hyperintense | n2=en:hypermagnesemia | rel=r_associated | relid=0 | w=10
  1251. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypermagnesiuria
    n1=en:hyperintense | n2=en:hypermagnesiuria | rel=r_associated | relid=0 | w=10
  1252. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypermethioninemia, progressive
    n1=en:hyperintense | n2=en:hypermethioninemia, progressive | rel=r_associated | relid=0 | w=10
  1253. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypernatremia
    n1=en:hyperintense | n2=en:hypernatremia | rel=r_associated | relid=0 | w=10
  1254. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypernatriuria
    n1=en:hyperintense | n2=en:hypernatriuria | rel=r_associated | relid=0 | w=10
  1255. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperornithinemia
    n1=en:hyperintense | n2=en:hyperornithinemia | rel=r_associated | relid=0 | w=10
  1256. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperorthokeratosis
    n1=en:hyperintense | n2=en:hyperorthokeratosis | rel=r_associated | relid=0 | w=10
  1257. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperosmolality
    n1=en:hyperintense | n2=en:hyperosmolality | rel=r_associated | relid=0 | w=10
  1258. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperosmolality and or hypernatremia
    n1=en:hyperintense | n2=en:hyperosmolality and or hypernatremia | rel=r_associated | relid=0 | w=10
  1259. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperosmolality with hypernatremia
    n1=en:hyperintense | n2=en:hyperosmolality with hypernatremia | rel=r_associated | relid=0 | w=10
  1260. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperoxalaemia
    n1=en:hyperintense | n2=en:hyperoxalaemia | rel=r_associated | relid=0 | w=10
  1261. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperoxaluria
    n1=en:hyperintense | n2=en:hyperoxaluria | rel=r_associated | relid=0 | w=10
  1262. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperparakeratosis
    n1=en:hyperintense | n2=en:hyperparakeratosis | rel=r_associated | relid=0 | w=10
  1263. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperphenylalaninemia
    n1=en:hyperintense | n2=en:hyperphenylalaninemia | rel=r_associated | relid=0 | w=10
  1264. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperphosphatemia
    n1=en:hyperintense | n2=en:hyperphosphatemia | rel=r_associated | relid=0 | w=10
  1265. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperphosphatemia, transient
    n1=en:hyperintense | n2=en:hyperphosphatemia, transient | rel=r_associated | relid=0 | w=10
  1266. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperprolactinemia
    n1=en:hyperintense | n2=en:hyperprolactinemia | rel=r_associated | relid=0 | w=10
  1267. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperprolinemia (10-15 times normal)
    n1=en:hyperintense | n2=en:hyperprolinemia (10-15 times normal) | rel=r_associated | relid=0 | w=10
  1268. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperprolinemia (5-10 times normal)
    n1=en:hyperintense | n2=en:hyperprolinemia (5-10 times normal) | rel=r_associated | relid=0 | w=10
  1269. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperprolinemia type 1
    n1=en:hyperintense | n2=en:hyperprolinemia type 1 | rel=r_associated | relid=0 | w=10
  1270. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperprostaglandinuria
    n1=en:hyperintense | n2=en:hyperprostaglandinuria | rel=r_associated | relid=0 | w=10
  1271. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperthreoninemia
    n1=en:hyperintense | n2=en:hyperthreoninemia | rel=r_associated | relid=0 | w=10
  1272. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperthreoninuria
    n1=en:hyperintense | n2=en:hyperthreoninuria | rel=r_associated | relid=0 | w=10
  1273. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypertriglyceridemia
    n1=en:hyperintense | n2=en:hypertriglyceridemia | rel=r_associated | relid=0 | w=10
  1274. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypertriglyceridemia (in some patients)
    n1=en:hyperintense | n2=en:hypertriglyceridemia (in some patients) | rel=r_associated | relid=0 | w=10
  1275. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypertriglyceridemia (rare)
    n1=en:hyperintense | n2=en:hypertriglyceridemia (rare) | rel=r_associated | relid=0 | w=10
  1276. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypertriglyceridemia, transient
    n1=en:hyperintense | n2=en:hypertriglyceridemia, transient | rel=r_associated | relid=0 | w=10
  1277. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypertryptophanemia
    n1=en:hyperintense | n2=en:hypertryptophanemia | rel=r_associated | relid=0 | w=10
  1278. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperuricemia
    n1=en:hyperintense | n2=en:hyperuricemia | rel=r_associated | relid=0 | w=10
  1279. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperuricosuria
    n1=en:hyperintense | n2=en:hyperuricosuria | rel=r_associated | relid=0 | w=10
  1280. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyperuricuria
    n1=en:hyperintense | n2=en:hyperuricuria | rel=r_associated | relid=0 | w=10
  1281. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypervolemia
    n1=en:hyperintense | n2=en:hypervolemia | rel=r_associated | relid=0 | w=10
  1282. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypo-osmolality and hyponatraemia
    n1=en:hyperintense | n2=en:hypo-osmolality and hyponatraemia | rel=r_associated | relid=0 | w=10
  1283. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoadrenocorticism, familial
    n1=en:hyperintense | n2=en:hypoadrenocorticism, familial | rel=r_associated | relid=0 | w=10
  1284. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoalbuminemia
    n1=en:hyperintense | n2=en:hypoalbuminemia | rel=r_associated | relid=0 | w=10
  1285. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoalbuminemia (in 83%)
    n1=en:hyperintense | n2=en:hypoalbuminemia (in 83%) | rel=r_associated | relid=0 | w=10
  1286. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoalphalipoproteinemia
    n1=en:hyperintense | n2=en:hypoalphalipoproteinemia | rel=r_associated | relid=0 | w=10
  1287. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypobetalipoproteinemias
    n1=en:hyperintense | n2=en:hypobetalipoproteinemias | rel=r_associated | relid=0 | w=10
  1288. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypocalcemia
    n1=en:hyperintense | n2=en:hypocalcemia | rel=r_associated | relid=0 | w=10
  1289. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypocalcemia (64% of adults)
    n1=en:hyperintense | n2=en:hypocalcemia (64% of adults) | rel=r_associated | relid=0 | w=10
  1290. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypocalcemia (male)
    n1=en:hyperintense | n2=en:hypocalcemia (male) | rel=r_associated | relid=0 | w=10
  1291. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypocalcemia, transient
    n1=en:hyperintense | n2=en:hypocalcemia, transient | rel=r_associated | relid=0 | w=10
  1292. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypocalciuria
    n1=en:hyperintense | n2=en:hypocalciuria | rel=r_associated | relid=0 | w=10
  1293. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypocalciuria or normocalciuria
    n1=en:hyperintense | n2=en:hypocalciuria or normocalciuria | rel=r_associated | relid=0 | w=10
  1294. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypochloremia (disorder)
    n1=en:hyperintense | n2=en:hypochloremia (disorder) | rel=r_associated | relid=0 | w=10
  1295. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypocholesterolemia
    n1=en:hyperintense | n2=en:hypocholesterolemia | rel=r_associated | relid=0 | w=10
  1296. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypochromia
    n1=en:hyperintense | n2=en:hypochromia | rel=r_associated | relid=0 | w=10
  1297. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypocitraturia
    n1=en:hyperintense | n2=en:hypocitraturia | rel=r_associated | relid=0 | w=10
  1298. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypofibrinogenemia
    n1=en:hyperintense | n2=en:hypofibrinogenemia | rel=r_associated | relid=0 | w=10
  1299. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypogammaglobulinemia
    n1=en:hyperintense | n2=en:hypogammaglobulinemia | rel=r_associated | relid=0 | w=10
  1300. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypogammaglobulinemia (in some patients)
    n1=en:hyperintense | n2=en:hypogammaglobulinemia (in some patients) | rel=r_associated | relid=0 | w=10
  1301. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypogammaglobulinemia, profound
    n1=en:hyperintense | n2=en:hypogammaglobulinemia, profound | rel=r_associated | relid=0 | w=10
  1302. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoglycemia
    n1=en:hyperintense | n2=en:hypoglycemia | rel=r_associated | relid=0 | w=10
  1303. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoglycemia, fasting
    n1=en:hyperintense | n2=en:hypoglycemia, fasting | rel=r_associated | relid=0 | w=10
  1304. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoglycemia, intermittent
    n1=en:hyperintense | n2=en:hypoglycemia, intermittent | rel=r_associated | relid=0 | w=10
  1305. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoglycorrhachia (low glucose in csf)
    n1=en:hyperintense | n2=en:hypoglycorrhachia (low glucose in csf) | rel=r_associated | relid=0 | w=10
  1306. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoglycosylated serum transferrin
    n1=en:hyperintense | n2=en:hypoglycosylated serum transferrin | rel=r_associated | relid=0 | w=10
  1307. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoglycosylation of plasma glycoproteins
    n1=en:hyperintense | n2=en:hypoglycosylation of plasma glycoproteins | rel=r_associated | relid=0 | w=10
  1308. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypokalemia
    n1=en:hyperintense | n2=en:hypokalemia | rel=r_associated | relid=0 | w=10
  1309. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypokalemia during attacks
    n1=en:hyperintense | n2=en:hypokalemia during attacks | rel=r_associated | relid=0 | w=10
  1310. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypokalemia during periodic paralysis (most patients)
    n1=en:hyperintense | n2=en:hypokalemia during periodic paralysis (most patients) | rel=r_associated | relid=0 | w=10
  1311. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypokalemia occurs during paralytic attacks
    n1=en:hyperintense | n2=en:hypokalemia occurs during paralytic attacks | rel=r_associated | relid=0 | w=10
  1312. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypokalemic alkalosis
    n1=en:hyperintense | n2=en:hypokalemic alkalosis | rel=r_associated | relid=0 | w=10
  1313. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoketotic dicarboxylic aciduria (in some patients)
    n1=en:hyperintense | n2=en:hypoketotic dicarboxylic aciduria (in some patients) | rel=r_associated | relid=0 | w=10
  1314. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoketotic hypoglycemia
    n1=en:hyperintense | n2=en:hypoketotic hypoglycemia | rel=r_associated | relid=0 | w=10
  1315. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypomagnesemia
    n1=en:hyperintense | n2=en:hypomagnesemia | rel=r_associated | relid=0 | w=10
  1316. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypomethioninemia
    n1=en:hyperintense | n2=en:hypomethioninemia | rel=r_associated | relid=0 | w=10
  1317. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypomethylation of alpha-satellite repeats on chromosome 9
    n1=en:hyperintense | n2=en:hypomethylation of alpha-satellite repeats on chromosome 9 | rel=r_associated | relid=0 | w=10
  1318. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypomethylation of satellite repeats on chromosome 1, 9, and 16
    n1=en:hyperintense | n2=en:hypomethylation of satellite repeats on chromosome 1, 9, and 16 | rel=r_associated | relid=0 | w=10
  1319. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyponatremia
    n1=en:hyperintense | n2=en:hyponatremia | rel=r_associated | relid=0 | w=10
  1320. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyponatremia in infancy
    n1=en:hyperintense | n2=en:hyponatremia in infancy | rel=r_associated | relid=0 | w=10
  1321. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyponatremic dehydration, rarely
    n1=en:hyperintense | n2=en:hyponatremic dehydration, rarely | rel=r_associated | relid=0 | w=10
  1322. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypophosphatemia
    n1=en:hyperintense | n2=en:hypophosphatemia | rel=r_associated | relid=0 | w=10
  1323. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypophosphatemia (less common)
    n1=en:hyperintense | n2=en:hypophosphatemia (less common) | rel=r_associated | relid=0 | w=10
  1324. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoprebetalipoproteinemia
    n1=en:hyperintense | n2=en:hypoprebetalipoproteinemia | rel=r_associated | relid=0 | w=10
  1325. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoprolactinemia
    n1=en:hyperintense | n2=en:hypoprolactinemia | rel=r_associated | relid=0 | w=10
  1326. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoproteinemia
    n1=en:hyperintense | n2=en:hypoproteinemia | rel=r_associated | relid=0 | w=10
  1327. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoproteinemia (in 1 patient)
    n1=en:hyperintense | n2=en:hypoproteinemia (in 1 patient) | rel=r_associated | relid=0 | w=10
  1328. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoproteinemia due to hypercatabolism
    n1=en:hyperintense | n2=en:hypoproteinemia due to hypercatabolism | rel=r_associated | relid=0 | w=10
  1329. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyposialylation of o-linked serum glycans
    n1=en:hyperintense | n2=en:hyposialylation of o-linked serum glycans | rel=r_associated | relid=0 | w=10
  1330. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyposmolality and/or hyponatremia
    n1=en:hyperintense | n2=en:hyposmolality and/or hyponatremia | rel=r_associated | relid=0 | w=10
  1331. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyposmolality syndrome
    n1=en:hyperintense | n2=en:hyposmolality syndrome | rel=r_associated | relid=0 | w=10
  1332. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hyposthenuria (inability to concentrate urine normally)
    n1=en:hyperintense | n2=en:hyposthenuria (inability to concentrate urine normally) | rel=r_associated | relid=0 | w=10
  1333. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypouricemia
    n1=en:hyperintense | n2=en:hypouricemia | rel=r_associated | relid=0 | w=10
  1334. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypovolemia
    n1=en:hyperintense | n2=en:hypovolemia | rel=r_associated | relid=0 | w=10
  1335. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoxemia
    n1=en:hyperintense | n2=en:hypoxemia | rel=r_associated | relid=0 | w=10
  1336. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:hypoxia
    n1=en:hyperintense | n2=en:hypoxia | rel=r_associated | relid=0 | w=10
  1337. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:i-cell disease
    n1=en:hyperintense | n2=en:i-cell disease | rel=r_associated | relid=0 | w=10
  1338. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ichthyosiform erythroderma, congenital
    n1=en:hyperintense | n2=en:ichthyosiform erythroderma, congenital | rel=r_associated | relid=0 | w=10
  1339. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ichthyosis
    n1=en:hyperintense | n2=en:ichthyosis | rel=r_associated | relid=0 | w=10
  1340. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ichthyosis acquisita
    n1=en:hyperintense | n2=en:ichthyosis acquisita | rel=r_associated | relid=0 | w=10
  1341. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ichthyosis aggravated
    n1=en:hyperintense | n2=en:ichthyosis aggravated | rel=r_associated | relid=0 | w=10
  1342. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ichthyosis bullosa of siemens
    n1=en:hyperintense | n2=en:ichthyosis bullosa of siemens | rel=r_associated | relid=0 | w=10
  1343. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ichthyosis congenita with biliary atresia
    n1=en:hyperintense | n2=en:ichthyosis congenita with biliary atresia | rel=r_associated | relid=0 | w=10
  1344. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ichthyosis hystrix
    n1=en:hyperintense | n2=en:ichthyosis hystrix | rel=r_associated | relid=0 | w=10
  1345. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ichthyosis inherited
    n1=en:hyperintense | n2=en:ichthyosis inherited | rel=r_associated | relid=0 | w=10
  1346. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ichthyosis vulgaris
    n1=en:hyperintense | n2=en:ichthyosis vulgaris | rel=r_associated | relid=0 | w=10
  1347. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ichthyosis, cyclic, with epidermolytic hyperkeratosis
    n1=en:hyperintense | n2=en:ichthyosis, cyclic, with epidermolytic hyperkeratosis | rel=r_associated | relid=0 | w=10
  1348. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ichtiosis hyperkeratosis
    n1=en:hyperintense | n2=en:ichtiosis hyperkeratosis | rel=r_associated | relid=0 | w=10
  1349. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:iduronate sulfatase deficiency in fibroblasts, amniocytes and white blood cells
    n1=en:hyperintense | n2=en:iduronate sulfatase deficiency in fibroblasts, amniocytes and white blood cells | rel=r_associated | relid=0 | w=10
  1350. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:iga antiendomysial antibodies (ema)
    n1=en:hyperintense | n2=en:iga antiendomysial antibodies (ema) | rel=r_associated | relid=0 | w=10
  1351. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:igg deficiency
    n1=en:hyperintense | n2=en:igg deficiency | rel=r_associated | relid=0 | w=10
  1352. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:igg, decreased
    n1=en:hyperintense | n2=en:igg, decreased | rel=r_associated | relid=0 | w=10
  1353. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:igg, elevated
    n1=en:hyperintense | n2=en:igg, elevated | rel=r_associated | relid=0 | w=10
  1354. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:igm deficiency
    n1=en:hyperintense | n2=en:igm deficiency | rel=r_associated | relid=0 | w=10
  1355. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:iiga and igg antigliadin antibodies (aga)
    n1=en:hyperintense | n2=en:iiga and igg antigliadin antibodies (aga) | rel=r_associated | relid=0 | w=10
  1356. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:immediate (type i) skin test reactivity
    n1=en:hyperintense | n2=en:immediate (type i) skin test reactivity | rel=r_associated | relid=0 | w=10
  1357. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:immotile cilia
    n1=en:hyperintense | n2=en:immotile cilia | rel=r_associated | relid=0 | w=10
  1358. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:immotile or weakly motile cilia
    n1=en:hyperintense | n2=en:immotile or weakly motile cilia | rel=r_associated | relid=0 | w=10
  1359. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:immunoglobulin a decreased
    n1=en:hyperintense | n2=en:immunoglobulin a decreased | rel=r_associated | relid=0 | w=10
  1360. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:immunoglobulin antibodies present
    n1=en:hyperintense | n2=en:immunoglobulin antibodies present | rel=r_associated | relid=0 | w=10
  1361. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:immunology aspects
    n1=en:hyperintense | n2=en:immunology aspects | rel=r_associated | relid=0 | w=10
  1362. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:immunoreactive pc protein
    n1=en:hyperintense | n2=en:immunoreactive pc protein | rel=r_associated | relid=0 | w=10
  1363. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:impaired carnitine uptake in muscle, heart, kidney, fibroblasts, and lymphocytes
    n1=en:hyperintense | n2=en:impaired carnitine uptake in muscle, heart, kidney, fibroblasts, and lymphocytes | rel=r_associated | relid=0 | w=10
  1364. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:impaired creatine uptake in fibroblasts
    n1=en:hyperintense | n2=en:impaired creatine uptake in fibroblasts | rel=r_associated | relid=0 | w=10
  1365. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:impaired long-chain fatty acid oxidation during prolonged, low-intensity exercise
    n1=en:hyperintense | n2=en:impaired long-chain fatty acid oxidation during prolonged, low-intensity exercise | rel=r_associated | relid=0 | w=10
  1366. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:impaired mitochondrial translation
    n1=en:hyperintense | n2=en:impaired mitochondrial translation | rel=r_associated | relid=0 | w=10
  1367. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:impaired n-glycosylation
    n1=en:hyperintense | n2=en:impaired n-glycosylation | rel=r_associated | relid=0 | w=10
  1368. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:impaired o-glycosylation
    n1=en:hyperintense | n2=en:impaired o-glycosylation | rel=r_associated | relid=0 | w=10
  1369. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:impaired oxidation of pyruvate
    n1=en:hyperintense | n2=en:impaired oxidation of pyruvate | rel=r_associated | relid=0 | w=10
  1370. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:impaired platelet aggregation
    n1=en:hyperintense | n2=en:impaired platelet aggregation | rel=r_associated | relid=0 | w=10
  1371. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:impaired response to gm-csf
    n1=en:hyperintense | n2=en:impaired response to gm-csf | rel=r_associated | relid=0 | w=10
  1372. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:impaired synthesis of fibroblast sulfated proteoglycans
    n1=en:hyperintense | n2=en:impaired synthesis of fibroblast sulfated proteoglycans | rel=r_associated | relid=0 | w=10
  1373. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:impairment of urinary concentration
    n1=en:hyperintense | n2=en:impairment of urinary concentration | rel=r_associated | relid=0 | w=10
  1374. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:in blood
    n1=en:hyperintense | n2=en:in blood | rel=r_associated | relid=0 | w=10
  1375. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:in cerebrospinal fluid
    n1=en:hyperintense | n2=en:in cerebrospinal fluid | rel=r_associated | relid=0 | w=10
  1376. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:in untreated patients - elevated blood galactose urine reducing substances (galactosuria), hyperchloremic metabolic acidosis, aminoaciduria, elevated liver enzymes, albuminuria
    n1=en:hyperintense | n2=en:in untreated patients - elevated blood galactose urine reducing substances (galactosuria), hyperchloremic metabolic acidosis, aminoaciduria, elevated liver enzymes, albuminuria | rel=r_associated | relid=0 | w=10
  1377. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:in urine
    n1=en:hyperintense | n2=en:in urine | rel=r_associated | relid=0 | w=10
  1378. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:inactive mutant form of red cell carbonic anhydrase b in one sibship
    n1=en:hyperintense | n2=en:inactive mutant form of red cell carbonic anhydrase b in one sibship | rel=r_associated | relid=0 | w=10
  1379. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:inappropriately increased urine osmolality
    n1=en:hyperintense | n2=en:inappropriately increased urine osmolality | rel=r_associated | relid=0 | w=10
  1380. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:inappropriately low urine osmolality
    n1=en:hyperintense | n2=en:inappropriately low urine osmolality | rel=r_associated | relid=0 | w=10
  1381. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:inappropriately normal or increased plasma hepcidin
    n1=en:hyperintense | n2=en:inappropriately normal or increased plasma hepcidin | rel=r_associated | relid=0 | w=10
  1382. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:inappropriately normal serum 1,25-dihydroxyvitamin d3
    n1=en:hyperintense | n2=en:inappropriately normal serum 1,25-dihydroxyvitamin d3 | rel=r_associated | relid=0 | w=10
  1383. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:inappropriately normal to low-normal serum 1,25-dihydroxyvitamin d3
    n1=en:hyperintense | n2=en:inappropriately normal to low-normal serum 1,25-dihydroxyvitamin d3 | rel=r_associated | relid=0 | w=10
  1384. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:inclusion bodies (membrane-bound vacuoles) in fibroblasts
    n1=en:hyperintense | n2=en:inclusion bodies (membrane-bound vacuoles) in fibroblasts | rel=r_associated | relid=0 | w=10
  1385. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:inclusions contain phospholipids, phosphatidylcholine, sphingolipids, gangliosides, mucopolysaccharides
    n1=en:hyperintense | n2=en:inclusions contain phospholipids, phosphatidylcholine, sphingolipids, gangliosides, mucopolysaccharides | rel=r_associated | relid=0 | w=10
  1386. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:incomplete n-glycosylation of cellular proteins
    n1=en:hyperintense | n2=en:incomplete n-glycosylation of cellular proteins | rel=r_associated | relid=0 | w=10
  1387. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increase urinary excretion of lysine, arginine, and ornithine
    n1=en:hyperintense | n2=en:increase urinary excretion of lysine, arginine, and ornithine | rel=r_associated | relid=0 | w=10
  1388. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased 11-deoxycorticosterone
    n1=en:hyperintense | n2=en:increased 11-deoxycorticosterone | rel=r_associated | relid=0 | w=10
  1389. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased 11-deoxycortisol
    n1=en:hyperintense | n2=en:increased 11-deoxycortisol | rel=r_associated | relid=0 | w=10
  1390. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased 18-hydroxycortisol
    n1=en:hyperintense | n2=en:increased 18-hydroxycortisol | rel=r_associated | relid=0 | w=10
  1391. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased 18-ohb to aldosterone ratio
    n1=en:hyperintense | n2=en:increased 18-ohb to aldosterone ratio | rel=r_associated | relid=0 | w=10
  1392. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased 18-oxocortisol
    n1=en:hyperintense | n2=en:increased 18-oxocortisol | rel=r_associated | relid=0 | w=10
  1393. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased acetoacetate: beta-hydroxybutyrate ratio (group b)
    n1=en:hyperintense | n2=en:increased acetoacetate: beta-hydroxybutyrate ratio (group b) | rel=r_associated | relid=0 | w=10
  1394. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased acetylcholinesterase (ache) in amniotic fluid
    n1=en:hyperintense | n2=en:increased acetylcholinesterase (ache) in amniotic fluid | rel=r_associated | relid=0 | w=10
  1395. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased activity of the prpp synthetase 1 enzyme
    n1=en:hyperintense | n2=en:increased activity of the prpp synthetase 1 enzyme | rel=r_associated | relid=0 | w=10
  1396. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased alpha-fetoprotein (1 patient)
    n1=en:hyperintense | n2=en:increased alpha-fetoprotein (1 patient) | rel=r_associated | relid=0 | w=10
  1397. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased alpha-fetoprotein in the mother during early pregnancy while carrying an affected fetus
    n1=en:hyperintense | n2=en:increased alpha-fetoprotein in the mother during early pregnancy while carrying an affected fetus | rel=r_associated | relid=0 | w=10
  1398. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased ammonia with exercise
    n1=en:hyperintense | n2=en:increased ammonia with exercise | rel=r_associated | relid=0 | w=10
  1399. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased beta-alanine (in 1 of 2 patients)
    n1=en:hyperintense | n2=en:increased beta-alanine (in 1 of 2 patients) | rel=r_associated | relid=0 | w=10
  1400. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased bile acid intermediates (dhca and thca)
    n1=en:hyperintense | n2=en:increased bile acid intermediates (dhca and thca) | rel=r_associated | relid=0 | w=10
  1401. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased biliverdin in bodily fluids
    n1=en:hyperintense | n2=en:increased biliverdin in bodily fluids | rel=r_associated | relid=0 | w=10
  1402. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased biopterin in urine and csf
    n1=en:hyperintense | n2=en:increased biopterin in urine and csf | rel=r_associated | relid=0 | w=10
  1403. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased blood alanine
    n1=en:hyperintense | n2=en:increased blood alanine | rel=r_associated | relid=0 | w=10
  1404. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased bone serum acid phosphatase
    n1=en:hyperintense | n2=en:increased bone serum acid phosphatase | rel=r_associated | relid=0 | w=10
  1405. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased bone-specific alkaline phosphatase
    n1=en:hyperintense | n2=en:increased bone-specific alkaline phosphatase | rel=r_associated | relid=0 | w=10
  1406. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased c10:2-carnitine
    n1=en:hyperintense | n2=en:increased c10:2-carnitine | rel=r_associated | relid=0 | w=10
  1407. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased cellular sensitivity to uv light
    n1=en:hyperintense | n2=en:increased cellular sensitivity to uv light | rel=r_associated | relid=0 | w=10
  1408. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased cerebrospinal fluid (csf) protein (>100mg/dl)
    n1=en:hyperintense | n2=en:increased cerebrospinal fluid (csf) protein (>100mg/dl) | rel=r_associated | relid=0 | w=10
  1409. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased cholesterol
    n1=en:hyperintense | n2=en:increased cholesterol | rel=r_associated | relid=0 | w=10
  1410. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased chromosomal breakage
    n1=en:hyperintense | n2=en:increased chromosomal breakage | rel=r_associated | relid=0 | w=10
  1411. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased chromosomal breaks in response to cross-linking agents and ionizing radiation
    n1=en:hyperintense | n2=en:increased chromosomal breaks in response to cross-linking agents and ionizing radiation | rel=r_associated | relid=0 | w=10
  1412. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased chromosomal rearrangements (bone marrow and fibroblast culture)
    n1=en:hyperintense | n2=en:increased chromosomal rearrangements (bone marrow and fibroblast culture) | rel=r_associated | relid=0 | w=10
  1413. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased circulating renin level
    n1=en:hyperintense | n2=en:increased circulating renin level | rel=r_associated | relid=0 | w=10
  1414. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased ck-mb
    n1=en:hyperintense | n2=en:increased ck-mb | rel=r_associated | relid=0 | w=10
  1415. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased coproporphyrin isomer iii:i ratio (hcp, feces)
    n1=en:hyperintense | n2=en:increased coproporphyrin isomer iii:i ratio (hcp, feces) | rel=r_associated | relid=0 | w=10
  1416. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased creatine kinase (ck)
    n1=en:hyperintense | n2=en:increased creatine kinase (ck) | rel=r_associated | relid=0 | w=10
  1417. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased creatine kinase, mild to moderate
    n1=en:hyperintense | n2=en:increased creatine kinase, mild to moderate | rel=r_associated | relid=0 | w=10
  1418. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased creatinine
    n1=en:hyperintense | n2=en:increased creatinine | rel=r_associated | relid=0 | w=10
  1419. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased cross-linked c-terminal telopeptide of type i collagen
    n1=en:hyperintense | n2=en:increased cross-linked c-terminal telopeptide of type i collagen | rel=r_associated | relid=0 | w=10
  1420. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf 3-methoxytyrosine (3-mt)
    n1=en:hyperintense | n2=en:increased csf 3-methoxytyrosine (3-mt) | rel=r_associated | relid=0 | w=10
  1421. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf and plasma gaba
    n1=en:hyperintense | n2=en:increased csf and plasma gaba | rel=r_associated | relid=0 | w=10
  1422. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf and plasma ghb
    n1=en:hyperintense | n2=en:increased csf and plasma ghb | rel=r_associated | relid=0 | w=10
  1423. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf glycine
    n1=en:hyperintense | n2=en:increased csf glycine | rel=r_associated | relid=0 | w=10
  1424. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf histidine
    n1=en:hyperintense | n2=en:increased csf histidine | rel=r_associated | relid=0 | w=10
  1425. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf homovanillic acid (hva)
    n1=en:hyperintense | n2=en:increased csf homovanillic acid (hva) | rel=r_associated | relid=0 | w=10
  1426. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf immunoglobulin levels
    n1=en:hyperintense | n2=en:increased csf immunoglobulin levels | rel=r_associated | relid=0 | w=10
  1427. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf interferon
    n1=en:hyperintense | n2=en:increased csf interferon | rel=r_associated | relid=0 | w=10
  1428. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf interferon alpha
    n1=en:hyperintense | n2=en:increased csf interferon alpha | rel=r_associated | relid=0 | w=10
  1429. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf lactate
    n1=en:hyperintense | n2=en:increased csf lactate | rel=r_associated | relid=0 | w=10
  1430. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf lactate during acute episodes
    n1=en:hyperintense | n2=en:increased csf lactate during acute episodes | rel=r_associated | relid=0 | w=10
  1431. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf protein
    n1=en:hyperintense | n2=en:increased csf protein | rel=r_associated | relid=0 | w=10
  1432. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf protein during acute illness
    n1=en:hyperintense | n2=en:increased csf protein during acute illness | rel=r_associated | relid=0 | w=10
  1433. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf pyruvic acid
    n1=en:hyperintense | n2=en:increased csf pyruvic acid | rel=r_associated | relid=0 | w=10
  1434. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf taurine
    n1=en:hyperintense | n2=en:increased csf taurine | rel=r_associated | relid=0 | w=10
  1435. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf threonine
    n1=en:hyperintense | n2=en:increased csf threonine | rel=r_associated | relid=0 | w=10
  1436. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf transferrin despite normal serum transferrin levels
    n1=en:hyperintense | n2=en:increased csf transferrin despite normal serum transferrin levels | rel=r_associated | relid=0 | w=10
  1437. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf, plasma, and urinary 3-methoxytyrosine
    n1=en:hyperintense | n2=en:increased csf, plasma, and urinary 3-methoxytyrosine | rel=r_associated | relid=0 | w=10
  1438. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf, plasma, and urinary 3-ortho-methyldopa (3-omd)
    n1=en:hyperintense | n2=en:increased csf, plasma, and urinary 3-ortho-methyldopa (3-omd) | rel=r_associated | relid=0 | w=10
  1439. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf, plasma, and urinary 5-hydroxytryptophan (5htp)
    n1=en:hyperintense | n2=en:increased csf, plasma, and urinary 5-hydroxytryptophan (5htp) | rel=r_associated | relid=0 | w=10
  1440. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased csf, plasma, and urinary l-dopa
    n1=en:hyperintense | n2=en:increased csf, plasma, and urinary l-dopa | rel=r_associated | relid=0 | w=10
  1441. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased d-glyceric acid in serum, urine, and csf
    n1=en:hyperintense | n2=en:increased d-glyceric acid in serum, urine, and csf | rel=r_associated | relid=0 | w=10
  1442. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased di- and asialo-transferrin
    n1=en:hyperintense | n2=en:increased di- and asialo-transferrin | rel=r_associated | relid=0 | w=10
  1443. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased di- and asialo-transferrin characteristic of type 1 pattern
    n1=en:hyperintense | n2=en:increased di- and asialo-transferrin characteristic of type 1 pattern | rel=r_associated | relid=0 | w=10
  1444. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased disialo- and asialotransferrin
    n1=en:hyperintense | n2=en:increased disialo- and asialotransferrin | rel=r_associated | relid=0 | w=10
  1445. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased disialotransferrin and asialotransferrin levels
    n1=en:hyperintense | n2=en:increased disialotransferrin and asialotransferrin levels | rel=r_associated | relid=0 | w=10
  1446. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased erythrocyte sedimentation rate, episodic
    n1=en:hyperintense | n2=en:increased erythrocyte sedimentation rate, episodic | rel=r_associated | relid=0 | w=10
  1447. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased erythrocyte-membrane calcium-magnesium-atpase
    n1=en:hyperintense | n2=en:increased erythrocyte-membrane calcium-magnesium-atpase | rel=r_associated | relid=0 | w=10
  1448. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased erythropoietin
    n1=en:hyperintense | n2=en:increased erythropoietin | rel=r_associated | relid=0 | w=10
  1449. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased excretion of urobilinogen
    n1=en:hyperintense | n2=en:increased excretion of urobilinogen | rel=r_associated | relid=0 | w=10
  1450. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased fas ligand
    n1=en:hyperintense | n2=en:increased fas ligand | rel=r_associated | relid=0 | w=10
  1451. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased ferritin
    n1=en:hyperintense | n2=en:increased ferritin | rel=r_associated | relid=0 | w=10
  1452. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased fibroblast free sialic acid
    n1=en:hyperintense | n2=en:increased fibroblast free sialic acid | rel=r_associated | relid=0 | w=10
  1453. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased folic acid
    n1=en:hyperintense | n2=en:increased folic acid | rel=r_associated | relid=0 | w=10
  1454. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased fractional excretion of urate (greater than 50%)
    n1=en:hyperintense | n2=en:increased fractional excretion of urate (greater than 50%) | rel=r_associated | relid=0 | w=10
  1455. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased fractional excretion of uric acid
    n1=en:hyperintense | n2=en:increased fractional excretion of uric acid | rel=r_associated | relid=0 | w=10
  1456. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased free cyanocobalamin in fibroblasts
    n1=en:hyperintense | n2=en:increased free cyanocobalamin in fibroblasts | rel=r_associated | relid=0 | w=10
  1457. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased free erythrocyte protoporphyrin
    n1=en:hyperintense | n2=en:increased free erythrocyte protoporphyrin | rel=r_associated | relid=0 | w=10
  1458. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased frequency of premature centromere disjunction (pcd) in cultured fibroblasts, esp. chromosome 3
    n1=en:hyperintense | n2=en:increased frequency of premature centromere disjunction (pcd) in cultured fibroblasts, esp. chromosome 3 | rel=r_associated | relid=0 | w=10
  1459. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased gamma-aminobutyric acid in plasma, urine, and cerebrospinal fluid (csf)
    n1=en:hyperintense | n2=en:increased gamma-aminobutyric acid in plasma, urine, and cerebrospinal fluid (csf) | rel=r_associated | relid=0 | w=10
  1460. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased gamma-interferon
    n1=en:hyperintense | n2=en:increased gamma-interferon | rel=r_associated | relid=0 | w=10
  1461. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased growth hormone (in 1 of 2 patients)
    n1=en:hyperintense | n2=en:increased growth hormone (in 1 of 2 patients) | rel=r_associated | relid=0 | w=10
  1462. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased harderoporphyrin excretion (feces, harderoporphyria)
    n1=en:hyperintense | n2=en:increased harderoporphyrin excretion (feces, harderoporphyria) | rel=r_associated | relid=0 | w=10
  1463. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased hepatic parenchymal cell stainable iron
    n1=en:hyperintense | n2=en:increased hepatic parenchymal cell stainable iron | rel=r_associated | relid=0 | w=10
  1464. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased histidine in blood, urine, and csf
    n1=en:hyperintense | n2=en:increased histidine in blood, urine, and csf | rel=r_associated | relid=0 | w=10
  1465. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased iga level
    n1=en:hyperintense | n2=en:increased iga level | rel=r_associated | relid=0 | w=10
  1466. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased ige level
    n1=en:hyperintense | n2=en:increased ige level | rel=r_associated | relid=0 | w=10
  1467. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased igg level
    n1=en:hyperintense | n2=en:increased igg level | rel=r_associated | relid=0 | w=10
  1468. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased igm level
    n1=en:hyperintense | n2=en:increased igm level | rel=r_associated | relid=0 | w=10
  1469. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased il-6
    n1=en:hyperintense | n2=en:increased il-6 | rel=r_associated | relid=0 | w=10
  1470. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased il-8
    n1=en:hyperintense | n2=en:increased il-8 | rel=r_associated | relid=0 | w=10
  1471. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased il18
    n1=en:hyperintense | n2=en:increased il18 | rel=r_associated | relid=0 | w=10
  1472. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased il1b increased soluble il2r
    n1=en:hyperintense | n2=en:increased il1b increased soluble il2r | rel=r_associated | relid=0 | w=10
  1473. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased il6, episodic
    n1=en:hyperintense | n2=en:increased il6, episodic | rel=r_associated | relid=0 | w=10
  1474. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased interferon-alpha signal
    n1=en:hyperintense | n2=en:increased interferon-alpha signal | rel=r_associated | relid=0 | w=10
  1475. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased interleukin 10
    n1=en:hyperintense | n2=en:increased interleukin 10 | rel=r_associated | relid=0 | w=10
  1476. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased intracellular fmrp mrna
    n1=en:hyperintense | n2=en:increased intracellular fmrp mrna | rel=r_associated | relid=0 | w=10
  1477. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased ketone body or lactate/pyruvate plasma ratios
    n1=en:hyperintense | n2=en:increased ketone body or lactate/pyruvate plasma ratios | rel=r_associated | relid=0 | w=10
  1478. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased l-2-hydroxyglutaric acid in urine, serum, and csf
    n1=en:hyperintense | n2=en:increased l-2-hydroxyglutaric acid in urine, serum, and csf | rel=r_associated | relid=0 | w=10
  1479. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased lactate in spinal fluid
    n1=en:hyperintense | n2=en:increased lactate in spinal fluid | rel=r_associated | relid=0 | w=10
  1480. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased lactate: pyruvate ratio (group b)
    n1=en:hyperintense | n2=en:increased lactate: pyruvate ratio (group b) | rel=r_associated | relid=0 | w=10
  1481. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased level of globotriaosylceramide (gb3) in plasma and urinary sediment
    n1=en:hyperintense | n2=en:increased level of globotriaosylceramide (gb3) in plasma and urinary sediment | rel=r_associated | relid=0 | w=10
  1482. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased levels of 3-alpha-7-alpha-12-alpha-trihydroxy-5-beta-cholestanoic acid (thca) in bile, urine, and serum
    n1=en:hyperintense | n2=en:increased levels of 3-alpha-7-alpha-12-alpha-trihydroxy-5-beta-cholestanoic acid (thca) in bile, urine, and serum | rel=r_associated | relid=0 | w=10
  1483. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased levels of carcinoembryonic antigen
    n1=en:hyperintense | n2=en:increased levels of carcinoembryonic antigen | rel=r_associated | relid=0 | w=10
  1484. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased levels of dihydroxyacetone phosphate (dhap) in tissues and red cells
    n1=en:hyperintense | n2=en:increased levels of dihydroxyacetone phosphate (dhap) in tissues and red cells | rel=r_associated | relid=0 | w=10
  1485. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased long-chain acylcarnitine
    n1=en:hyperintense | n2=en:increased long-chain acylcarnitine | rel=r_associated | relid=0 | w=10
  1486. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased lysine in serum and csf
    n1=en:hyperintense | n2=en:increased lysine in serum and csf | rel=r_associated | relid=0 | w=10
  1487. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased n-acetyl-l-aspartic acid (naa) in urine, csf, and blood
    n1=en:hyperintense | n2=en:increased n-acetyl-l-aspartic acid (naa) in urine, csf, and blood | rel=r_associated | relid=0 | w=10
  1488. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased nasal-potential difference (1 of 3 patients)
    n1=en:hyperintense | n2=en:increased nasal-potential difference (1 of 3 patients) | rel=r_associated | relid=0 | w=10
  1489. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased nasal-potential difference (some)
    n1=en:hyperintense | n2=en:increased nasal-potential difference (some) | rel=r_associated | relid=0 | w=10
  1490. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased neopterin in urine and csf
    n1=en:hyperintense | n2=en:increased neopterin in urine and csf | rel=r_associated | relid=0 | w=10
  1491. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased npn
    n1=en:hyperintense | n2=en:increased npn | rel=r_associated | relid=0 | w=10
  1492. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased or normal serum growth hormone (gh, 139250)
    n1=en:hyperintense | n2=en:increased or normal serum growth hormone (gh, 139250) | rel=r_associated | relid=0 | w=10
  1493. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased osmotic fragility
    n1=en:hyperintense | n2=en:increased osmotic fragility | rel=r_associated | relid=0 | w=10
  1494. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased oxygen affinity (e.g. hb nunobiki 141800.0109)
    n1=en:hyperintense | n2=en:increased oxygen affinity (e.g. hb nunobiki 141800.0109) | rel=r_associated | relid=0 | w=10
  1495. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased peripheral blood monocytes
    n1=en:hyperintense | n2=en:increased peripheral blood monocytes | rel=r_associated | relid=0 | w=10
  1496. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased phytanic acid in body tissues and fluids
    n1=en:hyperintense | n2=en:increased phytanic acid in body tissues and fluids | rel=r_associated | relid=0 | w=10
  1497. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma 2-methylbutyrylcarnitine
    n1=en:hyperintense | n2=en:increased plasma 2-methylbutyrylcarnitine | rel=r_associated | relid=0 | w=10
  1498. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma and urinary pipecolic acid
    n1=en:hyperintense | n2=en:increased plasma and urinary pipecolic acid | rel=r_associated | relid=0 | w=10
  1499. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma branched-chain fatty acids
    n1=en:hyperintense | n2=en:increased plasma branched-chain fatty acids | rel=r_associated | relid=0 | w=10
  1500. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma creatine
    n1=en:hyperintense | n2=en:increased plasma creatine | rel=r_associated | relid=0 | w=10
  1501. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma dihydroxyphenylacetic acid (dopac)
    n1=en:hyperintense | n2=en:increased plasma dihydroxyphenylacetic acid (dopac) | rel=r_associated | relid=0 | w=10
  1502. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma free cholesterol
    n1=en:hyperintense | n2=en:increased plasma free cholesterol | rel=r_associated | relid=0 | w=10
  1503. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma globotriaosylsphingosine (lyso-gb3)
    n1=en:hyperintense | n2=en:increased plasma globotriaosylsphingosine (lyso-gb3) | rel=r_associated | relid=0 | w=10
  1504. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma homogentisic acid (hga)
    n1=en:hyperintense | n2=en:increased plasma homogentisic acid (hga) | rel=r_associated | relid=0 | w=10
  1505. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma lactate
    n1=en:hyperintense | n2=en:increased plasma lactate | rel=r_associated | relid=0 | w=10
  1506. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma levels of bile acid intermediates
    n1=en:hyperintense | n2=en:increased plasma levels of bile acid intermediates | rel=r_associated | relid=0 | w=10
  1507. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma levels of very long-chain fatty acids (vlcfa)
    n1=en:hyperintense | n2=en:increased plasma levels of very long-chain fatty acids (vlcfa) | rel=r_associated | relid=0 | w=10
  1508. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma long-chain acylcarnitines
    n1=en:hyperintense | n2=en:increased plasma long-chain acylcarnitines | rel=r_associated | relid=0 | w=10
  1509. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma phospholipids
    n1=en:hyperintense | n2=en:increased plasma phospholipids | rel=r_associated | relid=0 | w=10
  1510. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma phytanic acid
    n1=en:hyperintense | n2=en:increased plasma phytanic acid | rel=r_associated | relid=0 | w=10
  1511. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma pipecolic acid
    n1=en:hyperintense | n2=en:increased plasma pipecolic acid | rel=r_associated | relid=0 | w=10
  1512. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma pristanic acid
    n1=en:hyperintense | n2=en:increased plasma pristanic acid | rel=r_associated | relid=0 | w=10
  1513. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma progastrin
    n1=en:hyperintense | n2=en:increased plasma progastrin | rel=r_associated | relid=0 | w=10
  1514. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma proglucagon
    n1=en:hyperintense | n2=en:increased plasma proglucagon | rel=r_associated | relid=0 | w=10
  1515. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma proinsulin
    n1=en:hyperintense | n2=en:increased plasma proinsulin | rel=r_associated | relid=0 | w=10
  1516. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma renin activity
    n1=en:hyperintense | n2=en:increased plasma renin activity | rel=r_associated | relid=0 | w=10
  1517. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased plasma vldl, ldl
    n1=en:hyperintense | n2=en:increased plasma vldl, ldl | rel=r_associated | relid=0 | w=10
  1518. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased platelet aggregation with ristocetin
    n1=en:hyperintense | n2=en:increased platelet aggregation with ristocetin | rel=r_associated | relid=0 | w=10
  1519. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased prevalence among the native american lumbee indians
    n1=en:hyperintense | n2=en:increased prevalence among the native american lumbee indians | rel=r_associated | relid=0 | w=10
  1520. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased pristanic acid
    n1=en:hyperintense | n2=en:increased pristanic acid | rel=r_associated | relid=0 | w=10
  1521. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased prv-1 (162860) mrna
    n1=en:hyperintense | n2=en:increased prv-1 (162860) mrna | rel=r_associated | relid=0 | w=10
  1522. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased pyruvate in serum and csf
    n1=en:hyperintense | n2=en:increased pyruvate in serum and csf | rel=r_associated | relid=0 | w=10
  1523. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased rai (radioactive iodine) uptake
    n1=en:hyperintense | n2=en:increased rai (radioactive iodine) uptake | rel=r_associated | relid=0 | w=10
  1524. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased red cell mass
    n1=en:hyperintense | n2=en:increased red cell mass | rel=r_associated | relid=0 | w=10
  1525. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased renal tubular phosphate reabsorption
    n1=en:hyperintense | n2=en:increased renal tubular phosphate reabsorption | rel=r_associated | relid=0 | w=10
  1526. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased sensitivity to adrenergic and cholinergic agents
    n1=en:hyperintense | n2=en:increased sensitivity to adrenergic and cholinergic agents | rel=r_associated | relid=0 | w=10
  1527. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum 1,25-dihydroxyvitamin d
    n1=en:hyperintense | n2=en:increased serum 1,25-dihydroxyvitamin d | rel=r_associated | relid=0 | w=10
  1528. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum 1,25-dihydroxyvitamin d3
    n1=en:hyperintense | n2=en:increased serum 1,25-dihydroxyvitamin d3 | rel=r_associated | relid=0 | w=10
  1529. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum 18-hydroxycorticosterone (18-ohb)
    n1=en:hyperintense | n2=en:increased serum 18-hydroxycorticosterone (18-ohb) | rel=r_associated | relid=0 | w=10
  1530. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum acyl carnitines
    n1=en:hyperintense | n2=en:increased serum acyl carnitines | rel=r_associated | relid=0 | w=10
  1531. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum acylcarnitine during febrile crisis
    n1=en:hyperintense | n2=en:increased serum acylcarnitine during febrile crisis | rel=r_associated | relid=0 | w=10
  1532. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum acylcarnitines
    n1=en:hyperintense | n2=en:increased serum acylcarnitines | rel=r_associated | relid=0 | w=10
  1533. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum alanine
    n1=en:hyperintense | n2=en:increased serum alanine | rel=r_associated | relid=0 | w=10
  1534. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum alanine (1 patient)
    n1=en:hyperintense | n2=en:increased serum alanine (1 patient) | rel=r_associated | relid=0 | w=10
  1535. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum alkaline phosphatase (in some patients)
    n1=en:hyperintense | n2=en:increased serum alkaline phosphatase (in some patients) | rel=r_associated | relid=0 | w=10
  1536. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum alkaline phosphatase activity of skeletal origin
    n1=en:hyperintense | n2=en:increased serum alkaline phosphatase activity of skeletal origin | rel=r_associated | relid=0 | w=10
  1537. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum alpha-interferon (ifna1, 147660)
    n1=en:hyperintense | n2=en:increased serum alpha-interferon (ifna1, 147660) | rel=r_associated | relid=0 | w=10
  1538. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum alpha-mannosidase
    n1=en:hyperintense | n2=en:increased serum alpha-mannosidase | rel=r_associated | relid=0 | w=10
  1539. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum ammonia (group b)
    n1=en:hyperintense | n2=en:increased serum ammonia (group b) | rel=r_associated | relid=0 | w=10
  1540. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum and cerebrospinal fluid levels of pipecolic acid
    n1=en:hyperintense | n2=en:increased serum and cerebrospinal fluid levels of pipecolic acid | rel=r_associated | relid=0 | w=10
  1541. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum and csf glycine
    n1=en:hyperintense | n2=en:increased serum and csf glycine | rel=r_associated | relid=0 | w=10
  1542. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum and csf lactate
    n1=en:hyperintense | n2=en:increased serum and csf lactate | rel=r_associated | relid=0 | w=10
  1543. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum and urinary 2-oxoglutarate
    n1=en:hyperintense | n2=en:increased serum and urinary 2-oxoglutarate | rel=r_associated | relid=0 | w=10
  1544. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum and urinary lactate
    n1=en:hyperintense | n2=en:increased serum and urinary lactate | rel=r_associated | relid=0 | w=10
  1545. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum aryl-sulfatase a (10-20x)
    n1=en:hyperintense | n2=en:increased serum aryl-sulfatase a (10-20x) | rel=r_associated | relid=0 | w=10
  1546. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum arylsulfatase a (10-20x)
    n1=en:hyperintense | n2=en:increased serum arylsulfatase a (10-20x) | rel=r_associated | relid=0 | w=10
  1547. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum arylsulfatase a.
    n1=en:hyperintense | n2=en:increased serum arylsulfatase a. | rel=r_associated | relid=0 | w=10
  1548. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum beta-carotene
    n1=en:hyperintense | n2=en:increased serum beta-carotene | rel=r_associated | relid=0 | w=10
  1549. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum beta-hexosaminidase
    n1=en:hyperintense | n2=en:increased serum beta-hexosaminidase | rel=r_associated | relid=0 | w=10
  1550. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum beta-hexosaminidase (10-20x)
    n1=en:hyperintense | n2=en:increased serum beta-hexosaminidase (10-20x) | rel=r_associated | relid=0 | w=10
  1551. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum bile acid concentration during pregnancy, resolves postpartum
    n1=en:hyperintense | n2=en:increased serum bile acid concentration during pregnancy, resolves postpartum | rel=r_associated | relid=0 | w=10
  1552. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum bile acids
    n1=en:hyperintense | n2=en:increased serum bile acids | rel=r_associated | relid=0 | w=10
  1553. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum bilirubin (in some patients)
    n1=en:hyperintense | n2=en:increased serum bilirubin (in some patients) | rel=r_associated | relid=0 | w=10
  1554. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum bilirubin due to hemolysis
    n1=en:hyperintense | n2=en:increased serum bilirubin due to hemolysis | rel=r_associated | relid=0 | w=10
  1555. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum butyryl carnitine
    n1=en:hyperintense | n2=en:increased serum butyryl carnitine | rel=r_associated | relid=0 | w=10
  1556. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum c-reactive protein (crp, 123260)
    n1=en:hyperintense | n2=en:increased serum c-reactive protein (crp, 123260) | rel=r_associated | relid=0 | w=10
  1557. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum c-reactive protein, episodic
    n1=en:hyperintense | n2=en:increased serum c-reactive protein, episodic | rel=r_associated | relid=0 | w=10
  1558. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum c26-bile-acid intermediates
    n1=en:hyperintense | n2=en:increased serum c26-bile-acid intermediates | rel=r_associated | relid=0 | w=10
  1559. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum c4 and c5 acylcarnitine esters
    n1=en:hyperintense | n2=en:increased serum c4 and c5 acylcarnitine esters | rel=r_associated | relid=0 | w=10
  1560. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum cholesterol (in 3 of 10 patients)
    n1=en:hyperintense | n2=en:increased serum cholesterol (in 3 of 10 patients) | rel=r_associated | relid=0 | w=10
  1561. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum citrulline (group b)
    n1=en:hyperintense | n2=en:increased serum citrulline (group b) | rel=r_associated | relid=0 | w=10
  1562. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum creatine kinase (1 family)
    n1=en:hyperintense | n2=en:increased serum creatine kinase (1 family) | rel=r_associated | relid=0 | w=10
  1563. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum creatine kinase (less common)
    n1=en:hyperintense | n2=en:increased serum creatine kinase (less common) | rel=r_associated | relid=0 | w=10
  1564. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum creatine kinase (patient a)
    n1=en:hyperintense | n2=en:increased serum creatine kinase (patient a) | rel=r_associated | relid=0 | w=10
  1565. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum creatine kinase during episodes
    n1=en:hyperintense | n2=en:increased serum creatine kinase during episodes | rel=r_associated | relid=0 | w=10
  1566. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum creatine kinase in acute stage
    n1=en:hyperintense | n2=en:increased serum creatine kinase in acute stage | rel=r_associated | relid=0 | w=10
  1567. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum creatine kinase in patients with muscle involvement
    n1=en:hyperintense | n2=en:increased serum creatine kinase in patients with muscle involvement | rel=r_associated | relid=0 | w=10
  1568. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum creatine kinase, mild
    n1=en:hyperintense | n2=en:increased serum creatine kinase, mild | rel=r_associated | relid=0 | w=10
  1569. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum deoxyuridine
    n1=en:hyperintense | n2=en:increased serum deoxyuridine | rel=r_associated | relid=0 | w=10
  1570. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum direct bilirubin
    n1=en:hyperintense | n2=en:increased serum direct bilirubin | rel=r_associated | relid=0 | w=10
  1571. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum erythropoietin (epo, 133170)
    n1=en:hyperintense | n2=en:increased serum erythropoietin (epo, 133170) | rel=r_associated | relid=0 | w=10
  1572. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum ferritin
    n1=en:hyperintense | n2=en:increased serum ferritin | rel=r_associated | relid=0 | w=10
  1573. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum ferritin (in some patients)
    n1=en:hyperintense | n2=en:increased serum ferritin (in some patients) | rel=r_associated | relid=0 | w=10
  1574. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum fgf23
    n1=en:hyperintense | n2=en:increased serum fgf23 | rel=r_associated | relid=0 | w=10
  1575. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum gamma-ggt (231950)
    n1=en:hyperintense | n2=en:increased serum gamma-ggt (231950) | rel=r_associated | relid=0 | w=10
  1576. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum glutamine
    n1=en:hyperintense | n2=en:increased serum glutamine | rel=r_associated | relid=0 | w=10
  1577. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum glycerol
    n1=en:hyperintense | n2=en:increased serum glycerol | rel=r_associated | relid=0 | w=10
  1578. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum glycine, leucine, isoleucine, valine
    n1=en:hyperintense | n2=en:increased serum glycine, leucine, isoleucine, valine | rel=r_associated | relid=0 | w=10
  1579. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum gm-csf
    n1=en:hyperintense | n2=en:increased serum gm-csf | rel=r_associated | relid=0 | w=10
  1580. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum growth hormone levels
    n1=en:hyperintense | n2=en:increased serum growth hormone levels | rel=r_associated | relid=0 | w=10
  1581. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum iduronate sulfatase
    n1=en:hyperintense | n2=en:increased serum iduronate sulfatase | rel=r_associated | relid=0 | w=10
  1582. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum iduronate sulfatase (10-20x)
    n1=en:hyperintense | n2=en:increased serum iduronate sulfatase (10-20x) | rel=r_associated | relid=0 | w=10
  1583. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum ige
    n1=en:hyperintense | n2=en:increased serum ige | rel=r_associated | relid=0 | w=10
  1584. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum insulin-like growth factor-1 (igf1, 147740)
    n1=en:hyperintense | n2=en:increased serum insulin-like growth factor-1 (igf1, 147740) | rel=r_associated | relid=0 | w=10
  1585. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum lactate
    n1=en:hyperintense | n2=en:increased serum lactate | rel=r_associated | relid=0 | w=10
  1586. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum lactate (in some patients)
    n1=en:hyperintense | n2=en:increased serum lactate (in some patients) | rel=r_associated | relid=0 | w=10
  1587. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum lactate (mild)
    n1=en:hyperintense | n2=en:increased serum lactate (mild) | rel=r_associated | relid=0 | w=10
  1588. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum lactate (patient a)
    n1=en:hyperintense | n2=en:increased serum lactate (patient a) | rel=r_associated | relid=0 | w=10
  1589. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum lactate dehydrogenase (in 1 family)
    n1=en:hyperintense | n2=en:increased serum lactate dehydrogenase (in 1 family) | rel=r_associated | relid=0 | w=10
  1590. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum lactate dehydrogenase (ldh)
    n1=en:hyperintense | n2=en:increased serum lactate dehydrogenase (ldh) | rel=r_associated | relid=0 | w=10
  1591. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum lactate during metabolic crisis
    n1=en:hyperintense | n2=en:increased serum lactate during metabolic crisis | rel=r_associated | relid=0 | w=10
  1592. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum lactate hydrogenase
    n1=en:hyperintense | n2=en:increased serum lactate hydrogenase | rel=r_associated | relid=0 | w=10
  1593. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum lactate in acute stage
    n1=en:hyperintense | n2=en:increased serum lactate in acute stage | rel=r_associated | relid=0 | w=10
  1594. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum lactate, particularly after exercise
    n1=en:hyperintense | n2=en:increased serum lactate, particularly after exercise | rel=r_associated | relid=0 | w=10
  1595. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum levels of free plasma thyroid hormones
    n1=en:hyperintense | n2=en:increased serum levels of free plasma thyroid hormones | rel=r_associated | relid=0 | w=10
  1596. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum lipoproteins
    n1=en:hyperintense | n2=en:increased serum lipoproteins | rel=r_associated | relid=0 | w=10
  1597. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum lysine (group b)
    n1=en:hyperintense | n2=en:increased serum lysine (group b) | rel=r_associated | relid=0 | w=10
  1598. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum manganese
    n1=en:hyperintense | n2=en:increased serum manganese | rel=r_associated | relid=0 | w=10
  1599. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum methionine
    n1=en:hyperintense | n2=en:increased serum methionine | rel=r_associated | relid=0 | w=10
  1600. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum methionine (reported in 2 cases)
    n1=en:hyperintense | n2=en:increased serum methionine (reported in 2 cases) | rel=r_associated | relid=0 | w=10
  1601. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum osteocalcin
    n1=en:hyperintense | n2=en:increased serum osteocalcin | rel=r_associated | relid=0 | w=10
  1602. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum pancreatic secretory trypsin inhibitor (psti)
    n1=en:hyperintense | n2=en:increased serum pancreatic secretory trypsin inhibitor (psti) | rel=r_associated | relid=0 | w=10
  1603. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum parathyroid hormone (pth)
    n1=en:hyperintense | n2=en:increased serum parathyroid hormone (pth) | rel=r_associated | relid=0 | w=10
  1604. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum plasminogen activator inhibitor-1 (pai1, 173360)
    n1=en:hyperintense | n2=en:increased serum plasminogen activator inhibitor-1 (pai1, 173360) | rel=r_associated | relid=0 | w=10
  1605. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum prostaglandin e2
    n1=en:hyperintense | n2=en:increased serum prostaglandin e2 | rel=r_associated | relid=0 | w=10
  1606. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum pyruvate
    n1=en:hyperintense | n2=en:increased serum pyruvate | rel=r_associated | relid=0 | w=10
  1607. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum pyruvate in acute stage
    n1=en:hyperintense | n2=en:increased serum pyruvate in acute stage | rel=r_associated | relid=0 | w=10
  1608. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum pyruvate, mild
    n1=en:hyperintense | n2=en:increased serum pyruvate, mild | rel=r_associated | relid=0 | w=10
  1609. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum ratio of corticosterone to 18-hydroxycorticosterone (18-ohb)
    n1=en:hyperintense | n2=en:increased serum ratio of corticosterone to 18-hydroxycorticosterone (18-ohb) | rel=r_associated | relid=0 | w=10
  1610. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum s-adenosylhomocysteine
    n1=en:hyperintense | n2=en:increased serum s-adenosylhomocysteine | rel=r_associated | relid=0 | w=10
  1611. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum s-adenosylmethionine
    n1=en:hyperintense | n2=en:increased serum s-adenosylmethionine | rel=r_associated | relid=0 | w=10
  1612. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum serotonin in 25%
    n1=en:hyperintense | n2=en:increased serum serotonin in 25% | rel=r_associated | relid=0 | w=10
  1613. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum thrombopoietin may occur
    n1=en:hyperintense | n2=en:increased serum thrombopoietin may occur | rel=r_associated | relid=0 | w=10
  1614. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum thymidine
    n1=en:hyperintense | n2=en:increased serum thymidine | rel=r_associated | relid=0 | w=10
  1615. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum thyroid-stimulating hormone (tsh)
    n1=en:hyperintense | n2=en:increased serum thyroid-stimulating hormone (tsh) | rel=r_associated | relid=0 | w=10
  1616. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum thyrotropin
    n1=en:hyperintense | n2=en:increased serum thyrotropin | rel=r_associated | relid=0 | w=10
  1617. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum total cholesterol
    n1=en:hyperintense | n2=en:increased serum total cholesterol | rel=r_associated | relid=0 | w=10
  1618. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum transaminases (in 1 of 3 patients)
    n1=en:hyperintense | n2=en:increased serum transaminases (in 1 of 3 patients) | rel=r_associated | relid=0 | w=10
  1619. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum transferrin
    n1=en:hyperintense | n2=en:increased serum transferrin | rel=r_associated | relid=0 | w=10
  1620. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum triglycerides (in some patients)
    n1=en:hyperintense | n2=en:increased serum triglycerides (in some patients) | rel=r_associated | relid=0 | w=10
  1621. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum triiodothyronine (t3)
    n1=en:hyperintense | n2=en:increased serum triiodothyronine (t3) | rel=r_associated | relid=0 | w=10
  1622. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum unconjugated bilirubin
    n1=en:hyperintense | n2=en:increased serum unconjugated bilirubin | rel=r_associated | relid=0 | w=10
  1623. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum uric acid
    n1=en:hyperintense | n2=en:increased serum uric acid | rel=r_associated | relid=0 | w=10
  1624. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum vascular endothelial growth factor (vegf, 192240)
    n1=en:hyperintense | n2=en:increased serum vascular endothelial growth factor (vegf, 192240) | rel=r_associated | relid=0 | w=10
  1625. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum vitamin b12
    n1=en:hyperintense | n2=en:increased serum vitamin b12 | rel=r_associated | relid=0 | w=10
  1626. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum, cerebrospinal fluid, and urinary levels of alpha-aminoadipic semialdehyde
    n1=en:hyperintense | n2=en:increased serum, cerebrospinal fluid, and urinary levels of alpha-aminoadipic semialdehyde | rel=r_associated | relid=0 | w=10
  1627. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum, urinary, and csf lysine
    n1=en:hyperintense | n2=en:increased serum, urinary, and csf lysine | rel=r_associated | relid=0 | w=10
  1628. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased serum, urinary, and csf saccharopine (in some patients)
    n1=en:hyperintense | n2=en:increased serum, urinary, and csf saccharopine (in some patients) | rel=r_associated | relid=0 | w=10
  1629. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased sodium-potassium pump activity
    n1=en:hyperintense | n2=en:increased sodium-potassium pump activity | rel=r_associated | relid=0 | w=10
  1630. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased soluble il2 receptor
    n1=en:hyperintense | n2=en:increased soluble il2 receptor | rel=r_associated | relid=0 | w=10
  1631. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased succinyladenosine (s-ado) in serum, urine, and csf
    n1=en:hyperintense | n2=en:increased succinyladenosine (s-ado) in serum, urine, and csf | rel=r_associated | relid=0 | w=10
  1632. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased succinylaminoimidazole carboxamide ribotide (saicar)
    n1=en:hyperintense | n2=en:increased succinylaminoimidazole carboxamide ribotide (saicar) | rel=r_associated | relid=0 | w=10
  1633. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased susceptibility to ebv infection
    n1=en:hyperintense | n2=en:increased susceptibility to ebv infection | rel=r_associated | relid=0 | w=10
  1634. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased thymine and dihydrothymine in bodily fluids
    n1=en:hyperintense | n2=en:increased thymine and dihydrothymine in bodily fluids | rel=r_associated | relid=0 | w=10
  1635. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased thyroid-stimulating hormone (tsh)
    n1=en:hyperintense | n2=en:increased thyroid-stimulating hormone (tsh) | rel=r_associated | relid=0 | w=10
  1636. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased tissue levels of free fatty acids
    n1=en:hyperintense | n2=en:increased tissue levels of free fatty acids | rel=r_associated | relid=0 | w=10
  1637. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased tissue levels of triglycerides
    n1=en:hyperintense | n2=en:increased tissue levels of triglycerides | rel=r_associated | relid=0 | w=10
  1638. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased tissue long-chain acylcarnitines
    n1=en:hyperintense | n2=en:increased tissue long-chain acylcarnitines | rel=r_associated | relid=0 | w=10
  1639. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased tissue long-chain fatty acids
    n1=en:hyperintense | n2=en:increased tissue long-chain fatty acids | rel=r_associated | relid=0 | w=10
  1640. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased total and conjugated bilirubin
    n1=en:hyperintense | n2=en:increased total and conjugated bilirubin | rel=r_associated | relid=0 | w=10
  1641. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased total bilirubin may occur
    n1=en:hyperintense | n2=en:increased total bilirubin may occur | rel=r_associated | relid=0 | w=10
  1642. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased toxic thioguanine nucleotides (tgns) on standard doses of thiopurine drugs
    n1=en:hyperintense | n2=en:increased toxic thioguanine nucleotides (tgns) on standard doses of thiopurine drugs | rel=r_associated | relid=0 | w=10
  1643. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased transferrin saturation (>60%)
    n1=en:hyperintense | n2=en:increased transferrin saturation (>60%) | rel=r_associated | relid=0 | w=10
  1644. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased triglycerides (less common)
    n1=en:hyperintense | n2=en:increased triglycerides (less common) | rel=r_associated | relid=0 | w=10
  1645. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased uracil and dihydrouracil in bodily fluids
    n1=en:hyperintense | n2=en:increased uracil and dihydrouracil in bodily fluids | rel=r_associated | relid=0 | w=10
  1646. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased uric acid level
    n1=en:hyperintense | n2=en:increased uric acid level | rel=r_associated | relid=0 | w=10
  1647. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased uric acid with exercise
    n1=en:hyperintense | n2=en:increased uric acid with exercise | rel=r_associated | relid=0 | w=10
  1648. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 2-alpha-ketoglutaric acid
    n1=en:hyperintense | n2=en:increased urinary 2-alpha-ketoglutaric acid | rel=r_associated | relid=0 | w=10
  1649. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 2-butanone
    n1=en:hyperintense | n2=en:increased urinary 2-butanone | rel=r_associated | relid=0 | w=10
  1650. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 2-hydroxybutyrate
    n1=en:hyperintense | n2=en:increased urinary 2-hydroxybutyrate | rel=r_associated | relid=0 | w=10
  1651. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 2-ketoglutarate (variable)
    n1=en:hyperintense | n2=en:increased urinary 2-ketoglutarate (variable) | rel=r_associated | relid=0 | w=10
  1652. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 2-methyl-3 hydroxybutyrate
    n1=en:hyperintense | n2=en:increased urinary 2-methyl-3 hydroxybutyrate | rel=r_associated | relid=0 | w=10
  1653. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 2-methyl-3-hydroxybutyric acid
    n1=en:hyperintense | n2=en:increased urinary 2-methyl-3-hydroxybutyric acid | rel=r_associated | relid=0 | w=10
  1654. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 2-methylacetoacetic acid
    n1=en:hyperintense | n2=en:increased urinary 2-methylacetoacetic acid | rel=r_associated | relid=0 | w=10
  1655. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 2-methylbutyryl glycine
    n1=en:hyperintense | n2=en:increased urinary 2-methylbutyryl glycine | rel=r_associated | relid=0 | w=10
  1656. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 2-methylbutyrylglycine
    n1=en:hyperintense | n2=en:increased urinary 2-methylbutyrylglycine | rel=r_associated | relid=0 | w=10
  1657. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 2-oxoglutaric acid
    n1=en:hyperintense | n2=en:increased urinary 2-oxoglutaric acid | rel=r_associated | relid=0 | w=10
  1658. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 3-methylcrotonylglycine
    n1=en:hyperintense | n2=en:increased urinary 3-methylcrotonylglycine | rel=r_associated | relid=0 | w=10
  1659. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 3-methylglutaconic acid
    n1=en:hyperintense | n2=en:increased urinary 3-methylglutaconic acid | rel=r_associated | relid=0 | w=10
  1660. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 3-oh-butyric acid
    n1=en:hyperintense | n2=en:increased urinary 3-oh-butyric acid | rel=r_associated | relid=0 | w=10
  1661. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 3-oh-isovaleric acid ketonuria
    n1=en:hyperintense | n2=en:increased urinary 3-oh-isovaleric acid ketonuria | rel=r_associated | relid=0 | w=10
  1662. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 3-oh-propionic acid
    n1=en:hyperintense | n2=en:increased urinary 3-oh-propionic acid | rel=r_associated | relid=0 | w=10
  1663. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary 7-biopterin (primapterin)
    n1=en:hyperintense | n2=en:increased urinary 7-biopterin (primapterin) | rel=r_associated | relid=0 | w=10
  1664. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary acetoacetic acid
    n1=en:hyperintense | n2=en:increased urinary acetoacetic acid | rel=r_associated | relid=0 | w=10
  1665. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary adenosine
    n1=en:hyperintense | n2=en:increased urinary adenosine | rel=r_associated | relid=0 | w=10
  1666. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary alpha-ketoglutaric acid, intermittent
    n1=en:hyperintense | n2=en:increased urinary alpha-ketoglutaric acid, intermittent | rel=r_associated | relid=0 | w=10
  1667. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary and serum glycine
    n1=en:hyperintense | n2=en:increased urinary and serum glycine | rel=r_associated | relid=0 | w=10
  1668. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary carnitine
    n1=en:hyperintense | n2=en:increased urinary carnitine | rel=r_associated | relid=0 | w=10
  1669. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary carnitine esters
    n1=en:hyperintense | n2=en:increased urinary carnitine esters | rel=r_associated | relid=0 | w=10
  1670. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary catecholamines
    n1=en:hyperintense | n2=en:increased urinary catecholamines | rel=r_associated | relid=0 | w=10
  1671. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary catecholamines (with pheochromocytoma)
    n1=en:hyperintense | n2=en:increased urinary catecholamines (with pheochromocytoma) | rel=r_associated | relid=0 | w=10
  1672. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary citric acid cycle intermediates
    n1=en:hyperintense | n2=en:increased urinary citric acid cycle intermediates | rel=r_associated | relid=0 | w=10
  1673. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary collagen type i n-telopeptide excretion (ntx) during hyperplastic callus formation
    n1=en:hyperintense | n2=en:increased urinary collagen type i n-telopeptide excretion (ntx) during hyperplastic callus formation | rel=r_associated | relid=0 | w=10
  1674. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary cortisol/cortisone ratio
    n1=en:hyperintense | n2=en:increased urinary cortisol/cortisone ratio | rel=r_associated | relid=0 | w=10
  1675. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary creatine
    n1=en:hyperintense | n2=en:increased urinary creatine | rel=r_associated | relid=0 | w=10
  1676. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary creatine-to-creatinine ratio
    n1=en:hyperintense | n2=en:increased urinary creatine-to-creatinine ratio | rel=r_associated | relid=0 | w=10
  1677. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary cross-linked n-telopetide of type i collagen
    n1=en:hyperintense | n2=en:increased urinary cross-linked n-telopetide of type i collagen | rel=r_associated | relid=0 | w=10
  1678. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary cyclic amp (camp) in response to ddavp administration
    n1=en:hyperintense | n2=en:increased urinary cyclic amp (camp) in response to ddavp administration | rel=r_associated | relid=0 | w=10
  1679. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary cystine, arginine, lysine, and ornithine (hcs and 2p21del)
    n1=en:hyperintense | n2=en:increased urinary cystine, arginine, lysine, and ornithine (hcs and 2p21del) | rel=r_associated | relid=0 | w=10
  1680. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary delta-aminolevulinic acid (ala) and porphobilinogen (pbg) during acute attacks
    n1=en:hyperintense | n2=en:increased urinary delta-aminolevulinic acid (ala) and porphobilinogen (pbg) during acute attacks | rel=r_associated | relid=0 | w=10
  1681. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary dicarboxylic acid, transient
    n1=en:hyperintense | n2=en:increased urinary dicarboxylic acid, transient | rel=r_associated | relid=0 | w=10
  1682. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary dihydropyrimidines
    n1=en:hyperintense | n2=en:increased urinary dihydropyrimidines | rel=r_associated | relid=0 | w=10
  1683. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary disaccharides (mannosyl-n-acetylglucosamine)
    n1=en:hyperintense | n2=en:increased urinary disaccharides (mannosyl-n-acetylglucosamine) | rel=r_associated | relid=0 | w=10
  1684. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary dopamine
    n1=en:hyperintense | n2=en:increased urinary dopamine | rel=r_associated | relid=0 | w=10
  1685. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary dopamine and dopamine metabolites (paradoxical)
    n1=en:hyperintense | n2=en:increased urinary dopamine and dopamine metabolites (paradoxical) | rel=r_associated | relid=0 | w=10
  1686. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary excretion of 4-hydroxybutyric acid (ghb)
    n1=en:hyperintense | n2=en:increased urinary excretion of 4-hydroxybutyric acid (ghb) | rel=r_associated | relid=0 | w=10
  1687. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary excretion of camp
    n1=en:hyperintense | n2=en:increased urinary excretion of camp | rel=r_associated | relid=0 | w=10
  1688. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary excretion of coproporphyrin i
    n1=en:hyperintense | n2=en:increased urinary excretion of coproporphyrin i | rel=r_associated | relid=0 | w=10
  1689. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary excretion of cystine
    n1=en:hyperintense | n2=en:increased urinary excretion of cystine | rel=r_associated | relid=0 | w=10
  1690. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary excretion of gamma-aminobutyric acid (gaba)
    n1=en:hyperintense | n2=en:increased urinary excretion of gamma-aminobutyric acid (gaba) | rel=r_associated | relid=0 | w=10
  1691. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary excretion of l-xylulose
    n1=en:hyperintense | n2=en:increased urinary excretion of l-xylulose | rel=r_associated | relid=0 | w=10
  1692. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary formiminoglutamic acid (figlu)
    n1=en:hyperintense | n2=en:increased urinary formiminoglutamic acid (figlu) | rel=r_associated | relid=0 | w=10
  1693. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary free sialic acid (n-acetylneuraminic acid, 20-200x normal)
    n1=en:hyperintense | n2=en:increased urinary free sialic acid (n-acetylneuraminic acid, 20-200x normal) | rel=r_associated | relid=0 | w=10
  1694. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary free sialic acid excretion (n-acetylneuraminic acid, 5-20x normal) enlarged lysosomal vacuoles in lymphocytes and fibroblasts
    n1=en:hyperintense | n2=en:increased urinary free sialic acid excretion (n-acetylneuraminic acid, 5-20x normal) enlarged lysosomal vacuoles in lymphocytes and fibroblasts | rel=r_associated | relid=0 | w=10
  1695. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary fumaric acid
    n1=en:hyperintense | n2=en:increased urinary fumaric acid | rel=r_associated | relid=0 | w=10
  1696. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary glutaric acid
    n1=en:hyperintense | n2=en:increased urinary glutaric acid | rel=r_associated | relid=0 | w=10
  1697. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary glycerol
    n1=en:hyperintense | n2=en:increased urinary glycerol | rel=r_associated | relid=0 | w=10
  1698. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary glycosphingolipids, particularly globotriaosylceramide
    n1=en:hyperintense | n2=en:increased urinary glycosphingolipids, particularly globotriaosylceramide | rel=r_associated | relid=0 | w=10
  1699. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary hga
    n1=en:hyperintense | n2=en:increased urinary hga | rel=r_associated | relid=0 | w=10
  1700. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary homovanillic acid (hva)
    n1=en:hyperintense | n2=en:increased urinary homovanillic acid (hva) | rel=r_associated | relid=0 | w=10
  1701. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary hydroxyisovaleric acid
    n1=en:hyperintense | n2=en:increased urinary hydroxyisovaleric acid | rel=r_associated | relid=0 | w=10
  1702. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary hypoxanthine
    n1=en:hyperintense | n2=en:increased urinary hypoxanthine | rel=r_associated | relid=0 | w=10
  1703. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary isobutyryl glycine
    n1=en:hyperintense | n2=en:increased urinary isobutyryl glycine | rel=r_associated | relid=0 | w=10
  1704. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary ketones
    n1=en:hyperintense | n2=en:increased urinary ketones | rel=r_associated | relid=0 | w=10
  1705. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary l-glycerate
    n1=en:hyperintense | n2=en:increased urinary l-glycerate | rel=r_associated | relid=0 | w=10
  1706. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary lactate
    n1=en:hyperintense | n2=en:increased urinary lactate | rel=r_associated | relid=0 | w=10
  1707. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary levels of maoa substrates (endogenous bioamines)
    n1=en:hyperintense | n2=en:increased urinary levels of maoa substrates (endogenous bioamines) | rel=r_associated | relid=0 | w=10
  1708. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary magnesium
    n1=en:hyperintense | n2=en:increased urinary magnesium | rel=r_associated | relid=0 | w=10
  1709. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary malic acid
    n1=en:hyperintense | n2=en:increased urinary malic acid | rel=r_associated | relid=0 | w=10
  1710. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary mannose-containing oligosaccharides
    n1=en:hyperintense | n2=en:increased urinary mannose-containing oligosaccharides | rel=r_associated | relid=0 | w=10
  1711. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary methylcitrate
    n1=en:hyperintense | n2=en:increased urinary methylcitrate | rel=r_associated | relid=0 | w=10
  1712. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary n-acetylated amino acids
    n1=en:hyperintense | n2=en:increased urinary n-acetylated amino acids | rel=r_associated | relid=0 | w=10
  1713. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary neopterin
    n1=en:hyperintense | n2=en:increased urinary neopterin | rel=r_associated | relid=0 | w=10
  1714. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary o-hydroxyphenylacetic acid, phenylpyruvic acid, phenylacetic acid and phenylacetylglutamine
    n1=en:hyperintense | n2=en:increased urinary o-hydroxyphenylacetic acid, phenylpyruvic acid, phenylacetic acid and phenylacetylglutamine | rel=r_associated | relid=0 | w=10
  1715. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary o-linked sialopeptides
    n1=en:hyperintense | n2=en:increased urinary o-linked sialopeptides | rel=r_associated | relid=0 | w=10
  1716. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary oligosaccharides
    n1=en:hyperintense | n2=en:increased urinary oligosaccharides | rel=r_associated | relid=0 | w=10
  1717. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary organic acids (in some patients)
    n1=en:hyperintense | n2=en:increased urinary organic acids (in some patients) | rel=r_associated | relid=0 | w=10
  1718. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary orotic acid (in some patients)
    n1=en:hyperintense | n2=en:increased urinary orotic acid (in some patients) | rel=r_associated | relid=0 | w=10
  1719. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary oxylate
    n1=en:hyperintense | n2=en:increased urinary oxylate | rel=r_associated | relid=0 | w=10
  1720. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary phospholipids
    n1=en:hyperintense | n2=en:increased urinary phospholipids | rel=r_associated | relid=0 | w=10
  1721. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary porphyrin precursors porphobilinogen (pbg) and delta-aminolevulinic acid (ala) during acute attacks
    n1=en:hyperintense | n2=en:increased urinary porphyrin precursors porphobilinogen (pbg) and delta-aminolevulinic acid (ala) during acute attacks | rel=r_associated | relid=0 | w=10
  1722. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary potassium
    n1=en:hyperintense | n2=en:increased urinary potassium | rel=r_associated | relid=0 | w=10
  1723. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary propionyl glycine
    n1=en:hyperintense | n2=en:increased urinary propionyl glycine | rel=r_associated | relid=0 | w=10
  1724. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary prostaglandin e2
    n1=en:hyperintense | n2=en:increased urinary prostaglandin e2 | rel=r_associated | relid=0 | w=10
  1725. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary s-sulfocysteine
    n1=en:hyperintense | n2=en:increased urinary s-sulfocysteine | rel=r_associated | relid=0 | w=10
  1726. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary sialylglycopeptides
    n1=en:hyperintense | n2=en:increased urinary sialylglycopeptides | rel=r_associated | relid=0 | w=10
  1727. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary succinic acid
    n1=en:hyperintense | n2=en:increased urinary succinic acid | rel=r_associated | relid=0 | w=10
  1728. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary sulfatide excretion
    n1=en:hyperintense | n2=en:increased urinary sulfatide excretion | rel=r_associated | relid=0 | w=10
  1729. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary sulfatides
    n1=en:hyperintense | n2=en:increased urinary sulfatides | rel=r_associated | relid=0 | w=10
  1730. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary sulfite
    n1=en:hyperintense | n2=en:increased urinary sulfite | rel=r_associated | relid=0 | w=10
  1731. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary taurine
    n1=en:hyperintense | n2=en:increased urinary taurine | rel=r_associated | relid=0 | w=10
  1732. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary thiosulfate
    n1=en:hyperintense | n2=en:increased urinary thiosulfate | rel=r_associated | relid=0 | w=10
  1733. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary thymine
    n1=en:hyperintense | n2=en:increased urinary thymine | rel=r_associated | relid=0 | w=10
  1734. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary tiglylglycine
    n1=en:hyperintense | n2=en:increased urinary tiglylglycine | rel=r_associated | relid=0 | w=10
  1735. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary tricarboxylic acid intermediates
    n1=en:hyperintense | n2=en:increased urinary tricarboxylic acid intermediates | rel=r_associated | relid=0 | w=10
  1736. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary uracil
    n1=en:hyperintense | n2=en:increased urinary uracil | rel=r_associated | relid=0 | w=10
  1737. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary urate
    n1=en:hyperintense | n2=en:increased urinary urate | rel=r_associated | relid=0 | w=10
  1738. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary vanillylmandelic acid (vma)
    n1=en:hyperintense | n2=en:increased urinary vanillylmandelic acid (vma) | rel=r_associated | relid=0 | w=10
  1739. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary, plasma, and csf d-2-hydroxyglutaric acid
    n1=en:hyperintense | n2=en:increased urinary, plasma, and csf d-2-hydroxyglutaric acid | rel=r_associated | relid=0 | w=10
  1740. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary, plasma, and csf dihydrothymine
    n1=en:hyperintense | n2=en:increased urinary, plasma, and csf dihydrothymine | rel=r_associated | relid=0 | w=10
  1741. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary, plasma, and csf dihydrouracil
    n1=en:hyperintense | n2=en:increased urinary, plasma, and csf dihydrouracil | rel=r_associated | relid=0 | w=10
  1742. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary, plasma, and csf l-2-hydroxyglutaric acid
    n1=en:hyperintense | n2=en:increased urinary, plasma, and csf l-2-hydroxyglutaric acid | rel=r_associated | relid=0 | w=10
  1743. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary, plasma, and csf n-carbamyl-beta-alanine
    n1=en:hyperintense | n2=en:increased urinary, plasma, and csf n-carbamyl-beta-alanine | rel=r_associated | relid=0 | w=10
  1744. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urinary, plasma, and csf n-carbamyl-beta-aminoisobutyric acid
    n1=en:hyperintense | n2=en:increased urinary, plasma, and csf n-carbamyl-beta-aminoisobutyric acid | rel=r_associated | relid=0 | w=10
  1745. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urine oligosaccharides
    n1=en:hyperintense | n2=en:increased urine oligosaccharides | rel=r_associated | relid=0 | w=10
  1746. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urine porphyrins at times
    n1=en:hyperintense | n2=en:increased urine porphyrins at times | rel=r_associated | relid=0 | w=10
  1747. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased urine vanillactic acid (vla)
    n1=en:hyperintense | n2=en:increased urine vanillactic acid (vla) | rel=r_associated | relid=0 | w=10
  1748. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased very-long chain fatty acids
    n1=en:hyperintense | n2=en:increased very-long chain fatty acids | rel=r_associated | relid=0 | w=10
  1749. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:increased vitamin e (alpha-tocopherol) levels
    n1=en:hyperintense | n2=en:increased vitamin e (alpha-tocopherol) levels | rel=r_associated | relid=0 | w=10
  1750. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:incresased urinary pyruvate
    n1=en:hyperintense | n2=en:incresased urinary pyruvate | rel=r_associated | relid=0 | w=10
  1751. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:indirect bilirubin increased
    n1=en:hyperintense | n2=en:indirect bilirubin increased | rel=r_associated | relid=0 | w=10
  1752. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:indirect hyperbilirubinemia
    n1=en:hyperintense | n2=en:indirect hyperbilirubinemia | rel=r_associated | relid=0 | w=10
  1753. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:infantile hypophosphatasia
    n1=en:hyperintense | n2=en:infantile hypophosphatasia | rel=r_associated | relid=0 | w=10
  1754. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:inner and outer dynein arm defects, variable
    n1=en:hyperintense | n2=en:inner and outer dynein arm defects, variable | rel=r_associated | relid=0 | w=10
  1755. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:inr increased
    n1=en:hyperintense | n2=en:inr increased | rel=r_associated | relid=0 | w=10
  1756. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:intermediate level of cellular sensitivity to uv light
    n1=en:hyperintense | n2=en:intermediate level of cellular sensitivity to uv light | rel=r_associated | relid=0 | w=10
  1757. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:intermittent 3-methylglutaconic aciduria
    n1=en:hyperintense | n2=en:intermittent 3-methylglutaconic aciduria | rel=r_associated | relid=0 | w=10
  1758. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:intermittent dicarbonic aciduria
    n1=en:hyperintense | n2=en:intermittent dicarbonic aciduria | rel=r_associated | relid=0 | w=10
  1759. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:intermittent ethylmalonic aciduria
    n1=en:hyperintense | n2=en:intermittent ethylmalonic aciduria | rel=r_associated | relid=0 | w=10
  1760. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:intermittent increase of urinary ethylmalonic acid
    n1=en:hyperintense | n2=en:intermittent increase of urinary ethylmalonic acid | rel=r_associated | relid=0 | w=10
  1761. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:intermittent severe hypoglycemia (in some patients)
    n1=en:hyperintense | n2=en:intermittent severe hypoglycemia (in some patients) | rel=r_associated | relid=0 | w=10
  1762. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:interstitial deletion of 17p11.2 (most common is 3.7mb)
    n1=en:hyperintense | n2=en:interstitial deletion of 17p11.2 (most common is 3.7mb) | rel=r_associated | relid=0 | w=10
  1763. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:interstitial or terminal deletion of 18q
    n1=en:hyperintense | n2=en:interstitial or terminal deletion of 18q | rel=r_associated | relid=0 | w=10
  1764. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:intracellular accumulation of unesterified cholesterol
    n1=en:hyperintense | n2=en:intracellular accumulation of unesterified cholesterol | rel=r_associated | relid=0 | w=10
  1765. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:intracellular fingerprint profiles on ultrastructural analysis
    n1=en:hyperintense | n2=en:intracellular fingerprint profiles on ultrastructural analysis | rel=r_associated | relid=0 | w=10
  1766. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:intracellular glycosphingolipid deposition in all tissues of the body
    n1=en:hyperintense | n2=en:intracellular glycosphingolipid deposition in all tissues of the body | rel=r_associated | relid=0 | w=10
  1767. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:intracellular granular material on ultrastructural analysis
    n1=en:hyperintense | n2=en:intracellular granular material on ultrastructural analysis | rel=r_associated | relid=0 | w=10
  1768. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:intracellular pas-positive polyglucosan inclusion bodies ('lafora' bodies) can be found in various tissues (brain, liver, muscle, heart, skin)
    n1=en:hyperintense | n2=en:intracellular pas-positive polyglucosan inclusion bodies ('lafora' bodies) can be found in various tissues (brain, liver, muscle, heart, skin) | rel=r_associated | relid=0 | w=10
  1769. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:intracellular redox disturbance (reduced cytoplasm and oxidized mitochondria (group b))
    n1=en:hyperintense | n2=en:intracellular redox disturbance (reduced cytoplasm and oxidized mitochondria (group b)) | rel=r_associated | relid=0 | w=10
  1770. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:inverted follicular keratosis
    n1=en:hyperintense | n2=en:inverted follicular keratosis | rel=r_associated | relid=0 | w=10
  1771. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:iodide organification defect
    n1=en:hyperintense | n2=en:iodide organification defect | rel=r_associated | relid=0 | w=10
  1772. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:iodine depletion
    n1=en:hyperintense | n2=en:iodine depletion | rel=r_associated | relid=0 | w=10
  1773. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:iron binding capacity total increased
    n1=en:hyperintense | n2=en:iron binding capacity total increased | rel=r_associated | relid=0 | w=10
  1774. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:iron deficiency
    n1=en:hyperintense | n2=en:iron deficiency | rel=r_associated | relid=0 | w=10
  1775. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:iron deposition in basal ganglia, liver, pancreas, visceral organs detectable by ct and mri
    n1=en:hyperintense | n2=en:iron deposition in basal ganglia, liver, pancreas, visceral organs detectable by ct and mri | rel=r_associated | relid=0 | w=10
  1776. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:iron low
    n1=en:hyperintense | n2=en:iron low | rel=r_associated | relid=0 | w=10
  1777. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:iron overload (in some patients)
    n1=en:hyperintense | n2=en:iron overload (in some patients) | rel=r_associated | relid=0 | w=10
  1778. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:irregular distribution of chondrocytes, enlarged chondrocyte lacunae, excessive fibrous matrix, perilacunar loss of glycosaminoglycan, excessive collagen aggregation
    n1=en:hyperintense | n2=en:irregular distribution of chondrocytes, enlarged chondrocyte lacunae, excessive fibrous matrix, perilacunar loss of glycosaminoglycan, excessive collagen aggregation | rel=r_associated | relid=0 | w=10
  1779. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:irregularly shaped sperm heads
    n1=en:hyperintense | n2=en:irregularly shaped sperm heads | rel=r_associated | relid=0 | w=10
  1780. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:isochromosome 12p (i(12p))
    n1=en:hyperintense | n2=en:isochromosome 12p (i(12p)) | rel=r_associated | relid=0 | w=10
  1781. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:isochromosome often missing in lymphocyte
    n1=en:hyperintense | n2=en:isochromosome often missing in lymphocyte | rel=r_associated | relid=0 | w=10
  1782. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:isolated hyperchlorhidrosis
    n1=en:hyperintense | n2=en:isolated hyperchlorhidrosis | rel=r_associated | relid=0 | w=10
  1783. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:isovaleric acidemia
    n1=en:hyperintense | n2=en:isovaleric acidemia | rel=r_associated | relid=0 | w=10
  1784. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:isovalericaciduria
    n1=en:hyperintense | n2=en:isovalericaciduria | rel=r_associated | relid=0 | w=10
  1785. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:isovalerylglycinuria
    n1=en:hyperintense | n2=en:isovalerylglycinuria | rel=r_associated | relid=0 | w=10
  1786. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:karyomegaly may be found in other visceral organs
    n1=en:hyperintense | n2=en:karyomegaly may be found in other visceral organs | rel=r_associated | relid=0 | w=10
  1787. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:karyotype analysis normal finding
    n1=en:hyperintense | n2=en:karyotype analysis normal finding | rel=r_associated | relid=0 | w=10
  1788. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:keratan sulfate excretion in urine that decreases with age
    n1=en:hyperintense | n2=en:keratan sulfate excretion in urine that decreases with age | rel=r_associated | relid=0 | w=10
  1789. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:keratan sulfaturia in some patients
    n1=en:hyperintense | n2=en:keratan sulfaturia in some patients | rel=r_associated | relid=0 | w=10
  1790. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:keratin clumping in suprabasal epidermal layers
    n1=en:hyperintense | n2=en:keratin clumping in suprabasal epidermal layers | rel=r_associated | relid=0 | w=10
  1791. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:keratin, type i cytoskeletal 10
    n1=en:hyperintense | n2=en:keratin, type i cytoskeletal 10 | rel=r_associated | relid=0 | w=10
  1792. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:keratin, type ii cytoskeletal 1
    n1=en:hyperintense | n2=en:keratin, type ii cytoskeletal 1 | rel=r_associated | relid=0 | w=10
  1793. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:keratitis-ichthyosis-deafness syndrome
    n1=en:hyperintense | n2=en:keratitis-ichthyosis-deafness syndrome | rel=r_associated | relid=0 | w=10
  1794. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:keratoderma
    n1=en:hyperintense | n2=en:keratoderma | rel=r_associated | relid=0 | w=10
  1795. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:keratoderma with scleroatrophy of the extremities
    n1=en:hyperintense | n2=en:keratoderma with scleroatrophy of the extremities | rel=r_associated | relid=0 | w=10
  1796. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:keratoderma, palmoplantar, diffuse
    n1=en:hyperintense | n2=en:keratoderma, palmoplantar, diffuse | rel=r_associated | relid=0 | w=10
  1797. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:keratomas
    n1=en:hyperintense | n2=en:keratomas | rel=r_associated | relid=0 | w=10
  1798. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:keratosis
    n1=en:hyperintense | n2=en:keratosis | rel=r_associated | relid=0 | w=10
  1799. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:keratosis obturans
    n1=en:hyperintense | n2=en:keratosis obturans | rel=r_associated | relid=0 | w=10
  1800. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:keratosis pilaris
    n1=en:hyperintense | n2=en:keratosis pilaris | rel=r_associated | relid=0 | w=10
  1801. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:keratotic
    n1=en:hyperintense | n2=en:keratotic | rel=r_associated | relid=0 | w=10
  1802. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ketoacidosis
    n1=en:hyperintense | n2=en:ketoacidosis | rel=r_associated | relid=0 | w=10
  1803. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ketonemia
    n1=en:hyperintense | n2=en:ketonemia | rel=r_associated | relid=0 | w=10
  1804. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ketonuria
    n1=en:hyperintense | n2=en:ketonuria | rel=r_associated | relid=0 | w=10
  1805. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ketonuria (1 patient)
    n1=en:hyperintense | n2=en:ketonuria (1 patient) | rel=r_associated | relid=0 | w=10
  1806. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ketonuria, acute
    n1=en:hyperintense | n2=en:ketonuria, acute | rel=r_associated | relid=0 | w=10
  1807. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ketoses, metabolic
    n1=en:hyperintense | n2=en:ketoses, metabolic | rel=r_associated | relid=0 | w=10
  1808. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ketosis
    n1=en:hyperintense | n2=en:ketosis | rel=r_associated | relid=0 | w=10
  1809. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt1 wt allele
    n1=en:hyperintense | n2=en:krt1 wt allele | rel=r_associated | relid=0 | w=10
  1810. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt1, asn187lys
    n1=en:hyperintense | n2=en:krt1, asn187lys | rel=r_associated | relid=0 | w=10
  1811. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt1, glu310gln
    n1=en:hyperintense | n2=en:krt1, glu310gln | rel=r_associated | relid=0 | w=10
  1812. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt1, leu160pro
    n1=en:hyperintense | n2=en:krt1, leu160pro | rel=r_associated | relid=0 | w=10
  1813. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt1, leu475pro
    n1=en:hyperintense | n2=en:krt1, leu475pro | rel=r_associated | relid=0 | w=10
  1814. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt1, tyr481cys
    n1=en:hyperintense | n2=en:krt1, tyr481cys | rel=r_associated | relid=0 | w=10
  1815. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt1, val155asp
    n1=en:hyperintense | n2=en:krt1, val155asp | rel=r_associated | relid=0 | w=10
  1816. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10 gene
    n1=en:hyperintense | n2=en:krt10 gene | rel=r_associated | relid=0 | w=10
  1817. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, 1-bp ins, 1325c
    n1=en:hyperintense | n2=en:krt10, 1-bp ins, 1325c | rel=r_associated | relid=0 | w=10
  1818. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, arg10cys
    n1=en:hyperintense | n2=en:krt10, arg10cys | rel=r_associated | relid=0 | w=10
  1819. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, arg10his
    n1=en:hyperintense | n2=en:krt10, arg10his | rel=r_associated | relid=0 | w=10
  1820. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, arg10leu
    n1=en:hyperintense | n2=en:krt10, arg10leu | rel=r_associated | relid=0 | w=10
  1821. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, arg156cys
    n1=en:hyperintense | n2=en:krt10, arg156cys | rel=r_associated | relid=0 | w=10
  1822. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, arg156his
    n1=en:hyperintense | n2=en:krt10, arg156his | rel=r_associated | relid=0 | w=10
  1823. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, asn8his
    n1=en:hyperintense | n2=en:krt10, asn8his | rel=r_associated | relid=0 | w=10
  1824. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, cys427ter
    n1=en:hyperintense | n2=en:krt10, cys427ter | rel=r_associated | relid=0 | w=10
  1825. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, gln434ter
    n1=en:hyperintense | n2=en:krt10, gln434ter | rel=r_associated | relid=0 | w=10
  1826. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, ivs5ds, g-a, +5
    n1=en:hyperintense | n2=en:krt10, ivs5ds, g-a, +5 | rel=r_associated | relid=0 | w=10
  1827. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, leu103gln
    n1=en:hyperintense | n2=en:krt10, leu103gln | rel=r_associated | relid=0 | w=10
  1828. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, leu15ser
    n1=en:hyperintense | n2=en:krt10, leu15ser | rel=r_associated | relid=0 | w=10
  1829. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, lys439glu
    n1=en:hyperintense | n2=en:krt10, lys439glu | rel=r_associated | relid=0 | w=10
  1830. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, met150arg
    n1=en:hyperintense | n2=en:krt10, met150arg | rel=r_associated | relid=0 | w=10
  1831. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, met150thr
    n1=en:hyperintense | n2=en:krt10, met150thr | rel=r_associated | relid=0 | w=10
  1832. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:krt10, tyr14asp
    n1=en:hyperintense | n2=en:krt10, tyr14asp | rel=r_associated | relid=0 | w=10
  1833. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:kypokalemia
    n1=en:hyperintense | n2=en:kypokalemia | rel=r_associated | relid=0 | w=10
  1834. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:kyrle disease
    n1=en:hyperintense | n2=en:kyrle disease | rel=r_associated | relid=0 | w=10
  1835. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:laboratory abnormalities
    n1=en:hyperintense | n2=en:laboratory abnormalities | rel=r_associated | relid=0 | w=10
  1836. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lack of ciliary motility
    n1=en:hyperintense | n2=en:lack of ciliary motility | rel=r_associated | relid=0 | w=10
  1837. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lack of excessive parenchymal iron storage
    n1=en:hyperintense | n2=en:lack of excessive parenchymal iron storage | rel=r_associated | relid=0 | w=10
  1838. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lack of lysosomal inclusions in visceral organs
    n1=en:hyperintense | n2=en:lack of lysosomal inclusions in visceral organs | rel=r_associated | relid=0 | w=10
  1839. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lactate dehydrogenase increased
    n1=en:hyperintense | n2=en:lactate dehydrogenase increased | rel=r_associated | relid=0 | w=10
  1840. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lactate high
    n1=en:hyperintense | n2=en:lactate high | rel=r_associated | relid=0 | w=10
  1841. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lactate pyruvate ratio normal
    n1=en:hyperintense | n2=en:lactate pyruvate ratio normal | rel=r_associated | relid=0 | w=10
  1842. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lactic acidemia
    n1=en:hyperintense | n2=en:lactic acidemia | rel=r_associated | relid=0 | w=10
  1843. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lactic acidemia (2p21del)
    n1=en:hyperintense | n2=en:lactic acidemia (2p21del) | rel=r_associated | relid=0 | w=10
  1844. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lactic acidosis
    n1=en:hyperintense | n2=en:lactic acidosis | rel=r_associated | relid=0 | w=10
  1845. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lacunar halos around chondrocytes in skeletal cartilage
    n1=en:hyperintense | n2=en:lacunar halos around chondrocytes in skeletal cartilage | rel=r_associated | relid=0 | w=10
  1846. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lamellar ichthyosis
    n1=en:hyperintense | n2=en:lamellar ichthyosis | rel=r_associated | relid=0 | w=10
  1847. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:large spermatozoa
    n1=en:hyperintense | n2=en:large spermatozoa | rel=r_associated | relid=0 | w=10
  1848. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:leukedema
    n1=en:hyperintense | n2=en:leukedema | rel=r_associated | relid=0 | w=10
  1849. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:leukocyte inclusion bodies (em) - intermediate filaments and ribosome clusters irregularly dispersed in cytoplasm
    n1=en:hyperintense | n2=en:leukocyte inclusion bodies (em) - intermediate filaments and ribosome clusters irregularly dispersed in cytoplasm | rel=r_associated | relid=0 | w=10
  1850. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:leukocytosis
    n1=en:hyperintense | n2=en:leukocytosis | rel=r_associated | relid=0 | w=10
  1851. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:leukokeratosis
    n1=en:hyperintense | n2=en:leukokeratosis | rel=r_associated | relid=0 | w=10
  1852. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:leukoplakia
    n1=en:hyperintense | n2=en:leukoplakia | rel=r_associated | relid=0 | w=10
  1853. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:leukotriene c4 synthetase deficiency
    n1=en:hyperintense | n2=en:leukotriene c4 synthetase deficiency | rel=r_associated | relid=0 | w=10
  1854. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lichenification
    n1=en:hyperintense | n2=en:lichenification | rel=r_associated | relid=0 | w=10
  1855. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lichenoid actinic keratosis
    n1=en:hyperintense | n2=en:lichenoid actinic keratosis | rel=r_associated | relid=0 | w=10
  1856. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:limb reduction-ichthyosis syndrome
    n1=en:hyperintense | n2=en:limb reduction-ichthyosis syndrome | rel=r_associated | relid=0 | w=10
  1857. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:linear arrays of macular hyperkeratoses in flexural areas
    n1=en:hyperintense | n2=en:linear arrays of macular hyperkeratoses in flexural areas | rel=r_associated | relid=0 | w=10
  1858. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lipid vacuoles in leukocytes (jordan bodies)
    n1=en:hyperintense | n2=en:lipid vacuoles in leukocytes (jordan bodies) | rel=r_associated | relid=0 | w=10
  1859. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lipopigment in extraneuronal cells
    n1=en:hyperintense | n2=en:lipopigment in extraneuronal cells | rel=r_associated | relid=0 | w=10
  1860. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:little to absent aspartylglucosaminuria activity
    n1=en:hyperintense | n2=en:little to absent aspartylglucosaminuria activity | rel=r_associated | relid=0 | w=10
  1861. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:liver enzymes abnormal
    n1=en:hyperintense | n2=en:liver enzymes abnormal | rel=r_associated | relid=0 | w=10
  1862. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:liver function tests normal
    n1=en:hyperintense | n2=en:liver function tests normal | rel=r_associated | relid=0 | w=10
  1863. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:liver phosphorylase kinase (phk) deficiency
    n1=en:hyperintense | n2=en:liver phosphorylase kinase (phk) deficiency | rel=r_associated | relid=0 | w=10
  1864. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:liver transaminases normal to slightly increased
    n1=en:hyperintense | n2=en:liver transaminases normal to slightly increased | rel=r_associated | relid=0 | w=10
  1865. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:localized bullous ichthyosiform erythroderma
    n1=en:hyperintense | n2=en:localized bullous ichthyosiform erythroderma | rel=r_associated | relid=0 | w=10
  1866. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:long-chain dicarboxylic aciduria
    n1=en:hyperintense | n2=en:long-chain dicarboxylic aciduria | rel=r_associated | relid=0 | w=10
  1867. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:long-chain ketonuria
    n1=en:hyperintense | n2=en:long-chain ketonuria | rel=r_associated | relid=0 | w=10
  1868. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:loss of ciliary beat coordination
    n1=en:hyperintense | n2=en:loss of ciliary beat coordination | rel=r_associated | relid=0 | w=10
  1869. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:loss of galactose and sialic acid from multiple branches of complex type n-glycans (in some patients)
    n1=en:hyperintense | n2=en:loss of galactose and sialic acid from multiple branches of complex type n-glycans (in some patients) | rel=r_associated | relid=0 | w=10
  1870. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:loss of heterozygosity in giant cell astrocytomas, angiomyolipomas, rhabdomyomas
    n1=en:hyperintense | n2=en:loss of heterozygosity in giant cell astrocytomas, angiomyolipomas, rhabdomyomas | rel=r_associated | relid=0 | w=10
  1871. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low 25-oh-vitamin d level
    n1=en:hyperintense | n2=en:low 25-oh-vitamin d level | rel=r_associated | relid=0 | w=10
  1872. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low absolute lymphocyte count
    n1=en:hyperintense | n2=en:low absolute lymphocyte count | rel=r_associated | relid=0 | w=10
  1873. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low acth level
    n1=en:hyperintense | n2=en:low acth level | rel=r_associated | relid=0 | w=10
  1874. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low alkaline phosphatase
    n1=en:hyperintense | n2=en:low alkaline phosphatase | rel=r_associated | relid=0 | w=10
  1875. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low apolipoprotein
    n1=en:hyperintense | n2=en:low apolipoprotein | rel=r_associated | relid=0 | w=10
  1876. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low cd4+ count
    n1=en:hyperintense | n2=en:low cd4+ count | rel=r_associated | relid=0 | w=10
  1877. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low cholesterol esterification rates
    n1=en:hyperintense | n2=en:low cholesterol esterification rates | rel=r_associated | relid=0 | w=10
  1878. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low copper and ceruloplasmin
    n1=en:hyperintense | n2=en:low copper and ceruloplasmin | rel=r_associated | relid=0 | w=10
  1879. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low csf creatine
    n1=en:hyperintense | n2=en:low csf creatine | rel=r_associated | relid=0 | w=10
  1880. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low csf creatinine
    n1=en:hyperintense | n2=en:low csf creatinine | rel=r_associated | relid=0 | w=10
  1881. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low density lipoprotein increased
    n1=en:hyperintense | n2=en:low density lipoprotein increased | rel=r_associated | relid=0 | w=10
  1882. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low fasting glucose (in some patients)
    n1=en:hyperintense | n2=en:low fasting glucose (in some patients) | rel=r_associated | relid=0 | w=10
  1883. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low free carnitine
    n1=en:hyperintense | n2=en:low free carnitine | rel=r_associated | relid=0 | w=10
  1884. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low growth hormone levels
    n1=en:hyperintense | n2=en:low growth hormone levels | rel=r_associated | relid=0 | w=10
  1885. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low ldl cholesterol
    n1=en:hyperintense | n2=en:low ldl cholesterol | rel=r_associated | relid=0 | w=10
  1886. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low leukocyte alkaline phosphatase activity
    n1=en:hyperintense | n2=en:low leukocyte alkaline phosphatase activity | rel=r_associated | relid=0 | w=10
  1887. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low level of c4 and c2
    n1=en:hyperintense | n2=en:low level of c4 and c2 | rel=r_associated | relid=0 | w=10
  1888. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low levels of cd11/cd18 (lfa-1 or leukocyte function antigen-1) glycoprotein
    n1=en:hyperintense | n2=en:low levels of cd11/cd18 (lfa-1 or leukocyte function antigen-1) glycoprotein | rel=r_associated | relid=0 | w=10
  1889. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low levels of serum mg(2+) in the absence of other electrolyte disturbances
    n1=en:hyperintense | n2=en:low levels of serum mg(2+) in the absence of other electrolyte disturbances | rel=r_associated | relid=0 | w=10
  1890. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low maximal oxygen uptake on exercise testing
    n1=en:hyperintense | n2=en:low maximal oxygen uptake on exercise testing | rel=r_associated | relid=0 | w=10
  1891. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or absent adrenocorticotropic hormone (acth)
    n1=en:hyperintense | n2=en:low or absent adrenocorticotropic hormone (acth) | rel=r_associated | relid=0 | w=10
  1892. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or absent adrenocorticotropic hormone (acth) in some patients
    n1=en:hyperintense | n2=en:low or absent adrenocorticotropic hormone (acth) in some patients | rel=r_associated | relid=0 | w=10
  1893. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or absent follicle stimulating hormone (fsh)
    n1=en:hyperintense | n2=en:low or absent follicle stimulating hormone (fsh) | rel=r_associated | relid=0 | w=10
  1894. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or absent growth hormone (gh)
    n1=en:hyperintense | n2=en:low or absent growth hormone (gh) | rel=r_associated | relid=0 | w=10
  1895. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or absent iga levels
    n1=en:hyperintense | n2=en:low or absent iga levels | rel=r_associated | relid=0 | w=10
  1896. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or absent igm levels
    n1=en:hyperintense | n2=en:low or absent igm levels | rel=r_associated | relid=0 | w=10
  1897. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or absent luteinizing hormone (lh)
    n1=en:hyperintense | n2=en:low or absent luteinizing hormone (lh) | rel=r_associated | relid=0 | w=10
  1898. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or absent prolactin (pl)
    n1=en:hyperintense | n2=en:low or absent prolactin (pl) | rel=r_associated | relid=0 | w=10
  1899. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or absent thyroid-stimulating hormone (tsh)
    n1=en:hyperintense | n2=en:low or absent thyroid-stimulating hormone (tsh) | rel=r_associated | relid=0 | w=10
  1900. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or absent thyrotropin (tsh)
    n1=en:hyperintense | n2=en:low or absent thyrotropin (tsh) | rel=r_associated | relid=0 | w=10
  1901. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or low-normal serum t4
    n1=en:hyperintense | n2=en:low or low-normal serum t4 | rel=r_associated | relid=0 | w=10
  1902. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or normal serum calcium
    n1=en:hyperintense | n2=en:low or normal serum calcium | rel=r_associated | relid=0 | w=10
  1903. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or normal serum erythropoietin
    n1=en:hyperintense | n2=en:low or normal serum erythropoietin | rel=r_associated | relid=0 | w=10
  1904. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or normal serum igm
    n1=en:hyperintense | n2=en:low or normal serum igm | rel=r_associated | relid=0 | w=10
  1905. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or undetectable c-peptide
    n1=en:hyperintense | n2=en:low or undetectable c-peptide | rel=r_associated | relid=0 | w=10
  1906. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low or undetectable insulin
    n1=en:hyperintense | n2=en:low or undetectable insulin | rel=r_associated | relid=0 | w=10
  1907. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low plasma arginine
    n1=en:hyperintense | n2=en:low plasma arginine | rel=r_associated | relid=0 | w=10
  1908. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low plasma citrulline
    n1=en:hyperintense | n2=en:low plasma citrulline | rel=r_associated | relid=0 | w=10
  1909. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low plasma free and total carnitine
    n1=en:hyperintense | n2=en:low plasma free and total carnitine | rel=r_associated | relid=0 | w=10
  1910. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low plasma hdl
    n1=en:hyperintense | n2=en:low plasma hdl | rel=r_associated | relid=0 | w=10
  1911. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low plasma methionine
    n1=en:hyperintense | n2=en:low plasma methionine | rel=r_associated | relid=0 | w=10
  1912. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low plasma triglyceride level
    n1=en:hyperintense | n2=en:low plasma triglyceride level | rel=r_associated | relid=0 | w=10
  1913. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low plasma tryptophan (inflammatory type b)
    n1=en:hyperintense | n2=en:low plasma tryptophan (inflammatory type b) | rel=r_associated | relid=0 | w=10
  1914. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low procollagen 1 c-peptide (in some patients)
    n1=en:hyperintense | n2=en:low procollagen 1 c-peptide (in some patients) | rel=r_associated | relid=0 | w=10
  1915. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low pyruvate carboxylase activity in liver and cultured fibroblasts
    n1=en:hyperintense | n2=en:low pyruvate carboxylase activity in liver and cultured fibroblasts | rel=r_associated | relid=0 | w=10
  1916. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low rai (radioactive iodine) uptake
    n1=en:hyperintense | n2=en:low rai (radioactive iodine) uptake | rel=r_associated | relid=0 | w=10
  1917. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low serum acth
    n1=en:hyperintense | n2=en:low serum acth | rel=r_associated | relid=0 | w=10
  1918. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low serum alkaline phosphatase in heterozygotes
    n1=en:hyperintense | n2=en:low serum alkaline phosphatase in heterozygotes | rel=r_associated | relid=0 | w=10
  1919. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low serum alpha-fetoprotein (recessive)
    n1=en:hyperintense | n2=en:low serum alpha-fetoprotein (recessive) | rel=r_associated | relid=0 | w=10
  1920. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low serum anti-mullerian hormone (amh) levels
    n1=en:hyperintense | n2=en:low serum anti-mullerian hormone (amh) levels | rel=r_associated | relid=0 | w=10
  1921. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low serum calcium
    n1=en:hyperintense | n2=en:low serum calcium | rel=r_associated | relid=0 | w=10
  1922. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low serum ceruloplasmin
    n1=en:hyperintense | n2=en:low serum ceruloplasmin | rel=r_associated | relid=0 | w=10
  1923. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low serum concentration of intercellular adhesion molecule 1 (icam1)
    n1=en:hyperintense | n2=en:low serum concentration of intercellular adhesion molecule 1 (icam1) | rel=r_associated | relid=0 | w=10
  1924. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low serum cortisol
    n1=en:hyperintense | n2=en:low serum cortisol | rel=r_associated | relid=0 | w=10
  1925. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low serum igg and iga
    n1=en:hyperintense | n2=en:low serum igg and iga | rel=r_associated | relid=0 | w=10
  1926. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low serum levels of branched-chain amino acids
    n1=en:hyperintense | n2=en:low serum levels of branched-chain amino acids | rel=r_associated | relid=0 | w=10
  1927. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low serum levels of ketone bodies
    n1=en:hyperintense | n2=en:low serum levels of ketone bodies | rel=r_associated | relid=0 | w=10
  1928. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low serum magnesium
    n1=en:hyperintense | n2=en:low serum magnesium | rel=r_associated | relid=0 | w=10
  1929. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low serum uric acid
    n1=en:hyperintense | n2=en:low serum uric acid | rel=r_associated | relid=0 | w=10
  1930. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low to absent apo a-i (detroit 107680.0011)
    n1=en:hyperintense | n2=en:low to absent apo a-i (detroit 107680.0011) | rel=r_associated | relid=0 | w=10
  1931. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low to absent high density lipoprotein (hdl) (detroit 107680.0011)
    n1=en:hyperintense | n2=en:low to absent high density lipoprotein (hdl) (detroit 107680.0011) | rel=r_associated | relid=0 | w=10
  1932. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low to low-normal magnesium
    n1=en:hyperintense | n2=en:low to low-normal magnesium | rel=r_associated | relid=0 | w=10
  1933. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low to normal plasma methionine
    n1=en:hyperintense | n2=en:low to normal plasma methionine | rel=r_associated | relid=0 | w=10
  1934. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low to normal serum calcium
    n1=en:hyperintense | n2=en:low to normal serum calcium | rel=r_associated | relid=0 | w=10
  1935. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low to normal tsh (values may vary depending on the measurement methods used)
    n1=en:hyperintense | n2=en:low to normal tsh (values may vary depending on the measurement methods used) | rel=r_associated | relid=0 | w=10
  1936. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low to very low hdl cholesterol
    n1=en:hyperintense | n2=en:low to very low hdl cholesterol | rel=r_associated | relid=0 | w=10
  1937. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low total serum protein
    n1=en:hyperintense | n2=en:low total serum protein | rel=r_associated | relid=0 | w=10
  1938. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low urinary cyclic amp response to pth administration
    n1=en:hyperintense | n2=en:low urinary cyclic amp response to pth administration | rel=r_associated | relid=0 | w=10
  1939. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low urinary excretion of neutral 17-ketosteroids
    n1=en:hyperintense | n2=en:low urinary excretion of neutral 17-ketosteroids | rel=r_associated | relid=0 | w=10
  1940. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low urinary orotic acid
    n1=en:hyperintense | n2=en:low urinary orotic acid | rel=r_associated | relid=0 | w=10
  1941. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low-molecular-weight proteinuria
    n1=en:hyperintense | n2=en:low-molecular-weight proteinuria | rel=r_associated | relid=0 | w=10
  1942. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low-normal igm
    n1=en:hyperintense | n2=en:low-normal igm | rel=r_associated | relid=0 | w=10
  1943. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low-normal platelet count (89-290 x 10(9)/l)
    n1=en:hyperintense | n2=en:low-normal platelet count (89-290 x 10(9)/l) | rel=r_associated | relid=0 | w=10
  1944. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low-to-normal csf lactate
    n1=en:hyperintense | n2=en:low-to-normal csf lactate | rel=r_associated | relid=0 | w=10
  1945. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:low-to-normal platelet count
    n1=en:hyperintense | n2=en:low-to-normal platelet count | rel=r_associated | relid=0 | w=10
  1946. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lower total cholesterol
    n1=en:hyperintense | n2=en:lower total cholesterol | rel=r_associated | relid=0 | w=10
  1947. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lymphedematous keratoderma
    n1=en:hyperintense | n2=en:lymphedematous keratoderma | rel=r_associated | relid=0 | w=10
  1948. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lysine-ketoglutarate reductase deficiency
    n1=en:hyperintense | n2=en:lysine-ketoglutarate reductase deficiency | rel=r_associated | relid=0 | w=10
  1949. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lysosomal-like storage vacuoles in various tissues
    n1=en:hyperintense | n2=en:lysosomal-like storage vacuoles in various tissues | rel=r_associated | relid=0 | w=10
  1950. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lysyl hydroxylase deficiency
    n1=en:hyperintense | n2=en:lysyl hydroxylase deficiency | rel=r_associated | relid=0 | w=10
  1951. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:lysyl pyridinoline/hydroxylysyl pyridinoline (lp/hp) ratio approximately 1
    n1=en:hyperintense | n2=en:lysyl pyridinoline/hydroxylysyl pyridinoline (lp/hp) ratio approximately 1 | rel=r_associated | relid=0 | w=10
  1952. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:magnesium overload
    n1=en:hyperintense | n2=en:magnesium overload | rel=r_associated | relid=0 | w=10
  1953. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:malignant hyperthermia syndrome
    n1=en:hyperintense | n2=en:malignant hyperthermia syndrome | rel=r_associated | relid=0 | w=10
  1954. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:march myoglobinuria
    n1=en:hyperintense | n2=en:march myoglobinuria | rel=r_associated | relid=0 | w=10
  1955. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:marked elevation of erythrocyte sedimentation rate
    n1=en:hyperintense | n2=en:marked elevation of erythrocyte sedimentation rate | rel=r_associated | relid=0 | w=10
  1956. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:marked elevation of serum c-reactive protein level (crp 123260)
    n1=en:hyperintense | n2=en:marked elevation of serum c-reactive protein level (crp 123260) | rel=r_associated | relid=0 | w=10
  1957. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:marked hypoalphalipoproteinemia (in some patients)
    n1=en:hyperintense | n2=en:marked hypoalphalipoproteinemia (in some patients) | rel=r_associated | relid=0 | w=10
  1958. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:marked hypobetalipoproteinemia
    n1=en:hyperintense | n2=en:marked hypobetalipoproteinemia | rel=r_associated | relid=0 | w=10
  1959. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:markedly decreased coproporphyrinogen oxidase activity (harderoporphyria, lymphocytes)
    n1=en:hyperintense | n2=en:markedly decreased coproporphyrinogen oxidase activity (harderoporphyria, lymphocytes) | rel=r_associated | relid=0 | w=10
  1960. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:markedly decreased or absent serum 1,25-dihydroxyvitamin d3
    n1=en:hyperintense | n2=en:markedly decreased or absent serum 1,25-dihydroxyvitamin d3 | rel=r_associated | relid=0 | w=10
  1961. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:markedly elevated sodium in urine, sweat, saliva, and stool
    n1=en:hyperintense | n2=en:markedly elevated sodium in urine, sweat, saliva, and stool | rel=r_associated | relid=0 | w=10
  1962. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:markedly increased serum creatine kinase
    n1=en:hyperintense | n2=en:markedly increased serum creatine kinase | rel=r_associated | relid=0 | w=10
  1963. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:markedly reduced iga levels
    n1=en:hyperintense | n2=en:markedly reduced iga levels | rel=r_associated | relid=0 | w=10
  1964. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:markedly reduced igg levels
    n1=en:hyperintense | n2=en:markedly reduced igg levels | rel=r_associated | relid=0 | w=10
  1965. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:may have increased serum parathyroid hormone (pth)
    n1=en:hyperintense | n2=en:may have increased serum parathyroid hormone (pth) | rel=r_associated | relid=0 | w=10
  1966. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mean platelet volume (mpv) 12.6fl
    n1=en:hyperintense | n2=en:mean platelet volume (mpv) 12.6fl | rel=r_associated | relid=0 | w=10
  1967. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mechanic's hand
    n1=en:hyperintense | n2=en:mechanic's hand | rel=r_associated | relid=0 | w=10
  1968. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:median mean platelet volume (mpv) 12.5fl
    n1=en:hyperintense | n2=en:median mean platelet volume (mpv) 12.5fl | rel=r_associated | relid=0 | w=10
  1969. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:median mean platelet volume (mpv) 18fl
    n1=en:hyperintense | n2=en:median mean platelet volume (mpv) 18fl | rel=r_associated | relid=0 | w=10
  1970. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:median mean platelet volume (mpv) 20fl
    n1=en:hyperintense | n2=en:median mean platelet volume (mpv) 20fl | rel=r_associated | relid=0 | w=10
  1971. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:median mean platelet volume 13fl
    n1=en:hyperintense | n2=en:median mean platelet volume 13fl | rel=r_associated | relid=0 | w=10
  1972. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:medium chain dicarboxylic aciduria
    n1=en:hyperintense | n2=en:medium chain dicarboxylic aciduria | rel=r_associated | relid=0 | w=10
  1973. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:medium-chain acyl-coa dehydrogenase deficiency
    n1=en:hyperintense | n2=en:medium-chain acyl-coa dehydrogenase deficiency | rel=r_associated | relid=0 | w=10
  1974. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:metabolic acidosis
    n1=en:hyperintense | n2=en:metabolic acidosis | rel=r_associated | relid=0 | w=10
  1975. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:metabolic aspects
    n1=en:hyperintense | n2=en:metabolic aspects | rel=r_associated | relid=0 | w=10
  1976. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:metachromasia of white blood cells and fibroblasts
    n1=en:hyperintense | n2=en:metachromasia of white blood cells and fibroblasts | rel=r_associated | relid=0 | w=10
  1977. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:metachromatic deposits (sulfatide-containing) in central and peripheral nervous systems and visceral organs
    n1=en:hyperintense | n2=en:metachromatic deposits (sulfatide-containing) in central and peripheral nervous systems and visceral organs | rel=r_associated | relid=0 | w=10
  1978. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:metachromatic leukodystrophy due to saposin b deficiency
    n1=en:hyperintense | n2=en:metachromatic leukodystrophy due to saposin b deficiency | rel=r_associated | relid=0 | w=10
  1979. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:methemoglobin concentration 12 to 19%
    n1=en:hyperintense | n2=en:methemoglobin concentration 12 to 19% | rel=r_associated | relid=0 | w=10
  1980. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:methemoglobinemia
    n1=en:hyperintense | n2=en:methemoglobinemia | rel=r_associated | relid=0 | w=10
  1981. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:methionine adenosyltransferase deficiency
    n1=en:hyperintense | n2=en:methionine adenosyltransferase deficiency | rel=r_associated | relid=0 | w=10
  1982. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:methioninuria
    n1=en:hyperintense | n2=en:methioninuria | rel=r_associated | relid=0 | w=10
  1983. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:methylenetetrahydrofolate reductase deficiency
    n1=en:hyperintense | n2=en:methylenetetrahydrofolate reductase deficiency | rel=r_associated | relid=0 | w=10
  1984. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:methylglutaconic aciduria, mild
    n1=en:hyperintense | n2=en:methylglutaconic aciduria, mild | rel=r_associated | relid=0 | w=10
  1985. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:methylmalonic acidemia
    n1=en:hyperintense | n2=en:methylmalonic acidemia | rel=r_associated | relid=0 | w=10
  1986. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:methylmalonic aciduria
    n1=en:hyperintense | n2=en:methylmalonic aciduria | rel=r_associated | relid=0 | w=10
  1987. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:methylmalonic aciduria, mild
    n1=en:hyperintense | n2=en:methylmalonic aciduria, mild | rel=r_associated | relid=0 | w=10
  1988. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:methylmalonyl-coenzyme a mutase deficiency
    n1=en:hyperintense | n2=en:methylmalonyl-coenzyme a mutase deficiency | rel=r_associated | relid=0 | w=10
  1989. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:methylsuccinic aciduria
    n1=en:hyperintense | n2=en:methylsuccinic aciduria | rel=r_associated | relid=0 | w=10
  1990. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:microbiological
    n1=en:hyperintense | n2=en:microbiological | rel=r_associated | relid=0 | w=10
  1991. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:microdeletion 22q11.2
    n1=en:hyperintense | n2=en:microdeletion 22q11.2 | rel=r_associated | relid=0 | w=10
  1992. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:microdeletion of chromosome 11q13 (43-490kb)
    n1=en:hyperintense | n2=en:microdeletion of chromosome 11q13 (43-490kb) | rel=r_associated | relid=0 | w=10
  1993. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:microduplication of chromosome 5p13
    n1=en:hyperintense | n2=en:microduplication of chromosome 5p13 | rel=r_associated | relid=0 | w=10
  1994. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:microscopic hematuria
    n1=en:hyperintense | n2=en:microscopic hematuria | rel=r_associated | relid=0 | w=10
  1995. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:microsomal hmg-coa reductase decreased
    n1=en:hyperintense | n2=en:microsomal hmg-coa reductase decreased | rel=r_associated | relid=0 | w=10
  1996. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:microtubule disorganization in some cilia
    n1=en:hyperintense | n2=en:microtubule disorganization in some cilia | rel=r_associated | relid=0 | w=10
  1997. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mild elevation of cholesterol
    n1=en:hyperintense | n2=en:mild elevation of cholesterol | rel=r_associated | relid=0 | w=10
  1998. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mild elevation of transaminases
    n1=en:hyperintense | n2=en:mild elevation of transaminases | rel=r_associated | relid=0 | w=10
  1999. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mild elevation of triglycerides
    n1=en:hyperintense | n2=en:mild elevation of triglycerides | rel=r_associated | relid=0 | w=10
  2000. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mild eosinophilia may occur
    n1=en:hyperintense | n2=en:mild eosinophilia may occur | rel=r_associated | relid=0 | w=10
  2001. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mild hyperammonemia
    n1=en:hyperintense | n2=en:mild hyperammonemia | rel=r_associated | relid=0 | w=10
  2002. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mild hypertriglyceridemia
    n1=en:hyperintense | n2=en:mild hypertriglyceridemia | rel=r_associated | relid=0 | w=10
  2003. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mild to moderate hyperammonemia
    n1=en:hyperintense | n2=en:mild to moderate hyperammonemia | rel=r_associated | relid=0 | w=10
  2004. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mild to moderate thrombocytopenia (40-120 x 10(9)/l)
    n1=en:hyperintense | n2=en:mild to moderate thrombocytopenia (40-120 x 10(9)/l) | rel=r_associated | relid=0 | w=10
  2005. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mild-moderate prolonged bleeding time
    n1=en:hyperintense | n2=en:mild-moderate prolonged bleeding time | rel=r_associated | relid=0 | w=10
  2006. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mildly abnormal glycosylation of serum transferrin, type 1 pattern
    n1=en:hyperintense | n2=en:mildly abnormal glycosylation of serum transferrin, type 1 pattern | rel=r_associated | relid=0 | w=10
  2007. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mildly decreased phosphaturic response to pth administration has been reported in some cases
    n1=en:hyperintense | n2=en:mildly decreased phosphaturic response to pth administration has been reported in some cases | rel=r_associated | relid=0 | w=10
  2008. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mildly decreased serum creatinine
    n1=en:hyperintense | n2=en:mildly decreased serum creatinine | rel=r_associated | relid=0 | w=10
  2009. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mildly elevated acth
    n1=en:hyperintense | n2=en:mildly elevated acth | rel=r_associated | relid=0 | w=10
  2010. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mildly elevated blood ammonia
    n1=en:hyperintense | n2=en:mildly elevated blood ammonia | rel=r_associated | relid=0 | w=10
  2011. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mildly elevated creatine phosphokinase
    n1=en:hyperintense | n2=en:mildly elevated creatine phosphokinase | rel=r_associated | relid=0 | w=10
  2012. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mildly elevated creatine phosphokinase (cpk) (120270.0002)
    n1=en:hyperintense | n2=en:mildly elevated creatine phosphokinase (cpk) (120270.0002) | rel=r_associated | relid=0 | w=10
  2013. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mildly elevated hdl in heterozygotes
    n1=en:hyperintense | n2=en:mildly elevated hdl in heterozygotes | rel=r_associated | relid=0 | w=10
  2014. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mildly elevated hepatic enzymes
    n1=en:hyperintense | n2=en:mildly elevated hepatic enzymes | rel=r_associated | relid=0 | w=10
  2015. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mildly elevated phosphoethanolamine urinary excretion in heterozygotes
    n1=en:hyperintense | n2=en:mildly elevated phosphoethanolamine urinary excretion in heterozygotes | rel=r_associated | relid=0 | w=10
  2016. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mildly elevated transaminases
    n1=en:hyperintense | n2=en:mildly elevated transaminases | rel=r_associated | relid=0 | w=10
  2017. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mildly elevated urinary mevalonic acid
    n1=en:hyperintense | n2=en:mildly elevated urinary mevalonic acid | rel=r_associated | relid=0 | w=10
  2018. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mildly increased serum creatine kinase (in some patients)
    n1=en:hyperintense | n2=en:mildly increased serum creatine kinase (in some patients) | rel=r_associated | relid=0 | w=10
  2019. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mildly increased serum lactate
    n1=en:hyperintense | n2=en:mildly increased serum lactate | rel=r_associated | relid=0 | w=10
  2020. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mildly prolonged bleeding time 10-12 minutes
    n1=en:hyperintense | n2=en:mildly prolonged bleeding time 10-12 minutes | rel=r_associated | relid=0 | w=10
  2021. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mitochondria dna deletion
    n1=en:hyperintense | n2=en:mitochondria dna deletion | rel=r_associated | relid=0 | w=10
  2022. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mitochondrial complex i deficiency in muscle
    n1=en:hyperintense | n2=en:mitochondrial complex i deficiency in muscle | rel=r_associated | relid=0 | w=10
  2023. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mitochondrial deletions
    n1=en:hyperintense | n2=en:mitochondrial deletions | rel=r_associated | relid=0 | w=10
  2024. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mitochondrial malic enzyme reduced
    n1=en:hyperintense | n2=en:mitochondrial malic enzyme reduced | rel=r_associated | relid=0 | w=10
  2025. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mitochondrial malonyl-coa decarboxylase activity in fibroblasts is very low (as low as 4%)
    n1=en:hyperintense | n2=en:mitochondrial malonyl-coa decarboxylase activity in fibroblasts is very low (as low as 4%) | rel=r_associated | relid=0 | w=10
  2026. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mitochondrial respiratory chain defects (skeletal muscle, fibroblasts)
    n1=en:hyperintense | n2=en:mitochondrial respiratory chain defects (skeletal muscle, fibroblasts) | rel=r_associated | relid=0 | w=10
  2027. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mitotic lymphocyte and fibroblast cultures show mosaic variegated aneuploidy
    n1=en:hyperintense | n2=en:mitotic lymphocyte and fibroblast cultures show mosaic variegated aneuploidy | rel=r_associated | relid=0 | w=10
  2028. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mitotic lymphocyte and fibroblast cultures show mosaic variegated aneuploidy (50%) affecting all chromosomes
    n1=en:hyperintense | n2=en:mitotic lymphocyte and fibroblast cultures show mosaic variegated aneuploidy (50%) affecting all chromosomes | rel=r_associated | relid=0 | w=10
  2029. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mixed acid-base balance disorder
    n1=en:hyperintense | n2=en:mixed acid-base balance disorder | rel=r_associated | relid=0 | w=10
  2030. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:moderate to severe thrombocytopenia (30-90 x 10(9)/l)
    n1=en:hyperintense | n2=en:moderate to severe thrombocytopenia (30-90 x 10(9)/l) | rel=r_associated | relid=0 | w=10
  2031. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:moderately decreased to normal phk activity in skeletal muscle
    n1=en:hyperintense | n2=en:moderately decreased to normal phk activity in skeletal muscle | rel=r_associated | relid=0 | w=10
  2032. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:molybdenum cofactor deficiency
    n1=en:hyperintense | n2=en:molybdenum cofactor deficiency | rel=r_associated | relid=0 | w=10
  2033. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:monoclonal gammopathy
    n1=en:hyperintense | n2=en:monoclonal gammopathy | rel=r_associated | relid=0 | w=10
  2034. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:monomeric igm
    n1=en:hyperintense | n2=en:monomeric igm | rel=r_associated | relid=0 | w=10
  2035. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mononuclear cell noncaseating granulomatous inflammation on biopsy (lung, skin, lip)
    n1=en:hyperintense | n2=en:mononuclear cell noncaseating granulomatous inflammation on biopsy (lung, skin, lip) | rel=r_associated | relid=0 | w=10
  2036. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:more than 50% of mitotic cells show premature chromatid separation (pcs) affecting all chromosomes
    n1=en:hyperintense | n2=en:more than 50% of mitotic cells show premature chromatid separation (pcs) affecting all chromosomes | rel=r_associated | relid=0 | w=10
  2037. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mosaic tetrasomy 12p in skin fibroblasts
    n1=en:hyperintense | n2=en:mosaic tetrasomy 12p in skin fibroblasts | rel=r_associated | relid=0 | w=10
  2038. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mucopolysaccharidosis type iiid
    n1=en:hyperintense | n2=en:mucopolysaccharidosis type iiid | rel=r_associated | relid=0 | w=10
  2039. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:multi-tailed spermatozoa
    n1=en:hyperintense | n2=en:multi-tailed spermatozoa | rel=r_associated | relid=0 | w=10
  2040. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:multiple autoantibodies
    n1=en:hyperintense | n2=en:multiple autoantibodies | rel=r_associated | relid=0 | w=10
  2041. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:multiple minute digitate hyperkeratosis of goldstein
    n1=en:hyperintense | n2=en:multiple minute digitate hyperkeratosis of goldstein | rel=r_associated | relid=0 | w=10
  2042. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:multiple organs (lung, liver, spleen, kidney, brain) contain foamy resident cells and histiocytes
    n1=en:hyperintense | n2=en:multiple organs (lung, liver, spleen, kidney, brain) contain foamy resident cells and histiocytes | rel=r_associated | relid=0 | w=10
  2043. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:multiple tissue biopsies show lysosomal storage disease
    n1=en:hyperintense | n2=en:multiple tissue biopsies show lysosomal storage disease | rel=r_associated | relid=0 | w=10
  2044. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:multiple visceral organs (lung, liver, spleen, kidney) contain foamy resident cells and histiocytes
    n1=en:hyperintense | n2=en:multiple visceral organs (lung, liver, spleen, kidney) contain foamy resident cells and histiocytes | rel=r_associated | relid=0 | w=10
  2045. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:muscle and liver tissue show decreased activities of mitochondrial complexes i, ii, and iii
    n1=en:hyperintense | n2=en:muscle and liver tissue show decreased activities of mitochondrial complexes i, ii, and iii | rel=r_associated | relid=0 | w=10
  2046. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:mutant mtdna threonine transfer rna gene (mttt, 590090) of questionable etiology
    n1=en:hyperintense | n2=en:mutant mtdna threonine transfer rna gene (mttt, 590090) of questionable etiology | rel=r_associated | relid=0 | w=10
  2047. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:myelin basic protein measurement, spinal fluid
    n1=en:hyperintense | n2=en:myelin basic protein measurement, spinal fluid | rel=r_associated | relid=0 | w=10
  2048. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:myoglobinuria
    n1=en:hyperintense | n2=en:myoglobinuria | rel=r_associated | relid=0 | w=10
  2049. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:myoglobinuria (reported in 1 patient)
    n1=en:hyperintense | n2=en:myoglobinuria (reported in 1 patient) | rel=r_associated | relid=0 | w=10
  2050. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:myoglobinuria after exertion
    n1=en:hyperintense | n2=en:myoglobinuria after exertion | rel=r_associated | relid=0 | w=10
  2051. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:myoglobinuria after exertion (in some patients)
    n1=en:hyperintense | n2=en:myoglobinuria after exertion (in some patients) | rel=r_associated | relid=0 | w=10
  2052. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:myoglobinuria with extreme exertion
    n1=en:hyperintense | n2=en:myoglobinuria with extreme exertion | rel=r_associated | relid=0 | w=10
  2053. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:myoglobinuria, particularly after physical exertion (25% of patients)
    n1=en:hyperintense | n2=en:myoglobinuria, particularly after physical exertion (25% of patients) | rel=r_associated | relid=0 | w=10
  2054. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:myopathy with type i fiber atrophy on muscle biopsy
    n1=en:hyperintense | n2=en:myopathy with type i fiber atrophy on muscle biopsy | rel=r_associated | relid=0 | w=10
  2055. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:n-acetyl-alpha-d-glucosaminidase deficiency in fibroblasts
    n1=en:hyperintense | n2=en:n-acetyl-alpha-d-glucosaminidase deficiency in fibroblasts | rel=r_associated | relid=0 | w=10
  2056. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:n-acetylgalactosamine-6-sulfatase deficiency in fibroblasts and leukocytes
    n1=en:hyperintense | n2=en:n-acetylgalactosamine-6-sulfatase deficiency in fibroblasts and leukocytes | rel=r_associated | relid=0 | w=10
  2057. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:n-glycosylation defect
    n1=en:hyperintense | n2=en:n-glycosylation defect | rel=r_associated | relid=0 | w=10
  2058. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:nadh-cytochrome b(5) reductase deficiency
    n1=en:hyperintense | n2=en:nadh-cytochrome b(5) reductase deficiency | rel=r_associated | relid=0 | w=10
  2059. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:near-complete absence of vldl peak on density gradient ultracentrifugation (in some patients)
    n1=en:hyperintense | n2=en:near-complete absence of vldl peak on density gradient ultracentrifugation (in some patients) | rel=r_associated | relid=0 | w=10
  2060. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:negative nitroblue tetrazolium (nbt) reduction test
    n1=en:hyperintense | n2=en:negative nitroblue tetrazolium (nbt) reduction test | rel=r_associated | relid=0 | w=10
  2061. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:neonatal hyperbilirubinemia
    n1=en:hyperintense | n2=en:neonatal hyperbilirubinemia | rel=r_associated | relid=0 | w=10
  2062. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:neonatal hypocalcemia
    n1=en:hyperintense | n2=en:neonatal hypocalcemia | rel=r_associated | relid=0 | w=10
  2063. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:neonatal research network terminology
    n1=en:hyperintense | n2=en:neonatal research network terminology | rel=r_associated | relid=0 | w=10
  2064. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:nephronophthisis 2
    n1=en:hyperintense | n2=en:nephronophthisis 2 | rel=r_associated | relid=0 | w=10
  2065. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:nephrotic syndrome
    n1=en:hyperintense | n2=en:nephrotic syndrome | rel=r_associated | relid=0 | w=10
  2066. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:netherton syndrome
    n1=en:hyperintense | n2=en:netherton syndrome | rel=r_associated | relid=0 | w=10
  2067. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:neuraminidase deficiency (white blood cells, fibroblasts, cultured amniotic cells)
    n1=en:hyperintense | n2=en:neuraminidase deficiency (white blood cells, fibroblasts, cultured amniotic cells) | rel=r_associated | relid=0 | w=10
  2068. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:neurofibrillary tangles and neuritic senile plaques rare
    n1=en:hyperintense | n2=en:neurofibrillary tangles and neuritic senile plaques rare | rel=r_associated | relid=0 | w=10
  2069. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:neutral hyperaminoaciduria
    n1=en:hyperintense | n2=en:neutral hyperaminoaciduria | rel=r_associated | relid=0 | w=10
  2070. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:neutropenia
    n1=en:hyperintense | n2=en:neutropenia | rel=r_associated | relid=0 | w=10
  2071. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:neutropenia (in 1 patient)
    n1=en:hyperintense | n2=en:neutropenia (in 1 patient) | rel=r_associated | relid=0 | w=10
  2072. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:neutrophilia, both basal and during infections
    n1=en:hyperintense | n2=en:neutrophilia, both basal and during infections | rel=r_associated | relid=0 | w=10
  2073. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no c8 antigen detected
    n1=en:hyperintense | n2=en:no c8 antigen detected | rel=r_associated | relid=0 | w=10
  2074. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no cartilage staining with toluidine blue
    n1=en:hyperintense | n2=en:no cartilage staining with toluidine blue | rel=r_associated | relid=0 | w=10
  2075. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no chromosomal breakage
    n1=en:hyperintense | n2=en:no chromosomal breakage | rel=r_associated | relid=0 | w=10
  2076. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no chromosome breakage
    n1=en:hyperintense | n2=en:no chromosome breakage | rel=r_associated | relid=0 | w=10
  2077. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no dicarboxylic aciduria
    n1=en:hyperintense | n2=en:no dicarboxylic aciduria | rel=r_associated | relid=0 | w=10
  2078. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no elevation of free fatty acids
    n1=en:hyperintense | n2=en:no elevation of free fatty acids | rel=r_associated | relid=0 | w=10
  2079. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no evidence of common prenatal infections
    n1=en:hyperintense | n2=en:no evidence of common prenatal infections | rel=r_associated | relid=0 | w=10
  2080. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no evidence of intrauterine infection in mother or newborn
    n1=en:hyperintense | n2=en:no evidence of intrauterine infection in mother or newborn | rel=r_associated | relid=0 | w=10
  2081. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no evidence of perinatal infection
    n1=en:hyperintense | n2=en:no evidence of perinatal infection | rel=r_associated | relid=0 | w=10
  2082. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no hematuria
    n1=en:hyperintense | n2=en:no hematuria | rel=r_associated | relid=0 | w=10
  2083. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no histochemical evidence of mitochondrial myopathy.
    n1=en:hyperintense | n2=en:no histochemical evidence of mitochondrial myopathy. | rel=r_associated | relid=0 | w=10
  2084. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no hyperphenylalaninemia
    n1=en:hyperintense | n2=en:no hyperphenylalaninemia | rel=r_associated | relid=0 | w=10
  2085. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no hyperuricemia
    n1=en:hyperintense | n2=en:no hyperuricemia | rel=r_associated | relid=0 | w=10
  2086. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no increase in urinary cyclic amp (camp) in response to vasopressin or ddavp
    n1=en:hyperintense | n2=en:no increase in urinary cyclic amp (camp) in response to vasopressin or ddavp | rel=r_associated | relid=0 | w=10
  2087. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no increase of muscle lactate with ischemic exercise testing
    n1=en:hyperintense | n2=en:no increase of muscle lactate with ischemic exercise testing | rel=r_associated | relid=0 | w=10
  2088. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no increased sensitivity to oxidative species
    n1=en:hyperintense | n2=en:no increased sensitivity to oxidative species | rel=r_associated | relid=0 | w=10
  2089. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no ketonuria
    n1=en:hyperintense | n2=en:no ketonuria | rel=r_associated | relid=0 | w=10
  2090. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no ketosis
    n1=en:hyperintense | n2=en:no ketosis | rel=r_associated | relid=0 | w=10
  2091. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no lactic acidosis
    n1=en:hyperintense | n2=en:no lactic acidosis | rel=r_associated | relid=0 | w=10
  2092. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no metabolic abnormalities
    n1=en:hyperintense | n2=en:no metabolic abnormalities | rel=r_associated | relid=0 | w=10
  2093. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:no mucopolysacchariduria
    n1=en:hyperintense | n2=en:no mucopolysacchariduria | rel=r_associated | relid=0 | w=10
  2094. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:non-bullous ichthyosiform erythroderma
    n1=en:hyperintense | n2=en:non-bullous ichthyosiform erythroderma | rel=r_associated | relid=0 | w=10
  2095. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:nonketotic hypoglycemia
    n1=en:hyperintense | n2=en:nonketotic hypoglycemia | rel=r_associated | relid=0 | w=10
  2096. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal 46,xy karyotype
    n1=en:hyperintense | n2=en:normal 46,xy karyotype | rel=r_associated | relid=0 | w=10
  2097. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal activity of von willebrand factor-cleaving protease
    n1=en:hyperintense | n2=en:normal activity of von willebrand factor-cleaving protease | rel=r_associated | relid=0 | w=10
  2098. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal aldosterone
    n1=en:hyperintense | n2=en:normal aldosterone | rel=r_associated | relid=0 | w=10
  2099. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal apoa-ii levels in homozygotes
    n1=en:hyperintense | n2=en:normal apoa-ii levels in homozygotes | rel=r_associated | relid=0 | w=10
  2100. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal arterial oxygen saturation
    n1=en:hyperintense | n2=en:normal arterial oxygen saturation | rel=r_associated | relid=0 | w=10
  2101. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal axonal flare response after intradermal histamine injection
    n1=en:hyperintense | n2=en:normal axonal flare response after intradermal histamine injection | rel=r_associated | relid=0 | w=10
  2102. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal b12
    n1=en:hyperintense | n2=en:normal b12 | rel=r_associated | relid=0 | w=10
  2103. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal baseline cortisol
    n1=en:hyperintense | n2=en:normal baseline cortisol | rel=r_associated | relid=0 | w=10
  2104. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal blood lactate
    n1=en:hyperintense | n2=en:normal blood lactate | rel=r_associated | relid=0 | w=10
  2105. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal calcium (female)
    n1=en:hyperintense | n2=en:normal calcium (female) | rel=r_associated | relid=0 | w=10
  2106. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal cd8+/cd4+ ratio
    n1=en:hyperintense | n2=en:normal cd8+/cd4+ ratio | rel=r_associated | relid=0 | w=10
  2107. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal cerebrospinal fluid
    n1=en:hyperintense | n2=en:normal cerebrospinal fluid | rel=r_associated | relid=0 | w=10
  2108. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal ciliary structure and function
    n1=en:hyperintense | n2=en:normal ciliary structure and function | rel=r_associated | relid=0 | w=10
  2109. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal collagen type i studies
    n1=en:hyperintense | n2=en:normal collagen type i studies | rel=r_associated | relid=0 | w=10
  2110. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal complex ii activity
    n1=en:hyperintense | n2=en:normal complex ii activity | rel=r_associated | relid=0 | w=10
  2111. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal concentration of parathyroid hormone
    n1=en:hyperintense | n2=en:normal concentration of parathyroid hormone | rel=r_associated | relid=0 | w=10
  2112. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal constitutional karyotype
    n1=en:hyperintense | n2=en:normal constitutional karyotype | rel=r_associated | relid=0 | w=10
  2113. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal csf 5-hiaa
    n1=en:hyperintense | n2=en:normal csf 5-hiaa | rel=r_associated | relid=0 | w=10
  2114. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal csf 5-hydroxyindoleacetic acid (5-hiaa)
    n1=en:hyperintense | n2=en:normal csf 5-hydroxyindoleacetic acid (5-hiaa) | rel=r_associated | relid=0 | w=10
  2115. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal csf neurotransmitters
    n1=en:hyperintense | n2=en:normal csf neurotransmitters | rel=r_associated | relid=0 | w=10
  2116. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal dermal hydroxylysine content
    n1=en:hyperintense | n2=en:normal dermal hydroxylysine content | rel=r_associated | relid=0 | w=10
  2117. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal ellsworth-howard test, normal urinary camp response to parathyroid hormone (pth) administration
    n1=en:hyperintense | n2=en:normal ellsworth-howard test, normal urinary camp response to parathyroid hormone (pth) administration | rel=r_associated | relid=0 | w=10
  2118. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal endocrinologic studies (growth hormone, somatomedin c, thyroid function)
    n1=en:hyperintense | n2=en:normal endocrinologic studies (growth hormone, somatomedin c, thyroid function) | rel=r_associated | relid=0 | w=10
  2119. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal eosinophil peroxidase activity
    n1=en:hyperintense | n2=en:normal eosinophil peroxidase activity | rel=r_associated | relid=0 | w=10
  2120. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal erythrocyte gs activity
    n1=en:hyperintense | n2=en:normal erythrocyte gs activity | rel=r_associated | relid=0 | w=10
  2121. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal exocrine pancreatic function
    n1=en:hyperintense | n2=en:normal exocrine pancreatic function | rel=r_associated | relid=0 | w=10
  2122. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal extrarenal responses to ddavp administration
    n1=en:hyperintense | n2=en:normal extrarenal responses to ddavp administration | rel=r_associated | relid=0 | w=10
  2123. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal free urinary cortisol
    n1=en:hyperintense | n2=en:normal free urinary cortisol | rel=r_associated | relid=0 | w=10
  2124. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal g(s)-alpha levels (139320)
    n1=en:hyperintense | n2=en:normal g(s)-alpha levels (139320) | rel=r_associated | relid=0 | w=10
  2125. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal growth hormone responses to arginine, l-dopa, and propranolol stimulation
    n1=en:hyperintense | n2=en:normal growth hormone responses to arginine, l-dopa, and propranolol stimulation | rel=r_associated | relid=0 | w=10
  2126. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal iga levels
    n1=en:hyperintense | n2=en:normal iga levels | rel=r_associated | relid=0 | w=10
  2127. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal igg levels
    n1=en:hyperintense | n2=en:normal igg levels | rel=r_associated | relid=0 | w=10
  2128. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal igm levels
    n1=en:hyperintense | n2=en:normal igm levels | rel=r_associated | relid=0 | w=10
  2129. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal isoelectric focusing of apolipoprotein ciii
    n1=en:hyperintense | n2=en:normal isoelectric focusing of apolipoprotein ciii | rel=r_associated | relid=0 | w=10
  2130. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal isoelectric focusing of serum transferrin
    n1=en:hyperintense | n2=en:normal isoelectric focusing of serum transferrin | rel=r_associated | relid=0 | w=10
  2131. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal lactate (hcs)
    n1=en:hyperintense | n2=en:normal lactate (hcs) | rel=r_associated | relid=0 | w=10
  2132. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal leukocyte and platelet counts
    n1=en:hyperintense | n2=en:normal leukocyte and platelet counts | rel=r_associated | relid=0 | w=10
  2133. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal levels of complement factor h, but impaired function
    n1=en:hyperintense | n2=en:normal levels of complement factor h, but impaired function | rel=r_associated | relid=0 | w=10
  2134. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal liver histology
    n1=en:hyperintense | n2=en:normal liver histology | rel=r_associated | relid=0 | w=10
  2135. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal lysl hydroxylase activity
    n1=en:hyperintense | n2=en:normal lysl hydroxylase activity | rel=r_associated | relid=0 | w=10
  2136. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal lysosomal hydrolases
    n1=en:hyperintense | n2=en:normal lysosomal hydrolases | rel=r_associated | relid=0 | w=10
  2137. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal lysyl hydroxylase activity
    n1=en:hyperintense | n2=en:normal lysyl hydroxylase activity | rel=r_associated | relid=0 | w=10
  2138. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal lysyl oxidase activity
    n1=en:hyperintense | n2=en:normal lysyl oxidase activity | rel=r_associated | relid=0 | w=10
  2139. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal male karyotype (46,xy)
    n1=en:hyperintense | n2=en:normal male karyotype (46,xy) | rel=r_associated | relid=0 | w=10
  2140. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal maltase, isomaltase, and sucrase activity
    n1=en:hyperintense | n2=en:normal maltase, isomaltase, and sucrase activity | rel=r_associated | relid=0 | w=10
  2141. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal mitochondrial respiratory chain complex i-v (hcs)
    n1=en:hyperintense | n2=en:normal mitochondrial respiratory chain complex i-v (hcs) | rel=r_associated | relid=0 | w=10
  2142. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal number of t and b lymphocytes
    n1=en:hyperintense | n2=en:normal number of t and b lymphocytes | rel=r_associated | relid=0 | w=10
  2143. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal or decreased serum erythropoietin (epo, 133170)
    n1=en:hyperintense | n2=en:normal or decreased serum erythropoietin (epo, 133170) | rel=r_associated | relid=0 | w=10
  2144. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal or decreased serum potassium
    n1=en:hyperintense | n2=en:normal or decreased serum potassium | rel=r_associated | relid=0 | w=10
  2145. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal or increased levels of serum arginine vasopressin (antidiuretic hormone, 192340)
    n1=en:hyperintense | n2=en:normal or increased levels of serum arginine vasopressin (antidiuretic hormone, 192340) | rel=r_associated | relid=0 | w=10
  2146. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal or increased serum creatine kinase
    n1=en:hyperintense | n2=en:normal or increased serum creatine kinase | rel=r_associated | relid=0 | w=10
  2147. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal or increased serum phosphate
    n1=en:hyperintense | n2=en:normal or increased serum phosphate | rel=r_associated | relid=0 | w=10
  2148. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal or increased serum phytanic acid
    n1=en:hyperintense | n2=en:normal or increased serum phytanic acid | rel=r_associated | relid=0 | w=10
  2149. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal or increased urinary cyclic amp response to pth administration
    n1=en:hyperintense | n2=en:normal or increased urinary cyclic amp response to pth administration | rel=r_associated | relid=0 | w=10
  2150. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal or mildly decreased arylsulfatase a activity
    n1=en:hyperintense | n2=en:normal or mildly decreased arylsulfatase a activity | rel=r_associated | relid=0 | w=10
  2151. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal or mildly decreased serum levels of free thyroid hormones
    n1=en:hyperintense | n2=en:normal or mildly decreased serum levels of free thyroid hormones | rel=r_associated | relid=0 | w=10
  2152. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal or mildly increased serum creatine kinase
    n1=en:hyperintense | n2=en:normal or mildly increased serum creatine kinase | rel=r_associated | relid=0 | w=10
  2153. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal or mildly increased serum gamma-ggt (231950)
    n1=en:hyperintense | n2=en:normal or mildly increased serum gamma-ggt (231950) | rel=r_associated | relid=0 | w=10
  2154. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal or mildly increased serum gamma-glutamyltransferase (ggt)
    n1=en:hyperintense | n2=en:normal or mildly increased serum gamma-glutamyltransferase (ggt) | rel=r_associated | relid=0 | w=10
  2155. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal or mildly increased thyroid-stimulating hormone (tsh)
    n1=en:hyperintense | n2=en:normal or mildly increased thyroid-stimulating hormone (tsh) | rel=r_associated | relid=0 | w=10
  2156. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal or mildly reduced serum cobalamin
    n1=en:hyperintense | n2=en:normal or mildly reduced serum cobalamin | rel=r_associated | relid=0 | w=10
  2157. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal or mildly reduced sphingomyelinase activity
    n1=en:hyperintense | n2=en:normal or mildly reduced sphingomyelinase activity | rel=r_associated | relid=0 | w=10
  2158. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal parathyroid hormone (female)
    n1=en:hyperintense | n2=en:normal parathyroid hormone (female) | rel=r_associated | relid=0 | w=10
  2159. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal phytanic acid
    n1=en:hyperintense | n2=en:normal phytanic acid | rel=r_associated | relid=0 | w=10
  2160. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal plasma and tissue carnitine
    n1=en:hyperintense | n2=en:normal plasma and tissue carnitine | rel=r_associated | relid=0 | w=10
  2161. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal plasma phytanic acid
    n1=en:hyperintense | n2=en:normal plasma phytanic acid | rel=r_associated | relid=0 | w=10
  2162. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal plasma renin
    n1=en:hyperintense | n2=en:normal plasma renin | rel=r_associated | relid=0 | w=10
  2163. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal plasma total homocysteine
    n1=en:hyperintense | n2=en:normal plasma total homocysteine | rel=r_associated | relid=0 | w=10
  2164. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal platelet aggregation response to arachidonic acid (aa)
    n1=en:hyperintense | n2=en:normal platelet aggregation response to arachidonic acid (aa) | rel=r_associated | relid=0 | w=10
  2165. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal platelet aggregation response to arachidonic acid (aa), adenosine 5'-diphosphate (adp), collagen, and ristocetin
    n1=en:hyperintense | n2=en:normal platelet aggregation response to arachidonic acid (aa), adenosine 5'-diphosphate (adp), collagen, and ristocetin | rel=r_associated | relid=0 | w=10
  2166. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal platelet aggregation response to epinephrine, adp, collagen, and ristocetin
    n1=en:hyperintense | n2=en:normal platelet aggregation response to epinephrine, adp, collagen, and ristocetin | rel=r_associated | relid=0 | w=10
  2167. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal platelet aggregation response to epinephrine, arachidonic acid (aa), adenosine 5'-diphosphate (adp), collagen, and ristocetin
    n1=en:hyperintense | n2=en:normal platelet aggregation response to epinephrine, arachidonic acid (aa), adenosine 5'-diphosphate (adp), collagen, and ristocetin | rel=r_associated | relid=0 | w=10
  2168. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal platelet aggregation studies with adp, collagen, and ristocetin
    n1=en:hyperintense | n2=en:normal platelet aggregation studies with adp, collagen, and ristocetin | rel=r_associated | relid=0 | w=10
  2169. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal platelet aggregation with adp, collagen, epinephrine
    n1=en:hyperintense | n2=en:normal platelet aggregation with adp, collagen, epinephrine | rel=r_associated | relid=0 | w=10
  2170. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal prolyl 4-hydroxylase activity
    n1=en:hyperintense | n2=en:normal prolyl 4-hydroxylase activity | rel=r_associated | relid=0 | w=10
  2171. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal pyridinoline excretion in urine
    n1=en:hyperintense | n2=en:normal pyridinoline excretion in urine | rel=r_associated | relid=0 | w=10
  2172. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal red cell counts
    n1=en:hyperintense | n2=en:normal red cell counts | rel=r_associated | relid=0 | w=10
  2173. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal renin level
    n1=en:hyperintense | n2=en:normal renin level | rel=r_associated | relid=0 | w=10
  2174. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal sedimentation rate
    n1=en:hyperintense | n2=en:normal sedimentation rate | rel=r_associated | relid=0 | w=10
  2175. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum 1,25-dihydroxyvitamin d3
    n1=en:hyperintense | n2=en:normal serum 1,25-dihydroxyvitamin d3 | rel=r_associated | relid=0 | w=10
  2176. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum 25-hydroxyvitamin d3
    n1=en:hyperintense | n2=en:normal serum 25-hydroxyvitamin d3 | rel=r_associated | relid=0 | w=10
  2177. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum and mucosal iga
    n1=en:hyperintense | n2=en:normal serum and mucosal iga | rel=r_associated | relid=0 | w=10
  2178. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum bile acids
    n1=en:hyperintense | n2=en:normal serum bile acids | rel=r_associated | relid=0 | w=10
  2179. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum biotin concentration
    n1=en:hyperintense | n2=en:normal serum biotin concentration | rel=r_associated | relid=0 | w=10
  2180. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum cobalamin
    n1=en:hyperintense | n2=en:normal serum cobalamin | rel=r_associated | relid=0 | w=10
  2181. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum cobalamin (vitamin b12)
    n1=en:hyperintense | n2=en:normal serum cobalamin (vitamin b12) | rel=r_associated | relid=0 | w=10
  2182. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum complement levels
    n1=en:hyperintense | n2=en:normal serum complement levels | rel=r_associated | relid=0 | w=10
  2183. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum creatine kinase
    n1=en:hyperintense | n2=en:normal serum creatine kinase | rel=r_associated | relid=0 | w=10
  2184. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum erythropoietin (epo, 133170)
    n1=en:hyperintense | n2=en:normal serum erythropoietin (epo, 133170) | rel=r_associated | relid=0 | w=10
  2185. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum folate levels
    n1=en:hyperintense | n2=en:normal serum folate levels | rel=r_associated | relid=0 | w=10
  2186. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum levels of gamma-ggt (231950)
    n1=en:hyperintense | n2=en:normal serum levels of gamma-ggt (231950) | rel=r_associated | relid=0 | w=10
  2187. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum lipoprotein levels
    n1=en:hyperintense | n2=en:normal serum lipoprotein levels | rel=r_associated | relid=0 | w=10
  2188. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum liver enzymes
    n1=en:hyperintense | n2=en:normal serum liver enzymes | rel=r_associated | relid=0 | w=10
  2189. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum parathyroid hormone (pth)
    n1=en:hyperintense | n2=en:normal serum parathyroid hormone (pth) | rel=r_associated | relid=0 | w=10
  2190. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum phosphorus
    n1=en:hyperintense | n2=en:normal serum phosphorus | rel=r_associated | relid=0 | w=10
  2191. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum phytanic and pristanic acid
    n1=en:hyperintense | n2=en:normal serum phytanic and pristanic acid | rel=r_associated | relid=0 | w=10
  2192. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum plasmalogen
    n1=en:hyperintense | n2=en:normal serum plasmalogen | rel=r_associated | relid=0 | w=10
  2193. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal serum transferrin profiles
    n1=en:hyperintense | n2=en:normal serum transferrin profiles | rel=r_associated | relid=0 | w=10
  2194. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal sweat chloride (3 of 3 patients)
    n1=en:hyperintense | n2=en:normal sweat chloride (3 of 3 patients) | rel=r_associated | relid=0 | w=10
  2195. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal sweat electrolytes
    n1=en:hyperintense | n2=en:normal sweat electrolytes | rel=r_associated | relid=0 | w=10
  2196. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal to elevated serum 1,25-dihydroxycholecalciferol (calcitriol)
    n1=en:hyperintense | n2=en:normal to elevated serum 1,25-dihydroxycholecalciferol (calcitriol) | rel=r_associated | relid=0 | w=10
  2197. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal to elevated total plasma carnitine
    n1=en:hyperintense | n2=en:normal to elevated total plasma carnitine | rel=r_associated | relid=0 | w=10
  2198. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal to increased plasma glycine
    n1=en:hyperintense | n2=en:normal to increased plasma glycine | rel=r_associated | relid=0 | w=10
  2199. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal to increased plasma threonine
    n1=en:hyperintense | n2=en:normal to increased plasma threonine | rel=r_associated | relid=0 | w=10
  2200. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal to mildly increased mucopolysacchariduria
    n1=en:hyperintense | n2=en:normal to mildly increased mucopolysacchariduria | rel=r_associated | relid=0 | w=10
  2201. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal to mildly increased serum creatine kinase
    n1=en:hyperintense | n2=en:normal to mildly increased serum creatine kinase | rel=r_associated | relid=0 | w=10
  2202. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal to mildly increased serum parathyroid hormone (pth)
    n1=en:hyperintense | n2=en:normal to mildly increased serum parathyroid hormone (pth) | rel=r_associated | relid=0 | w=10
  2203. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal to prolonged bleeding time
    n1=en:hyperintense | n2=en:normal to prolonged bleeding time | rel=r_associated | relid=0 | w=10
  2204. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal to slightly elevated plasma cholesterol
    n1=en:hyperintense | n2=en:normal to slightly elevated plasma cholesterol | rel=r_associated | relid=0 | w=10
  2205. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal to slightly high alkaline phosphatase
    n1=en:hyperintense | n2=en:normal to slightly high alkaline phosphatase | rel=r_associated | relid=0 | w=10
  2206. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal total urinary coproporphyrin
    n1=en:hyperintense | n2=en:normal total urinary coproporphyrin | rel=r_associated | relid=0 | w=10
  2207. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal transferrin isoelectric profile
    n1=en:hyperintense | n2=en:normal transferrin isoelectric profile | rel=r_associated | relid=0 | w=10
  2208. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal transferrin saturation
    n1=en:hyperintense | n2=en:normal transferrin saturation | rel=r_associated | relid=0 | w=10
  2209. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal tyrosinase
    n1=en:hyperintense | n2=en:normal tyrosinase | rel=r_associated | relid=0 | w=10
  2210. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal urinary 17-ketosteroids
    n1=en:hyperintense | n2=en:normal urinary 17-ketosteroids | rel=r_associated | relid=0 | w=10
  2211. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal urinary cyclic amp response to pth administration
    n1=en:hyperintense | n2=en:normal urinary cyclic amp response to pth administration | rel=r_associated | relid=0 | w=10
  2212. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal urinary orotic acid
    n1=en:hyperintense | n2=en:normal urinary orotic acid | rel=r_associated | relid=0 | w=10
  2213. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal urinary pterins
    n1=en:hyperintense | n2=en:normal urinary pterins | rel=r_associated | relid=0 | w=10
  2214. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal-elevated plasma testosterone (male range)
    n1=en:hyperintense | n2=en:normal-elevated plasma testosterone (male range) | rel=r_associated | relid=0 | w=10
  2215. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal-to-decreased plasma glycine (fasting)
    n1=en:hyperintense | n2=en:normal-to-decreased plasma glycine (fasting) | rel=r_associated | relid=0 | w=10
  2216. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normal-to-slightly decreased glcnac phosphotransferase using artificial substrate (e.g., alpha-methylmannoside)
    n1=en:hyperintense | n2=en:normal-to-slightly decreased glcnac phosphotransferase using artificial substrate (e.g., alpha-methylmannoside) | rel=r_associated | relid=0 | w=10
  2217. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:normocalcemia
    n1=en:hyperintense | n2=en:normocalcemia | rel=r_associated | relid=0 | w=10
  2218. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:nursing therapy
    n1=en:hyperintense | n2=en:nursing therapy | rel=r_associated | relid=0 | w=10
  2219. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:nutritional and metabolic diseases
    n1=en:hyperintense | n2=en:nutritional and metabolic diseases | rel=r_associated | relid=0 | w=10
  2220. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:nutritional management
    n1=en:hyperintense | n2=en:nutritional management | rel=r_associated | relid=0 | w=10
  2221. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:occasional hypomagnesemia
    n1=en:hyperintense | n2=en:occasional hypomagnesemia | rel=r_associated | relid=0 | w=10
  2222. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:occasionally mild elevation of csf protein
    n1=en:hyperintense | n2=en:occasionally mild elevation of csf protein | rel=r_associated | relid=0 | w=10
  2223. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:oestradiol decreased
    n1=en:hyperintense | n2=en:oestradiol decreased | rel=r_associated | relid=0 | w=10
  2224. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:often integrated hbv sequences in hepatocellular carcinomas
    n1=en:hyperintense | n2=en:often integrated hbv sequences in hepatocellular carcinomas | rel=r_associated | relid=0 | w=10
  2225. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:oligospermia or azoospermia
    n1=en:hyperintense | n2=en:oligospermia or azoospermia | rel=r_associated | relid=0 | w=10
  2226. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:olmsted syndrome
    n1=en:hyperintense | n2=en:olmsted syndrome | rel=r_associated | relid=0 | w=10
  2227. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:organic aciduria
    n1=en:hyperintense | n2=en:organic aciduria | rel=r_associated | relid=0 | w=10
  2228. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:organic aciduria (elevated beta-hydroxyisovalerate, beta-methylcrotonylglycine, beta-hydroxypropionate, methylcitrate, lactate, tiglylglycine)
    n1=en:hyperintense | n2=en:organic aciduria (elevated beta-hydroxyisovalerate, beta-methylcrotonylglycine, beta-hydroxypropionate, methylcitrate, lactate, tiglylglycine) | rel=r_associated | relid=0 | w=10
  2229. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:organic aciduria (elevated beta-hydroxyisovalerate, lactate, beta-methylcrotonylglycine, beta-hydroxypropionate, methylcitrate)
    n1=en:hyperintense | n2=en:organic aciduria (elevated beta-hydroxyisovalerate, lactate, beta-methylcrotonylglycine, beta-hydroxypropionate, methylcitrate) | rel=r_associated | relid=0 | w=10
  2230. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:organic aciduria, mild (in some patients)
    n1=en:hyperintense | n2=en:organic aciduria, mild (in some patients) | rel=r_associated | relid=0 | w=10
  2231. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ornithine-delta-aminotransferase (oat) deficiency
    n1=en:hyperintense | n2=en:ornithine-delta-aminotransferase (oat) deficiency | rel=r_associated | relid=0 | w=10
  2232. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:orotic acid crystalluria
    n1=en:hyperintense | n2=en:orotic acid crystalluria | rel=r_associated | relid=0 | w=10
  2233. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:orotic aciduria
    n1=en:hyperintense | n2=en:orotic aciduria | rel=r_associated | relid=0 | w=10
  2234. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:osmolality disturbance
    n1=en:hyperintense | n2=en:osmolality disturbance | rel=r_associated | relid=0 | w=10
  2235. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:osteocalcin increased
    n1=en:hyperintense | n2=en:osteocalcin increased | rel=r_associated | relid=0 | w=10
  2236. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:other congenital ichthyosis
    n1=en:hyperintense | n2=en:other congenital ichthyosis | rel=r_associated | relid=0 | w=10
  2237. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:other cytogenic abnormalities have been associated with dgs phenotype including monosomy 10p13, 11p13, and 4q21
    n1=en:hyperintense | n2=en:other cytogenic abnormalities have been associated with dgs phenotype including monosomy 10p13, 11p13, and 4q21 | rel=r_associated | relid=0 | w=10
  2238. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:other disorders of electrolyte and fluid balance, not elsewhere classified
    n1=en:hyperintense | n2=en:other disorders of electrolyte and fluid balance, not elsewhere classified | rel=r_associated | relid=0 | w=10
  2239. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:other disorders of fluid, electrolyte and acid-base balance
    n1=en:hyperintense | n2=en:other disorders of fluid, electrolyte and acid-base balance | rel=r_associated | relid=0 | w=10
  2240. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:p5c levels increased in urine
    n1=en:hyperintense | n2=en:p5c levels increased in urine | rel=r_associated | relid=0 | w=10
  2241. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:palmar hyperkeratosis
    n1=en:hyperintense | n2=en:palmar hyperkeratosis | rel=r_associated | relid=0 | w=10
  2242. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:palmoplantar keratoderma
    n1=en:hyperintense | n2=en:palmoplantar keratoderma | rel=r_associated | relid=0 | w=10
  2243. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pancreatic enzymes decreased
    n1=en:hyperintense | n2=en:pancreatic enzymes decreased | rel=r_associated | relid=0 | w=10
  2244. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pancreatic trypsinogen deficiency
    n1=en:hyperintense | n2=en:pancreatic trypsinogen deficiency | rel=r_associated | relid=0 | w=10
  2245. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:panhypogammaglobulinemia
    n1=en:hyperintense | n2=en:panhypogammaglobulinemia | rel=r_associated | relid=0 | w=10
  2246. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:paradoxical increase or no change in serum aldosterone and blood pressure after dexamethasone administration
    n1=en:hyperintense | n2=en:paradoxical increase or no change in serum aldosterone and blood pressure after dexamethasone administration | rel=r_associated | relid=0 | w=10
  2247. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:paradoxical increased cortisol secretion on dexamethasone suppression test
    n1=en:hyperintense | n2=en:paradoxical increased cortisol secretion on dexamethasone suppression test | rel=r_associated | relid=0 | w=10
  2248. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:parakeratosis
    n1=en:hyperintense | n2=en:parakeratosis | rel=r_associated | relid=0 | w=10
  2249. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:paraproteinemia
    n1=en:hyperintense | n2=en:paraproteinemia | rel=r_associated | relid=0 | w=10
  2250. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:parasitology
    n1=en:hyperintense | n2=en:parasitology | rel=r_associated | relid=0 | w=10
  2251. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:parathyroid hormone (pth) absent to low
    n1=en:hyperintense | n2=en:parathyroid hormone (pth) absent to low | rel=r_associated | relid=0 | w=10
  2252. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:parathyroid hormone level increased
    n1=en:hyperintense | n2=en:parathyroid hormone level increased | rel=r_associated | relid=0 | w=10
  2253. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:parathyroid hormone normal
    n1=en:hyperintense | n2=en:parathyroid hormone normal | rel=r_associated | relid=0 | w=10
  2254. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:parathyroid hormone-related peptide (pthrp) absent to low
    n1=en:hyperintense | n2=en:parathyroid hormone-related peptide (pthrp) absent to low | rel=r_associated | relid=0 | w=10
  2255. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:partial deficiency of factor xi (less common)
    n1=en:hyperintense | n2=en:partial deficiency of factor xi (less common) | rel=r_associated | relid=0 | w=10
  2256. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:partial deficiency of factor xi(c)
    n1=en:hyperintense | n2=en:partial deficiency of factor xi(c) | rel=r_associated | relid=0 | w=10
  2257. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:partial deficiency of factor xii(c)
    n1=en:hyperintense | n2=en:partial deficiency of factor xii(c) | rel=r_associated | relid=0 | w=10
  2258. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:partial deficiency of factor xiii (less common)
    n1=en:hyperintense | n2=en:partial deficiency of factor xiii (less common) | rel=r_associated | relid=0 | w=10
  2259. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:partial deficiency of factor xiii(c)
    n1=en:hyperintense | n2=en:partial deficiency of factor xiii(c) | rel=r_associated | relid=0 | w=10
  2260. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:partial deletion of long arm of chromosome 11 (11q23-qter)
    n1=en:hyperintense | n2=en:partial deletion of long arm of chromosome 11 (11q23-qter) | rel=r_associated | relid=0 | w=10
  2261. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:partial terminal deletion of short arm of chromosome 1 (1p36)
    n1=en:hyperintense | n2=en:partial terminal deletion of short arm of chromosome 1 (1p36) | rel=r_associated | relid=0 | w=10
  2262. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pathological aspects
    n1=en:hyperintense | n2=en:pathological aspects | rel=r_associated | relid=0 | w=10
  2263. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:patient cells have increased levels of lmnb1 mrna and protein
    n1=en:hyperintense | n2=en:patient cells have increased levels of lmnb1 mrna and protein | rel=r_associated | relid=0 | w=10
  2264. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:patient cells show a defect in transcription-coupled and global genome nucleotide excision repair
    n1=en:hyperintense | n2=en:patient cells show a defect in transcription-coupled and global genome nucleotide excision repair | rel=r_associated | relid=0 | w=10
  2265. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:patient cells show abnormal mitochondrial morphology
    n1=en:hyperintense | n2=en:patient cells show abnormal mitochondrial morphology | rel=r_associated | relid=0 | w=10
  2266. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:patient cells show defective dna repair in response to irradiation and free radical damage
    n1=en:hyperintense | n2=en:patient cells show defective dna repair in response to irradiation and free radical damage | rel=r_associated | relid=0 | w=10
  2267. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:patient cells show defective transcription-coupled and global genome nucleotide excision repair (ner)
    n1=en:hyperintense | n2=en:patient cells show defective transcription-coupled and global genome nucleotide excision repair (ner) | rel=r_associated | relid=0 | w=10
  2268. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:patient cells show increased chromosome breakage
    n1=en:hyperintense | n2=en:patient cells show increased chromosome breakage | rel=r_associated | relid=0 | w=10
  2269. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:patient fibroblasts and muscle show decreased activities of mitochondrial complexes i, iii, and iv
    n1=en:hyperintense | n2=en:patient fibroblasts and muscle show decreased activities of mitochondrial complexes i, iii, and iv | rel=r_associated | relid=0 | w=10
  2270. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:patients have supernumerary chromosome - 47,xx(or xy), +der(22), +(11:22)(q23:q11)
    n1=en:hyperintense | n2=en:patients have supernumerary chromosome - 47,xx(or xy), +der(22), +(11:22)(q23:q11) | rel=r_associated | relid=0 | w=10
  2271. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:patients with factor xiii alpha subunit deficiency usually also have decreased levels of plasma factor xiii beta subunit
    n1=en:hyperintense | n2=en:patients with factor xiii alpha subunit deficiency usually also have decreased levels of plasma factor xiii beta subunit | rel=r_associated | relid=0 | w=10
  2272. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:patients with factor xiii beta subunit deficiency usually also have decreased levels of plasma factor xiii alpha subunit
    n1=en:hyperintense | n2=en:patients with factor xiii beta subunit deficiency usually also have decreased levels of plasma factor xiii alpha subunit | rel=r_associated | relid=0 | w=10
  2273. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pcd shows separate and rod-shaped x chromosomes without discernible centromeres
    n1=en:hyperintense | n2=en:pcd shows separate and rod-shaped x chromosomes without discernible centromeres | rel=r_associated | relid=0 | w=10
  2274. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pcs involves most of all chromosomes of a metaphase
    n1=en:hyperintense | n2=en:pcs involves most of all chromosomes of a metaphase | rel=r_associated | relid=0 | w=10
  2275. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pcs shows separate and splayed chromatids with discernible centromeres
    n1=en:hyperintense | n2=en:pcs shows separate and splayed chromatids with discernible centromeres | rel=r_associated | relid=0 | w=10
  2276. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pediatric adverse events terminology
    n1=en:hyperintense | n2=en:pediatric adverse events terminology | rel=r_associated | relid=0 | w=10
  2277. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pediatric terminology
    n1=en:hyperintense | n2=en:pediatric terminology | rel=r_associated | relid=0 | w=10
  2278. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pentagastrin stimulation test
    n1=en:hyperintense | n2=en:pentagastrin stimulation test | rel=r_associated | relid=0 | w=10
  2279. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:percentage of bone-derived alkaline phosphatase is >60% in patients versus 40% in healthy adult subjects
    n1=en:hyperintense | n2=en:percentage of bone-derived alkaline phosphatase is >60% in patients versus 40% in healthy adult subjects | rel=r_associated | relid=0 | w=10
  2280. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:perifollicular hyperkeratosis
    n1=en:hyperintense | n2=en:perifollicular hyperkeratosis | rel=r_associated | relid=0 | w=10
  2281. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:peroxisome deficiency
    n1=en:hyperintense | n2=en:peroxisome deficiency | rel=r_associated | relid=0 | w=10
  2282. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:persistent ebv viremia
    n1=en:hyperintense | n2=en:persistent ebv viremia | rel=r_associated | relid=0 | w=10
  2283. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ph homeostasis
    n1=en:hyperintense | n2=en:ph homeostasis | rel=r_associated | relid=0 | w=10
  2284. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pharmacotherapeutic
    n1=en:hyperintense | n2=en:pharmacotherapeutic | rel=r_associated | relid=0 | w=10
  2285. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:phosphate normal
    n1=en:hyperintense | n2=en:phosphate normal | rel=r_associated | relid=0 | w=10
  2286. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:phosphate overload
    n1=en:hyperintense | n2=en:phosphate overload | rel=r_associated | relid=0 | w=10
  2287. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:phosphaturia
    n1=en:hyperintense | n2=en:phosphaturia | rel=r_associated | relid=0 | w=10
  2288. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:phosphaturia (in some)
    n1=en:hyperintense | n2=en:phosphaturia (in some) | rel=r_associated | relid=0 | w=10
  2289. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:phosphaturia may disappear after a long period of time
    n1=en:hyperintense | n2=en:phosphaturia may disappear after a long period of time | rel=r_associated | relid=0 | w=10
  2290. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:phospholipid antibody positive
    n1=en:hyperintense | n2=en:phospholipid antibody positive | rel=r_associated | relid=0 | w=10
  2291. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:phosphomannomutase deficiency in leukocytes, fibroblasts, or liver
    n1=en:hyperintense | n2=en:phosphomannomutase deficiency in leukocytes, fibroblasts, or liver | rel=r_associated | relid=0 | w=10
  2292. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:phosphomannose isomerase deficiency in leukocytes, fibroblasts, or liver
    n1=en:hyperintense | n2=en:phosphomannose isomerase deficiency in leukocytes, fibroblasts, or liver | rel=r_associated | relid=0 | w=10
  2293. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:phosphorylase kinase deficiency in liver and muscle
    n1=en:hyperintense | n2=en:phosphorylase kinase deficiency in liver and muscle | rel=r_associated | relid=0 | w=10
  2294. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:phosphorylase kinase normal in muscle
    n1=en:hyperintense | n2=en:phosphorylase kinase normal in muscle | rel=r_associated | relid=0 | w=10
  2295. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:phrynoderma
    n1=en:hyperintense | n2=en:phrynoderma | rel=r_associated | relid=0 | w=10
  2296. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:physiopathological
    n1=en:hyperintense | n2=en:physiopathological | rel=r_associated | relid=0 | w=10
  2297. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:phytanic acid accumulation
    n1=en:hyperintense | n2=en:phytanic acid accumulation | rel=r_associated | relid=0 | w=10
  2298. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:phytanic acid increased
    n1=en:hyperintense | n2=en:phytanic acid increased | rel=r_associated | relid=0 | w=10
  2299. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pink urine
    n1=en:hyperintense | n2=en:pink urine | rel=r_associated | relid=0 | w=10
  2300. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pipecolic acid accumulation.
    n1=en:hyperintense | n2=en:pipecolic acid accumulation. | rel=r_associated | relid=0 | w=10
  2301. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pipecolic acidemia
    n1=en:hyperintense | n2=en:pipecolic acidemia | rel=r_associated | relid=0 | w=10
  2302. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pityriasis rotunda
    n1=en:hyperintense | n2=en:pityriasis rotunda | rel=r_associated | relid=0 | w=10
  2303. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:placental steroid sulfatase deficiency
    n1=en:hyperintense | n2=en:placental steroid sulfatase deficiency | rel=r_associated | relid=0 | w=10
  2304. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:plantar hyperkeratosis
    n1=en:hyperintense | n2=en:plantar hyperkeratosis | rel=r_associated | relid=0 | w=10
  2305. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:plasma aldosterone increased
    n1=en:hyperintense | n2=en:plasma aldosterone increased | rel=r_associated | relid=0 | w=10
  2306. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:plasma aldosterone normal
    n1=en:hyperintense | n2=en:plasma aldosterone normal | rel=r_associated | relid=0 | w=10
  2307. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:plasma ammonia not elevated
    n1=en:hyperintense | n2=en:plasma ammonia not elevated | rel=r_associated | relid=0 | w=10
  2308. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:plasma catecholamines decreased
    n1=en:hyperintense | n2=en:plasma catecholamines decreased | rel=r_associated | relid=0 | w=10
  2309. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:plasma protein c deficiency
    n1=en:hyperintense | n2=en:plasma protein c deficiency | rel=r_associated | relid=0 | w=10
  2310. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:plasma triglycerides increased
    n1=en:hyperintense | n2=en:plasma triglycerides increased | rel=r_associated | relid=0 | w=10
  2311. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:plasmalogen deficiency
    n1=en:hyperintense | n2=en:plasmalogen deficiency | rel=r_associated | relid=0 | w=10
  2312. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:platelet aggregation decreased
    n1=en:hyperintense | n2=en:platelet aggregation decreased | rel=r_associated | relid=0 | w=10
  2313. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:platelet antibody positive
    n1=en:hyperintense | n2=en:platelet antibody positive | rel=r_associated | relid=0 | w=10
  2314. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:platelet count normal
    n1=en:hyperintense | n2=en:platelet count normal | rel=r_associated | relid=0 | w=10
  2315. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:platelet factor 4 decreased
    n1=en:hyperintense | n2=en:platelet factor 4 decreased | rel=r_associated | relid=0 | w=10
  2316. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:platelet function test normal
    n1=en:hyperintense | n2=en:platelet function test normal | rel=r_associated | relid=0 | w=10
  2317. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:platelet glycoprotein iiia deficiency
    n1=en:hyperintense | n2=en:platelet glycoprotein iiia deficiency | rel=r_associated | relid=0 | w=10
  2318. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:platelets have decreased number of alpha-granules, large vacuoles, normal number of dense bodies on electron microscopy
    n1=en:hyperintense | n2=en:platelets have decreased number of alpha-granules, large vacuoles, normal number of dense bodies on electron microscopy | rel=r_associated | relid=0 | w=10
  2319. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pms excrete 10 to 200 times less metabolite in urine than wildtype (em)
    n1=en:hyperintense | n2=en:pms excrete 10 to 200 times less metabolite in urine than wildtype (em) | rel=r_associated | relid=0 | w=10
  2320. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pms have increased metabolic ratio of unchanged drug-to-metabolite in urine
    n1=en:hyperintense | n2=en:pms have increased metabolic ratio of unchanged drug-to-metabolite in urine | rel=r_associated | relid=0 | w=10
  2321. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pms show decreased levels of hepatic cyp2d6 enzyme
    n1=en:hyperintense | n2=en:pms show decreased levels of hepatic cyp2d6 enzyme | rel=r_associated | relid=0 | w=10
  2322. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pms show deficient oxidation of debrisoquine
    n1=en:hyperintense | n2=en:pms show deficient oxidation of debrisoquine | rel=r_associated | relid=0 | w=10
  2323. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:polychromasia
    n1=en:hyperintense | n2=en:polychromasia | rel=r_associated | relid=0 | w=10
  2324. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:polycythemia
    n1=en:hyperintense | n2=en:polycythemia | rel=r_associated | relid=0 | w=10
  2325. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:polymorphonuclear leukocytosis, episodic
    n1=en:hyperintense | n2=en:polymorphonuclear leukocytosis, episodic | rel=r_associated | relid=0 | w=10
  2326. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:polyploid sperm heads
    n1=en:hyperintense | n2=en:polyploid sperm heads | rel=r_associated | relid=0 | w=10
  2327. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:poor anticoagulant response to exogenous activated protein c as measured by the activated partial thromboplastin time (aptt)
    n1=en:hyperintense | n2=en:poor anticoagulant response to exogenous activated protein c as measured by the activated partial thromboplastin time (aptt) | rel=r_associated | relid=0 | w=10
  2328. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:poor mitogenic response to growth factors
    n1=en:hyperintense | n2=en:poor mitogenic response to growth factors | rel=r_associated | relid=0 | w=10
  2329. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:porokeratosis
    n1=en:hyperintense | n2=en:porokeratosis | rel=r_associated | relid=0 | w=10
  2330. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:positive antinuclear antibody test
    n1=en:hyperintense | n2=en:positive antinuclear antibody test | rel=r_associated | relid=0 | w=10
  2331. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:positive kveim-siltzbach skin test
    n1=en:hyperintense | n2=en:positive kveim-siltzbach skin test | rel=r_associated | relid=0 | w=10
  2332. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:positive urinary bratton-marshall test
    n1=en:hyperintense | n2=en:positive urinary bratton-marshall test | rel=r_associated | relid=0 | w=10
  2333. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:positive urine dnph screening test
    n1=en:hyperintense | n2=en:positive urine dnph screening test | rel=r_associated | relid=0 | w=10
  2334. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:postnatal-onset ichthyosiform erythroderma
    n1=en:hyperintense | n2=en:postnatal-onset ichthyosiform erythroderma | rel=r_associated | relid=0 | w=10
  2335. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:postprandial hyperglycemia (early in disease course)
    n1=en:hyperintense | n2=en:postprandial hyperglycemia (early in disease course) | rel=r_associated | relid=0 | w=10
  2336. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium
    n1=en:hyperintense | n2=en:potassium | rel=r_associated | relid=0 | w=10
  2337. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium abnormality
    n1=en:hyperintense | n2=en:potassium abnormality | rel=r_associated | relid=0 | w=10
  2338. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium acetate
    n1=en:hyperintense | n2=en:potassium acetate | rel=r_associated | relid=0 | w=10
  2339. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium acetate 0.2 meq/ml injectable solution
    n1=en:hyperintense | n2=en:potassium acetate 0.2 meq/ml injectable solution | rel=r_associated | relid=0 | w=10
  2340. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium acetate 2 meq/ml injectable solution
    n1=en:hyperintense | n2=en:potassium acetate 2 meq/ml injectable solution | rel=r_associated | relid=0 | w=10
  2341. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium acetate 4 meq/ml injectable solution
    n1=en:hyperintense | n2=en:potassium acetate 4 meq/ml injectable solution | rel=r_associated | relid=0 | w=10
  2342. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium bicarbonate
    n1=en:hyperintense | n2=en:potassium bicarbonate | rel=r_associated | relid=0 | w=10
  2343. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium bicarbonate 0.208 meq/ml oral solution
    n1=en:hyperintense | n2=en:potassium bicarbonate 0.208 meq/ml oral solution | rel=r_associated | relid=0 | w=10
  2344. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium bicarbonate 10 meq effervescent oral tablet
    n1=en:hyperintense | n2=en:potassium bicarbonate 10 meq effervescent oral tablet | rel=r_associated | relid=0 | w=10
  2345. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium bicarbonate 20 meq effervescent oral tablet
    n1=en:hyperintense | n2=en:potassium bicarbonate 20 meq effervescent oral tablet | rel=r_associated | relid=0 | w=10
  2346. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium bicarbonate 25 meq effervescent oral tablet
    n1=en:hyperintense | n2=en:potassium bicarbonate 25 meq effervescent oral tablet | rel=r_associated | relid=0 | w=10
  2347. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium bicarbonate 6.5 meq oral tablet
    n1=en:hyperintense | n2=en:potassium bicarbonate 6.5 meq oral tablet | rel=r_associated | relid=0 | w=10
  2348. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium bicarbonate 99 mg oral capsule
    n1=en:hyperintense | n2=en:potassium bicarbonate 99 mg oral capsule | rel=r_associated | relid=0 | w=10
  2349. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium bicarbonate pwdr
    n1=en:hyperintense | n2=en:potassium bicarbonate pwdr | rel=r_associated | relid=0 | w=10
  2350. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium bitartrate
    n1=en:hyperintense | n2=en:potassium bitartrate | rel=r_associated | relid=0 | w=10
  2351. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium bitartrate pwdr
    n1=en:hyperintense | n2=en:potassium bitartrate pwdr | rel=r_associated | relid=0 | w=10
  2352. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride
    n1=en:hyperintense | n2=en:potassium chloride | rel=r_associated | relid=0 | w=10
  2353. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 0.1 meq/ml injectable solution
    n1=en:hyperintense | n2=en:potassium chloride 0.1 meq/ml injectable solution | rel=r_associated | relid=0 | w=10
  2354. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 0.125 meq/ml oral solution
    n1=en:hyperintense | n2=en:potassium chloride 0.125 meq/ml oral solution | rel=r_associated | relid=0 | w=10
  2355. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 0.167 meq/ml oral solution
    n1=en:hyperintense | n2=en:potassium chloride 0.167 meq/ml oral solution | rel=r_associated | relid=0 | w=10
  2356. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 0.2 meq/ml injectable solution
    n1=en:hyperintense | n2=en:potassium chloride 0.2 meq/ml injectable solution | rel=r_associated | relid=0 | w=10
  2357. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 0.3 meq/ml injectable solution
    n1=en:hyperintense | n2=en:potassium chloride 0.3 meq/ml injectable solution | rel=r_associated | relid=0 | w=10
  2358. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 0.4 meq/ml injectable solution
    n1=en:hyperintense | n2=en:potassium chloride 0.4 meq/ml injectable solution | rel=r_associated | relid=0 | w=10
  2359. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 0.67 meq/ml injectable solution
    n1=en:hyperintense | n2=en:potassium chloride 0.67 meq/ml injectable solution | rel=r_associated | relid=0 | w=10
  2360. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 1.33 meq/ml oral solution
    n1=en:hyperintense | n2=en:potassium chloride 1.33 meq/ml oral solution | rel=r_associated | relid=0 | w=10
  2361. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 1.5 meq/ml injectable solution
    n1=en:hyperintense | n2=en:potassium chloride 1.5 meq/ml injectable solution | rel=r_associated | relid=0 | w=10
  2362. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 10 meq extended release oral capsule
    n1=en:hyperintense | n2=en:potassium chloride 10 meq extended release oral capsule | rel=r_associated | relid=0 | w=10
  2363. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 10 meq extended release oral tablet
    n1=en:hyperintense | n2=en:potassium chloride 10 meq extended release oral tablet | rel=r_associated | relid=0 | w=10
  2364. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 10 meq extended release oral tablet [k-dur]
    n1=en:hyperintense | n2=en:potassium chloride 10 meq extended release oral tablet [k-dur] | rel=r_associated | relid=0 | w=10
  2365. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 10 meq oral tablet
    n1=en:hyperintense | n2=en:potassium chloride 10 meq oral tablet | rel=r_associated | relid=0 | w=10
  2366. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 13 meq delayed release oral tablet
    n1=en:hyperintense | n2=en:potassium chloride 13 meq delayed release oral tablet | rel=r_associated | relid=0 | w=10
  2367. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 15 meq extended release oral tablet
    n1=en:hyperintense | n2=en:potassium chloride 15 meq extended release oral tablet | rel=r_associated | relid=0 | w=10
  2368. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 2 meq/ml oral solution
    n1=en:hyperintense | n2=en:potassium chloride 2 meq/ml oral solution | rel=r_associated | relid=0 | w=10
  2369. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 2.4 meq delayed release oral tablet
    n1=en:hyperintense | n2=en:potassium chloride 2.4 meq delayed release oral tablet | rel=r_associated | relid=0 | w=10
  2370. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 2.4 meq/ml injectable solution
    n1=en:hyperintense | n2=en:potassium chloride 2.4 meq/ml injectable solution | rel=r_associated | relid=0 | w=10
  2371. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 2.67 meq/ml oral solution
    n1=en:hyperintense | n2=en:potassium chloride 2.67 meq/ml oral solution | rel=r_associated | relid=0 | w=10
  2372. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 20 meq extended release oral tablet
    n1=en:hyperintense | n2=en:potassium chloride 20 meq extended release oral tablet | rel=r_associated | relid=0 | w=10
  2373. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 20 meq extended release oral tablet [k-dur]
    n1=en:hyperintense | n2=en:potassium chloride 20 meq extended release oral tablet [k-dur] | rel=r_associated | relid=0 | w=10
  2374. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 25meq tablet
    n1=en:hyperintense | n2=en:potassium chloride 25meq tablet | rel=r_associated | relid=0 | w=10
  2375. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 3 meq/ml injectable solution
    n1=en:hyperintense | n2=en:potassium chloride 3 meq/ml injectable solution | rel=r_associated | relid=0 | w=10
  2376. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 3.2 meq/ml injectable solution
    n1=en:hyperintense | n2=en:potassium chloride 3.2 meq/ml injectable solution | rel=r_associated | relid=0 | w=10
  2377. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 4 meq delayed release oral tablet
    n1=en:hyperintense | n2=en:potassium chloride 4 meq delayed release oral tablet | rel=r_associated | relid=0 | w=10
  2378. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 4 meq/ml oral solution
    n1=en:hyperintense | n2=en:potassium chloride 4 meq/ml oral solution | rel=r_associated | relid=0 | w=10
  2379. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 6.7 meq delayed release oral tablet
    n1=en:hyperintense | n2=en:potassium chloride 6.7 meq delayed release oral tablet | rel=r_associated | relid=0 | w=10
  2380. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 6.7 meq extended release oral tablet
    n1=en:hyperintense | n2=en:potassium chloride 6.7 meq extended release oral tablet | rel=r_associated | relid=0 | w=10
  2381. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 7.5% syrup
    n1=en:hyperintense | n2=en:potassium chloride 7.5% syrup | rel=r_associated | relid=0 | w=10
  2382. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 8 meq delayed release oral tablet
    n1=en:hyperintense | n2=en:potassium chloride 8 meq delayed release oral tablet | rel=r_associated | relid=0 | w=10
  2383. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 8 meq extended release oral capsule
    n1=en:hyperintense | n2=en:potassium chloride 8 meq extended release oral capsule | rel=r_associated | relid=0 | w=10
  2384. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 8 meq extended release oral tablet
    n1=en:hyperintense | n2=en:potassium chloride 8 meq extended release oral tablet | rel=r_associated | relid=0 | w=10
  2385. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride 8 meq oral tablet
    n1=en:hyperintense | n2=en:potassium chloride 8 meq oral tablet | rel=r_associated | relid=0 | w=10
  2386. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium chloride strong 15% injection solution 10ml ampule
    n1=en:hyperintense | n2=en:potassium chloride strong 15% injection solution 10ml ampule | rel=r_associated | relid=0 | w=10
  2387. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium citrate
    n1=en:hyperintense | n2=en:potassium citrate | rel=r_associated | relid=0 | w=10
  2388. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium citrate 10 meq extended release oral tablet
    n1=en:hyperintense | n2=en:potassium citrate 10 meq extended release oral tablet | rel=r_associated | relid=0 | w=10
  2389. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium citrate 15 meq extended release oral tablet
    n1=en:hyperintense | n2=en:potassium citrate 15 meq extended release oral tablet | rel=r_associated | relid=0 | w=10
  2390. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium citrate 260 mg oral tablet
    n1=en:hyperintense | n2=en:potassium citrate 260 mg oral tablet | rel=r_associated | relid=0 | w=10
  2391. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium citrate 5 meq extended release oral tablet
    n1=en:hyperintense | n2=en:potassium citrate 5 meq extended release oral tablet | rel=r_associated | relid=0 | w=10
  2392. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium disorder
    n1=en:hyperintense | n2=en:potassium disorder | rel=r_associated | relid=0 | w=10
  2393. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium gluconate
    n1=en:hyperintense | n2=en:potassium gluconate | rel=r_associated | relid=0 | w=10
  2394. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium gluconate 1.33 meq/ml oral solution
    n1=en:hyperintense | n2=en:potassium gluconate 1.33 meq/ml oral solution | rel=r_associated | relid=0 | w=10
  2395. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium gluconate 2 meq oral tablet
    n1=en:hyperintense | n2=en:potassium gluconate 2 meq oral tablet | rel=r_associated | relid=0 | w=10
  2396. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium gluconate 2.2 meq oral tablet
    n1=en:hyperintense | n2=en:potassium gluconate 2.2 meq oral tablet | rel=r_associated | relid=0 | w=10
  2397. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium gluconate 2.35 meq oral tablet
    n1=en:hyperintense | n2=en:potassium gluconate 2.35 meq oral tablet | rel=r_associated | relid=0 | w=10
  2398. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium gluconate 2.5 meq oral tablet
    n1=en:hyperintense | n2=en:potassium gluconate 2.5 meq oral tablet | rel=r_associated | relid=0 | w=10
  2399. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium gluconate 2.6 meq oral tablet
    n1=en:hyperintense | n2=en:potassium gluconate 2.6 meq oral tablet | rel=r_associated | relid=0 | w=10
  2400. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium gluconate 5 meq oral tablet
    n1=en:hyperintense | n2=en:potassium gluconate 5 meq oral tablet | rel=r_associated | relid=0 | w=10
  2401. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium gluconate 6.66 meq oral tablet
    n1=en:hyperintense | n2=en:potassium gluconate 6.66 meq oral tablet | rel=r_associated | relid=0 | w=10
  2402. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium imbalance
    n1=en:hyperintense | n2=en:potassium imbalance | rel=r_associated | relid=0 | w=10
  2403. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium intoxication
    n1=en:hyperintense | n2=en:potassium intoxication | rel=r_associated | relid=0 | w=10
  2404. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium iodide
    n1=en:hyperintense | n2=en:potassium iodide | rel=r_associated | relid=0 | w=10
  2405. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium iodide 1000 mg/ml oral solution
    n1=en:hyperintense | n2=en:potassium iodide 1000 mg/ml oral solution | rel=r_associated | relid=0 | w=10
  2406. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium iodide 130 mg oral tablet
    n1=en:hyperintense | n2=en:potassium iodide 130 mg oral tablet | rel=r_associated | relid=0 | w=10
  2407. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium iodide 300 mg delayed release oral tablet
    n1=en:hyperintense | n2=en:potassium iodide 300 mg delayed release oral tablet | rel=r_associated | relid=0 | w=10
  2408. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium iodide 65mg tablet
    n1=en:hyperintense | n2=en:potassium iodide 65mg tablet | rel=r_associated | relid=0 | w=10
  2409. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium iodide 65mg/ml oral solution
    n1=en:hyperintense | n2=en:potassium iodide 65mg/ml oral solution | rel=r_associated | relid=0 | w=10
  2410. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium iodide granules
    n1=en:hyperintense | n2=en:potassium iodide granules | rel=r_associated | relid=0 | w=10
  2411. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium phosphate
    n1=en:hyperintense | n2=en:potassium phosphate | rel=r_associated | relid=0 | w=10
  2412. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium phosphate 1450 mg oral capsule
    n1=en:hyperintense | n2=en:potassium phosphate 1450 mg oral capsule | rel=r_associated | relid=0 | w=10
  2413. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium phosphate monobase 500mg tablet
    n1=en:hyperintense | n2=en:potassium phosphate monobase 500mg tablet | rel=r_associated | relid=0 | w=10
  2414. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium phosphate monobasic
    n1=en:hyperintense | n2=en:potassium phosphate monobasic | rel=r_associated | relid=0 | w=10
  2415. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium phosphate, dibasic
    n1=en:hyperintense | n2=en:potassium phosphate, dibasic | rel=r_associated | relid=0 | w=10
  2416. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium retention
    n1=en:hyperintense | n2=en:potassium retention | rel=r_associated | relid=0 | w=10
  2417. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium tripolyphosphate
    n1=en:hyperintense | n2=en:potassium tripolyphosphate | rel=r_associated | relid=0 | w=10
  2418. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium, increased level
    n1=en:hyperintense | n2=en:potassium, increased level | rel=r_associated | relid=0 | w=10
  2419. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium,chelated
    n1=en:hyperintense | n2=en:potassium,chelated | rel=r_associated | relid=0 | w=10
  2420. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:potassium,chelated 99 mg oral tablet
    n1=en:hyperintense | n2=en:potassium,chelated 99 mg oral tablet | rel=r_associated | relid=0 | w=10
  2421. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:predominance of the d-stereoisomer
    n1=en:hyperintense | n2=en:predominance of the d-stereoisomer | rel=r_associated | relid=0 | w=10
  2422. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pregnant mothers of affected children have decreased plasma and urinary estrogen
    n1=en:hyperintense | n2=en:pregnant mothers of affected children have decreased plasma and urinary estrogen | rel=r_associated | relid=0 | w=10
  2423. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:premature centromere division (pcd) of the x chromosome observed in cultured lymphocytes during metaphase
    n1=en:hyperintense | n2=en:premature centromere division (pcd) of the x chromosome observed in cultured lymphocytes during metaphase | rel=r_associated | relid=0 | w=10
  2424. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:premature chromatid separation (pcs) observed in 5% to 50% cultured lymphocytes during metaphase
    n1=en:hyperintense | n2=en:premature chromatid separation (pcs) observed in 5% to 50% cultured lymphocytes during metaphase | rel=r_associated | relid=0 | w=10
  2425. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:premature chromosome condensation
    n1=en:hyperintense | n2=en:premature chromosome condensation | rel=r_associated | relid=0 | w=10
  2426. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:premature separation of centromeric heterochromatin
    n1=en:hyperintense | n2=en:premature separation of centromeric heterochromatin | rel=r_associated | relid=0 | w=10
  2427. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:presence of cytochrome b(-245)
    n1=en:hyperintense | n2=en:presence of cytochrome b(-245) | rel=r_associated | relid=0 | w=10
  2428. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:presence of glial fibrillary acidic proteins (gfap) in astrocytes
    n1=en:hyperintense | n2=en:presence of glial fibrillary acidic proteins (gfap) in astrocytes | rel=r_associated | relid=0 | w=10
  2429. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:presence of pc mrna
    n1=en:hyperintense | n2=en:presence of pc mrna | rel=r_associated | relid=0 | w=10
  2430. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:presence of rosenthal fibers (cytoplasmic inclusions) in astrocytes
    n1=en:hyperintense | n2=en:presence of rosenthal fibers (cytoplasmic inclusions) in astrocytes | rel=r_associated | relid=0 | w=10
  2431. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:presence of serum anti-lu3 antibodies
    n1=en:hyperintense | n2=en:presence of serum anti-lu3 antibodies | rel=r_associated | relid=0 | w=10
  2432. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:presence of the philadelphia chromosome (translocation of 9q34 and 22q11) in greater than 95% of patients
    n1=en:hyperintense | n2=en:presence of the philadelphia chromosome (translocation of 9q34 and 22q11) in greater than 95% of patients | rel=r_associated | relid=0 | w=10
  2433. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:presence of vacuoles on muscle biopsy
    n1=en:hyperintense | n2=en:presence of vacuoles on muscle biopsy | rel=r_associated | relid=0 | w=10
  2434. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:primary immunoglobulin-related amyloidosis (al)
    n1=en:hyperintense | n2=en:primary immunoglobulin-related amyloidosis (al) | rel=r_associated | relid=0 | w=10
  2435. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:prolidase deficiency
    n1=en:hyperintense | n2=en:prolidase deficiency | rel=r_associated | relid=0 | w=10
  2436. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:prolinuria
    n1=en:hyperintense | n2=en:prolinuria | rel=r_associated | relid=0 | w=10
  2437. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:prolonged activated partial prothrombin time (appt)
    n1=en:hyperintense | n2=en:prolonged activated partial prothrombin time (appt) | rel=r_associated | relid=0 | w=10
  2438. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:prolonged activated partial thromboplastin time (aptt)
    n1=en:hyperintense | n2=en:prolonged activated partial thromboplastin time (aptt) | rel=r_associated | relid=0 | w=10
  2439. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:prolonged bleeding time
    n1=en:hyperintense | n2=en:prolonged bleeding time | rel=r_associated | relid=0 | w=10
  2440. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:prolonged bleeding time (10 - >30 minutes)
    n1=en:hyperintense | n2=en:prolonged bleeding time (10 - >30 minutes) | rel=r_associated | relid=0 | w=10
  2441. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:prolonged partial thromboplastin time
    n1=en:hyperintense | n2=en:prolonged partial thromboplastin time | rel=r_associated | relid=0 | w=10
  2442. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:prolonged partial thromboplastin time (ptt)
    n1=en:hyperintense | n2=en:prolonged partial thromboplastin time (ptt) | rel=r_associated | relid=0 | w=10
  2443. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:prolonged prothrombin and partial thromboplastin times
    n1=en:hyperintense | n2=en:prolonged prothrombin and partial thromboplastin times | rel=r_associated | relid=0 | w=10
  2444. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:prolonged prothrombin time (pt)
    n1=en:hyperintense | n2=en:prolonged prothrombin time (pt) | rel=r_associated | relid=0 | w=10
  2445. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:prominent leukocytosis (30,000/ml)
    n1=en:hyperintense | n2=en:prominent leukocytosis (30,000/ml) | rel=r_associated | relid=0 | w=10
  2446. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:proper antibody response to protein vaccinations
    n1=en:hyperintense | n2=en:proper antibody response to protein vaccinations | rel=r_associated | relid=0 | w=10
  2447. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:propionic acidemia
    n1=en:hyperintense | n2=en:propionic acidemia | rel=r_associated | relid=0 | w=10
  2448. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:protein c decreased
    n1=en:hyperintense | n2=en:protein c decreased | rel=r_associated | relid=0 | w=10
  2449. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:protein total decreased
    n1=en:hyperintense | n2=en:protein total decreased | rel=r_associated | relid=0 | w=10
  2450. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:protein urine absent
    n1=en:hyperintense | n2=en:protein urine absent | rel=r_associated | relid=0 | w=10
  2451. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:proteinuria
    n1=en:hyperintense | n2=en:proteinuria | rel=r_associated | relid=0 | w=10
  2452. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:proteinuria (type ii, congenital)
    n1=en:hyperintense | n2=en:proteinuria (type ii, congenital) | rel=r_associated | relid=0 | w=10
  2453. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:proteinuria in those with cystic kidneys
    n1=en:hyperintense | n2=en:proteinuria in those with cystic kidneys | rel=r_associated | relid=0 | w=10
  2454. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:prothrombin time increased
    n1=en:hyperintense | n2=en:prothrombin time increased | rel=r_associated | relid=0 | w=10
  2455. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:prothrombin time low
    n1=en:hyperintense | n2=en:prothrombin time low | rel=r_associated | relid=0 | w=10
  2456. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pseudohyperkalaemia
    n1=en:hyperintense | n2=en:pseudohyperkalaemia | rel=r_associated | relid=0 | w=10
  2457. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pseudohyperkalemia cardiff
    n1=en:hyperintense | n2=en:pseudohyperkalemia cardiff | rel=r_associated | relid=0 | w=10
  2458. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pseudohyperkalemia, due to ex vivo efflux of potassium from red cells (in some patients)
    n1=en:hyperintense | n2=en:pseudohyperkalemia, due to ex vivo efflux of potassium from red cells (in some patients) | rel=r_associated | relid=0 | w=10
  2459. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pseudohyperkalemia, familial, 2, due to red cell leak
    n1=en:hyperintense | n2=en:pseudohyperkalemia, familial, 2, due to red cell leak | rel=r_associated | relid=0 | w=10
  2460. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pseudohypertriglyceridemia in adult form
    n1=en:hyperintense | n2=en:pseudohypertriglyceridemia in adult form | rel=r_associated | relid=0 | w=10
  2461. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pseudohypoaldosteronism, type i, autosomal dominant
    n1=en:hyperintense | n2=en:pseudohypoaldosteronism, type i, autosomal dominant | rel=r_associated | relid=0 | w=10
  2462. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pseudohypoaldosteronism, type i, autosomal recessive
    n1=en:hyperintense | n2=en:pseudohypoaldosteronism, type i, autosomal recessive | rel=r_associated | relid=0 | w=10
  2463. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pseudohypoaldosteronism, type iia
    n1=en:hyperintense | n2=en:pseudohypoaldosteronism, type iia | rel=r_associated | relid=0 | w=10
  2464. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:psychology qualifier
    n1=en:hyperintense | n2=en:psychology qualifier | rel=r_associated | relid=0 | w=10
  2465. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pt normal
    n1=en:hyperintense | n2=en:pt normal | rel=r_associated | relid=0 | w=10
  2466. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:punctate keratosis
    n1=en:hyperintense | n2=en:punctate keratosis | rel=r_associated | relid=0 | w=10
  2467. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:punctate palmar and solar hyperkeratosis
    n1=en:hyperintense | n2=en:punctate palmar and solar hyperkeratosis | rel=r_associated | relid=0 | w=10
  2468. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pyrimidinuria
    n1=en:hyperintense | n2=en:pyrimidinuria | rel=r_associated | relid=0 | w=10
  2469. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pyruvate-induced insulin secretion
    n1=en:hyperintense | n2=en:pyruvate-induced insulin secretion | rel=r_associated | relid=0 | w=10
  2470. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:pyruvic acidemia
    n1=en:hyperintense | n2=en:pyruvic acidemia | rel=r_associated | relid=0 | w=10
  2471. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:radiotherapeutic
    n1=en:hyperintense | n2=en:radiotherapeutic | rel=r_associated | relid=0 | w=10
  2472. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:raised c-reactive protein
    n1=en:hyperintense | n2=en:raised c-reactive protein | rel=r_associated | relid=0 | w=10
  2473. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:raised tsh level
    n1=en:hyperintense | n2=en:raised tsh level | rel=r_associated | relid=0 | w=10
  2474. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:rapid high rai (radioactive iodine) uptake and turnover
    n1=en:hyperintense | n2=en:rapid high rai (radioactive iodine) uptake and turnover | rel=r_associated | relid=0 | w=10
  2475. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:rapid radioactive iodide (rai) discharge after thiocyanate or perchlorate
    n1=en:hyperintense | n2=en:rapid radioactive iodide (rai) discharge after thiocyanate or perchlorate | rel=r_associated | relid=0 | w=10
  2476. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:rare occurrences of 9+0 or 8+1 cilia
    n1=en:hyperintense | n2=en:rare occurrences of 9+0 or 8+1 cilia | rel=r_associated | relid=0 | w=10
  2477. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reactive hypoglycemia
    n1=en:hyperintense | n2=en:reactive hypoglycemia | rel=r_associated | relid=0 | w=10
  2478. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:rectilinear intracellular accumulation of autofluorescent lipopigment storage material
    n1=en:hyperintense | n2=en:rectilinear intracellular accumulation of autofluorescent lipopigment storage material | rel=r_associated | relid=0 | w=10
  2479. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:recurring t(11,14) and t(14,19)(q32,q13.1) translocations
    n1=en:hyperintense | n2=en:recurring t(11,14) and t(14,19)(q32,q13.1) translocations | rel=r_associated | relid=0 | w=10
  2480. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced (50%) activity of protoporphyrinogen oxidase (proto oxidase)
    n1=en:hyperintense | n2=en:reduced (50%) activity of protoporphyrinogen oxidase (proto oxidase) | rel=r_associated | relid=0 | w=10
  2481. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced aspartoacylase activity in cultured skin fibroblasts
    n1=en:hyperintense | n2=en:reduced aspartoacylase activity in cultured skin fibroblasts | rel=r_associated | relid=0 | w=10
  2482. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced beating amplitudes in cilia
    n1=en:hyperintense | n2=en:reduced beating amplitudes in cilia | rel=r_associated | relid=0 | w=10
  2483. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced bending capacity of cilia
    n1=en:hyperintense | n2=en:reduced bending capacity of cilia | rel=r_associated | relid=0 | w=10
  2484. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced cd4+ count and proportionally increased cd8+ count
    n1=en:hyperintense | n2=en:reduced cd4+ count and proportionally increased cd8+ count | rel=r_associated | relid=0 | w=10
  2485. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced cytosolic superoxide dismutase-1 (sod1)
    n1=en:hyperintense | n2=en:reduced cytosolic superoxide dismutase-1 (sod1) | rel=r_associated | relid=0 | w=10
  2486. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced electroretinogram (scotopic > photopic) becoming extinguished in older patients
    n1=en:hyperintense | n2=en:reduced electroretinogram (scotopic > photopic) becoming extinguished in older patients | rel=r_associated | relid=0 | w=10
  2487. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced erythrocyte adenosine deaminase activity
    n1=en:hyperintense | n2=en:reduced erythrocyte adenosine deaminase activity | rel=r_associated | relid=0 | w=10
  2488. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced erythrocyte glucose/hexose transport
    n1=en:hyperintense | n2=en:reduced erythrocyte glucose/hexose transport | rel=r_associated | relid=0 | w=10
  2489. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced erythrocyte gs activity
    n1=en:hyperintense | n2=en:reduced erythrocyte gs activity | rel=r_associated | relid=0 | w=10
  2490. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced erythrocyte purine nucleoside phosphorylase activity
    n1=en:hyperintense | n2=en:reduced erythrocyte purine nucleoside phosphorylase activity | rel=r_associated | relid=0 | w=10
  2491. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced ferrochelatase activity
    n1=en:hyperintense | n2=en:reduced ferrochelatase activity | rel=r_associated | relid=0 | w=10
  2492. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced iga
    n1=en:hyperintense | n2=en:reduced iga | rel=r_associated | relid=0 | w=10
  2493. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced ige levels
    n1=en:hyperintense | n2=en:reduced ige levels | rel=r_associated | relid=0 | w=10
  2494. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced igg levels, particularly igg2 subclass
    n1=en:hyperintense | n2=en:reduced igg levels, particularly igg2 subclass | rel=r_associated | relid=0 | w=10
  2495. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced liver and red cell uroporphyrinogen decarboxylase (uro decarboxylase)
    n1=en:hyperintense | n2=en:reduced liver and red cell uroporphyrinogen decarboxylase (uro decarboxylase) | rel=r_associated | relid=0 | w=10
  2496. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced oxygen affinity (e.g. hb thionville 141800.0168)
    n1=en:hyperintense | n2=en:reduced oxygen affinity (e.g. hb thionville 141800.0168) | rel=r_associated | relid=0 | w=10
  2497. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced platelet aggregation response to adp, collagen, epinephrine
    n1=en:hyperintense | n2=en:reduced platelet aggregation response to adp, collagen, epinephrine | rel=r_associated | relid=0 | w=10
  2498. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced platelet aggregation response to collagen and thrombin
    n1=en:hyperintense | n2=en:reduced platelet aggregation response to collagen and thrombin | rel=r_associated | relid=0 | w=10
  2499. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced platelet glycoprotein ib complex
    n1=en:hyperintense | n2=en:reduced platelet glycoprotein ib complex | rel=r_associated | relid=0 | w=10
  2500. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced serum uric acid
    n1=en:hyperintense | n2=en:reduced serum uric acid | rel=r_associated | relid=0 | w=10
  2501. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced total and free carnitine in plasma and tissue
    n1=en:hyperintense | n2=en:reduced total and free carnitine in plasma and tissue | rel=r_associated | relid=0 | w=10
  2502. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reduced unsaturated serum cobalamin binding capacity
    n1=en:hyperintense | n2=en:reduced unsaturated serum cobalamin binding capacity | rel=r_associated | relid=0 | w=10
  2503. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:rehabilitation aspects
    n1=en:hyperintense | n2=en:rehabilitation aspects | rel=r_associated | relid=0 | w=10
  2504. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:relatively low urinary pge-m levels
    n1=en:hyperintense | n2=en:relatively low urinary pge-m levels | rel=r_associated | relid=0 | w=10
  2505. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:renin decreased
    n1=en:hyperintense | n2=en:renin decreased | rel=r_associated | relid=0 | w=10
  2506. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:resistance to 1,25-dihydroxyvitamin d3
    n1=en:hyperintense | n2=en:resistance to 1,25-dihydroxyvitamin d3 | rel=r_associated | relid=0 | w=10
  2507. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:resistance to activated protein c due to factor v leiden
    n1=en:hyperintense | n2=en:resistance to activated protein c due to factor v leiden | rel=r_associated | relid=0 | w=10
  2508. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:respiratory cilia and sperm flagella show reduced coordination of beating activity
    n1=en:hyperintense | n2=en:respiratory cilia and sperm flagella show reduced coordination of beating activity | rel=r_associated | relid=0 | w=10
  2509. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:respiratory epithelial show lack of ciliary movement or abnormal movement
    n1=en:hyperintense | n2=en:respiratory epithelial show lack of ciliary movement or abnormal movement | rel=r_associated | relid=0 | w=10
  2510. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:retention hyperkeratosis
    n1=en:hyperintense | n2=en:retention hyperkeratosis | rel=r_associated | relid=0 | w=10
  2511. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reticulocyte count increased
    n1=en:hyperintense | n2=en:reticulocyte count increased | rel=r_associated | relid=0 | w=10
  2512. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:reticulocytosis
    n1=en:hyperintense | n2=en:reticulocytosis | rel=r_associated | relid=0 | w=10
  2513. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:rhabdomyolysis in response to alcohol
    n1=en:hyperintense | n2=en:rhabdomyolysis in response to alcohol | rel=r_associated | relid=0 | w=10
  2514. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:rheumatoid factor negative
    n1=en:hyperintense | n2=en:rheumatoid factor negative | rel=r_associated | relid=0 | w=10
  2515. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:rheumatoid factor positive (finding)
    n1=en:hyperintense | n2=en:rheumatoid factor positive (finding) | rel=r_associated | relid=0 | w=10
  2516. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:roentgenographic
    n1=en:hyperintense | n2=en:roentgenographic | rel=r_associated | relid=0 | w=10
  2517. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:round, yellow-brown dha urine crystals
    n1=en:hyperintense | n2=en:round, yellow-brown dha urine crystals | rel=r_associated | relid=0 | w=10
  2518. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:routine liver function tests normal
    n1=en:hyperintense | n2=en:routine liver function tests normal | rel=r_associated | relid=0 | w=10
  2519. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:rud syndrome
    n1=en:hyperintense | n2=en:rud syndrome | rel=r_associated | relid=0 | w=10
  2520. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:russell's viper venom assay may be prolonged or normal, depending on the genetic defect
    n1=en:hyperintense | n2=en:russell's viper venom assay may be prolonged or normal, depending on the genetic defect | rel=r_associated | relid=0 | w=10
  2521. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:saccharopine dehydrogenase deficiency
    n1=en:hyperintense | n2=en:saccharopine dehydrogenase deficiency | rel=r_associated | relid=0 | w=10
  2522. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:salt overload
    n1=en:hyperintense | n2=en:salt overload | rel=r_associated | relid=0 | w=10
  2523. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:saposin a deficiency (finding)
    n1=en:hyperintense | n2=en:saposin a deficiency (finding) | rel=r_associated | relid=0 | w=10
  2524. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:scaly skin
    n1=en:hyperintense | n2=en:scaly skin | rel=r_associated | relid=0 | w=10
  2525. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:sce normal in heterozygotes
    n1=en:hyperintense | n2=en:sce normal in heterozygotes | rel=r_associated | relid=0 | w=10
  2526. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:schirmer test shows alacrima
    n1=en:hyperintense | n2=en:schirmer test shows alacrima | rel=r_associated | relid=0 | w=10
  2527. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:seborrheic keratosis
    n1=en:hyperintense | n2=en:seborrheic keratosis | rel=r_associated | relid=0 | w=10
  2528. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:secondary decrease of plasma free carnitine
    n1=en:hyperintense | n2=en:secondary decrease of plasma free carnitine | rel=r_associated | relid=0 | w=10
  2529. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:secondary decreased activity of argininosuccinate synthetase (ass1)
    n1=en:hyperintense | n2=en:secondary decreased activity of argininosuccinate synthetase (ass1) | rel=r_associated | relid=0 | w=10
  2530. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:secondary decreases in complex i and iv activity
    n1=en:hyperintense | n2=en:secondary decreases in complex i and iv activity | rel=r_associated | relid=0 | w=10
  2531. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:sepiapterin reductase deficiency (fibroblasts)
    n1=en:hyperintense | n2=en:sepiapterin reductase deficiency (fibroblasts) | rel=r_associated | relid=0 | w=10
  2532. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum acid phosphatase normal
    n1=en:hyperintense | n2=en:serum acid phosphatase normal | rel=r_associated | relid=0 | w=10
  2533. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum acylcarnitine returns to borderline high or normal after resolution of fever
    n1=en:hyperintense | n2=en:serum acylcarnitine returns to borderline high or normal after resolution of fever | rel=r_associated | relid=0 | w=10
  2534. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum albumin low result
    n1=en:hyperintense | n2=en:serum albumin low result | rel=r_associated | relid=0 | w=10
  2535. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum aldosterone elevated
    n1=en:hyperintense | n2=en:serum aldosterone elevated | rel=r_associated | relid=0 | w=10
  2536. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum alkaline phosphatase normal or mildly increased
    n1=en:hyperintense | n2=en:serum alkaline phosphatase normal or mildly increased | rel=r_associated | relid=0 | w=10
  2537. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum alpha-1-antitrypsin (pi) deficiency
    n1=en:hyperintense | n2=en:serum alpha-1-antitrypsin (pi) deficiency | rel=r_associated | relid=0 | w=10
  2538. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum ammonia increased
    n1=en:hyperintense | n2=en:serum ammonia increased | rel=r_associated | relid=0 | w=10
  2539. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum amylase increased
    n1=en:hyperintense | n2=en:serum amylase increased | rel=r_associated | relid=0 | w=10
  2540. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum and csf lactate may be increased
    n1=en:hyperintense | n2=en:serum and csf lactate may be increased | rel=r_associated | relid=0 | w=10
  2541. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum bicarbonate decreased
    n1=en:hyperintense | n2=en:serum bicarbonate decreased | rel=r_associated | relid=0 | w=10
  2542. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum bicarbonate increased
    n1=en:hyperintense | n2=en:serum bicarbonate increased | rel=r_associated | relid=0 | w=10
  2543. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum bilirubin increased
    n1=en:hyperintense | n2=en:serum bilirubin increased | rel=r_associated | relid=0 | w=10
  2544. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum c-peptide and glucagon levels measurable
    n1=en:hyperintense | n2=en:serum c-peptide and glucagon levels measurable | rel=r_associated | relid=0 | w=10
  2545. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum c-reactive protein may be increased
    n1=en:hyperintense | n2=en:serum c-reactive protein may be increased | rel=r_associated | relid=0 | w=10
  2546. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum calcitonin level increased
    n1=en:hyperintense | n2=en:serum calcitonin level increased | rel=r_associated | relid=0 | w=10
  2547. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum calcitonin, increased
    n1=en:hyperintense | n2=en:serum calcitonin, increased | rel=r_associated | relid=0 | w=10
  2548. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum calcium elevated
    n1=en:hyperintense | n2=en:serum calcium elevated | rel=r_associated | relid=0 | w=10
  2549. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum calcium normal
    n1=en:hyperintense | n2=en:serum calcium normal | rel=r_associated | relid=0 | w=10
  2550. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum carnitine deficiency
    n1=en:hyperintense | n2=en:serum carnitine deficiency | rel=r_associated | relid=0 | w=10
  2551. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum chloride level decreased (finding)
    n1=en:hyperintense | n2=en:serum chloride level decreased (finding) | rel=r_associated | relid=0 | w=10
  2552. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum cholesterol low or normal
    n1=en:hyperintense | n2=en:serum cholesterol low or normal | rel=r_associated | relid=0 | w=10
  2553. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum cholesterol normal
    n1=en:hyperintense | n2=en:serum cholesterol normal | rel=r_associated | relid=0 | w=10
  2554. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum cholesterol raised
    n1=en:hyperintense | n2=en:serum cholesterol raised | rel=r_associated | relid=0 | w=10
  2555. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum complement decreased
    n1=en:hyperintense | n2=en:serum complement decreased | rel=r_associated | relid=0 | w=10
  2556. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum copper decreased
    n1=en:hyperintense | n2=en:serum copper decreased | rel=r_associated | relid=0 | w=10
  2557. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum corticosterone increased
    n1=en:hyperintense | n2=en:serum corticosterone increased | rel=r_associated | relid=0 | w=10
  2558. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum cortisol decreased
    n1=en:hyperintense | n2=en:serum cortisol decreased | rel=r_associated | relid=0 | w=10
  2559. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum cortisol elevated
    n1=en:hyperintense | n2=en:serum cortisol elevated | rel=r_associated | relid=0 | w=10
  2560. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum creatine kinase 20-70 times normal
    n1=en:hyperintense | n2=en:serum creatine kinase 20-70 times normal | rel=r_associated | relid=0 | w=10
  2561. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum creatine kinase may be increased
    n1=en:hyperintense | n2=en:serum creatine kinase may be increased | rel=r_associated | relid=0 | w=10
  2562. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum creatine kinase may be normal
    n1=en:hyperintense | n2=en:serum creatine kinase may be normal | rel=r_associated | relid=0 | w=10
  2563. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum creatine kinase may be normal or elevated
    n1=en:hyperintense | n2=en:serum creatine kinase may be normal or elevated | rel=r_associated | relid=0 | w=10
  2564. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum creatine kinase may be normal or increased
    n1=en:hyperintense | n2=en:serum creatine kinase may be normal or increased | rel=r_associated | relid=0 | w=10
  2565. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum creatinine raised
    n1=en:hyperintense | n2=en:serum creatinine raised | rel=r_associated | relid=0 | w=10
  2566. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum ferritin high
    n1=en:hyperintense | n2=en:serum ferritin high | rel=r_associated | relid=0 | w=10
  2567. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum ferritin hyperglycosylation
    n1=en:hyperintense | n2=en:serum ferritin hyperglycosylation | rel=r_associated | relid=0 | w=10
  2568. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum ferritin normal
    n1=en:hyperintense | n2=en:serum ferritin normal | rel=r_associated | relid=0 | w=10
  2569. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum folate low
    n1=en:hyperintense | n2=en:serum folate low | rel=r_associated | relid=0 | w=10
  2570. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum folate normal
    n1=en:hyperintense | n2=en:serum folate normal | rel=r_associated | relid=0 | w=10
  2571. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum gastrin increased
    n1=en:hyperintense | n2=en:serum gastrin increased | rel=r_associated | relid=0 | w=10
  2572. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum growth hormone increased
    n1=en:hyperintense | n2=en:serum growth hormone increased | rel=r_associated | relid=0 | w=10
  2573. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum homocysteine normal
    n1=en:hyperintense | n2=en:serum homocysteine normal | rel=r_associated | relid=0 | w=10
  2574. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum immunoglobulin free light chain increased
    n1=en:hyperintense | n2=en:serum immunoglobulin free light chain increased | rel=r_associated | relid=0 | w=10
  2575. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum immunoglobulin free light chain ratio abnormal
    n1=en:hyperintense | n2=en:serum immunoglobulin free light chain ratio abnormal | rel=r_associated | relid=0 | w=10
  2576. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum iron low (finding)
    n1=en:hyperintense | n2=en:serum iron low (finding) | rel=r_associated | relid=0 | w=10
  2577. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum iron normal
    n1=en:hyperintense | n2=en:serum iron normal | rel=r_associated | relid=0 | w=10
  2578. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum iron raised
    n1=en:hyperintense | n2=en:serum iron raised | rel=r_associated | relid=0 | w=10
  2579. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum lactate is usually normal
    n1=en:hyperintense | n2=en:serum lactate is usually normal | rel=r_associated | relid=0 | w=10
  2580. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum lactate may be increased during encephalopathic exacerbations
    n1=en:hyperintense | n2=en:serum lactate may be increased during encephalopathic exacerbations | rel=r_associated | relid=0 | w=10
  2581. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum mitochondrial autoantibodies
    n1=en:hyperintense | n2=en:serum mitochondrial autoantibodies | rel=r_associated | relid=0 | w=10
  2582. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum osmolality decreased
    n1=en:hyperintense | n2=en:serum osmolality decreased | rel=r_associated | relid=0 | w=10
  2583. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum phosphate concentration below normal
    n1=en:hyperintense | n2=en:serum phosphate concentration below normal | rel=r_associated | relid=0 | w=10
  2584. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum phosphate normal
    n1=en:hyperintense | n2=en:serum phosphate normal | rel=r_associated | relid=0 | w=10
  2585. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum potassium measurement
    n1=en:hyperintense | n2=en:serum potassium measurement | rel=r_associated | relid=0 | w=10
  2586. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum pristanic acid increased
    n1=en:hyperintense | n2=en:serum pristanic acid increased | rel=r_associated | relid=0 | w=10
  2587. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum prolactin decreased
    n1=en:hyperintense | n2=en:serum prolactin decreased | rel=r_associated | relid=0 | w=10
  2588. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum prolactin increased
    n1=en:hyperintense | n2=en:serum prolactin increased | rel=r_associated | relid=0 | w=10
  2589. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum prostate specific antigen increased
    n1=en:hyperintense | n2=en:serum prostate specific antigen increased | rel=r_associated | relid=0 | w=10
  2590. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum soluble fas ligand level increased
    n1=en:hyperintense | n2=en:serum soluble fas ligand level increased | rel=r_associated | relid=0 | w=10
  2591. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum t3 level high
    n1=en:hyperintense | n2=en:serum t3 level high | rel=r_associated | relid=0 | w=10
  2592. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum testosterone decreased
    n1=en:hyperintense | n2=en:serum testosterone decreased | rel=r_associated | relid=0 | w=10
  2593. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum testosterone level normal
    n1=en:hyperintense | n2=en:serum testosterone level normal | rel=r_associated | relid=0 | w=10
  2594. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum thiamine is normal
    n1=en:hyperintense | n2=en:serum thiamine is normal | rel=r_associated | relid=0 | w=10
  2595. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum thyroxine may be decreased or normal
    n1=en:hyperintense | n2=en:serum thyroxine may be decreased or normal | rel=r_associated | relid=0 | w=10
  2596. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum total tryptase levels increased
    n1=en:hyperintense | n2=en:serum total tryptase levels increased | rel=r_associated | relid=0 | w=10
  2597. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum transaminase increased
    n1=en:hyperintense | n2=en:serum transaminase increased | rel=r_associated | relid=0 | w=10
  2598. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum transferrin glycosylation is normal
    n1=en:hyperintense | n2=en:serum transferrin glycosylation is normal | rel=r_associated | relid=0 | w=10
  2599. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum transferrin isoelectric focusing shows type 2 pattern
    n1=en:hyperintense | n2=en:serum transferrin isoelectric focusing shows type 2 pattern | rel=r_associated | relid=0 | w=10
  2600. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum transferrin shows normal or mild hypo-glycosylation
    n1=en:hyperintense | n2=en:serum transferrin shows normal or mild hypo-glycosylation | rel=r_associated | relid=0 | w=10
  2601. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum triglycerides increased
    n1=en:hyperintense | n2=en:serum triglycerides increased | rel=r_associated | relid=0 | w=10
  2602. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:serum triglycerides normal
    n1=en:hyperintense | n2=en:serum triglycerides normal | rel=r_associated | relid=0 | w=10
  2603. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:severe amyloid angiopathy
    n1=en:hyperintense | n2=en:severe amyloid angiopathy | rel=r_associated | relid=0 | w=10
  2604. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:severe hypernatremia in neonatal period
    n1=en:hyperintense | n2=en:severe hypernatremia in neonatal period | rel=r_associated | relid=0 | w=10
  2605. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:severe ichthyoses
    n1=en:hyperintense | n2=en:severe ichthyoses | rel=r_associated | relid=0 | w=10
  2606. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:severe thrombocytopenia (30-60 x 10(9)/l)
    n1=en:hyperintense | n2=en:severe thrombocytopenia (30-60 x 10(9)/l) | rel=r_associated | relid=0 | w=10
  2607. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:severely decreased activity of beta-1,4-mannosyltransferase (less than 10% of normal)
    n1=en:hyperintense | n2=en:severely decreased activity of beta-1,4-mannosyltransferase (less than 10% of normal) | rel=r_associated | relid=0 | w=10
  2608. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:severely decreased antigen levels of vwf and factor viii
    n1=en:hyperintense | n2=en:severely decreased antigen levels of vwf and factor viii | rel=r_associated | relid=0 | w=10
  2609. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:severely decreased carnitine palmitoyltransferase ii (cpt ii) activity (less than 10% of normal) in multiple tissues
    n1=en:hyperintense | n2=en:severely decreased carnitine palmitoyltransferase ii (cpt ii) activity (less than 10% of normal) in multiple tissues | rel=r_associated | relid=0 | w=10
  2610. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:severely decreased palmitate oxidation
    n1=en:hyperintense | n2=en:severely decreased palmitate oxidation | rel=r_associated | relid=0 | w=10
  2611. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:severely impaired ciliary motility
    n1=en:hyperintense | n2=en:severely impaired ciliary motility | rel=r_associated | relid=0 | w=10
  2612. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:shortened metaphase
    n1=en:hyperintense | n2=en:shortened metaphase | rel=r_associated | relid=0 | w=10
  2613. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:shortened telomeres (1 patient)
    n1=en:hyperintense | n2=en:shortened telomeres (1 patient) | rel=r_associated | relid=0 | w=10
  2614. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:shortened telomeres (classic feature, nola3 patient)
    n1=en:hyperintense | n2=en:shortened telomeres (classic feature, nola3 patient) | rel=r_associated | relid=0 | w=10
  2615. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:shortened telomeres (in 1 of 2 patients)
    n1=en:hyperintense | n2=en:shortened telomeres (in 1 of 2 patients) | rel=r_associated | relid=0 | w=10
  2616. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:sialylation defects
    n1=en:hyperintense | n2=en:sialylation defects | rel=r_associated | relid=0 | w=10
  2617. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:sjogren-larsson syndrome
    n1=en:hyperintense | n2=en:sjogren-larsson syndrome | rel=r_associated | relid=0 | w=10
  2618. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:skeletal muscle shows decreased activities of mitochondrial respiratory complexes i, iii, iv, and v
    n1=en:hyperintense | n2=en:skeletal muscle shows decreased activities of mitochondrial respiratory complexes i, iii, iv, and v | rel=r_associated | relid=0 | w=10
  2619. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:skewed x-inactivation in females
    n1=en:hyperintense | n2=en:skewed x-inactivation in females | rel=r_associated | relid=0 | w=10
  2620. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:skin blisters
    n1=en:hyperintense | n2=en:skin blisters | rel=r_associated | relid=0 | w=10
  2621. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:skin callus
    n1=en:hyperintense | n2=en:skin callus | rel=r_associated | relid=0 | w=10
  2622. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:skin diseases, vesiculobullous
    n1=en:hyperintense | n2=en:skin diseases, vesiculobullous | rel=r_associated | relid=0 | w=10
  2623. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:skin fibroblasts contain cytoplasmic membrane-bound granular inclusions
    n1=en:hyperintense | n2=en:skin fibroblasts contain cytoplasmic membrane-bound granular inclusions | rel=r_associated | relid=0 | w=10
  2624. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:skin keratosis
    n1=en:hyperintense | n2=en:skin keratosis | rel=r_associated | relid=0 | w=10
  2625. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:slightly elevated 24-hour mean plasma cortisol
    n1=en:hyperintense | n2=en:slightly elevated 24-hour mean plasma cortisol | rel=r_associated | relid=0 | w=10
  2626. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:slightly increased serum alkaline phosphatase may occur
    n1=en:hyperintense | n2=en:slightly increased serum alkaline phosphatase may occur | rel=r_associated | relid=0 | w=10
  2627. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:smooth muscle antibodies positive
    n1=en:hyperintense | n2=en:smooth muscle antibodies positive | rel=r_associated | relid=0 | w=10
  2628. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:soft corn
    n1=en:hyperintense | n2=en:soft corn | rel=r_associated | relid=0 | w=10
  2629. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:some cilia show abnormal beating patterns or immotility
    n1=en:hyperintense | n2=en:some cilia show abnormal beating patterns or immotility | rel=r_associated | relid=0 | w=10
  2630. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:some cilia show central complex and radial spoke defects
    n1=en:hyperintense | n2=en:some cilia show central complex and radial spoke defects | rel=r_associated | relid=0 | w=10
  2631. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:some fragmented or disrupted golgi
    n1=en:hyperintense | n2=en:some fragmented or disrupted golgi | rel=r_associated | relid=0 | w=10
  2632. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:some increase in monosialo- and trisialotransferrin (type 1/2 pattern)
    n1=en:hyperintense | n2=en:some increase in monosialo- and trisialotransferrin (type 1/2 pattern) | rel=r_associated | relid=0 | w=10
  2633. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:some patients carry a deletion of minimum of 8.1 mb on 2q32-q33
    n1=en:hyperintense | n2=en:some patients carry a deletion of minimum of 8.1 mb on 2q32-q33 | rel=r_associated | relid=0 | w=10
  2634. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:some tissues may have normal levels of 3-hydroxyacyl-coa dehydrogenase activity
    n1=en:hyperintense | n2=en:some tissues may have normal levels of 3-hydroxyacyl-coa dehydrogenase activity | rel=r_associated | relid=0 | w=10
  2635. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:spironolactone
    n1=en:hyperintense | n2=en:spironolactone | rel=r_associated | relid=0 | w=10
  2636. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:spironolactone 100mg tablet
    n1=en:hyperintense | n2=en:spironolactone 100mg tablet | rel=r_associated | relid=0 | w=10
  2637. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:spironolactone 25mg tablet
    n1=en:hyperintense | n2=en:spironolactone 25mg tablet | rel=r_associated | relid=0 | w=10
  2638. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:spironolactone 50mg tablet
    n1=en:hyperintense | n2=en:spironolactone 50mg tablet | rel=r_associated | relid=0 | w=10
  2639. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:spironolactone pwdr
    n1=en:hyperintense | n2=en:spironolactone pwdr | rel=r_associated | relid=0 | w=10
  2640. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:spongy degeneration of brain on histology
    n1=en:hyperintense | n2=en:spongy degeneration of brain on histology | rel=r_associated | relid=0 | w=10
  2641. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:sterol 27-hydroxylase deficiency
    n1=en:hyperintense | n2=en:sterol 27-hydroxylase deficiency | rel=r_associated | relid=0 | w=10
  2642. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:stimulation of sympathetic fibers results in release of dopamine, not norepinephrine
    n1=en:hyperintense | n2=en:stimulation of sympathetic fibers results in release of dopamine, not norepinephrine | rel=r_associated | relid=0 | w=10
  2643. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:streaks of hyperkeratosis along each finger onto the palm
    n1=en:hyperintense | n2=en:streaks of hyperkeratosis along each finger onto the palm | rel=r_associated | relid=0 | w=10
  2644. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:structural abnormalities seen on chromosome analysis
    n1=en:hyperintense | n2=en:structural abnormalities seen on chromosome analysis | rel=r_associated | relid=0 | w=10
  2645. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:stucco keratosis
    n1=en:hyperintense | n2=en:stucco keratosis | rel=r_associated | relid=0 | w=10
  2646. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:subepithelial fibrin deposition with inflammation (pseudomembranous inflammation) of mucosal tissues
    n1=en:hyperintense | n2=en:subepithelial fibrin deposition with inflammation (pseudomembranous inflammation) of mucosal tissues | rel=r_associated | relid=0 | w=10
  2647. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:submucosal macrophages filled with sphingolipids
    n1=en:hyperintense | n2=en:submucosal macrophages filled with sphingolipids | rel=r_associated | relid=0 | w=10
  2648. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:subsarcolemmal pleomorphic mitochondria on em
    n1=en:hyperintense | n2=en:subsarcolemmal pleomorphic mitochondria on em | rel=r_associated | relid=0 | w=10
  2649. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:subtelomeric deletion of chromosome 16p
    n1=en:hyperintense | n2=en:subtelomeric deletion of chromosome 16p | rel=r_associated | relid=0 | w=10
  2650. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:subtelomeric deletion of long arm of chromosome 3 (3q29)
    n1=en:hyperintense | n2=en:subtelomeric deletion of long arm of chromosome 3 (3q29) | rel=r_associated | relid=0 | w=10
  2651. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:subungual hyperkeratosis
    n1=en:hyperintense | n2=en:subungual hyperkeratosis | rel=r_associated | relid=0 | w=10
  2652. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:subungual hyperkeratotic fragments
    n1=en:hyperintense | n2=en:subungual hyperkeratotic fragments | rel=r_associated | relid=0 | w=10
  2653. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:surgical aspects
    n1=en:hyperintense | n2=en:surgical aspects | rel=r_associated | relid=0 | w=10
  2654. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:sweat test normal
    n1=en:hyperintense | n2=en:sweat test normal | rel=r_associated | relid=0 | w=10
  2655. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:symmetrical keratoderma
    n1=en:hyperintense | n2=en:symmetrical keratoderma | rel=r_associated | relid=0 | w=10
  2656. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:syndrome of inappropriate antidiuretic hormone secretion
    n1=en:hyperintense | n2=en:syndrome of inappropriate antidiuretic hormone secretion | rel=r_associated | relid=0 | w=10
  2657. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:systemic accumulation of very long chain fatty acids (vlcfa)
    n1=en:hyperintense | n2=en:systemic accumulation of very long chain fatty acids (vlcfa) | rel=r_associated | relid=0 | w=10
  2658. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:systemic amyloidosis may occur
    n1=en:hyperintense | n2=en:systemic amyloidosis may occur | rel=r_associated | relid=0 | w=10
  2659. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:t cells may be increased or decreased
    n1=en:hyperintense | n2=en:t cells may be increased or decreased | rel=r_associated | relid=0 | w=10
  2660. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:t-cell deficit
    n1=en:hyperintense | n2=en:t-cell deficit | rel=r_associated | relid=0 | w=10
  2661. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:t-lymphocytopenia
    n1=en:hyperintense | n2=en:t-lymphocytopenia | rel=r_associated | relid=0 | w=10
  2662. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:t1 transport protein (glucose-6-phosphate translocase) defect
    n1=en:hyperintense | n2=en:t1 transport protein (glucose-6-phosphate translocase) defect | rel=r_associated | relid=0 | w=10
  2663. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:taxonomic
    n1=en:hyperintense | n2=en:taxonomic | rel=r_associated | relid=0 | w=10
  2664. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:tay-sachs disease
    n1=en:hyperintense | n2=en:tay-sachs disease | rel=r_associated | relid=0 | w=10
  2665. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:telomere shortening
    n1=en:hyperintense | n2=en:telomere shortening | rel=r_associated | relid=0 | w=10
  2666. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ten percent of cases are secondary to submicroscopic deletions of 16p13.3 detectable by fish
    n1=en:hyperintense | n2=en:ten percent of cases are secondary to submicroscopic deletions of 16p13.3 detectable by fish | rel=r_associated | relid=0 | w=10
  2667. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:tenascin x deficiency (serum and fibroblasts)
    n1=en:hyperintense | n2=en:tenascin x deficiency (serum and fibroblasts) | rel=r_associated | relid=0 | w=10
  2668. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:therapeutic aspects
    n1=en:hyperintense | n2=en:therapeutic aspects | rel=r_associated | relid=0 | w=10
  2669. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:thrombocytopenia
    n1=en:hyperintense | n2=en:thrombocytopenia | rel=r_associated | relid=0 | w=10
  2670. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:thrombocytopenia (33-120 x 10(9)/l)
    n1=en:hyperintense | n2=en:thrombocytopenia (33-120 x 10(9)/l) | rel=r_associated | relid=0 | w=10
  2671. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:thrombocytopenia, mild-moderate (60-100 x 10(9)/l)
    n1=en:hyperintense | n2=en:thrombocytopenia, mild-moderate (60-100 x 10(9)/l) | rel=r_associated | relid=0 | w=10
  2672. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:thrombocytosis (in some patients)
    n1=en:hyperintense | n2=en:thrombocytosis (in some patients) | rel=r_associated | relid=0 | w=10
  2673. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:thymic hormone decreased
    n1=en:hyperintense | n2=en:thymic hormone decreased | rel=r_associated | relid=0 | w=10
  2674. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:thyroid dyshormonogenesis 3
    n1=en:hyperintense | n2=en:thyroid dyshormonogenesis 3 | rel=r_associated | relid=0 | w=10
  2675. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:thyroid dyshormonogenesis 4
    n1=en:hyperintense | n2=en:thyroid dyshormonogenesis 4 | rel=r_associated | relid=0 | w=10
  2676. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:thyroid dyshormonogenesis 5
    n1=en:hyperintense | n2=en:thyroid dyshormonogenesis 5 | rel=r_associated | relid=0 | w=10
  2677. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:thyroid hormone organification defect
    n1=en:hyperintense | n2=en:thyroid hormone organification defect | rel=r_associated | relid=0 | w=10
  2678. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:thyroid hormones increased
    n1=en:hyperintense | n2=en:thyroid hormones increased | rel=r_associated | relid=0 | w=10
  2679. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:thyroid peroxidase defect
    n1=en:hyperintense | n2=en:thyroid peroxidase defect | rel=r_associated | relid=0 | w=10
  2680. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:tonofibril defect (cross-beta-protein structure)
    n1=en:hyperintense | n2=en:tonofibril defect (cross-beta-protein structure) | rel=r_associated | relid=0 | w=10
  2681. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:tonofilament aggregation in suprabasal keratinocytes
    n1=en:hyperintense | n2=en:tonofilament aggregation in suprabasal keratinocytes | rel=r_associated | relid=0 | w=10
  2682. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:transaminitis
    n1=en:hyperintense | n2=en:transaminitis | rel=r_associated | relid=0 | w=10
  2683. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:transcobalamin ii deficiency
    n1=en:hyperintense | n2=en:transcobalamin ii deficiency | rel=r_associated | relid=0 | w=10
  2684. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:transferase deficiency galactosemia
    n1=en:hyperintense | n2=en:transferase deficiency galactosemia | rel=r_associated | relid=0 | w=10
  2685. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:transferrin saturation increased
    n1=en:hyperintense | n2=en:transferrin saturation increased | rel=r_associated | relid=0 | w=10
  2686. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:transient eosinophilia in first decade
    n1=en:hyperintense | n2=en:transient eosinophilia in first decade | rel=r_associated | relid=0 | w=10
  2687. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:transient hyperlipidemia
    n1=en:hyperintense | n2=en:transient hyperlipidemia | rel=r_associated | relid=0 | w=10
  2688. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:transient hyperphenylalaninemia occurs on oral loading test with phenylalanine
    n1=en:hyperintense | n2=en:transient hyperphenylalaninemia occurs on oral loading test with phenylalanine | rel=r_associated | relid=0 | w=10
  2689. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:transient neonatal hypocalcemia (2p21del)
    n1=en:hyperintense | n2=en:transient neonatal hypocalcemia (2p21del) | rel=r_associated | relid=0 | w=10
  2690. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:transient neonatal hypoglycemia (2p21del)
    n1=en:hyperintense | n2=en:transient neonatal hypoglycemia (2p21del) | rel=r_associated | relid=0 | w=10
  2691. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:translocation (x,7)(p11.3,q11.21) - in some patients
    n1=en:hyperintense | n2=en:translocation (x,7)(p11.3,q11.21) - in some patients | rel=r_associated | relid=0 | w=10
  2692. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:translocation between 18q21 and 14q32
    n1=en:hyperintense | n2=en:translocation between 18q21 and 14q32 | rel=r_associated | relid=0 | w=10
  2693. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:translocation of chromosomes 9 and 13
    n1=en:hyperintense | n2=en:translocation of chromosomes 9 and 13 | rel=r_associated | relid=0 | w=10
  2694. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:translocation or deletions involving 7p13 (severe case reports)
    n1=en:hyperintense | n2=en:translocation or deletions involving 7p13 (severe case reports) | rel=r_associated | relid=0 | w=10
  2695. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:transmission electron microscopy (tem) of patient respiratory cilia shows normal 9+2 axonemal composition
    n1=en:hyperintense | n2=en:transmission electron microscopy (tem) of patient respiratory cilia shows normal 9+2 axonemal composition | rel=r_associated | relid=0 | w=10
  2696. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:triamterene
    n1=en:hyperintense | n2=en:triamterene | rel=r_associated | relid=0 | w=10
  2697. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:triamterene 100mg capsule
    n1=en:hyperintense | n2=en:triamterene 100mg capsule | rel=r_associated | relid=0 | w=10
  2698. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:triamterene 50mg capsule
    n1=en:hyperintense | n2=en:triamterene 50mg capsule | rel=r_associated | relid=0 | w=10
  2699. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:triglyceride decreased
    n1=en:hyperintense | n2=en:triglyceride decreased | rel=r_associated | relid=0 | w=10
  2700. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:tryptophanuria
    n1=en:hyperintense | n2=en:tryptophanuria | rel=r_associated | relid=0 | w=10
  2701. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:tsh decreased
    n1=en:hyperintense | n2=en:tsh decreased | rel=r_associated | relid=0 | w=10
  2702. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:tumor may secrete vasoactive intestinal peptide (vip)
    n1=en:hyperintense | n2=en:tumor may secrete vasoactive intestinal peptide (vip) | rel=r_associated | relid=0 | w=10
  2703. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:two alternative chimeric oncogene products called p210(bcr-abl) and p185(bcr-abl)
    n1=en:hyperintense | n2=en:two alternative chimeric oncogene products called p210(bcr-abl) and p185(bcr-abl) | rel=r_associated | relid=0 | w=10
  2704. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:tyloma
    n1=en:hyperintense | n2=en:tyloma | rel=r_associated | relid=0 | w=10
  2705. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:tylose
    n1=en:hyperintense | n2=en:tylose | rel=r_associated | relid=0 | w=10
  2706. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:tylosis
    n1=en:hyperintense | n2=en:tylosis | rel=r_associated | relid=0 | w=10
  2707. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:type 1 collagen overmodification
    n1=en:hyperintense | n2=en:type 1 collagen overmodification | rel=r_associated | relid=0 | w=10
  2708. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:type i, classic, decreased antithrombin iii levels
    n1=en:hyperintense | n2=en:type i, classic, decreased antithrombin iii levels | rel=r_associated | relid=0 | w=10
  2709. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:type ii, normal antithrombin iii level but decreased activity
    n1=en:hyperintense | n2=en:type ii, normal antithrombin iii level but decreased activity | rel=r_associated | relid=0 | w=10
  2710. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:type iii collagen defect
    n1=en:hyperintense | n2=en:type iii collagen defect | rel=r_associated | relid=0 | w=10
  2711. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:tyrosine iodination defect
    n1=en:hyperintense | n2=en:tyrosine iodination defect | rel=r_associated | relid=0 | w=10
  2712. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:tyrosine loss
    n1=en:hyperintense | n2=en:tyrosine loss | rel=r_associated | relid=0 | w=10
  2713. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:tyrosinemia
    n1=en:hyperintense | n2=en:tyrosinemia | rel=r_associated | relid=0 | w=10
  2714. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:tyrosinemia (transient, resolves in infancy)
    n1=en:hyperintense | n2=en:tyrosinemia (transient, resolves in infancy) | rel=r_associated | relid=0 | w=10
  2715. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:udp-galactose-4-epimerase deficiency in all cells ('generalized' or 'severe' form)
    n1=en:hyperintense | n2=en:udp-galactose-4-epimerase deficiency in all cells ('generalized' or 'severe' form) | rel=r_associated | relid=0 | w=10
  2716. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:ultra large von willebrand factor (ul-vwf) in plasma
    n1=en:hyperintense | n2=en:ultra large von willebrand factor (ul-vwf) in plasma | rel=r_associated | relid=0 | w=10
  2717. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:undetectable dopamine beta-hydroxylase (dbh) protein in plasma, csf, or sympathetic fibers
    n1=en:hyperintense | n2=en:undetectable dopamine beta-hydroxylase (dbh) protein in plasma, csf, or sympathetic fibers | rel=r_associated | relid=0 | w=10
  2718. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:undetectable epinephrine (adrenaline) in plasma, urine, csf
    n1=en:hyperintense | n2=en:undetectable epinephrine (adrenaline) in plasma, urine, csf | rel=r_associated | relid=0 | w=10
  2719. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:undetectable norepinephrine (noradrenaline) in plasma, urine, csf
    n1=en:hyperintense | n2=en:undetectable norepinephrine (noradrenaline) in plasma, urine, csf | rel=r_associated | relid=0 | w=10
  2720. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:undetectable plasma dbh activity
    n1=en:hyperintense | n2=en:undetectable plasma dbh activity | rel=r_associated | relid=0 | w=10
  2721. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:undetectable serum arginine vasopressin, or antidiuretic hormone (adh, avp, 192340)
    n1=en:hyperintense | n2=en:undetectable serum arginine vasopressin, or antidiuretic hormone (adh, avp, 192340) | rel=r_associated | relid=0 | w=10
  2722. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:undetectable serum l-transferrin (homozygous patient)
    n1=en:hyperintense | n2=en:undetectable serum l-transferrin (homozygous patient) | rel=r_associated | relid=0 | w=10
  2723. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:undetectable urinary hypoxanthine
    n1=en:hyperintense | n2=en:undetectable urinary hypoxanthine | rel=r_associated | relid=0 | w=10
  2724. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:unprocessed 3-oxoacyl coa thiolase
    n1=en:hyperintense | n2=en:unprocessed 3-oxoacyl coa thiolase | rel=r_associated | relid=0 | w=10
  2725. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:unresponsive to acth stimulation
    n1=en:hyperintense | n2=en:unresponsive to acth stimulation | rel=r_associated | relid=0 | w=10
  2726. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:upregulation of alpha-interferon-stimulated genes
    n1=en:hyperintense | n2=en:upregulation of alpha-interferon-stimulated genes | rel=r_associated | relid=0 | w=10
  2727. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:uremia
    n1=en:hyperintense | n2=en:uremia | rel=r_associated | relid=0 | w=10
  2728. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:uric acid normal
    n1=en:hyperintense | n2=en:uric acid normal | rel=r_associated | relid=0 | w=10
  2729. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urinary calcium-creatinine ratio < 0.01:1 supports diagnosis
    n1=en:hyperintense | n2=en:urinary calcium-creatinine ratio < 0.01:1 supports diagnosis | rel=r_associated | relid=0 | w=10
  2730. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urinary excretion of 2-ethyl-3-hydroxy-hexanoic acid
    n1=en:hyperintense | n2=en:urinary excretion of 2-ethyl-3-hydroxy-hexanoic acid | rel=r_associated | relid=0 | w=10
  2731. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urinary excretion of 2-ethyl-3-keto-hexanoic acid
    n1=en:hyperintense | n2=en:urinary excretion of 2-ethyl-3-keto-hexanoic acid | rel=r_associated | relid=0 | w=10
  2732. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urinary excretion of 2-ethyl-hexanedioic acid
    n1=en:hyperintense | n2=en:urinary excretion of 2-ethyl-hexanedioic acid | rel=r_associated | relid=0 | w=10
  2733. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urinary excretion of 3-hydroxyisovaleric acid, chronic
    n1=en:hyperintense | n2=en:urinary excretion of 3-hydroxyisovaleric acid, chronic | rel=r_associated | relid=0 | w=10
  2734. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urinary excretion of 3-methylcrotonylglycine, chronic
    n1=en:hyperintense | n2=en:urinary excretion of 3-methylcrotonylglycine, chronic | rel=r_associated | relid=0 | w=10
  2735. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urinary excretion of cationic amino acids (lysine, arginine, ornithine)
    n1=en:hyperintense | n2=en:urinary excretion of cationic amino acids (lysine, arginine, ornithine) | rel=r_associated | relid=0 | w=10
  2736. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urinary excretion of low-molecular-weight proteins, mild
    n1=en:hyperintense | n2=en:urinary excretion of low-molecular-weight proteins, mild | rel=r_associated | relid=0 | w=10
  2737. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urinary excretion of mucopolysaccharides
    n1=en:hyperintense | n2=en:urinary excretion of mucopolysaccharides | rel=r_associated | relid=0 | w=10
  2738. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urinary excretion of retinol-binding proteins (rbp) and vitamin d-binding proteins (dbp)
    n1=en:hyperintense | n2=en:urinary excretion of retinol-binding proteins (rbp) and vitamin d-binding proteins (dbp) | rel=r_associated | relid=0 | w=10
  2739. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urinary excretion of sialylated oligosaccharides
    n1=en:hyperintense | n2=en:urinary excretion of sialylated oligosaccharides | rel=r_associated | relid=0 | w=10
  2740. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urinary loss of potassium, sodium, calcium, and chloride
    n1=en:hyperintense | n2=en:urinary loss of potassium, sodium, calcium, and chloride | rel=r_associated | relid=0 | w=10
  2741. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urinary prostaglandin e
    n1=en:hyperintense | n2=en:urinary prostaglandin e | rel=r_associated | relid=0 | w=10
  2742. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urine cortisol, increased
    n1=en:hyperintense | n2=en:urine cortisol, increased | rel=r_associated | relid=0 | w=10
  2743. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urine occasionally port-wine in color secondary to porphobilinogen
    n1=en:hyperintense | n2=en:urine occasionally port-wine in color secondary to porphobilinogen | rel=r_associated | relid=0 | w=10
  2744. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urine odor, maple syrup
    n1=en:hyperintense | n2=en:urine odor, maple syrup | rel=r_associated | relid=0 | w=10
  2745. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urine osmolarity decreased
    n1=en:hyperintense | n2=en:urine osmolarity decreased | rel=r_associated | relid=0 | w=10
  2746. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urine uric acid decreased
    n1=en:hyperintense | n2=en:urine uric acid decreased | rel=r_associated | relid=0 | w=10
  2747. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:urocanase deficiency
    n1=en:hyperintense | n2=en:urocanase deficiency | rel=r_associated | relid=0 | w=10
  2748. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:uroporphyrin i and coproporphyrin i are found in plasma, red blood cells, urine, and feces
    n1=en:hyperintense | n2=en:uroporphyrin i and coproporphyrin i are found in plasma, red blood cells, urine, and feces | rel=r_associated | relid=0 | w=10
  2749. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:uroporphyrinogen iii cosynthase (uro cosynthase) deficiency in blood and fibroblasts
    n1=en:hyperintense | n2=en:uroporphyrinogen iii cosynthase (uro cosynthase) deficiency in blood and fibroblasts | rel=r_associated | relid=0 | w=10
  2750. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:use of ultrasonography
    n1=en:hyperintense | n2=en:use of ultrasonography | rel=r_associated | relid=0 | w=10
  2751. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:vacuolated lymphocytes
    n1=en:hyperintense | n2=en:vacuolated lymphocytes | rel=r_associated | relid=0 | w=10
  2752. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:vacuolation of stratum granulosum
    n1=en:hyperintense | n2=en:vacuolation of stratum granulosum | rel=r_associated | relid=0 | w=10
  2753. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:variable defects of inner dynein arms
    n1=en:hyperintense | n2=en:variable defects of inner dynein arms | rel=r_associated | relid=0 | w=10
  2754. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:variable hyperlipidemia
    n1=en:hyperintense | n2=en:variable hyperlipidemia | rel=r_associated | relid=0 | w=10
  2755. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:variable hypoglycemia
    n1=en:hyperintense | n2=en:variable hypoglycemia | rel=r_associated | relid=0 | w=10
  2756. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:variable respiratory chain enzyme deficiency
    n1=en:hyperintense | n2=en:variable respiratory chain enzyme deficiency | rel=r_associated | relid=0 | w=10
  2757. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:variably decreased activity of mitochondrial respiratory complexes i, iii, iv, and v in fibroblasts and muscle
    n1=en:hyperintense | n2=en:variably decreased activity of mitochondrial respiratory complexes i, iii, iv, and v in fibroblasts and muscle | rel=r_associated | relid=0 | w=10
  2758. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:variably increased serum creatine kinase
    n1=en:hyperintense | n2=en:variably increased serum creatine kinase | rel=r_associated | relid=0 | w=10
  2759. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:variegated translocation mosaicism in cultured fibroblasts
    n1=en:hyperintense | n2=en:variegated translocation mosaicism in cultured fibroblasts | rel=r_associated | relid=0 | w=10
  2760. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:very long chain fatty acid accumulation
    n1=en:hyperintense | n2=en:very long chain fatty acid accumulation | rel=r_associated | relid=0 | w=10
  2761. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:very long-chain fatty acids may be normal or increased
    n1=en:hyperintense | n2=en:very long-chain fatty acids may be normal or increased | rel=r_associated | relid=0 | w=10
  2762. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:very low density lipoprotein increased
    n1=en:hyperintense | n2=en:very low density lipoprotein increased | rel=r_associated | relid=0 | w=10
  2763. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:very low iga
    n1=en:hyperintense | n2=en:very low iga | rel=r_associated | relid=0 | w=10
  2764. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:very low igg
    n1=en:hyperintense | n2=en:very low igg | rel=r_associated | relid=0 | w=10
  2765. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:very low igm
    n1=en:hyperintense | n2=en:very low igm | rel=r_associated | relid=0 | w=10
  2766. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:very low leptin level
    n1=en:hyperintense | n2=en:very low leptin level | rel=r_associated | relid=0 | w=10
  2767. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:veterinary aspects
    n1=en:hyperintense | n2=en:veterinary aspects | rel=r_associated | relid=0 | w=10
  2768. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:viremia
    n1=en:hyperintense | n2=en:viremia | rel=r_associated | relid=0 | w=10
  2769. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:viruses
    n1=en:hyperintense | n2=en:viruses | rel=r_associated | relid=0 | w=10
  2770. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:vitamin b12 deficiency (in some patients)
    n1=en:hyperintense | n2=en:vitamin b12 deficiency (in some patients) | rel=r_associated | relid=0 | w=10
  2771. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:vitamin b12 deficiency (uncommon)
    n1=en:hyperintense | n2=en:vitamin b12 deficiency (uncommon) | rel=r_associated | relid=0 | w=10
  2772. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:vitamin d deficiency
    n1=en:hyperintense | n2=en:vitamin d deficiency | rel=r_associated | relid=0 | w=10
  2773. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:vitamin k deficiency
    n1=en:hyperintense | n2=en:vitamin k deficiency | rel=r_associated | relid=0 | w=10
  2774. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:vohwinkel syndrome, variant form
    n1=en:hyperintense | n2=en:vohwinkel syndrome, variant form | rel=r_associated | relid=0 | w=10
  2775. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:warty thickening of flexural skin
    n1=en:hyperintense | n2=en:warty thickening of flexural skin | rel=r_associated | relid=0 | w=10
  2776. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:water intoxication
    n1=en:hyperintense | n2=en:water intoxication | rel=r_associated | relid=0 | w=10
  2777. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:water-electrolyte imbalance
    n1=en:hyperintense | n2=en:water-electrolyte imbalance | rel=r_associated | relid=0 | w=10
  2778. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:widespread interstitial fibrosis (visceral organs)
    n1=en:hyperintense | n2=en:widespread interstitial fibrosis (visceral organs) | rel=r_associated | relid=0 | w=10
  2779. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:Wilson-Brocq's disease
    n1=en:hyperintense | n2=en:Wilson-Brocq's disease | rel=r_associated | relid=0 | w=10
  2780. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:x-linked ichthyosis
    n1=en:hyperintense | n2=en:x-linked ichthyosis | rel=r_associated | relid=0 | w=10
  2781. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:xanthine nephrolithiasis
    n1=en:hyperintense | n2=en:xanthine nephrolithiasis | rel=r_associated | relid=0 | w=10
  2782. en:hyperintense -- r_associated #0: 10 / 0.2 -> en:xeroderma
    n1=en:hyperintense | n2=en:xeroderma | rel=r_associated | relid=0 | w=10
  2783. en:hyperintense -- r_associated #0: 10 / 0.2 -> épaisseur
    n1=en:hyperintense | n2=épaisseur | rel=r_associated | relid=0 | w=10
  2784. en:hyperintense -- r_associated #0: 10 / 0.2 -> épaissie
    n1=en:hyperintense | n2=épaissie | rel=r_associated | relid=0 | w=10
  2785. en:hyperintense -- r_associated #0: 10 / 0.2 -> épiderme
    n1=en:hyperintense | n2=épiderme | rel=r_associated | relid=0 | w=10
  2786. en:hyperintense -- r_associated #0: 10 / 0.2 -> épidermolytique
    n1=en:hyperintense | n2=épidermolytique | rel=r_associated | relid=0 | w=10
  2787. en:hyperintense -- r_associated #0: 10 / 0.2 -> érythrodermie
    n1=en:hyperintense | n2=érythrodermie | rel=r_associated | relid=0 | w=10
  2788. en:hyperintense -- r_associated #0: 10 / 0.2 -> érythrodermie congénitale ichtyosiforme bulleuse
    n1=en:hyperintense | n2=érythrodermie congénitale ichtyosiforme bulleuse | rel=r_associated | relid=0 | w=10
  2789. en:hyperintense -- r_associated #0: 10 / 0.2 -> érythrodermie ichtioïde congénitale
    n1=en:hyperintense | n2=érythrodermie ichtioïde congénitale | rel=r_associated | relid=0 | w=10
  2790. en:hyperintense -- r_associated #0: 10 / 0.2 -> érythrodermie ichtyosiforme bulleuse
    n1=en:hyperintense | n2=érythrodermie ichtyosiforme bulleuse | rel=r_associated | relid=0 | w=10
  2791. en:hyperintense -- r_associated #0: 10 / 0.2 -> Érythrodermie ichtyosiforme bulleuse
    n1=en:hyperintense | n2=Érythrodermie ichtyosiforme bulleuse | rel=r_associated | relid=0 | w=10
  2792. en:hyperintense -- r_associated #0: 10 / 0.2 -> érythrodermie ichtyosiforme bulleuse congénitale
    n1=en:hyperintense | n2=érythrodermie ichtyosiforme bulleuse congénitale | rel=r_associated | relid=0 | w=10
  2793. en:hyperintense -- r_associated #0: 10 / 0.2 -> érythrodermie ichtyosiforme congénitale bulleuse
    n1=en:hyperintense | n2=érythrodermie ichtyosiforme congénitale bulleuse | rel=r_associated | relid=0 | w=10
  2794. en:hyperintense -- r_associated #0: 10 / 0.2 -> Érythrodermie ichtyosiforme congénitale bulleuse
    n1=en:hyperintense | n2=Érythrodermie ichtyosiforme congénitale bulleuse | rel=r_associated | relid=0 | w=10
  2795. en:hyperintense -- r_associated #0: 10 / 0.2 -> érythrodermie ichtyosiforme congénitale dominante
    n1=en:hyperintense | n2=érythrodermie ichtyosiforme congénitale dominante | rel=r_associated | relid=0 | w=10
  2796. en:hyperintense -- r_associated #0: 10 / 0.2 -> excès
    n1=en:hyperintense | n2=excès | rel=r_associated | relid=0 | w=10
  2797. en:hyperintense -- r_associated #0: 10 / 0.2 -> excès de potassium (k)
    n1=en:hyperintense | n2=excès de potassium (k) | rel=r_associated | relid=0 | w=10
  2798. en:hyperintense -- r_associated #0: 10 / 0.2 -> Gordon (syndrome de)
    n1=en:hyperintense | n2=Gordon (syndrome de) | rel=r_associated | relid=0 | w=10
  2799. en:hyperintense -- r_associated #0: 10 / 0.2 -> hémodialyse
    n1=en:hyperintense | n2=hémodialyse | rel=r_associated | relid=0 | w=10
  2800. en:hyperintense -- r_associated #0: 10 / 0.2 -> hyperkaliémies
    n1=en:hyperintense | n2=hyperkaliémies | rel=r_associated | relid=0 | w=10
  2801. en:hyperintense -- r_associated #0: 10 / 0.2 -> hyperkaliémique
    n1=en:hyperintense | n2=hyperkaliémique | rel=r_associated | relid=0 | w=10
  2802. en:hyperintense -- r_associated #0: 10 / 0.2 -> hyperkératose de la peau
    n1=en:hyperintense | n2=hyperkératose de la peau | rel=r_associated | relid=0 | w=10
  2803. en:hyperintense -- r_associated #0: 10 / 0.2 -> hyperkératose excentrique de Respighi
    n1=en:hyperintense | n2=hyperkératose excentrique de Respighi | rel=r_associated | relid=0 | w=10
  2804. en:hyperintense -- r_associated #0: 10 / 0.2 -> hyperkératose ichtyosiforme bulleuse congénitale
    n1=en:hyperintense | n2=hyperkératose ichtyosiforme bulleuse congénitale | rel=r_associated | relid=0 | w=10
  2805. en:hyperintense -- r_associated #0: 10 / 0.2 -> hyperkératose ichtyosiforme dominante
    n1=en:hyperintense | n2=hyperkératose ichtyosiforme dominante | rel=r_associated | relid=0 | w=10
  2806. en:hyperintense -- r_associated #0: 10 / 0.2 -> hyperkératose palmo-plantaire diffuse
    n1=en:hyperintense | n2=hyperkératose palmo-plantaire diffuse | rel=r_associated | relid=0 | w=10
  2807. en:hyperintense -- r_associated #0: 10 / 0.2 -> hyperkératose palmoplantaire diffuse
    n1=en:hyperintense | n2=hyperkératose palmoplantaire diffuse | rel=r_associated | relid=0 | w=10
  2808. en:hyperintense -- r_associated #0: 10 / 0.2 -> hyperkératoses
    n1=en:hyperintense | n2=hyperkératoses | rel=r_associated | relid=0 | w=10
  2809. en:hyperintense -- r_associated #0: 10 / 0.2 -> hyperkératosique
    n1=en:hyperintense | n2=hyperkératosique | rel=r_associated | relid=0 | w=10
  2810. en:hyperintense -- r_associated #0: 10 / 0.2 -> hyperpotassémie
    n1=en:hyperintense | n2=hyperpotassémie | rel=r_associated | relid=0 | w=10
  2811. en:hyperintense -- r_associated #0: 10 / 0.2 -> hyperpotassémie chronique
    n1=en:hyperintense | n2=hyperpotassémie chronique | rel=r_associated | relid=0 | w=10
  2812. en:hyperintense -- r_associated #0: 10 / 0.2 -> hyperpotassiémie
    n1=en:hyperintense | n2=hyperpotassiémie | rel=r_associated | relid=0 | w=10
  2813. en:hyperintense -- r_associated #0: 10 / 0.2 -> hypoaldostéronisme
    n1=en:hyperintense | n2=hypoaldostéronisme | rel=r_associated | relid=0 | w=10
  2814. en:hyperintense -- r_associated #0: 10 / 0.2 -> ichthyose
    n1=en:hyperintense | n2=ichthyose | rel=r_associated | relid=0 | w=10
  2815. en:hyperintense -- r_associated #0: 10 / 0.2 -> ichtiosiforme
    n1=en:hyperintense | n2=ichtiosiforme | rel=r_associated | relid=0 | w=10
  2816. en:hyperintense -- r_associated #0: 10 / 0.2 -> ichtyose
    n1=en:hyperintense | n2=ichtyose | rel=r_associated | relid=0 | w=10
  2817. en:hyperintense -- r_associated #0: 10 / 0.2 -> ichtyosiforme
    n1=en:hyperintense | n2=ichtyosiforme | rel=r_associated | relid=0 | w=10
  2818. en:hyperintense -- r_associated #0: 10 / 0.2 -> inhibiteurs de l'enzyme de conversion
    n1=en:hyperintense | n2=inhibiteurs de l'enzyme de conversion | rel=r_associated | relid=0 | w=10
  2819. en:hyperintense -- r_associated #0: 10 / 0.2 -> insuffisance rénale
    n1=en:hyperintense | n2=insuffisance rénale | rel=r_associated | relid=0 | w=10
  2820. en:hyperintense -- r_associated #0: 10 / 0.2 -> kératine
    n1=en:hyperintense | n2=kératine | rel=r_associated | relid=0 | w=10
  2821. en:hyperintense -- r_associated #0: 10 / 0.2 -> kératinisation
    n1=en:hyperintense | n2=kératinisation | rel=r_associated | relid=0 | w=10
  2822. en:hyperintense -- r_associated #0: 10 / 0.2 -> kératinisation excessive
    n1=en:hyperintense | n2=kératinisation excessive | rel=r_associated | relid=0 | w=10
  2823. en:hyperintense -- r_associated #0: 10 / 0.2 -> kératodermie
    n1=en:hyperintense | n2=kératodermie | rel=r_associated | relid=0 | w=10
  2824. en:hyperintense -- r_associated #0: 10 / 0.2 -> kératodermie acquise
    n1=en:hyperintense | n2=kératodermie acquise | rel=r_associated | relid=0 | w=10
  2825. en:hyperintense -- r_associated #0: 10 / 0.2 -> kératodermie de type thost-unna
    n1=en:hyperintense | n2=kératodermie de type thost-unna | rel=r_associated | relid=0 | w=10
  2826. en:hyperintense -- r_associated #0: 10 / 0.2 -> kératodermie palmo-plantaire diffuse
    n1=en:hyperintense | n2=kératodermie palmo-plantaire diffuse | rel=r_associated | relid=0 | w=10
  2827. en:hyperintense -- r_associated #0: 10 / 0.2 -> kératodermie palmoplantaire diffuse
    n1=en:hyperintense | n2=kératodermie palmoplantaire diffuse | rel=r_associated | relid=0 | w=10
  2828. en:hyperintense -- r_associated #0: 10 / 0.2 -> kératome
    n1=en:hyperintense | n2=kératome | rel=r_associated | relid=0 | w=10
  2829. en:hyperintense -- r_associated #0: 10 / 0.2 -> kératose
    n1=en:hyperintense | n2=kératose | rel=r_associated | relid=0 | w=10
  2830. en:hyperintense -- r_associated #0: 10 / 0.2 -> kératoses
    n1=en:hyperintense | n2=kératoses | rel=r_associated | relid=0 | w=10
  2831. en:hyperintense -- r_associated #0: 10 / 0.2 -> kératosique
    n1=en:hyperintense | n2=kératosique | rel=r_associated | relid=0 | w=10
  2832. en:hyperintense -- r_associated #0: 10 / 0.2 -> lichen plan
    n1=en:hyperintense | n2=lichen plan | rel=r_associated | relid=0 | w=10
  2833. en:hyperintense -- r_associated #0: 10 / 0.2 -> maladie de Wilson-Brocq
    n1=en:hyperintense | n2=maladie de Wilson-Brocq | rel=r_associated | relid=0 | w=10
  2834. en:hyperintense -- r_associated #0: 10 / 0.2 -> maladies
    n1=en:hyperintense | n2=maladies | rel=r_associated | relid=0 | w=10
  2835. en:hyperintense -- r_associated #0: 10 / 0.2 -> médecine
    n1=en:hyperintense | n2=médecine | rel=r_associated | relid=0 | w=10
  2836. en:hyperintense -- r_associated #0: 10 / 0.2 -> paralysie périodique hyperkaliémique
    n1=en:hyperintense | n2=paralysie périodique hyperkaliémique | rel=r_associated | relid=0 | w=10
  2837. en:hyperintense -- r_associated #0: 10 / 0.2 -> pathologie
    n1=en:hyperintense | n2=pathologie | rel=r_associated | relid=0 | w=10
  2838. en:hyperintense -- r_associated #0: 10 / 0.2 -> peau
    n1=en:hyperintense | n2=peau | rel=r_associated | relid=0 | w=10
  2839. en:hyperintense -- r_associated #0: 10 / 0.2 -> potassium
    n1=en:hyperintense | n2=potassium | rel=r_associated | relid=0 | w=10
  2840. en:hyperintense -- r_associated #0: 10 / 0.2 -> pseudohypoaldostéronisme
    n1=en:hyperintense | n2=pseudohypoaldostéronisme | rel=r_associated | relid=0 | w=10
  2841. en:hyperintense -- r_associated #0: 10 / 0.2 -> Quinquaud (folliculite décalvante de)
    n1=en:hyperintense | n2=Quinquaud (folliculite décalvante de) | rel=r_associated | relid=0 | w=10
  2842. en:hyperintense -- r_associated #0: 10 / 0.2 -> sodium
    n1=en:hyperintense | n2=sodium | rel=r_associated | relid=0 | w=10
  2843. en:hyperintense -- r_associated #0: 10 / 0.2 -> stuccokératose
    n1=en:hyperintense | n2=stuccokératose | rel=r_associated | relid=0 | w=10
  2844. en:hyperintense -- r_associated #0: 10 / 0.2 -> surcharge en potassium (k)
    n1=en:hyperintense | n2=surcharge en potassium (k) | rel=r_associated | relid=0 | w=10
  2845. en:hyperintense -- r_associated #0: 10 / 0.2 -> syndrome d'ectrodactylie-dysplasie ectodermique-fente labiopalatine
    n1=en:hyperintense | n2=syndrome d'ectrodactylie-dysplasie ectodermique-fente labiopalatine | rel=r_associated | relid=0 | w=10
  2846. en:hyperintense -- r_associated #0: 10 / 0.2 -> syndrome de van den Bosch
    n1=en:hyperintense | n2=syndrome de van den Bosch | rel=r_associated | relid=0 | w=10
  2847. en:hyperintense -- r_associated #0: 10 / 0.2 -> syndrome hyperkaliémique
    n1=en:hyperintense | n2=syndrome hyperkaliémique | rel=r_associated | relid=0 | w=10
  2848. en:hyperintense -- r_associated #0: 10 / 0.2 -> transport membranaire
    n1=en:hyperintense | n2=transport membranaire | rel=r_associated | relid=0 | w=10
  2849. en:hyperintense -- r_associated #0: 10 / 0.2 -> tyloma
    n1=en:hyperintense | n2=tyloma | rel=r_associated | relid=0 | w=10
  2850. en:hyperintense -- r_associated #0: 10 / 0.2 -> tylose
    n1=en:hyperintense | n2=tylose | rel=r_associated | relid=0 | w=10
  2851. en:hyperintense -- r_associated #0: 10 / 0.2 -> tylose palmo-plantaire
    n1=en:hyperintense | n2=tylose palmo-plantaire | rel=r_associated | relid=0 | w=10
  2852. en:hyperintense -- r_associated #0: 10 / 0.2 -> tylose palmoplantaire
    n1=en:hyperintense | n2=tylose palmoplantaire | rel=r_associated | relid=0 | w=10
  2853. en:hyperintense -- r_associated #0: 10 / 0.2 -> tylosis
    n1=en:hyperintense | n2=tylosis | rel=r_associated | relid=0 | w=10
  2854. en:hyperintense -- r_associated #0: 10 / 0.2 -> verrue séborrhéique
    n1=en:hyperintense | n2=verrue séborrhéique | rel=r_associated | relid=0 | w=10
  2855. en:hyperintense -- r_associated #0: 10 / 0.2 -> vitamine A (défaut métabolique en)
    n1=en:hyperintense | n2=vitamine A (défaut métabolique en) | rel=r_associated | relid=0 | w=10
  2856. en:hyperintense -- r_associated #0: 10 / 0.2 -> Wilson-Brocq (maladie de)
    n1=en:hyperintense | n2=Wilson-Brocq (maladie de) | rel=r_associated | relid=0 | w=10
  2857. en:hyperintense -- r_associated #0: 1 / 0.02 -> en:quantitative concept
    n1=en:hyperintense | n2=en:quantitative concept | rel=r_associated | relid=0 | w=1
≈ 47 relations entrantes

  1. en:high signal intensity --- r_associated #0: 38 --> en:hyperintense
    n1=en:high signal intensity | n2=en:hyperintense | rel=r_associated | relid=0 | w=38
  2. en:hypointense --- r_associated #0: 31 --> en:hyperintense
    n1=en:hypointense | n2=en:hyperintense | rel=r_associated | relid=0 | w=31
  3. hypo-intense (signal IRM) --- r_associated #0: 31 --> en:hyperintense
    n1=hypo-intense (signal IRM) | n2=en:hyperintense | rel=r_associated | relid=0 | w=31
  4. hyperintense --- r_associated #0: 30 --> en:hyperintense
    n1=hyperintense | n2=en:hyperintense | rel=r_associated | relid=0 | w=30
  5. hyperintense (signal IRM) --- r_associated #0: 29 --> en:hyperintense
    n1=hyperintense (signal IRM) | n2=en:hyperintense | rel=r_associated | relid=0 | w=29
  6. en:low signal intensity --- r_associated #0: 27 --> en:hyperintense
    n1=en:low signal intensity | n2=en:hyperintense | rel=r_associated | relid=0 | w=27
  7. en:hyperintense lesions in the basal ganglia and brainstem --- r_associated #0: 26 --> en:hyperintense
    n1=en:hyperintense lesions in the basal ganglia and brainstem | n2=en:hyperintense | rel=r_associated | relid=0 | w=26
  8. en:hyperintense lesions in the thalamus and basal ganglia --- r_associated #0: 26 --> en:hyperintense
    n1=en:hyperintense lesions in the thalamus and basal ganglia | n2=en:hyperintense | rel=r_associated | relid=0 | w=26
  9. en:isointense --- r_associated #0: 26 --> en:hyperintense
    n1=en:isointense | n2=en:hyperintense | rel=r_associated | relid=0 | w=26
  10. en:hyperintense lesions in the basal ganglia on mri --- r_associated #0: 25 --> en:hyperintense
    n1=en:hyperintense lesions in the basal ganglia on mri | n2=en:hyperintense | rel=r_associated | relid=0 | w=25
  11. en:hyperintense lesions in the putamina --- r_associated #0: 25 --> en:hyperintense
    n1=en:hyperintense lesions in the putamina | n2=en:hyperintense | rel=r_associated | relid=0 | w=25
  12. en:hyperintense lesions in the putamina (1 patient) --- r_associated #0: 25 --> en:hyperintense
    n1=en:hyperintense lesions in the putamina (1 patient) | n2=en:hyperintense | rel=r_associated | relid=0 | w=25
  13. en:hyperintense lesions of the globi pallidi --- r_associated #0: 25 --> en:hyperintense
    n1=en:hyperintense lesions of the globi pallidi | n2=en:hyperintense | rel=r_associated | relid=0 | w=25
  14. en:hyperintense signaling of dorsal aspect of spinal cord seen on mri (inversion recovery images) --- r_associated #0: 25 --> en:hyperintense
    n1=en:hyperintense signaling of dorsal aspect of spinal cord seen on mri (inversion recovery images) | n2=en:hyperintense | rel=r_associated | relid=0 | w=25
  15. en:hyperintense white matter abnormalities (recessive) --- r_associated #0: 25 --> en:hyperintense
    n1=en:hyperintense white matter abnormalities (recessive) | n2=en:hyperintense | rel=r_associated | relid=0 | w=25
  16. en:intermediate signal intensity --- r_associated #0: 20 --> en:hyperintense
    n1=en:intermediate signal intensity | n2=en:hyperintense | rel=r_associated | relid=0 | w=20
  17. hypersignal (en IRM) --- r_associated #0: 20 --> en:hyperintense
    n1=hypersignal (en IRM) | n2=en:hyperintense | rel=r_associated | relid=0 | w=20
  18. hypo-intense --- r_associated #0: 20 --> en:hyperintense
    n1=hypo-intense | n2=en:hyperintense | rel=r_associated | relid=0 | w=20
  19. signal --- r_associated #0: 20 --> en:hyperintense
    n1=signal | n2=en:hyperintense | rel=r_associated | relid=0 | w=20
  20. hyperkaliémie --- r_associated #0: 15 --> en:hyperintense
    n1=hyperkaliémie | n2=en:hyperintense | rel=r_associated | relid=0 | w=15
  21. hyperkaliémie chronique --- r_associated #0: 15 --> en:hyperintense
    n1=hyperkaliémie chronique | n2=en:hyperintense | rel=r_associated | relid=0 | w=15
  22. hyperkératose --- r_associated #0: 15 --> en:hyperintense
    n1=hyperkératose | n2=en:hyperintense | rel=r_associated | relid=0 | w=15
  23. hyperkératose ichtiosiforme --- r_associated #0: 15 --> en:hyperintense
    n1=hyperkératose ichtiosiforme | n2=en:hyperintense | rel=r_associated | relid=0 | w=15
  24. hyperkératose épidermolytique --- r_associated #0: 15 --> en:hyperintense
    n1=hyperkératose épidermolytique | n2=en:hyperintense | rel=r_associated | relid=0 | w=15
  25. Hyperkaliémie --- r_associated #0: 10 --> en:hyperintense
    n1=Hyperkaliémie | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  26. en:chronic hyperkaliemia --- r_associated #0: 10 --> en:hyperintense
    n1=en:chronic hyperkaliemia | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  27. en:epidermolytic hyperkeratosis --- r_associated #0: 10 --> en:hyperintense
    n1=en:epidermolytic hyperkeratosis | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  28. en:hyperkaliaemia --- r_associated #0: 10 --> en:hyperintense
    n1=en:hyperkaliaemia | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  29. en:hyperkeratosis --- r_associated #0: 10 --> en:hyperintense
    n1=en:hyperkeratosis | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  30. en:ichtiosis hyperkeratosis --- r_associated #0: 10 --> en:hyperintense
    n1=en:ichtiosis hyperkeratosis | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  31. hypo-osmie --- r_associated #0: 10 --> en:hyperintense
    n1=hypo-osmie | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  32. hypo-osmolalité plasmatique --- r_associated #0: 10 --> en:hyperintense
    n1=hypo-osmolalité plasmatique | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  33. hypo-osmolarité plasmatique --- r_associated #0: 10 --> en:hyperintense
    n1=hypo-osmolarité plasmatique | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  34. hypo-uricémiant --- r_associated #0: 10 --> en:hyperintense
    n1=hypo-uricémiant | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  35. hypo-uricémie --- r_associated #0: 10 --> en:hyperintense
    n1=hypo-uricémie | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  36. hypoabsorbant --- r_associated #0: 10 --> en:hyperintense
    n1=hypoabsorbant | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  37. hypoaccommodation --- r_associated #0: 10 --> en:hyperintense
    n1=hypoaccommodation | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  38. hypoacousie --- r_associated #0: 10 --> en:hyperintense
    n1=hypoacousie | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  39. hypoacousie chez l'enfant --- r_associated #0: 10 --> en:hyperintense
    n1=hypoacousie chez l'enfant | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  40. hypoaction d'un muscle oculomoteur --- r_associated #0: 10 --> en:hyperintense
    n1=hypoaction d'un muscle oculomoteur | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  41. hypoactivité vésicale --- r_associated #0: 10 --> en:hyperintense
    n1=hypoactivité vésicale | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  42. hypoadrénocorticisme avec hypoparathyroïdie et moniliase superficielle --- r_associated #0: 10 --> en:hyperintense
    n1=hypoadrénocorticisme avec hypoparathyroïdie et moniliase superficielle | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  43. hypoalbuminémie --- r_associated #0: 10 --> en:hyperintense
    n1=hypoalbuminémie | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  44. hypoaminoacidémie --- r_associated #0: 10 --> en:hyperintense
    n1=hypoaminoacidémie | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  45. hypoazoturie --- r_associated #0: 10 --> en:hyperintense
    n1=hypoazoturie | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  46. hypobare --- r_associated #0: 10 --> en:hyperintense
    n1=hypobare | n2=en:hyperintense | rel=r_associated | relid=0 | w=10
  47. Hyperkératose --- r_associated #0: 5 --> en:hyperintense
    n1=Hyperkératose | n2=en:hyperintense | rel=r_associated | relid=0 | w=5
Le service Rézo permet d'énumérer les relations existant pour un terme. Ce service est interrogeable par programme.
Projet JeuxDeMots - url: http://www.jeuxdemots.org
contact: mathieu.lafourcade@lirmm.fr